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Abstract	  
Tissue	   inhibitor	   of	   metalloproteinases-­‐3	   (TIMP-­‐3)	   is	   an	   endogenous	   inhibitor	   of	  
metalloproteinases	   (MMPs),	   adamalysins	   (ADAMs)	   and	   adamalysins	   with	  
thrombospondin	   motifs	   (ADAMTSs),	   and	   consequently	   TIMP-­‐3	   is	   an	   important	  
regulator	   of	   extracellular	   matrix	   (ECM)	   turnover.	   It	   has	   been	   shown	   that	   TIMP-­‐3	  
levels	   in	   the	   tissue	   are	   regulated	   post-­‐translationally	   by	   endocytosis.	   This	   study	  
aimed	  to	  characterize	  the	  mechanism	  of	  TIMP-­‐3	  endocytosis	  in	  more	  detail.	  
In	   this	   thesis,	   I	   demonstrated	   that	   TIMP-­‐3	   is	   endocytosed	   and	   degraded	   by	   a	  
number	   of	   cell	   types	   including	   chondrocytes,	   fibroblasts,	   and	   monocytes.	   I	   found	  
that	  the	  endocytic	  receptor	  low-­‐density	  lipoprotein	  receptor-­‐related	  protein-­‐1	  (LRP-­‐
1)	  plays	  a	  major	  role	   in	  TIMP-­‐3	  endocytosis.	  Nevertheless,	   I	   found	  that	  TIMP-­‐3	  can	  
also	   be	   internalized	   by	   LRP-­‐1-­‐null	   cells,	   indicating	   that	   an	   LRP-­‐1-­‐independent	  
endocytic	   pathway	   also	   occurs.	   CHO-­‐cells	   lacking	   heparan	   sulfate	   proteoglycans	  
(HSPGs)	  efficiently	  endocytosed	  TIMP-­‐3,	  indicating	  that	  HSPGs	  are	  not	  involved	  in	  its	  
endocytosis.	  	  
Shedding	  of	  LRP-­‐1	  has	  been	  shown	  to	  reduce	  cell	  surface	  levels	  of	  the	  receptor,	  
and	   hence	   to	   modulate	   endocytosis	   of	   its	   ligands.	   I	   demonstrated	   that	   LRP-­‐1	  
shedding	   leads	   to	   accumulation	   of	   soluble	   LRP-­‐1	   (sLRP-­‐1)	   in	   the	   medium	   of	  
chondrosarcoma	  cells.	   sLRP-­‐1	   interacted	  with	  TIMP-­‐3	  and	   inhibited	   its	  endocytosis,	  
but	  had	  no	  effect	  on	  TIMP-­‐3	  inhibition	  of	  target	  metalloproteinases,	   indicating	  that	  
sLRP-­‐1	  negatively	  regulates	  TIMP-­‐3	  endocytosis.	  
TIMP-­‐3	   endocytosis	   was	   not	   affected	   by	   addition	   of	   GM6001,	   which	   inhibits	  
interaction	   with	   target	   metalloproteinases,	   indicating	   that	   TIMP-­‐3	   can	   be	  
internalized	   independently.	   Internalization	  of	  TIMP-­‐3	   in	   complex	  with	  a	  number	  of	  
metalloproteinases	   occurred	   with	   the	   same	   kinetics	   as	   that	   of	   TIMP-­‐3	   alone.	  
Furthermore,	  TIMP-­‐3	  promoted	  the	  endocytosis	  of	  MMP-­‐1,	  suggesting	  that	  TIMP-­‐3	  
can	  mediate	  the	  scavenging	  of	  metalloproteinases	  by	  cells.	  	  
The	  study	  thus	  identifies	  LRP-­‐1	  as	  a	  central	  mediator	  of	  TIMP-­‐3	  endocytosis,	  and	  
indicates	  that	  this	  process	  regulates	  levels	  of	  TIMP-­‐3	  in	  the	  ECM,	  thus	  contributing	  to	  
the	  maintenance	  of	  tissue	  homeostasis.	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  hanno	  brindato	  con	  me,	  cantato	  con	  me,	  danzato	  con	  me.	  
Grazie	   per	   avermi	   fatto	   sentire	   a	   casa	   quando	  mi	   sentivo	   solo,	   grazie	   per	   avermi	  
tirato	  su	  il	  morale	  quando	  mi	  sentivo	  triste	  e	  grazie	  per	  avere	  riso	  con	  me	  quando	  mi	  
sentivo	  felice.	  Il	  mio	  fegato	  vi	  ringrazia	  un	  po'	  meno....	  
	   Grazie	   Amore	   per	   aver	   aspettato	   pazientemente	   questo	   momento,	  





alla	  nonna	  Vita	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  alla	  nonna	  Angela,	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  state	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  di	  me.....	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Abbreviations	  
	  
α2M	  α2-­‐macroglobulin	  	  
α2M*	  activated	  α2-­‐macroglobulin	  	  
β-­‐Me	  β-­‐mercaptoethanol	  	  
Ab	  A-­‐beta	  peptide	  
AD	  Alzheimer's	  disease	  
ADAM	  a	  disintegrin	  and	  metalloproteinase	  	  
ADAMTS	  a	  disintegrin	  and	  metalloproteinase	  with	  thrombospondin	  type	  I	  motifs	  	  
AP	  alkaline	  phosphatase	  	  
apoE	  apolipoprotein	  E	  
APP	  amyloid	  precursor	  protein	  	  
APS	  ammonium	  persulfate	  	  
AP-­‐2	  adaptor	  protein-­‐2	  
ARF6	  ADP-­‐ribosylation	  factor	  6	  
ATP	  adenosin-­‐5'-­‐triphosphate	  
BACE	  β	  site	  of	  APP-­‐cleaving	  enzyme	  
BAR	  bin–amphiphysin–rvs	  
BBB	  blood-­‐brain	  barrier	  	  
BSA	  bovine	  serum	  albumin	  	  
CaPPS	  calcium	  pentosan	  polysulfate	  	  
CD	  cluster	  of	  differentiation	  
Cdc42	  Cell	  division	  control	  protein	  42	  
CDE	  clathrin-­‐dependent	  endocytosis	  
CIE	  clathrin-­‐independent	  endocytosis	  
CHO	  Chinese	  hamster	  ovary	  	  
CLASPs	  clatrin-­‐associated	  sorting	  proteins	  
COMP	  cartilage	  oligomeric	  protein	  	  
CR	  complement-­‐type	  repeats	  
CS	  chondroitin	  sulfate	  	  
CTB	  cholera	  toxin	  B	  
CTGF	  connective	  tissue	  growth	  factor	  	  
DMEM	  Dulbecco’s	  modified	  Eagle’s	  medium	  	  
DMF	  N,	  N-­‐dimethylformamide	  	  
DMSO	  dimethyl	  sulfoxide	  DS	  dermatan	  sulfate	  	  
ECM	  extracellular	  matrix	  	  
EDTA	  ethylenediaminetetraacetic	  acid	  	  
EGF	  epidermal	  growth	  factor	  	  
ER	  endoplasmic	  reticulum	  	  
ERC	  endosomal	  recycling	  compartment	  	  
ERK	  extracellular	  signal-­‐regulated	  kinases	  
FCS	  fetal	  calf	  serum	  	  
FGF	  fibroblast	  growth	  factor	  
GAG	  glycosaminoglycan	  	  
GAPDH	  glyceraldehyde	  3-­‐phosphate	  dehydrogenase	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GLUT	  glucose	  transporter	  
GPI	  glycosylphosphatidylinositol	  
GTP	  guanosine-­‐5'-­‐triphosphate	  
HA	  hylauronic	  acid	  	  
HEPES	  4-­‐(2-­‐hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	  acid	  
HIV	  human	  immunodeficiency	  virus	  	  
HMGB1	  high	  mobility	  group	  box-­‐1	  protein	  	  
HRP	  horseradish	  peroxidase	  
HS	  heparan	  sulfate	  
HSC	  heat	  shock	  cognate	  
HSPG	  heparan	  sulfate	  proteoglycan	  	  
HUCF	  human	  uterine	  cervical	  fibroblasts	  
IFN-­‐γ	  interferon-­‐gamma	  	  
IGD	  interglobular	  domain	  	  




iNOS	  inducible	  nitric	  oxide	  synthase	  
KS	  keratan	  sulfate	  	  
kDa	  kilo	  Daltons	  	  
LDL	  low-­‐density	  lipoprotein	  	  
LDL-­‐R	  low-­‐density	  lipoprotein	  receptor	  	  
LMP-­‐1	  latent	  membrane	  protein	  1	  
L-­‐NMA	  L-­‐N-­‐methyl-­‐arginine	  
LPS	  lipopolysaccharides	  
LpL	  lipoprotein	  lipase	  	  
LPS	  lipopolysaccharides	  
LRAD3	  LDL	  receptor	  class	  A	  domain	  containing	  3	  
LRP	  low-­‐density	  lipoprotein	  receptor-­‐related	  protein	  	  
LRR	  leucine-­‐rich	  repeat	  	  
MCF-­‐7	  Michigan	  Cancer	  Foundation	  -­‐	  7	  
mDab1	  mammalian	  Disabled	  	  
MAPK	  mitogen-­‐activated	  protein	  kinase	  
MEGF	  multiple	  EGF-­‐like	  domain	  
Mek1	  mitogen-­‐activated	  protein	  kinase	  kinase	  1	  
MHC	  major	  histocompatibility	  complex	  
miR	  micro-­‐RNA	  
MMP	  matrix	  metalloproteinase	  	  
MT-­‐MMP	  membrane-­‐type	  MMP	  	  
MTT	  3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐diphenyl	  tetrazolium	  bromide	  	  
NaOH	  sodium	  hydroxate	  
NO	  nitric	  oxide	  
N-­‐TIMP	  N-­‐terminal	  domain	  of	  tissue	  inhibitor	  of	  metalloproteinase	  	  
OA	  osteoarthritis	  	  
OSM	  oncostatin	  M	  
PAI-­‐1	  plasminogen	  activator	  inhibitor	  type-­‐1	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PAGE	  polyacrylamide	  gel	  electrophoresis	  	  
PAMPs	  pathogen	  associated	  molecular	  patterns	  
PBS	  phosphate-­‐buffered	  saline	  	  
PDGF	  platelet-­‐derived	  growth	  factor	  
PDGFR	  PDGF-­‐receptor	  
PFA	  paraformaldehyde	  
PI(4,5)P2	  phosphatidylinositol	  4,5-­‐bisphosphate	  
PLAC	  protease	  and	  lacunin	  	   	  
PN-­‐1	  protease	  nexin-­‐1	  	  
PTEN	  phosphatase	  and	  tensin	  homolog	  
PTH	  parathyroid	  hormone	  
PVDF	  polyvinylidene	  difluoride	  	  
RA	  rheumatoid	  arthrytis	   	  
Rac1	  Ras-­‐related	  C3	  botulinum	  toxin	  substrate	  1	  
RAGE	  receptor	  for	  advanced	  glycan	  endproducts	  
RAP	  receptor-­‐associated	  protein	  	  
RPMI	  Roswell	  Park	  Memorial	  Institute	  
RT	  room	  temperature	  	  
sAPP	  soluble	  amyloid	  precursor	  protein	  	  
SDS	  sodium	  dodecyl	  sulfate	  	  
Sepp1	  selenoprotein	  P,	  plasma,	  1	  
SH3	  Src	  homology	  3	  
siRNA	  short	  interfering	  RNA	  	  
SLRPs	  small	  leucine-­‐rich	  proteoglycans	  	   	  
SNAP	  soluble	  N-­‐ethylmaleimide	  sensitive	  fusion	  protein	  (NSF)	  attachment	  protein	  
SNARE	  soluble	  N-­‐ethylmaleimide	  sensitive	   fusion	  protein	   (NSF)	  attachment	  protein	  
receptor	  
SNP	  sodium	  nitroprusside	  	  
SorLA	  sorting	  protein-­‐related	  receptor	  containing	  LDLR	  class	  A	  repeats	  
Sp-­‐1	  specificity	  Protein	  1	  
SV40	  simian	  virus	  40	  
t1/2	  half-­‐life	  	  
TACE	  TNF-­‐α	  converting	  enzyme	  
TBS	  Tris-­‐buffered	  saline	  	  
TCA	  trichloroacetic	  acid	  	  
TEMED	  N,	  N,	  N’,	  N’-­‐Tetramethylethylenediamine	  	  
TFPI	  tissue	  factor	  pathway	  inhibitor	  
TGF	  transforming	  growth	  factor	  	  
TGFα	  transforming	  growth	  factor	  alpha	  
TGN	  trans-­‐Golgi	  network	  
TIMPs	  inhibitor	  of	  metalloproteinases	  	  
TLR	  toll-­‐like	  receptor	  
TM	  transmembrane	  domain	  	  
TNF-­‐α	  tumour	  necrosis	  factor-­‐alpha	  	  
TNFR	  TNF-­‐receptor	  
tPA	  tissue-­‐type	  plasminogen	  activator	  
TRAIL	  TNF-­‐related	  apoptosis-­‐inducing	  ligand	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TS	  thrombospondin	  	  
TSP	  thrombospondin	  
TTP	  thrombocytic	  thrombocytopenic	  purpura	  	  
uPA	  urinary-­‐type	  plasminogen	  activator	  	  
uPAR	  urinary-­‐type	  plasminogen	  activator	  receptor	  	  
VWF	  von	  Willebrand	  factor	  	  
VEGF	  vascular	  endothelial	  growth	  factor	  
VLDL	  very	  low-­‐density	  lipoprotein	  
VLDLR	  very	  low-­‐density	  lipoprotein	  receptor	  
VSMC	  vascular	  smooth	  muscle	  cell	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Extracellular	  matrix	   (ECM)	  turnover	   is	  an	   important	  feature	  of	  several	  physiological	  
processes	   such	   as	   development,	   organogenesis,	   wound	   healing	   and	   tissue	  
remodeling.	   Timely	   degradation	   of	   the	   ECM	   is	   finely	   balanced	   under	   normal	  
conditions	  (Brew	  and	  Nagase,	  2010).	  Various	  types	  of	  proteinases	  are	  implicated	  in	  
ECM	  turnover,	  but	  the	  major	  enzymes	  responsible	  for	  this	  process	  are	  considered	  to	  
be	   the	  matrix	  metalloproteinases	   (MMPs),	  which	   include	  collagenases,	   gelatinases,	  
stromelysins,	  matrilysins	  and	  membrane-­‐type	  MMPs	  (Nagase	  and	  Woessner,	  1999).	  
The	  related	  metalloproteinases	  with	  a	  disintegrin	  domain	  (ADAMs)	  and	  ADAMs	  with	  
thrombospondin	   motifs	   (ADAMTSs)	   are	   also	   involved	   in	   shedding	   of	   cell	   surface	  
molecules	  and	  turnover	  of	  various	  ECM	  components	  respectively	  (Apte,	  2009;	  Seals	  
and	   Courtneidge,	   2003).	   Under	   physiological	   conditions	   the	   activity	   of	   these	  
metalloproteinases	   is	   precisely	   regulated	   at	   the	   levels	   of	   transcription,	   translation	  
and	   post-­‐translation,	   including	   zymogen	   activation,	   inhibition	   by	   endogenous	  
inhibitors	  and	  clearance	  by	  receptor-­‐mediated	  endocytosis	  (Murphy,	  2009;	  Murphy	  
and	   Nagase,	   2008a;	   Nagase,	   1997).	   Disruption	   of	   these	   balances	   may	   result	   in	  
pathological	  conditions	  associated	  with	  enhanced	  ECM	  degradation	  such	  as	  arthritis,	  
cancer	  and	  cardiovascular	  disorders	  (Egeblad	  and	  Werb,	  2002;	  Murphy	  and	  Nagase,	  
2008b;	  Nagase	  et	  al.,	  2006;	  Newby	  et	  al.,	  2006).	  
	   Tissue	   inhibitors	   of	   metalloproteinases	   (TIMPs)	   inhibit	   MMPs,	   ADAMs	   and	  
ADAMTSs	  (Brew	  and	  Nagase,	  2010).	  Four	  TIMPs	  are	  known	  in	  mammals,	  and	  among	  
them	  TIMP-­‐3	  plays	  a	  key	   role	   in	   the	   regulation	  of	  ECM	  turnover	  as	   it	   can	  uniquely	  
inhibit	   MMPs	   and	   some	   ADAMs	   and	   ADAMTSs.	   Reduced	   levels	   of	   TIMP-­‐3	   are	  
associated	   with	   different	   pathological	   conditions,	   including	   cancer	   and	  
atherosclerosis	  (Cardellini	  et	  al.,	  2009;	  Cruz-­‐Munoz	  et	  al.,	  2006a;	  Cruz-­‐Munoz	  et	  al.,	  
2006b).	   Conversely,	   overexpression	   of	   TIMP-­‐3	   inhibits	   tumor	   growth	   and	   invasion,	  
and	  reduces	  the	  development	  of	  sclerotic	  plaques	  (Ahonen	  et	  al.,	  1998;	  Baker	  et	  al.,	  
1999;	  Casagrande	  et	  al.,	  2012).	  It	  also	  blocks	  cartilage	  breakdown	  when	  it	  is	  added	  to	  
porcine	  explants	  in	  culture	  (Gendron	  et	  al.,	  2003).	  This	  suggests	  a	  protective	  role	  of	  
TIMP-­‐3	  in	  progression	  of	  a	  number	  of	  diseases.	  	  
	   In	   2008,	   Troeberg	   et	   al.	   reported	   that	   TIMP-­‐3	   levels	   in	   the	   tissue	   are	  
regulated	  post-­‐translationally	  by	  endocytosis.	  	  This	  study	  aims	  to	  define	  in	  detail	  the	  
endocytic	   pathways	   of	   TIMP-­‐3,	   including	   identification	   of	   the	   major	   receptors	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involved	  in	  the	  process,	  molecules	  that	  modulate	  the	  endocytosis	  and	  whether	  the	  
inhibitor	  can	  scavenge	  proteinases	  from	  the	  ECM.	  
1.1 Endocytosis	  
Endocytosis	   is	   the	   process	   by	  which	   cells	   internalize	   a	   wide	   range	   of	   extracellular	  
materials,	   such	   as	   liquids,	   small	   molecules	   (e.	   g.	   vitamins),	   macromolecules	   (e.	   g.	  
proteins	   and	   glycoproteins),	   lipids,	   cell	   debris	   and	  microorganisms.	   In	   this	   process	  
the	  cell	  membrane	  first	   invaginates	  to	  surround	  the	  particle	  due	  to	  be	  internalized,	  
and	   then	   pinches	   off,	   forming	   a	   vesicle	   that	   contains	   the	   particle.	   This	   removal	   of	  
membrane	  from	  the	  cell	  surface	  is	  balanced	  by	  recycling	  pathways	  that	  return	  much	  
of	  the	  endocytosed	  proteins	  and	  lipids	  back	  to	  the	  plasma	  membrane.	  The	  balance	  
between	   endocytic	   uptake	   and	   recycling	   controls	   the	   composition	   of	   the	   plasma	  
membrane	  and	  contributes	  to	  diverse	  cellular	  processes,	   including	  nutrient	  uptake,	  
cell	  adhesion,	  junction	  formation,	  cell	  migration,	  cytokinesis,	  cell	  polarity	  and	  signal	  
transduction	  (Grant	  and	  Donaldson,	  2009).	  	  
	   Ligands	  can	  be	  internalized	  by	  cells	  through	  a	  number	  of	  different	  endocytic	  
pathways.	   Some	   of	   them	   are	   well	   characterized,	   while	   others	   are	   still	   poorly	  
understood.	   Generally,	   endocytic	   pathways	   can	   be	   divided	   into	   two	   major	  
categories:	  clathrin-­‐dependent	  and	  clathrin-­‐independent	  (Conner	  and	  Schmid,	  2003;	  
Doherty	  and	  McMahon,	  2009;	  Sandvig	  et	  al.,	  2011;	  Sandvig	  et	  al.,	  2008).	  Receptor-­‐
mediated	   endocytosis	   is	   usually	   mediated	   by	   clathrin-­‐dependent	   pathways.	  
Transferrin	   and	   the	   receptors	   for	   low-­‐density	   lipoproteins	   (LDLRs)	   are	   two	   classic	  
examples	   of	   cargo	   proteins	   that	   undergo	   clathrin-­‐dependent	   endocytosis	   (CDE)	  
(Doherty	   and	   McMahon,	   2009).	   The	   cytoplasmic	   tail	   of	   these	   transmembrane	  
proteins	   contains	   sequences	   that	  are	   recognized	  by	  adaptor	  proteins	   that	  mediate	  
the	  polymerization	  of	  a	  clathrin	  coat	  around	  the	  forming	  vesicle.	   In	  contrast,	  other	  
ligands	   can	   enter	   the	   cells	   by	   clathrin-­‐independent	   endocytosis	   (CIE),	   and	   being	  
packaged	  in	  vesicles	  that	  are	  not	  clathrin	  coated.	  Regardless	  of	  the	  way	  of	  entry	  into	  
the	  cell,	   internalized	  cargo	   is	  delivered	  to	  the	  early	  endosome,	  where	  sorting	  takes	  
place.	  Some	  molecules	  are	  sorted	  to	  late	  endosomes	  and	  lysosomes	  for	  degradation,	  
while	  others	  are	   recycled	   to	   the	   cell	  membrane	   (Grant	  and	  Donaldson,	  2009).	   The	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recycling	   route	   can	  be	  direct,	  where	   cargo	   is	   sorted	  directly	   to	   the	   cell	  membrane	  
from	  the	  early	  endosome,	  or	   indirect,	  where	  cargo	   is	   firstly	  delivered	   to	   the	   trans-­‐
Golgi	  network	  before	  recycling	  to	  the	  membrane.	  	  
1.1.1 Clathrin-­‐dependent	  endocytosis	  (CDE)	  
Many	  different	  cargoes	  can	  be	  endocytosed	  by	  CDE.	  In	  all	  cases	  budding	  of	  endocytic	  
vesicles	   involves	   the	   construction	   of	   a	   clathrin	   lattice	   coat	   around	   them	   (Pearse,	  
1976).	   CDE	   has	   several	   different	   functions:	   it	   uptakes	   nutrients	   such	   as	   the	   iron	  
carrier	   transferrin	   (Hopkins	   et	   al.,	   1985)	   and	   LDL	   particles	   (Maurer	   and	   Cooper,	  
2006),	   it	   regulates	   receptor	   availability	   on	   the	   cell	   surface	   and	   cellular	  
responsiveness	   to	  external	   stimuli	   (Di	   Fiore	  and	  De	  Camilli,	   2001).	   The	   recycling	  of	  
vesicles	  from	  the	  plasma	  membrane	  also	  plays	  a	  key	  role	  in	  synaptic	  transmission	  by	  
recycling	   membranes	   at	   the	   outer	   margin	   of	   the	   active	   zone.	   When	   neurons	   are	  
stimulated	   to	   secrete	   neurotransmitters,	   vesicles	   containing	   neurotransmitters	  
continuously	  fuse	  with	  the	  pre-­‐synaptic	  plasma	  membrane.	  To	  prevent	  expansion	  of	  
the	  plasma	  membrane,	  synaptic	  vesicles	  can	  be	  retrieved	  by	  CDE	  (Galli	  and	  Haucke,	  
2001).	  	  Many	  toxins	  and	  viruses	  are	  also	  reported	  to	  enter	  the	  cell	  via	  CDE	  (Harrison	  
and	  McKnight,	  2011;	  Nauwynck	  et	  al.,	  1999;	  Pho	  et	  al.,	  2000;	  Torgersen	  et	  al.,	  2001).	  
1.1.1.1 Clathrin	  coated	  vescicle	  cycle	  
This	   process	   includes	   nucleation,	   cargo	   selection,	   clathrin	   coat	   assembly,	   vesicle	  
scission	  and	  depolymerization	  of	  clathrin-­‐coated	  vesicles.	  
Nucleation.	   The	   first	   step	   in	   clathrin-­‐coated	   endocytosis	   is	   the	   formation	   of	   an	  
invagination	   of	   the	   membrane,	   called	   a	   pit,	   and	   the	   recruitment	   of	   the	   highly	  
conserved	   adaptor	   protein	   2	   (AP2)	   to	   the	   plasma	   membrane.	   AP2	   binds	   to	   the	  
plasma	   membrane	   specific	   lipid	   phosphatidylinositol-­‐4,5,-­‐bisphosphate	   [PI(4,5)P2]	  
(Honing	  et	  al.,	  2005)	  and	  endocytic	  motifs	  in	  cytoplasmic	  tails	  of	  receptors	  (Ohno	  et	  
al.,	  1996;	  Ohno	  et	  al.,	  1995).	  Recent	  studies	  reported	  that	  recruitment	  of	  AP2	  to	  the	  
correct	  site	  at	   the	  plasma	  membrane,	  where	  the	  vesicle	  will	  bud,	   is	  mediated	  by	  a	  
nucleation	   module,	   which	   includes	   the	   membrane-­‐sculpting	   F-­‐BAR	   domain-­‐
containing	   Fer/Cip4	   homology	   domain-­‐only	   proteins	   1	   and	   2	   (FCHo1/2),	   the	  
epidermal	  growth	   factor	   receptor	  pathway	  substrate	  15	   (EPS15)	  homology	  domain	  
proteins	  and	  intersectins	  (Henne	  et	  al.,	  2010).	  Depletion	  of	  any	  of	  these	  proteins	  has	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been	   shown	   to	   inhibit	   clathrin	   coat	   recruitment,	   corroborating	   the	   crucial	   role	  
played	  by	  these	  proteins	  in	  CDE	  (Henne	  et	  al.,	  2010).	  
Cargo	   selection.	   A	   wide	   range	   of	   accessory	   proteins	   [clathrin-­‐associated	   sorting	  
proteins	  (CLASPs)]	  drive	  the	  efficient	  sorting	  of	  specific	  cargoes	  into	  a	  clathrin-­‐coated	  
pit	  (Edeling	  et	  al.,	  2006).	  Like	  AP2,	  CLASPs	  recognize	  the	  cytoplasmic	  tail	  of	  specific	  
receptors	   (Jung	   et	   al.,	   2007).	   For	   instance,	   NPXY-­‐motifs,	   which	   are	   present	   in	   the	  
cytoplasmic	  tails	  of	  all	  LDL	  receptor	  superfamily	  members,	  are	  recognized	  by	  adaptor	  
proteins	  including	  Numb,	  ARH	  and	  Dab2	  (Traub,	  2003).	  These	  cargo-­‐specific	  adaptor	  
proteins	   bind	   AP2,	   which	   serves	   as	   a	   “hub”	   to	   connect	   PI(4,5)P2,	   cargo	   proteins,	  
accessory	  proteins	  and	  clathrin.	  The	  efficient	  coat	  formation	  and	  release	  depend	  on	  
the	  coordinated	  activity	  of	  PI	  kinases	  and	  phosphatases	  (Honing	  et	  al.,	  2005).	  
Clathrin	  coat	  assembly	  and	  vesicle	  scission.	  Purified	  clathrin	  has	  the	  form	  of	  a	  three-­‐
legged	   triskelion,	   where	   every	   leg	   contains	   one	   clathrin	   heavy	   (180	   kDa)	   and	   one	  
clathrin	   light	   chain	   (35-­‐40	   kDa).	   The	   clathrin	   heavy	   chain	   consists	   of	   multiple	  
subdomains,	  starting	  with	  the	  N-­‐terminal	  domain,	  followed	  by	  the	  ankle,	  distal	   leg,	  
knee,	  proximal	  leg,	  and	  trimerization	  domains.	  After	  cargo	  selection	  and	  nucleation	  
complex	   assembly,	   triskelia	   of	   clathrin	   are	   recruited	   to	   the	   budding	   vesicle	   and	  
polymerize	  to	  form	  a	  lattice	  around	  the	  vesicle	  (Pearse,	  1976).	  This	  lattice	  mediates	  
membrane	  bending	  after	  the	  coated	  pit	  invaginates	  (Saffarian	  et	  al.,	  2009).	  
	   The	  GTPase	   dynamin	   is	   necessary	   for	   coated-­‐vesicle	   formation,	   as	   blocking	  
dynamin	  activity	  or	  depletion	  of	  the	  enzyme	  blocks	  membrane	  scission	  (Hinshaw	  and	  
Schmid,	  1995;	  Sweitzer	  and	  Hinshaw,	  1998).	  Dynamin	  is	  recruited	  at	  the	  vesicle	  neck	  
by	   BAR	   (Bin–Amphiphysin–Rvs)	   domain-­‐containing	   proteins	   that	   recognize	   the	  
curvature	  at	  the	  vesicle	  neck	  (Ferguson	  et	  al.,	  2009).	  The	  precise	  mechanism	  of	  how	  
dynamin	  mediates	   vesicle	   pinching	   off	   from	   the	   plasma	  membrane	   is	   not	   clear.	   It	  
seems	  to	  polymerize	  at	  the	  neck	  of	  the	  pit	  and	  induce	  membrane	  scission	  upon	  GTP	  
hydrolysis	  (Stowell	  et	  al.,	  1999).	  
Depolymerization	   of	   clathrin-­‐coated	   vesicles.	   After	   budding	   from	   the	   plasma	  
membrane,	  vesicles	  need	  to	  be	  addressed	  to	  and	  fuse	  with	  the	  target	  endosome.	  For	  
this	   reason	   the	   clathrin-­‐coat	   needs	   to	   be	   disassembled	   from	   the	   vesicle.	  
Depolymerization	  of	  clathrin	  is	  driven	  by	  the	  ATPase	  heat	  shock	  cognate	  70	  (HSC70)	  
and	  by	  its	  cofactor	  auxilin	  (Schlossman	  et	  al.,	  1984;	  Schmid	  et	  al.,	  1984;	  Ungewickell	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et	  al.,	  1995).	  After	  vesicle	  budding,	  auxilin	  binds	  to	  the	  terminal	  domains	  of	  clathrin	  
triskelia,	  and	  it	  recruits	  HSC70	  which	  binds	  to	  clathrin	  light	  chains	  and	  starts	  clathrin	  
coat	  depolymerization	  by	  cycles	  of	  ATP	  hydrolysis	  (Rothnie	  et	  al.,	  2011).	  	  
	  
	  
Figure	  1.	  The	  clathrin	  coated	  vesicle	  cycle.	  
Schematic	   diagram	   demonstrating	   the	   stages	   and	   the	   proteins	   involved	   in	   the	  
budding	  and	  scission	  of	  clathrin	  coated	  pits.	  
	  
1.1.2 Receptor-­‐mediated	  endocytosis	  and	  endocytic	  recycling	  
The	  endocytosis	  of	  ligands	  in	  a	  receptor-­‐mediated	  manner	  requires	  the	  formation	  of	  
clathrin-­‐coated	  pits.	  The	  low-­‐density	  lipoproteins	  (LDL)	  are	  endocytosed	  through	  LDL	  
receptors	  through	  a	  classical	  example	  of	  receptor-­‐mediated	  and	  clathrin-­‐dependent	  
endocytosis	  (Doherty	  and	  McMahon,	  2009).	  The	  endocytic	  receptors	  contain	  specific	  
sequences	   in	   their	   cytoplasmic	   domains	   that	   are	   recognized	   by	   adaptor	   proteins	  
(Traub,	  2009).	  Thus,	  after	  ligand-­‐binding	  and	  subsequent	  activation,	  these	  receptors	  
can	   trigger	   clathrin-­‐coat	   assembly	   and	   vesicle	   formation.	   After	   endocytosis,	  
membrane	  lipids	  and	  proteins	  have	  to	  return	  to	  the	  plasma	  membrane	  or	  move	  to	  
intracellular	  compartments,	  such	  as	  late	  endosomes	  or	  the	  Golgi,	  to	  maintain	  cellular	  
homeostasis	  (Maxfield	  and	  McGraw,	  2004).	  This	  process	   is	  referred	  to	  as	  endocytic	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recycling.	  Conversely,	  many	  of	   the	   ligands	  have	   to	  be	  sorted	   to	   late	  endosomes	  or	  
lysosomes	  for	  degradation.	  	  
	   After	  budding,	   the	  newly	  generated	  vesicle	   fuses	  with	  a	  pre-­‐existing	  sorting	  
endosome	   (Traub,	  2009).	   This	  process	   is	  mediated	  by	  proteins	   such	  as	   the	  GTPase	  
Rab5,	   and	   by	   proteins	   that	   mediate	   vesicle	   fusion,	   including	   the	   early	   endosome	  
antigen	  1	   (EEA1)	  and	  the	  "SNAP	  [Soluble	  N-­‐ethylmaleimide	  sensitive	   fusion	  protein	  
(NSF)	  Attachment	  Protein]	  REceptor"	   (SNARE)	  proteins	   (Cho	  et	  al.,	  2005;	  Dumas	  et	  
al.,	  2001).	  The	  sorting	  endosome	  is	  an	  organelle	  formed	  by	  vesicles	  and	  tubules	  that	  
usually	  localizes	  at	  the	  periphery	  of	  the	  cytoplasm.	  The	  pH	  of	  its	  lumen	  is	  about	  6.0,	  
and	  it	  becomes	  increasingly	  acidic	  during	  a	  process	  called	  endosome	  maturation	  due	  
to	   the	  action	  of	  a	   vacuolar	  ATPase	   that	  pumps	  protons	   from	   the	  cytoplasm	   to	   the	  
lumen	   (Huotari	   and	   Helenius,	   2011;	   Lafourcade	   et	   al.,	   2008).	   The	   endosome	  
maturation	   terminates	   with	   the	   generation	   of	   late	   endosomes	   from	   sorting	  
endosomes.	   Late	   endosomes	   have	   a	   more	   acidic	   pH	   in	   the	   lumen	   and	   are	   not	  
capable	   to	   accept	   plasma	   vesicles.	   The	   acidification	   of	   the	   lumen	   during	   the	  
maturation	  from	  sorting	  to	  late	  endosome	  causes	  the	  release	  of	  many	  ligands	  from	  
their	   receptors.	   After	   dissociation	   of	   ligands	   from	   their	   specific	   transmembrane	  
receptors,	   vesicles	   containing	   ligands	   are	   sorted	   to	   lysosomes,	   where	   ligands	   are	  
degraded.	   On	   the	   other	   hand,	   receptors	   usually	   undergo	   recycling	   (Maxfield	   and	  
McGraw,	  2004).	  
	   There	  are	  two	  different	  routes	  of	  receptor	  recycling,	  the	  rapid	  route	  and	  the	  
slow	   route	   (Grant	   and	   Donaldson,	   2009).	   In	   the	   rapid	   route,	   some	   receptors	   are	  
recycled	  back	  to	  the	  plasma	  membrane	  directly	  from	  early	  endosomes.	  Alternatively,	  
other	   receptors	   are	   first	   delivered	   to	   a	   tubular	   organelle,	   called	   the	   endosomal	  
recycling	  compartment	  (ERC).	  The	  ERC	  sorts	  molecules	  to	  different	  destinations,	  but	  
mostly	  to	  the	  plasma	  membrane,	  which	  is	  the	  case	  for	  LDLRs.	  	  
1.1.3 Caveolae/lipid	  raft-­‐dependent	  endocytosis	  
Clathrin-­‐dependent	   endocytosis	   represents	   the	   main	   mechanism	   for	   the	  
internalization	  of	  extracellular	  ligands	  and	  plasma	  membrane	  components,	  however	  
other	   clathrin-­‐independent	   uptake	  mechanisms	   also	   exist.	   One	   of	   these	   pathways	  
involves	  the	  formation	  of	  typical	  plasma	  membrane	  invaginations	  called	  “caveolae”	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(Montesano	   et	   al.,	   1982).	   Caveolae	   are	   smaller	   in	   diameter	   than	   clathrin-­‐coated	  
vesicles	  (50-­‐80	  nm	  against	  100	  nm)	  and	  they	  appear	  flask-­‐shaped	  (Stan	  et	  al.,	  1997).	  
Almost	   all	   molecules	   that	   are	   known	   to	   be	   internalized	   in	   a	   clathrin-­‐independent	  
manner	   localize	   to	   defined	   microcompartments	   of	   the	   plasma	   membrane	   called	  
“lipid	   rafts”.	   Lipid	   rafts	   are	   enriched	   in	   cholesterol,	   glycosphingolipids,	  
sphingomyelin,	   and	   several	   lipid-­‐anchored	   proteins,	   such	   as	   GPI-­‐linked	   proteins	  
(Brown,	  1998;	  Simons	  and	  Ikonen,	  1997;	  Simons	  and	  Toomre,	  2000;	  Simons	  and	  van	  
Meer,	  1988).	  Another	  factor	  to	  discriminate	  lipid	  rafts	  is	  their	  resistance	  to	  detergent	  
solubilization	  (Heerklotz,	  2002;	  Heerklotz	  et	  al.,	  2003).	  	  
	   The	   coat	   of	   caveolae	   is	   mainly	   composed	   of	   a	   protein	   called	   caveolin-­‐1	  
(Rothberg	   et	   al.,	   1992).	   Caveolin-­‐1	   and	   the	   other	   two	   members	   of	   the	   family	  
(caveolin-­‐2	   and	   -­‐3),	   harbor	   a	   hairpin-­‐like	   topology	   presenting	   both	   the	   C-­‐terminus	  
and	  N-­‐terminus	  in	  the	  cytosolic	  side	  of	  the	  membrane	  (Cohen	  et	  al.,	  2004).	  	  
	   One	  of	  the	  best	  studied	  endocytic	  pathways	  mediated	  by	  caveolae	  is	  that	  of	  
simian	  virus	  40	  (SV40)	  for	  its	  entry	  into	  the	  cell	  (Pelkmans	  et	  al.,	  2001).	  This	  pathway	  
includes:	  i)	  sequestration	  and	  internalization;	  and	  ii)	  transport	  to	  caveosome.	  
Sequestration	   and	   internalization.	   After	   binding	   to	   MHC	   class	   I	   molecules,	   SV40	  
particles	   diffuse	   laterally	   until	   they	   are	   trapped	   in	   caveolae.	   	  When	   SV40	   particles	  
arrive	   in	   caveolae,	   an	   “endocytosis	   signal”	   is	   triggered	   by	   tyrosine	   kinase	  
phosphorylation	   in	   proteins	   associated	  with	   caveolae	   (Pelkmans	   et	   al.,	   2002).	  One	  
effect	  of	  this	  signal	  cascade	  is	  the	  disassembly	  of	  actin	  fibers	  in	  the	  proximity	  of	  the	  
caveola-­‐budding	  site	  on	  the	  plasma	  membrane,	  and	  their	  polymerization	  around	  the	  
caveola	  with	  formation	  of	  a	  structure	  called	  the	  “actin	  tail”	  (Pelkmans	  et	  al.,	  2002).	  
At	  this	  point	  dynamin	  is	  recruited	  to	  mediate	  pinching	  off	  of	  the	  caveola	  (Pelkmans	  
et	  al.,	  2002).	  
Transport	  to	  caveosome.	  After	  efficient	  caveolae	  budding	  from	  the	  membrane,	  the	  
actin	   tail	   is	   rapidly	   depolymerized	   and	   caveolae	   are	   targeted	   to	   more	   complex	  
tubular	  organelles	  called	  “caveosomes”,	  where	  SV40	  particles	  accumulate	  (Pelkmans	  
et	   al.,	   2002).	   Interestingly,	   caveosomes	  are	  directly	   transported	   to	   the	   smooth	  ER,	  
bypassing	  all	  the	  other	  organelles	  involved	  in	  clathrin-­‐dependent	  vesicle	  endocytosis	  
(Kartenbeck	  et	  al.,	  1989).	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1.1.4 Clathrin	  Independent	  Carriers-­‐	  Dynamin	  dependent	  (CLIC-­‐D)	  
Some	   lipid	   raft-­‐dependent	  endocytic	  pathways	  are	  dynamin-­‐dependent	  but	  do	  not	  
require	   caveolins.	   Endocytosis	   of	   the	   IL-­‐2	   receptor	   and	   the	   gamma	   chain	   cytokine	  
receptor	   are	   the	   most	   well	   established	   endocytic	   pathways	   falling	   within	   this	  
category	   (Lamaze	   et	   al.,	   2001;	   Sauvonnet	   et	   al.,	   2005).	   Both	   pathways	   need	   the	  
GTPase	  activity	  of	  Rho	  for	  budding,	  probably	  because	  it	  is	  involved	  in	  remodeling	  of	  
the	   actin	   cytoskeleton	   and	   might	   therefore	   coordinate	   plasma	   membrane	  
invagination.	  
1.1.5 Clathrin	  Independent	  Carriers-­‐	  Dynamin	  Independent	  (CLIC-­‐DI)	  	  
Some	   endocytic	  mechanisms	   require	   neither	   clathrin	   nor	   dynamin.	   Some	   of	   them	  
use	   a	   different	  GTPase	   from	  dynamin,	   such	   as	   Cdc42,	   Rac	   or	   Arf6,	   and	   others	   are	  
dependent	  on	  flotillins,	  a	  group	  of	  raft-­‐associated,	  integral	  membrane	  proteins.	  
Cdc42	  dependent	  uptake.	  SV40	  and	  the	  cholera	  toxin	  B	  (CTB),	  which	  are	  internalized	  
by	  cells	  via	  caveolae,	  have	  been	  reported	  to	  also	  be	  able	  to	  enter	  cells	  in	  a	  dynamin-­‐
independent	  manner	  (Damm	  et	  al.,	  2005;	  Kirkham	  et	  al.,	  2005).	  These	  pathways	  use	  
Cdc42	   as	   a	   GTPase	   and	   are	   reported	   to	   be	   dependent	   on	   lipid	   rafts	   for	   vesicle	  
formation.	  Cdc42-­‐dependent	  endocytosis	   is	  also	   responsible	   for	   the	  uptake	  of	  GPI-­‐
anchored	   proteins,	   also	   called	   GPI-­‐Enriched	   Endocytic	   Compartments	   (GEEC)	  
pathway	  (Sabharanjak	  et	  al.,	  2002).	  
Flotillin-­‐dependent	   endocytosis.	  The	   lipid	   raft-­‐associated	   proteins	   flotillin-­‐1	   and	   -­‐2	  
are	  also	  reported	  to	  play	  a	  role	   in	  caveolin-­‐independent	  endocytosis	  (Glebov	  et	  al.,	  
2006).	  Flotillins	  have	  similar	  topology	  to	  caveolins,	  with	  both	  C-­‐	  and	  N-­‐termini	  in	  the	  
cytosolic	  side	  of	  the	  plasma	  membrane.	  Interestingly,	  endocytic	  pathways	  involving	  
flotillins	   can	   be	   either	   dynamin-­‐dependent	   or	   -­‐independent.	   For	   instance,	  
endocytosis	   of	   heparan	   sulfate	   proteoglycans	   is	   flotillin-­‐	   and	   dynamin-­‐dependent,	  
while	   endocytosis	   of	   GPI-­‐anchored	   proteins	   are	   flotillin-­‐dependent	   but	   does	   not	  
need	   dynamin	   activity	   (Ait-­‐Slimane	   et	   al.,	   2009;	   Payne	   et	   al.,	   2007).	   Flotillin-­‐
dependent	   endocytosis	   is	   slow,	  with	   a	   very	   low	   frequency	   of	  membrane-­‐budding.	  
Nevertheless,	  this	  process	  seems	  to	  be	  regulated	  by	  kinases	  (Riento	  et	  al.,	  2009).	  
Arf-­‐6-­‐associated	  endocytosis.	   ADP-­‐ribosylation	   factor	  6	   (ARF6)	   is	   a	  member	  of	   the	  
ADP	  ribosylation	  factor	  family	  of	  GTP-­‐binding	  proteins.	  ARF6	  has	  a	  variety	  of	  cellular	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functions	  that	  are	  frequently	  involved	  in	  trafficking	  of	  membranes	  and	  endocytosis.	  
Various	   proteins,	   including	   MHC	   class	   I	   proteins,	   β-­‐integrins,	   the	   GPI-­‐anchored	  
protein	   CD59	   and	   the	   glucose	   transporter	   GLUT1	   have	   been	   reported	   to	   be	  
internalized	  in	  ARF6-­‐dependent	  manner	  (Brown	  et	  al.,	  2001;	  Naslavsky	  et	  al.,	  2004;	  
Powelka	  et	  al.,	  2004;	  Radhakrishna	  and	  Donaldson,	  1997).	  	  
Macropinocytosis.	  This	  involves	  membrane	  ruffling	  and	  formation	  of	  relatively	  large	  
vesicles,	  called	  macropinosomes	  (Swanson	  and	  Watts,	  1995).	  This	  mechanism	  is	  used	  
by	   cells	   to	   endocytose	   liquid	   and	   solutes	   from	   the	   extracellular	   space.	  
Macropinocytosis	  seems	  to	  be	  dynamin-­‐independent	  and	  it	  requires	  GTPases	  such	  as	  
Cdc42,	  Rac	  and	  ARF6	  (Kerr	  et	  al.,	  2009).	  	  
1.1.6 Phagocytosis	  
Phagocytosis	   is	   an	   endocytic	   process	   used	   only	   by	   specialized	   cells	   such	   as	  
monocytes,	   neutrophils	   and	   macrophages.	   Classically,	   phagocytosis	   has	   been	  
considered	   to	   be	   the	   means	   through	   which	   macrophages	   remove	   “nonself”	   cells	  
(such	   as	   invading	  microbes),	   “altered	   self”	   cells	   (for	   instance	   apoptotic	   or	   necrotic	  
cells)	   and	   cell	   debris	   (Han	   and	   Ravichandran,	   2011;	   Ishimoto	   et	   al.,	   2008).	  
Phagocytosis	  has	  been	  also	  documented	  as	  a	  means	  of	  acquiring	  nutrients	  from	  the	  
extracellular	  space.	  Phagocytosis	  in	  mammalian	  immune	  cells	  is	  activated	  by	  “eat-­‐me	  
signals”,	  namely	  pathogen	  associated	  molecular	  patterns	  (PAMPS),	  which	  lead	  to	  NF-­‐
κB	  activation	   (Fournier	   and	  Philpott,	   2005).	   PAMPs	  are	  microbial	   structures,	  which	  
upon	   interaction	   with	   elements	   of	   the	   host	   innate	   immune	   system	   trigger	   the	  
initiation	   of	   host	   protective	   responses	   with	   the	   clearance	   of	   the	   pathogen	   by	  
phagocytic	  cells	  (Elward	  and	  Gasque,	  2003;	  Fournier	  and	  Philpott,	  2005).	  Opsonins,	  
which	  are	  molecules	  that	  target	  an	  antigen	  for	  immune	  response,	  such	  as	  antibodies	  
or	  complement	  molecules,	  aid	  phagocytosis	  of	  pathogens	  (Rosenzweig	  and	  Holland,	  
2011).	  Engulfment	  of	  material	   is	   facilitated	  by	   the	  actin-­‐myosin	  contractile	   system.	  
The	   phagosome	   of	   ingested	   material	   is	   then	   fused	   with	   the	   lysosome,	   leading	   to	  
degradation.	  
	   Following	  apoptosis,	  the	  dying	  cells	  need	  to	  be	  taken	  up	  into	  the	  surrounding	  
tissues	   by	  macrophages	   in	   a	   process	   called	   efferocytosis.	   Apoptotic	   cells	   (and	   also	  
necrotic	   cells)	   show	   on	   the	   cell	   surface	   molecules	   that	   usually	   are	   located	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intracellularly,	  including	  calreticulin,	  oxidised	  LDL	  and	  annexin	  V.	  Phospholipids	  (such	  
as	  phosphatidylserine)	  which	  are	  usually	  in	  the	  inner	  layer	  of	  the	  membrane	  can	  be	  
relocated	   in	   the	   outer	   layer	   in	   apoptotic	   cells	   (Elward	   and	   Gasque,	   2003).	   These	  
molecules	  are	  recognised	  by	  specific	  receptors	  on	  the	  cell	  surface	  of	  the	  macrophage	  
and	   trigger	  phagocytosis.	  Defects	   in	  apoptotic	   cell	   clearance	  are	  usually	  associated	  
with	   impaired	   phagocytosis	   of	   macrophages.	   Accumulation	   of	   apoptotic	   cell	  
remnants	  often	  causes	  autoimmune	  disorders,	  thus	  pharmacological	  potentiation	  of	  
phagocytosis	  has	  a	  medical	  potential	   in	  treatment	  of	  certain	   forms	  of	  autoimmune	  
disorders	  (Kruse	  et	  al.,	  2010).	  	  
	   	  
Chapter	  1	   	   Introduction	  
	   28	  
Table	  1:	  Examples	  of	  endocytic	  pathways	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1.2 LDL	  receptor	  superfamily	  
The	   LDL	   receptor	   (LDLR)	   superfamily	   consists	   of	   several	   structurally	   homologous	  
receptors,	  seven	  of	  which	  are	  very	  closely	  related:	  LDL	  receptor	  (LDLR),	  LDL	  receptor-­‐
related	   protein-­‐1	   (LRP-­‐1),	   LRP-­‐1b,	   megalin/LRP-­‐2,	   very-­‐low	   density	   lipoprotein	  
receptor	   (VLDLR),	   LRP-­‐4/multiple	   EGF-­‐like	   domain	   7	   (MEGF7)	   and	  
LRP8/apolipoprotein	   E	   receptor	   2	   (apoER2)	   (Figure	   2).	   Other	   members	   are	   more	  
distantly	   related	   such	   as	   sorting	   protein-­‐related	   receptor	   containing	   LDLR	   class	   A	  
repeats	  (SorLa/LRP11),	  LRP-­‐5	  and	  LRP-­‐6.	  All	  members	  of	  the	  LDLR	  family	  are	  type	  1	  
transmembrane	   receptors	  and	  consist	  of	  an	  extracellular	  N-­‐terminal	   ligand	  binding	  
domain,	   containing	   cysteine-­‐rich	   ligand-­‐binding	   repeats,	   epidermal	   growth	   factor	  
(EGF)-­‐like	  domains	  and	  β-­‐propeller	  domains,	  a	  single	  transmembrane	  domain	  and	  all	  
except	   LRP-­‐5/-­‐6	   contain	   NPXY	   motifs	   in	   their	   cytoplasmic	   tail	   (Marzolo	   and	   Bu,	  
2009).	   The	   NPXY	  motifs	  mediate	   binding	   of	   the	   receptor	   to	   coated	   pits	   and	   have	  
been	   shown	   to	   bind	   cytosolic	   adaptor	   proteins	   such	   as	   mammalian	   Disabled	  
(mDab1)	   and	   FE65.	   The	   tyrosine	   of	   some	   NPXY	   motifs	   in	   LDL	   receptors	   is	  
phosphorylated,	   indicating	   that	   they	  may	  activate	   intracellular	   signaling	   (Barnes	  et	  
al.,	  2003;	  Hiesberger	  et	  al.,	  1999).	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Figure	  2.	  Modular	  domain	  organization	  of	  LDL	  receptor	  family	  members	  	  
Members	   of	   the	   LDL	   receptor	   family	   share	   the	   same	   common	   structural	   motifs.	  
Ligand-­‐binding	  domains	  contain	  between	  2	  and	  12	  complement-­‐like	  repeats.	  These	  
are	   interspersed	  with	  epidermal	   growth	   factor	   (EGF)-­‐homology	  domains	   consisting	  
of	   EGF	   and	   β-­‐propeller	   domains.	   The	   receptors	   have	   a	   single	  membrane-­‐spanning	  
segment,	   followed	   by	   a	   cytoplasmic	   tail	   that	   contains	   at	   least	   one	   NPXY	   motif	  
(except	  for	  LRP-­‐5	  and	  -­‐6	  which	  contain	  no	  NPXY	  domains	  in	  their	  cytoplasmic	  tail).	  	  	  
	  
1.2.1 LDLR	  
The	  most	  characterized	  and	  founder	  member	  of	  the	  LDL	  receptor	  superfamily	  is	  the	  
low-­‐density	   lipoprotein	   receptor	   (LDLR),	   which	   was	   identified	   by	   Brown	   and	  
Goldstein	  in	  1974	  (Brown	  and	  Goldstein,	  1974).	  This	  receptor	  mediates	  the	  uptake	  of	  
LDL	  from	  plasma	  and	  therefore	  regulates	   levels	  of	  cholesterol	   in	  circulation	  (Brown	  
et	  al.,	  1986).	   	  LDLR	  binds	  to	   lipoproteins	  that	  contain	  apolipoprotein	  (Apo)B-­‐100	  or	  
ApoE	  (Brown	  et	  al.,	  1986).	  Because	  of	  its	  role	  in	  modulating	  the	  uptake	  of	  cholesterol	  
from	  the	  plasma	  and	  cholesterol	  content	  in	  the	  plasma	  membranes,	  LDLR	  expression	  
needs	  to	  be	  finely	  regulated.	  Expression	  of	  newly	  synthesized	  LDLRs	  is	  suppressed	  by	  
cholesterol	   with	   a	   negative	   feedback	   mechanism	   that	   therefore	   prevents	   further	  
cellular	   entry	   of	   LDL	   and	   cholesterol	   overloading	   (Nimpf	   and	   Schneider,	   2000).	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Mutations	  within	   the	  LDLR	  gene	  cause	   familial	  hypercholesterolemia	   (Hobbs	  et	  al.,	  
1990).	   In	   this	   condition,	   the	   clearance	   of	   lipoproteins	   from	   the	   bloodstream	   is	  
impaired	   which	   results	   in	   increased	   LDL	   levels	   in	   the	   circulation.	   Ishibashi	   et	   al.	  
(1993)	   generated	   a	   transgenic	   mouse	   in	   which	   the	   LDLR	   gene	   was	   inactivated	   by	  
homologous	  recombination	  (Ishibashi	  et	  al.,	  1993).	  This	  mouse	  line	  has	  been	  widely	  
used	  as	  a	  model	  for	  investigating	  atherosclerosis	  and	  cardiovascular	  diseases	  due	  to	  
increased	  deposition	  of	  cholesterol	  in	  the	  arteries.	  	  
1.2.2 LRP-­‐1	  	  
LRP-­‐1,	  also	  known	  as	  CD91,	  was	  first	  described	  as	  the	  receptor	  for	  α2-­‐macroglobulin	  
(α2M)	   (Hanover	   et	   al.,	   1983).	   In	   1988,	   Herz	   et	   al.	   screened	   a	   mouse	   lymphocyte	  
cDNA	   library	   and	   identified	   a	   cell	   surface	   receptor	  with	   sequence	   similarity	   to	   the	  
LDL-­‐receptor,	   naming	   it	   LDL-­‐receptor	   related	   protein	   (LRP)	   (Herz	   et	   al.,	   1988).	  
Sequencing	  of	  both	  the	  α2M	  receptor	  and	  LRP	  identified	  them	  as	  the	  same	  molecule	  
(Strickland	  et	  al.,	  1990).	  LRP-­‐1	  is	  synthesized	  as	  a	  600	  kDa	  precursor	  which	  is	  cleaved	  
in	   the	   trans-­‐Golgi	   by	   a	   furin-­‐like	   protease	   to	   produce	   a	   non-­‐covalently	   associated	  
receptor	  of	  85	  kDa	  and	  515	  kDa	  subunits	  (Willnow	  et	  al.,	  1996).	  The	  85	  kDa	  subunit	  
contains	  a	  small	  ectodomain,	  single	  transmembrane	  domain	  and	  cytoplasmic	  tail	  and	  
the	   515	   kDa	   extracellular	   subunit	   contains	   four	   ligand-­‐binding	   sites,	   each	   of	   them	  
consisting	  of	  several	  complement-­‐type	  repeats	  (CRs)	  (Herz	  et	  al.,	  1990;	  Willnow	  and	  
Herz,	   1994).	   Each	   CR	   contains	   40	   amino	   acids	   and	   folds	   into	   a	   cage-­‐like	   structure.	  
Negatively	  charged	  residues	  drive	  the	   interaction	  with	  positive	  charged	  residues	  of	  
ligands	   (Andersen	   et	   al.,	   2000).	   In	   several	   LRP-­‐1	   ligands,	   including	   receptor-­‐
associated	  protein	   (RAP)	   (Migliorini	  et	  al.,	  2003),	   lipoprotein	   lipase	   (Williams	  et	  al.,	  
1994),	  α2M	  (Arandjelovic	  et	  al.,	  2005),	  and	  plasminogen	  activator	  inhibitor-­‐1	  (PAI-­‐1)	  
(Stefansson	   et	   al.,	   1998),	   it	   has	   been	   shown	   that	   clusters	   of	   lysines	   and	   arginines	  
interact	  electrostatically	  with	  CR	  domains.	  
	   Deletion	   of	   the	   LRP-­‐1	   gene	   is	   embryonic	   lethal	   as	   LRP-­‐1-­‐null	   mice	   die	   at	  
around	  embryonic	   day	   10	   (Herz	   et	   al.,	   1992).	   LRP-­‐1	   expression	   is	  widespread:	   it	   is	  
found	  abundantly	  in	  the	  placenta,	   liver	  and	  brain	  and	  is	  highly	  expressed	  in	  several	  
cell	   types	   including	   hepatocytes,	   fibroblasts	   and	   macrophages	   (Moestrup	   et	   al.,	  
1992;	  Zheng	  et	  al.,	  1994).	  Aside	  from	  activated	  α2M,	  LRP-­‐1	  binds	  and	  internalizes	  a	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variety	   of	   other	   ligands,	   including	   the	   matrix	   molecules	   decorin	   (Brandan	   et	   al.,	  
2006)	   and	   fibronectin	   (Salicioni	   et	   al.,	   2002).	   Many	   proteases	   or	   molecules	  
associated	  with	   regulating	  protease	  activity	  are	  also	   LRP-­‐1	   ligands	   including	   tissue-­‐
type	   plasminogen	   activator	   (tPA)	   (Bu	   et	   al.,	   1992),	   urokinase-­‐type	   plasminogen	  
activator	   (uPA)	   (Kounnas	  et	  al.,	   1993),	   tPA	  or	  uPA	  bound	   to	  plasminogen	  activator	  
inhibitor	  type	  I	  (PAI-­‐1)	  (Nykjaer	  et	  al.,	  1992a;	  Orth	  et	  al.,	  1994),	  MMP-­‐2	  (Emonard	  et	  
al.,	  2004),	  MMP-­‐9	  (Hahn-­‐Dantona	  et	  al.,	  2001)	  and	  MMP-­‐13	  (Barmina	  et	  al.,	  1999).	  
LRP-­‐1	  is	  also	  the	  endocytic	  receptor	  for	  thrombospondin-­‐1	  and	  -­‐2	  (Chen	  et	  al.,	  1996;	  
Mikhailenko	  et	   al.,	   1995),	  Pseudomonas	   exotoxin	  A	   (Kounnas	  et	   al.,	   1992)	   and	   the	  
transcriptional	   transactivator	   HIV-­‐1-­‐Tat	   (Liu	   et	   al.,	   2000b).	   In	   addition,	   LRP-­‐1	  
internalizes	  ApoE-­‐enriched	  lipoproteins	  and	  lipoprotein	  lipase	  (LpL)	  (Beisiegel	  et	  al.,	  
1989;	  Herz	  et	  al.,	  1988).	  LRP-­‐1	  has	  four	  ligand	  binding	  clusters	  (I-­‐IV),	  of	  which	  ligand-­‐
binding	  clusters	  II	  and	  IV	  are	  recognized	  by	  the	  majority	  of	  LRP-­‐1-­‐ligands.	  
	  
Table	  2:	  List	  of	  a	  selection	  of	  LRP-­‐1	  ligands	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1.2.2.1 Cell	  trafficking	  of	  LRP-­‐1	  and	  role	  of	  RAP	  
Because	   LRP-­‐1	   recognizes	   such	   a	   variety	   of	   ligands,	   mechanisms	   exist	   to	   prevent	  
newly	   translated	   LRP-­‐1	   from	  associating	  with	   ligands	   in	   the	  endoplasmic	   reticulum	  
(ER),	  which	  would	  lead	  to	  aggregation	  and	  degradation	  instead	  of	  proper	  targeting	  to	  
the	  plasma	  membrane.	  The	  LRP-­‐1	   ligand	  midkine,	   for	  example,	   is	  overexpressed	   in	  
colorectal	   carcinomas	   and	   its	   premature	   binding	   to	   LRP-­‐1	   in	   the	   ER	  was	   found	   to	  
interfere	  with	  LRP-­‐1	  maturation	  and	  secretion	  (Sakamoto	  et	  al.,	  2011).	  A	  chaperone,	  
termed	  receptor	  associated	  protein	  (RAP),	  binds	  tightly	  to	  LRP-­‐1	  and	  other	  members	  
of	  the	  LDL	  receptor	  family	  in	  the	  ER,	  enabling	  them	  to	  be	  correctly	  delivered	  to	  the	  
plasma	   membrane	   (Williams	   et	   al.,	   1992).	   RAP	   is	   a	   39	   kDa	   protein	   which	   was	  
identified	  co-­‐purifying	  with	  LRP-­‐1	  (Ashcom	  et	  al.,	  1990).	  RAP	  binds	  to	  LRP-­‐1	   ligand-­‐
binding	  clusters	   II	  and	   IV	  with	  a	  Kd	  of	  3	  nM	  (Iadonato	  et	  al.,	  1993)	  and	   inhibits	   the	  
binding	  and/or	  uptake	  of	  all	  known	  LRP-­‐1	  ligands	  (Bu	  et	  al.,	  1992;	  Herz	  et	  al.,	  1992;	  
Nykjaer	  et	  al.,	  1992a).	  	  
	   RAP-­‐/-­‐	  mice	  showed	  a	  reduced	  abundance	  of	  LRP-­‐1	   in	  different	  tissues,	  such	  
as	   liver	   and	   brain	   (Willnow	   et	   al.,	   1995).	   Conversely,	   overexpression	   of	   RAP	   in	  
colorectal	   carcinomas	  promoted	  LRP1	  maturation	  and	   secretion	   to	   the	  cell	   surface	  
(Sakamoto	   et	   al.,	   2011).	   Site-­‐directed	  mutagenesis	   showed	   that	   binding	   of	   RAP	   to	  
LRP-­‐1	  is	  mediated	  by	  two	  critical	  lysines	  (K256	  and	  K270).	  These	  two	  lysines	  interact	  
with	  a	  pocket	   formed	  by	   two	   juxtaposed	  CRs	  and	  drive	   the	  high	  affinity	  binding	  of	  
RAP	   to	   LRP-­‐1.	   When	   only	   one	   of	   these	   two	   lysines	   is	   mutated	   to	   an	   arginine	   or	  
alanine,	  the	  binding	  affinity	  decreased,	  but	  RAP	  could	  be	  still	  endocytosed	  by	  LRP-­‐1	  
(van	   den	   Biggelaar	   et	   al.,	   2011).	   When	   both	   lysines	   are	   mutated	   to	   alanines	   or	  
arginines,	  binding	  is	  completely	  lost	  and	  endocytosis	  impaired.	  	  
1.2.2.2 Endocytosis	  of	  MMPs	  	  
LRP-­‐1	   mediates	   endocytosis	   of	   different	   proteinases	   from	   the	   extracellular	   milieu	  
and	  thus	  it	  plays	  a	  major	  role	  in	  the	  regulation	  of	  extracellular	  matrix	  turnover.	  LRP-­‐
1-­‐dependent	   endocytosis	   has	   been	   shown	   to	   regulate	   levels	   of	   different	  
metalloproteinases,	  including	  MMP-­‐2,	  -­‐9	  and	  -­‐13	  (Barmina	  et	  al.,	  1999;	  Emonard	  et	  
al.,	   2004;	   Hahn-­‐Dantona	   et	   al.,	   2001;	   Van	   den	   Steen	   et	   al.,	   2006).	   The	   first	  MMP	  
shown	  to	  be	  internalized	  by	  LRP1	  was	  MMP-­‐13	  in	  1999.	  Barmina	  et	  al.	  reported	  that	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the	  endocytosis	  of	  MMP-­‐13	  occurred	  via	  a	  two-­‐step	  mechanism.	  The	  proteinase	  first	  
binds	  to	  a	  Ca2+-­‐sensitive	  receptor	  and	  then	  it	  is	  transferred	  to	  LRP-­‐1,	  which	  mediates	  
its	   internalization	   (Barmina	  et	  al.,	  1999).	  RAP	  did	  not	   inhibit	  binding	  of	  MMP-­‐13	  to	  
cells,	  but	  impaired	  its	  internalization,	  and	  the	  enzyme	  was	  also	  able	  to	  bind	  the	  cell	  
surface	   of	   LRP-­‐1-­‐null	   MEFs,	   supporting	   the	   involvement	   of	   an	   initial	   cell	   receptor	  
other	   than	   LRP-­‐1.	   LRP-­‐1-­‐mediated	   catabolism	   of	   MMP-­‐13	   was	   later	   shown	   to	   be	  
impaired	   in	   human	   osteoarthritic	   chondrocytes	   in	   vitro	   (Walling	   et	   al.,	   2003),	  
indicating	   that	   LRP-­‐1-­‐mediated	   endocytosis	   may	   be	   an	   important	   mechanism	  
regulating	  the	  extracellular	  levels	  of	  MMP-­‐13	  in	  the	  cartilage	  matrix.	  
Subsequently,	  MMP-­‐2	  was	   also	   reported	   to	   be	   internalized	   by	   LRP-­‐1,	   via	   a	  
mechanism	  that	  involves	  the	  formation	  of	  a	  complex	  with	  thrombospondin-­‐2	  (Yang	  
et	   al.,	   2001).	   Later,	   Emonard	   et	   al.	   (2004)	   showed	   that	   MMP-­‐2	   could	   also	   be	  
endocytosed	  by	  cells	  in	  a	  thrombospondin-­‐independent	  manner	  when	  in	  a	  pro-­‐form	  
(proMMP-­‐2).	   Furthermore,	   proMMP-­‐2	   can	   be	   endocytosed	   by	   LRP-­‐1	   alone	   or	   in	   a	  
complex	  with	  TIMP-­‐2.	  Binding	  of	  the	  proMMP-­‐2—TIMP-­‐2	  to	  the	  surface	  of	  HT1080	  
cells	  was	  not	   inhibited	  by	  RAP,	  whereas	  endocytosis	  and	   lysosomal	  degradation	  of	  
pre-­‐bound	   complex	   was	   inhibited	   by	   RAP	   (Emonard	   et	   al.,	   2004).	   The	   authors	  
suggested	   that	   an	   unknown	   RAP-­‐insensitive	   co-­‐receptor	   might	   be	   involved	   in	   the	  
initial	   binding	   of	   proMMP-­‐2—TIMP-­‐2	   to	   the	   cell	   surface.	   This	   initial	   binding	   may	  
function	   to	   concentrate	   ligands	   in	   specialized	   microdomains	   of	   the	   plasma	  
membrane,	   which	   would	   facilitate	   transfer	   to	   LRP-­‐1.	   Blocking	   the	   interaction	   of	  
thrombospondin-­‐1	   with	   proMMP-­‐2	   by	   anti-­‐thrombospondin	   antibodies	   inhibited	  
LRP-­‐1-­‐mediated	  endocytosis	  of	  proMMP-­‐2,	  but	  had	  no	  affect	  on	  the	  endocytosis	  of	  
the	  proMMP-­‐2—TIMP-­‐2	  complex	  (Emonard	  et	  al.,	  2004).	  Conversely,	  complexing	  of	  
proMMP-­‐2	  with	   thrombospondin-­‐1	  accelerated	   the	  enzyme	  clearance	   (Emonard	  et	  
al.,	   2004).	   This	   suggests	   that	   pro-­‐MMP-­‐2	   and	   proMMP-­‐2—TIMP-­‐2	   are	   internalized	  
through	  a	  different	  mechanism	  (Emonard	  et	  al.,	  2004).	  	  
MMP-­‐9	  was	  also	  reported	  to	  be	  an	  LRP-­‐1	  ligand,	  either	  as	  a	  free	  enzyme	  or	  in	  
complex	   with	   TIMP-­‐1	   (Hahn-­‐Dantona	   et	   al.,	   2001).	   Another	   member	   of	   the	   LDL	  
receptor	   family,	   megalin	   has	   also	   been	   shown	   to	   internalize	   MMP-­‐9	   through	   the	  
enzyme's	   hemopexin	   domain	   (Van	   den	   Steen	   et	   al.,	   2006).	   Functions	   of	   LRP-­‐1	   in	  
regulating	  growth	  and	  invasion	  of	  cancer	  cells	  have	  been	  investigated.	  Whether	  the	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abrogation	   of	   LRP-­‐1	   activity	   induces	   increased	   invasiveness	   is	   still	   under	   debate.	  
Neutralizing	   the	   endocytic	   function	   of	   LRP-­‐1	   has	   been	   shown	   to	   lead	   to	   increased	  
invasiveness	  of	  human	  malignant	  cells	  (Sid	  et	  al.,	  2006;	  Webb	  et	  al.,	  2000).	  It	  is	  also	  
reported	   that	   LRP-­‐1	   induces	   the	   expression	   of	   MMP-­‐2	   and	   MMP-­‐9	   and	   thereby	  
promotes	   the	  migration	   and	   invasion	   of	   human	   glioblastoma	   cells.	   Knockdown	   of	  
LRP-­‐1	  expression	  greatly	  decreased	  cell	  migration	  and	   invasion,	  which	  was	  rescued	  
by	   the	   forced	   expression	   of	   a	   functional	   LRP-­‐1	   minireceptor	   (Song	   et	   al.,	   2009).	  
However,	   Dedieu	   et	   al.	   (2008)	   showed	   that	   silencing	   LRP-­‐1	   in	   carcinoma	   cells	  
prevents	   invasion	  despite	  a	  strong	  stimulation	  of	  proteolytic	  activity	   (Dedieu	  et	  al.,	  
2008).	  	  
1.2.2.3 Endocytosis	   of	   proteinase-­‐proteinase	   inhibitor	   complex	   and	   ECM	  
proteins	  	  
In	   1992,	   Nykjaer	   et	   al.	   showed	   that	   uPA	   had	   no	   affinity	   for	   LRP-­‐1	  when	   in	   a	   free	  
form.	  However,	  when	  the	  protease	  was	   in	  complex	  with	   its	  specific	   inhibitor	  PAI-­‐1,	  
the	  affinity	  of	  uPA—PAI-­‐1	  complex	  was	  comparable	  to	  that	  of	  RAP.	  In	  the	  same	  year,	  
Herz	   et	   al.	   showed	   that	   LRP	   mediates	   uptake	   and	   degradation	   of	   uPA—PAI-­‐1	  
complexes.	   Interestingly,	  when	  uPA	   is	   in	  a	  pro-­‐form	   it	  can	  also	  be	   internalized	  and	  
degraded	   by	   cells	   independently	   from	   the	   interaction	   with	   PAI-­‐1.	   In	   addition,	  
another	   uPA-­‐inhibitor,	   protease	   nexin-­‐1	   (PN-­‐1),	   can	  mediate	   the	   LRP-­‐1-­‐dependent	  
endocytosis	  of	  uPA	  (Conese	  et	  al.,	  1994).	  Similarly,	  tPA	  is	  poorly	  endocytosed	  when	  
in	   a	   free	   form,	   but	   upon	   binding	   to	   PAI-­‐1	   the	   complex	   affinity	   for	   LRP-­‐1	   and	  
subsequently	  its	  endocytosis	  is	  enhanced	  (Lee	  et	  al.,	  2010).	  	  
	   A	  number	  of	  ECM	  proteins	  are	  endocytosed	  via	  LRP-­‐1.	  Thrombospondin-­‐1	  is	  a	  
secreted	  glycoprotein	  located	  in	  the	  extracellular	  matrix	  that	  has	  been	  shown	  to	  be	  a	  
potent	  inhibitor	  of	  angiogenesis	  (Lawler,	  2002).	  Thrombospondin-­‐1	  was	  shown	  to	  be	  
internalized	   by	   LRP-­‐1	   (Mikhailenko	   et	   al.,	   1995)	   and	  mediate	   VEGF	   scavenging	   by	  
binding	  the	  growth	  factor	  and	  driving	  its	  uptake	  via	  LRP-­‐1	  (Greenaway	  et	  al.,	  2007).	  
Thrombospondin-­‐2	  is	  also	  a	  LRP-­‐1	  ligand	  and,	  as	  already	  mentioned,	  it	  mediates	  the	  
scavenging	   of	   MMP-­‐2	   (Yang	   et	   al.,	   2001).	   Extracellular	   levels	   of	   decorin	   are	  
controlled	  by	  LRP	  receptor-­‐mediated	  catabolism	  (Brandan	  et	  al.,	  2006).	  Decorin	  is	  a	  
small	   proteoglycan	   that	  modulates	   the	   activity	   of	   TGF-­‐β	   and	   other	   growth	   factors	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and	  thereby	  influences	  the	  processes	  of	  proliferation	  and	  differentiation.	  LRP-­‐1	  can	  
modulate	   signaling	   induced	   by	   several	   growth	   factors	   by	   receptor-­‐mediated	  
endocytosis.	  The	  platelet-­‐derived	  growth	  factor	  (PDGF)	  binds	  to	  PDGF-­‐receptor	  and	  
triggers	  cell-­‐division	   in	   fibroblasts	  and	  smooth	  muscle	  cells	   (Betsholtz	  et	  al.,	  2004).	  
LRP-­‐1	   functions	   to	   reduce	  PDGF	   levels	  and	  PDGFR	  activation	  by	  directly	  binding	   to	  
and	   mediating	   internalization	   of	   PDGF	   (Loukinova	   et	   al.,	   2002).	   TGF-­‐β	   regulates	  
several	   cellular	   processes	   in	   a	   context-­‐dependent	  manner.	   LRP-­‐1	   was	   reported	   to	  
bind	  to	  and	  endocytose	  TGF-­‐β,	  therefore	  regulating	  its	  activity	  (Huang	  et	  al.,	  2003).	  
LRP-­‐1	  mediates	   internalization	   and	   transcytosis	   of	   connective	   tissue	   growth	   factor	  
(CTGF)	   in	   chondrocytes,	   determining	   the	   distribution	   of	   this	   growth	   factor	   in	  
cartilage	   (Kawata	   et	   al.,	   2012;	   Segarini	   et	   al.,	   2001).	  Midkine	   is	   a	   heparin	   binding	  
growth	   factor	   that	  has	   several	  biological	   functions	   including	   in	   cancer	  progression,	  
neuronal	   survival	   and	   differentiation,	   and	   inflammation	   (Kadomatsu,	   2005).	   LRP-­‐1	  
mediates	   the	   internalization	   of	   midkine.	   Interestingly,	   after	   LRP-­‐1-­‐dependent	  
endocytosis,	  midkine	  is	  not	  targeted	  for	  degradation	  but	  it	  binds	  to	  nucleolin	  and	  it	  
translocates	  into	  nucleus,	  where	  it	  activates	  anti-­‐apoptotic	  responses	  (Muramatsu	  et	  
al.,	  2000;	  Shibata	  et	  al.,	  2002).	  	  
1.2.2.4 	  Clearance	  of	  plasma	  proteins	  
LRP-­‐1	  is	  highly	  expressed	  in	  the	  liver	  where	  it	  recognizes	  a	  variety	  of	  molecules	  in	  the	  
circulation	   including	   proteinases-­‐inhibitor	   complexes,	   activated	   coagulation	   factors	  
and	  chylomicron	  remnants.	  
α2M-­‐protease	  complexes.	  α2M	   is	  a	  general	  protease	   inhibitor	   capable	  of	   inhibiting	  
different	  classes	  of	  proteinases.	   It	  has	  been	   found	   in	   the	  circulation	  of	  vertebrates	  
and	   several	   invertebrate	   species	  (Sottrup-­‐Jensen,	  1989).	   In	  humans,	  α2M	  circulates	  
at	   relatively	   high	   plasma	   concentrations	   of	   2–4	   μM.	   α2M	   is	   a	   tetramer	   of	   four	  
identical	   185	   kDa	   subunits	   linked	   in	   pairs	   by	   disulfide	   bonds	   (Barrett	   et	   al.,	   1979).	  
Each	   subunit	   has	   a	   “bait	   region”,	   a	   segment	   of	   the	   α2M	   that	   is	   particularly	  
susceptible	   to	   cleavage	   by	   proteinases.	   The	   mechanism	   of	   protease	   inhibition	  
involves	   protease	   cleavage	   of	   the	   bait	   region,	   which	   initiates	   a	   conformational	  
change	   such	   that	   the	   α2M	   engulfs	   the	   protease.	   In	   the	   resulting	   α2M—protease	  
complex,	   the	   active	   site	   of	   the	   protease	   is	   sterically	   shielded,	   but	   the	   trapped	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protease	  remains	  active	  towards	  low	  molecular	  mass	  substrates.	  However,	  protease	  
activity	   towards	   large	  molecular	  mass	   substrates	   is	   inhibited	   (Barrett	   and	   Starkey,	  
1973;	  Harpel,	  1973;	  Starkey	  and	  Barrett,	  1973).	  After	  the	  cleavage	  of	  the	  bait	  region	  
and	  the	  conformational	  change,	  α2M	  exposes	  a	  receptor-­‐binding	  site,	  which	  enables	  
the	   inhibitor-­‐protease	  complex	  to	   interact	  with	  LRP-­‐1	   (Sottrup-­‐Jensen	  et	  al.,	  1986).	  
LRP-­‐1	   is	   therefore	  the	  key	  receptor	   for	  clearing	  α2M—protease	  complexes.	   Indeed,	  
cells	   genetically	   deficient	   in	   LRP-­‐1	   lack	   the	   ability	   to	   mediate	   endocytosis	   and	  
degradation	   of	   125I-­‐labeled	   α2M—protease	   complexes	   (Poller	   et	   al.,	   1995).	   As	  
discussed	   in	   section	   1.2.2.1,	   RAP	   chaperones	   the	   correct	   folding	   of	   LRP-­‐1.	   RAP-­‐
deficient	  mice	  display	  decreased	  hepatic	  levels	  of	  LRP-­‐1	  and	  consequently	  they	  have	  
delayed	  clearance	  of	  α2M—protease	  complexes	  from	  the	  circulation	  (Willnow	  et	  al.,	  
1995).	   On	   the	   other	   hand,	   RAP	   was	   demonstrated	   to	   compete	   with	   125I-­‐labeled	  
α2M—protease	  complexes	  when	  co-­‐injected	  in	  mice	  and	  inhibit	  their	  clearance	  from	  
the	  circulation,	  (Kounnas	  et	  al.,	  1996).	  	  
Aβ-­‐peptide.	   The	   amyloid	   precursor	   protein	   (APP)	   is	   a	   type-­‐1	   integral	   membrane	  
protein	  that	   is	  mainly	  expressed	   in	  neurons.	  APP	  can	  undergo	  proteolytic	  shedding	  
through	  the	  action	  of	  two	  proteases,	  ADAM-­‐10	  and	  beta-­‐site	  APP	  cleaving	  enzyme	  1	  
(BACE1	   or	   BACE),	   known	   as	   the	   α-­‐	   or	   β-­‐secretase	   respectively,	   which	   release	   two	  
forms	  of	  the	  ectodomain	  into	  the	  extracellular	  space	  (Kuhn	  et	  al.,	  2010;	  Vassar	  et	  al.,	  
1999).	  The	  secreted	  APP	  (sAPP)	  is	  the	  protease	  inhibitor	  protease	  nexin	  2,	  with	  the	  
serine	   protease	   inhibitory	   activity	   localized	   in	   a	   Kunitz	   domain	   within	   the	   APP	  
molecule.	  After	  ectodomain	  shedding,	   the	  part	  of	  APP	  remaining	  associated	   to	   the	  
cell	  membrane	  can	  be	   further	  processed	  by	  γ-­‐secretase.	  This	  cleavage	   leads	   to	   the	  
formation	  of	  two	  forms	  of	  Aβ:	  Aβ40	  and	  Aβ42.	  The	  Aβ42	  form	  is	  highly	  fibrillogenic	  and	  
its	   accumulation	   in	   the	   extracellular	   space	   provokes	   the	   formation	   of	   β-­‐amyloid	  
plaques,	  which	  are	  thought	  to	  be	  a	  possible	  cause	  of	  Alzheimer's	  disease	  (Deane	  et	  
al.,	   2008).	   There	   is	   increasing	   interest	   in	   the	   role	   of	   LRP-­‐1	   in	   the	   development	   of	  
Alzheimer’s	  disease	  because	  it	  is	  responsible	  for	  the	  binding	  and	  the	  internalization	  
of	  APP,	  the	  soluble	  ectodomain	  of	  APP	  (sAPP),	  Aβ	  and	  other	  molecules	  which	  have	  
been	  genetically	  associated	  with	  Alzheimer’s	  disease,	  such	  as	  apoE,	   lactoferrin,	  and	  
α2M	  (Herz	  and	  Strickland,	  2001;	  Kounnas	  et	  al.,	  1995).	  A	  study	  by	  Ulery	  et	  al.	  (2001)	  
showed	   that	   transfection	   of	   APP	   and	   LRP-­‐1	   in	   LRP-­‐1-­‐deficient	   cells	   led	   to	   a	   3-­‐fold	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increase	   in	   Aβ,	   demonstrating	   that	   LRP-­‐1	   promotes	   APP	   endocytosis	   and	   APP	  
processing	   to	   Aβ	   (Ulery	   et	   al.,	   2000).	   Other	   reports	   have	   also	   indicated	   that	  
polymorphisms	  within	   the	   LRP-­‐1	  gene	  are	  associated	  with	  Alzheimer’s	  disease	  and	  
the	  levels	  of	  LRP-­‐1	  decrease	  with	  age	  (Kang	  et	  al.,	  2000;	  Kang	  et	  al.,	  1997;	  Kolsch	  et	  
al.,	   2003).	   Knauer	   et	   al.	   (1996)	   showed	   that	   LRP-­‐1	   can	   internalize	   the	  membrane	  
associated	   APP,	   although	   the	   mechanism	   by	   which	   LRP-­‐1	   mediates	   the	  
internalization	   of	   APP	   is	   not	   yet	   well	   understood	   (Knauer	   et	   al.,	   1996).	   The	  
ectodomains	  of	  LRP-­‐1	  and	  APP	  can	   interact,	  either	  directly	  or	   indirectly,	  after	  APP,	  
through	  its	  Kunitz	  domain,	  binds	  to	  the	  binding	  protein	  for	  epidermal	  growth	  factor	  
(EGFBP),	  which	   functions	   as	   a	   bridge	   between	   the	   two	   receptors	   (Kinoshita	   et	   al.,	  
2001;	   Knauer	   et	   al.,	   1996).	   There	   is	   also	   some	   evidence	   that	   LRP-­‐1	   also	   indirectly	  
interacts	   with	   APP	   in	   the	   cytoplasm,	   through	   adaptor	   proteins	   such	   as	   Fe65	  
(Kinoshita	   et	   al.,	   2001).	   LRP-­‐1	  was	   shown	   to	   bind	   the	   Aβ-­‐peptide	   and	  mediate	   its	  
transcytosis	  across	  the	  blood-­‐brain	  barrier	  (BBB)	  from	  the	  brain	  to	  blood	  (Shibata	  et	  
al.,	   2000).	   In	   the	   liver,	   LRP-­‐1	  mediates	   the	   systemic	   clearance	   of	   Aβ.	   Sagare	  et	   al.	  
(2007)	   showed	   that	   the	   soluble	   form	   of	   LRP-­‐1,	   which	   normally	   circulates	   in	   the	  
plasma,	   binds	   to	   Aβ	   reducing	   its	   transcytosis	   across	   the	   BBB	   via	   receptor	   for	  
advanced	  glycation	  endproducts	  (RAGE)	  and	  preventing	  its	  accumulation	  in	  the	  brain	  
(Sagare	  et	  al.,	  2007).	  	  
Chylomicron	   remnants.	   Chylomicrons	  are	   lipoprotein	  particles	   composed	  of	  a	   core	  
of	   triglycerides	   and	   cholesterol,	   surrounded	  by	   phospholipids	   and	   apolipoproteins.	  
Chylomicrons	  are	  vehicles	  to	  transport	  hydrophobic	  lipids	  in	  the	  circulation	  (Hussain,	  
2000).	  They	  are	  adsorbed	  by	  the	  vascular	  endothelial	  cells	  of	  tissues	  that	  have	  a	  high	  
requirement	  for	  triglycerides,	  such	  as	  skeletal	  and	  cardiac	  muscle	  (for	  the	  production	  
of	   energy)	   and	   adipose	   tissue	   (for	   storage).	   Lipoprotein	   lipase,	   which	   is	   highly	  
expressed	  in	  these	  cells,	  releases	  the	  triglycerides	  from	  the	  core	  of	  the	  chylomicron	  
hydrolyzing	   them	   to	   fatty	   acids.	   The	   residual	   lipoproteins	   particles,	   deprived	   of	  
triglycerides,	   are	   called	   chylomicron	   remnants.	   The	   apoE	   lipoprotein	   contained	   in	  
chylomicron	   remnants	   has	   a	   binding	   site	   for	   LRP-­‐1.	   Such	   remnants	   are	   therefore	  
rapidly	   cleared	   by	   LRP-­‐1	   in	   the	   liver	   (Willnow	   et	   al.,	   1992).	   Indeed,	   deletion	   of	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hepatic	   LRP-­‐1	   leads	   to	   increased	   plasma	   levels	   of	   remnant	   lipoproteins	   and	  
accelerates	  atherosclerosis	  (Rohlmann	  et	  al.,	  1998).	  
Serpin-­‐enzyme	  complexes.	  The	  serine	  proteinase	  inhibitors	  (serpins)	  are	  a	  family	  of	  
proteins	   that	   inhibit	   serine	   proteases.	   Serpins	   are	   the	   largest	   family	   of	   protease	  
inhibitors,	   with	   over	   1000	   member	   that	   have	   been	   identified	   in	   many	   different	  
species,	   spanning	   from	   bacteria	   to	   humans.	   The	   first	   serpins	   identified	   in	   human	  
were	  anti-­‐thrombin	  and	  anti-­‐trypsin	  (Bundy	  and	  Mehl,	  1959;	  Rosenberg	  and	  Damus,	  
1973).	  After	  these,	  thirty-­‐four	  other	  members	  have	  been	  added	  to	  the	  serpin	  family	  
in	   human.	   Serpins	   play	   a	   key	   role	   in	   several	   biological	   processes,	   including	  
coagulation,	   inflammation	   and	   tissue	   remodeling.	   Serpin	   complex	   formation	   with	  
target	  serine	  proteinases	  that	  is	  initiated	  when	  a	  loop	  of	  the	  inhibitor	  is	  cleaved	  and	  
the	   inhibitor	   undergoes	   a	   conformational	   change.	   The	   activated	   serpin-­‐proteinase	  
complex	   is	   recognized	   by	   a	   receptor	   system	   and	   directed	   to	   endocytosis	   and	  
degradation	  (Ohlsson	  et	  al.,	  1971).	  LRP-­‐1	  is	  the	  main	  receptor	  mediating	  the	  hepatic	  
clearance	  of	  serpin—enzyme	  complexes	  (Mast	  et	  al.,	  1991).	  	  
	   An	   interesting	   example	   of	   how	   serpin—protease	   complex	   formation	  
mediates	  enzyme	  inhibition	  and	  its	  LRP-­‐1-­‐dependent	  clearance	  is	  that	  of	  uPA—PAI-­‐1.	  
Nykjaer	  et	  al.	  (1992)	  demonstrated	  that	  uPA	  can	  interact	  with	  LRP-­‐1	  only	  when	  it	  is	  
complexed	  with	   PAI-­‐1,	  whereas	   no	   binding	  was	   observed	  when	  uPA	  was	   in	   a	   free	  
form	  (Nykjaer	  et	  al.,	  1992b).	  On	  the	  other	  hand,	  the	  tPA	  can	  bind	  to	  LRP-­‐1	  directly,	  in	  
a	  manner	  that	  is	   independent	  from	  the	  formation	  of	  a	  complex	  with	  PAI-­‐1	  (Orth	  et	  
al.,	  1994).	  	  	  
Factor	   VIII.	   After	   an	   injury	   to	   blood	   vessels,	   blood	   initiates	   the	   process	   of	  
coagulation,	  which	  leads	  to	  the	  formation	  of	  blood	  clots.	  Coagulation	  is	  a	  very	  well	  
orchestrated	   process	   that	   involves	   several	   proteins.	   Factor	   VIII	   is	   a	   key	   plasma	  
protein	  and	  a	  member	  of	  the	  coagulation	  cascade,	  and	  its	  deficiency	  causes	  the	  well-­‐
characterized	   bleeding	   disorder	   hemophilia	   A	   in	   humans.	   Factor	   VIII	   normally	  
circulates	  with	  its	  carrier,	  the	  von	  Willebrand	  factor,	  as	  an	  inactive	  cofactor	  (Fay	  and	  
Jenkins,	  2005).	  Upon	   injury	  within	   the	  vasculature,	   factor	  VIII	   is	  activated	   to	   factor	  
VIIIa	   by	   thrombin	   and	   it	   dissociates	   from	   the	   von	  Willebrand	   factor	   and	   interacts	  
with	  the	  cell-­‐surface	  factor	  IX	  to	  form	  a	  macromolecular	  complex	  which	  plays	  a	  key	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role	   in	   the	   coagulation	   cascade.	   The	   activated	   factor	   VIII	   forms	   with	   factor	   IX	   a	  
complex	   called	   tenase,	   which,	   in	   turn,	   activates	   factor	   X.	   The	   activated	   factor	   X	  
mediates	   the	   activation	   of	   pro-­‐thrombin	   to	   thrombin.	   LRP-­‐1	   has	   been	   reported	   to	  
mediate	   clearance	   of	   the	   activated	   factor	   VIII,	   and	   thus	   contributes	   to	   the	  
maintenance	  of	  blood	  coagulation	  homeostasis	   (Lenting	  et	  al.,	  1999;	  Saenko	  et	  al.,	  
1999).	  	  
1.2.2.5 Regulation	  of	  the	  plasma	  membrane	  proteome	  
While	  LRP-­‐1	  was	  originally	  believed	  to	  function	  only	  as	  an	  endocytic	  receptor,	  many	  
other	   roles	   have	   now	   been	   reported	   for	   LRP-­‐1	   in	   different	   physiological	   and	  
pathological	   conditions.	   LRP-­‐1	   plays	   a	   key	   role	   in	   regulating	   the	   composition	   of	  
plasma	  membrane.	  In	  addition	  to	  diffusible	  proteins,	  it	  mediates	  the	  internalization	  
of	  a	  number	  of	  transmembrane	  proteins,	  including	  integrins	  and	  the	  urokinase-­‐type	  
plasminogen	   activator	   receptor	   (uPAR).	   There	   is	   emerging	   evidence	   that	   this	  
endocytic	  receptor	  can	  also	  trigger	  signaling	  pathways	  by	  its	  cytoplasmic	  tail.	  LRP-­‐1	  
regulates	   levels	   of	   several	   plasma	   membrane-­‐anchored	   proteins,	   including	  
receptors,	  by	  endocytosis,	  and	  therefore	  it	  negatively	  modulates	  signal	  transduction	  
triggered	  by	  other	  cell	  surface	  receptors.	  Well-­‐characterized	  examples	  of	  this	  LRP-­‐1	  
function	  are	  uPAR	  and	  integrins.	  
uPAR.	   uPAR	   is	   a	   glycosylphosphatidylinositol	   (GPI)-­‐anchored	   protein	   found	  
associated	   with	   lipid	   rafts/caveolae	   (Stahl	   and	   Mueller,	   1995).	   It	   functions	   as	  
receptor	  for	  both	  uPA	  and	  vitronectin	  (Kanse	  et	  al.,	  1996;	  Ploug	  et	  al.,	  1991).	  It	  has	  
been	  reported	  that	  uPA	  bound	  to	  uPAR	  is	  stable	  on	  the	  cell	  surface.	  However,	  when	  
the	   specific	   uPA	   inhibitor,	   PAI-­‐1,	   binds	   covalently	   to	   uPAR-­‐bound	  uPA,	   the	   ternary	  
complex	  of	  uPAR,	  uPA	  and	  PAI-­‐1	  associates	  with	  LRP-­‐1	  and	  is	  sequestered	  in	  clathrin-­‐
coated	  pits	  for	  subsequent	  endocytosis	  (Jensen	  et	  al.,	  1990;	  Nykjaer	  et	  al.,	  1992b).	  In	  
migrating	   cancer	   cells,	   uPAR	   localizes	   in	   lamellipodia	   where	   it	   assembles	   uPA	  
molecules,	  promoting	  ECM	  degradation	  and	  cell	  migration	  (Conese	  and	  Blasi,	  1995).	  
RAP	   blocks	   the	   LRP-­‐1-­‐dependent	   catabolism	   of	   uPAR	   (Conese	   et	   al.,	   1995).	   Breast	  
cancer	   cells	   cultured	   in	   the	   presence	   of	   RAP	   have	   been	   reported	   to	   have	   an	  
increased	  level	  of	  cell	  surface	  uPAR,	  and	  therefore	  higher	  motility	   in	  vitro	  (Webb	  et	  
al.,	   1999).	   In	   addition,	   uPAR	   can	   itself	   transduce	   cell	   signaling.	   Binding	   of	   uPA	   to	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uPAR	  activates	   the	  ERK	  pathway	  and	  controls	  cell	  growth,	  apoptosis	  and	  migration	  
(Nguyen	  et	  al.,	  2000).	  Through	  uPAR,	  vitronectin	  activates	  Rac1,	  which	  controls	  actin	  
remodeling	   (Kjoller,	   2002).	   Therefore,	   by	   mediating	   the	   catabolism	   of	   plasma	  
membrane	   levels	   of	   uPAR	   through	   a	  mechanism	   that	   involves	   the	   formation	   of	   a	  
ternary	  complex	  with	  uPA	  and	  PAI-­‐1,	  LRP-­‐1	  suppresses	  uPAR-­‐mediated	  activation	  of	  
ERK	  and	  Rac1.	  This	  mechanism	   represents	  an	  example	  of	  how	  LRP-­‐1	   can	   influence	  
cell-­‐signaling	  indirectly.	  	  
Integrins.	   LRP-­‐1	   has	   been	   shown	   to	   facilitate	   the	   indirect	   endocytosis	   of	   integrins	  
αvβ3	   and	   α5β5,	   that	   form	   interactions	  with	   uPAR	   on	   the	   cell	   surface	   (Lillis	   et	   al.,	  
2008).	   It	   was	   reported	   that	   LRP-­‐1	   interacts	   with	   integrin	   αMβ2	   in	   macrophages,	  
mediating	   its	   internalization	   directly	   and	   therefore	   modulating	   the	   ability	   of	  
macrophages	  to	  migrate	  towards	  sites	  of	  inflammation	  (Ranganathan	  et	  al.,	  2011a).	  	  
Salicioni	  et	  al.	  (2004)	  reported	  that	  cell-­‐surface	  levels	  of	  integrin	  β1	  increase	  with	  the	  
expression	   of	   LRP-­‐1	   (Salicioni	   et	   al.,	   2004).	   LRP-­‐1	   did	   not	   directly	   modulate	  
endocytosis	  of	   the	   integrin,	  but	   the	   increase	   in	   integrin	  β1	  on	   the	  cell	   surface	  was	  
rather	   due	   to	   LRP-­‐1-­‐mediated	   promotion	   of	   its	   maturation	   and	   transport	   to	   the	  
plasma	  membrane.	   This	   ability	   of	   LRP-­‐1	   to	   facilitate	   protein	   trafficking	   to	   the	   cell	  
surface	   constitutes	   a	   novel	   mechanism	   by	   which	   LRP-­‐1	   regulates	   the	   plasma	  
membrane	  composition.	  	  
1.2.2.6 Cell-­‐signalling	  
The	   cytoplasmic	   tail	   of	   LRP-­‐1	   contains	   four	   tyrosine	   residues,	   two	   of	   which	   are	  
present	   in	   a	   NPXY	   motif	   (Lillis	   et	   al.,	   2008).	   Intracellularly,	   LRP-­‐1	   was	   found	   to	  
interact	   with	   some	   adapter	   proteins,	   including	   Dab-­‐1	   and	   Shc,	   and	   non-­‐receptor	  
tyrosines	  kinases	   such	  as	  Src	  and	  Fyn	   (Ranganathan	  et	  al.,	  2004).	   	   Interaction	  with	  
such	  proteins	  and	  the	  presence	  of	  NPXY	  motifs	   in	   the	  cytoplasmic	  tail	   suggest	   that	  
LRP-­‐1	  is	  able	  to	  transduce	  cell	  signals,	  although	  the	  exact	  mechanism	  by	  which	  this	  
occurs	  has	  not	  been	  clearly	  elucidated.	  Such	  investigation	  is	  limited	  by	  the	  difficulties	  
in	   cloning	   and	  expressing	   full-­‐length	   LRP-­‐1,	  which	   is	   a	   600	   kDa	  protein.	   Therefore,	  
the	   majority	   of	   approaches	   are	   based	   on	   the	   use	   of	   chimeras	   containing	   the	  
cytoplasmic	  domain	  of	  LRP-­‐1	  fused	  with	  different	  extracellular	  moieties.	  Barnes	  et	  al.	  
(2003)	   showed	   that	  when	  an	  LRP-­‐1-­‐Myc	  chimera	  was	  expressed	   together	  with	  Src,	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tyrosine	   63	   in	   the	   cytoplasmic	   domain	   of	   LRP-­‐1	  was	   phosphorylated	   (in	   this	   work	  
residues	  were	  numbered	  starting	  at	  the	  first	  residue	  of	  the	  cytoplasmic	  domain,	  thus	  
tyrosine	  63	  corresponds	  with	  4473	  in	  LRP-­‐1	  sequence).	  The	  phosphorylated	  tyrosine	  
63	  was	  able	  to	  interact	  with	  Shc,	  a	  signaling	  protein	  involved	  in	  the	  activation	  of	  Ras	  
(Barnes	  et	  al.,	  2003).	  Hu	  et	  al.	   (2006)	  showed	  that	  binding	  of	   tPA	  to	  LRP-­‐1	   induces	  
tyrosine	   phosphorylation	   on	   the	   receptor	  which	   triggers	   the	   expression	   of	  MMP-­‐9	  
through	   a	   cascade	   involving	   MAP	   (Mitogen-­‐Activated	   Protein)	   Kinase/ERK	  
(Extracellular	   Signal-­‐Regulated	   Kinase)	   Kinase	   1	   (MEK1)	   and	   its	   downstream	  
extracellular	   signal-­‐regulated	   kinases	   1	   and	   2	   (ERK-­‐1	   and	   -­‐2)	   (Hu	   et	   al.,	   2006).	   In	  
addition,	  LRP-­‐1	  promotes	  glioblastoma	  cell	  migration	  and	  invasion	  by	  increasing	  the	  
expression	  of	  MMP-­‐2	  and	  MMP-­‐9	  via	  an	  ERK-­‐dependent	  signaling	  pathway	  (Song	  et	  
al.,	  2009).	  
1.2.2.7 Inflammation	  and	  atherosclerosis	  
LRP-­‐1	  has	  been	  implicated	  in	  the	  regulation	  of	  inflammation.	  Gaultier	  et	  al.	  (2008b)	  
showed	   that	   LRP-­‐1-­‐null	  macrophages	   had	   an	   aberrant	   activation	   of	   the	   IκB	   kinase	  
(IKK)-­‐NF-­‐κB	   pathway,	   leading	   to	   a	   dysregulated	   secretion	   of	   pro-­‐inflammatory	  
cytokines.	   They	   reported	   that	   LRP-­‐1	   could	   indirectly	   downregulate	   this	   pro-­‐
inflammatory	   pathway	   by	   mediating	   the	   internalization	   of	   tumor	   necrosis	   factor	  
receptor	   1	   (TNFR-­‐1)	   (Gaultier	   et	   al.,	   2008b).	   Studies	   in	   LRP-­‐1-­‐null	   vascular	   smooth	  
muscle	   cells	   (VSMC)	   and	  macrophages	   have	   indicated	   that	   LRP-­‐1	   has	   a	   protective	  
role	   in	   atherosclerosis	   (Boucher	   et	   al.,	   2003).	   LRP-­‐1	   regulates	   smooth	  muscle	   cell	  
proliferation	   by	   internalizing	   PDGF	   (Boucher	   et	   al.,	   2003).	   Mice	   carrying	   an	   LRP-­‐1	  
deletion	  in	  VSMCs	  exhibited	  more	  atherosclerotic	  lesions	  and	  an	  aberrant	  activation	  
of	   the	  PDGF-­‐PDGFR	  pathway	   in	  VSMCs	   compared	   to	  wild-­‐type	   animals,	   suggesting	  
that	  LRP-­‐1	  plays	  a	  role	  in	  protecting	  the	  integrity	  of	  the	  vascular	  wall	  and	  preventing	  
atherosclerosis	   by	   suppressing	   the	   PDGFR	   pathway	   (Boucher	   et	   al.,	   2003).	   In	  
addition,	   a	   deficiency	   of	   LRP-­‐1	   in	   macrophages	   increased	   atherogenesis	   in	  
hypercholesterolemic	   mice,	   with	   40	   %	  more	   atherosclerotic	   lesions	   being	   present	  
compared	  to	  wild-­‐type	  mice	  (Overton	  et	  al.,	  2007).	  In	  these	  studies,	  deletion	  of	  LRP-­‐
1	   led	   to	   a	   decrease	   in	   the	   uptake	   of	   chylomicron	   remnants	   and	   VLDL,	   without	  
altering	  plasma	  levels	  of	  triglycerides	  and	  cholesterol.	  MMP-­‐9,	  which	  participates	  in	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atherosclerosis	  progression	  due	  to	  its	  ability	  to	  degrade	  the	  ECM	  and	  promote	  VSMC	  
invasion,	  was	   significantly	  upregulated	   in	   the	  absence	  of	  macrophage	   LRP-­‐1.	  More	  
recently,	   Yancey	   et	   al.	   (2011)	   confirmed	   previous	   findings	   by	   demonstrating	  
increased	  atherogenesis	  in	  the	  absence	  of	  macrophages	  expressing	  functional	  LRP-­‐1.	  
This	   mutation	   enhances	   macrophage	   recruitment	   to	   the	   lesion	   site	   and	   their	  
apoptosis	  (Yancey	  et	  al.,	  2011).	  In	  addition,	  LRP-­‐1	  plays	  a	  key	  role	  in	  maintaining	  the	  
integrity	  of	  the	  blood-­‐brain	  barrier.	  Endothelial	  cells	  present	   in	  the	  central	  nervous	  
system	  form	  a	  barrier	  along	  all	  capillaries,	  which	  separates	  circulating	  blood	  from	  the	  
brain	  extracellular	  fluid	  (Rubin	  and	  Staddon,	  1999).	  This	  serrate	  barrier	  is	  maintained	  
by	  specific	  tight	  junctions	  between	  adjacent	  endothelial	  cells	  and	  protects	  the	  brain	  
from	  harmful	  substances	  circulating	  in	  the	  blood.	  The	  blood-­‐brain	  barrier	  is	  carefully	  
regulated	   under	   physiological	   conditions,	   and	   any	   dysregulation	   can	   lead	   to	  
pathological	  conditions.	  LRP-­‐1	  is	  widely	  expressed	  by	  different	  cell-­‐types	  in	  the	  brain,	  
including	  VSMCs,	  pericytes,	  astrocytes	  and	  neurons	  (Lillis	  et	  al.,	  2008).	  Its	  function	  in	  
maintaining	  the	  integrity	  of	  the	  blood-­‐brain	  barrier	  was	  firstly	  reported	  by	  Yepes	  et	  
al.	  (2003),	  who	  found	  that	  tPA	  regulates	  blood-­‐brain	  barrier	  permeability	  through	  an	  
as	   yet	   uncharacterized	  mechanism	   that	   may	   involve	   LRP-­‐1-­‐mediated	   cell-­‐signaling	  
(Yepes	  et	  al.,	  2003).	  
1.2.2.8 Shedding	  of	  LRP-­‐1	  and	  biological	  functions	  of	  sLRP-­‐1	  
It	  has	  been	   reported	   that	   LRP-­‐1	  can	  undergo	  proteolytic	   shedding,	   in	  which	   the	  β-­‐
chain	  is	  cleaved	  near	  the	  plasma	  membrane.	  Thus,	  the	  soluble	  form	  of	  LRP-­‐1	  (sLRP-­‐1)	  
consists	  of	  the	  entire	  α-­‐chain	  interacting	  with	  a	  small	  portion	  of	  the	  β-­‐chain.	  sLRP-­‐1	  
is	  still	  able	  to	  bind	  α2M	  and	  tPA,	  suggesting	  that	  the	  ligand-­‐binding	  clusters	  remain	  
intact	   after	   LRP-­‐1	   shedding	   (Quinn	   et	   al.,	   1997).	   sLRP1	   is	   found	   in	   human	   plasma	  
(Quinn	  et	  al.,	  1997),	  in	  cerebral	  spinal	  fluid	  (Liu	  et	  al.,	  2009)	  and	  in	  the	  conditioned	  
medium	  of	  HT1080	  cultured	  cells	  (Selvais	  et	  al.,	  2011).	  Different	  metalloproteinases,	  
such	  as	  ADAM10,	  ADAM12	  and	  the	  tumor	  necrosis	   factor	  alpha	  (TNF-­‐α)	  converting	  
enzyme	   (TACE)	   and	   BACE	   have	   been	   shown	   to	   cleave	   the	   ectodomain	   of	   LRP-­‐1	   in	  
vitro	  (Liu	  et	  al.,	  2009;	  Selvais	  et	  al.,	  2009;	  von	  Arnim	  et	  al.,	  2005),	  and	  sLRP-­‐1	  can	  also	  
be	   further	   proteolytically	   fragmented	   by	   MT1-­‐MMP	   (Rozanov	   et	   al.,	   2004).	   Both	  
shedding	  and	  further	  degradation	  modulate	  the	  amount	  of	  functional	  LRP-­‐1	  on	  the	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cell	   membrane,	   and	   consequently	   modulate	   the	   scavenging	   of	   LRP-­‐1	   ligands.	   The	  
level	   of	   functional	   LRP-­‐1	   on	   the	   cell	   surface	   and	   consequent	   modulation	   of	   its	  
clearance	  of	  ligands,	  such	  as	  MMP-­‐2	  and	  MMP-­‐9,	  can	  be	  regulated	  by	  shedding	  in	  a	  
“loss	  of	  function”	  manner	  (Selvais	  et	  al.,	  2011).	  Shedding	  of	  LRP-­‐1	  is	  induced	  by	  LPS	  
and	  IFN-­‐γ	  both	   in	  vitro	  and	   in	  vivo	  (Gorovoy	  et	  al.,	  2010),	  and	  it	  was	  observed	  that	  
cholesterol	  prevents	  LRP-­‐1	  shedding	  in	  HT1080	  cells	  (Selvais	  et	  al.,	  2011).	  sLRP-­‐1	  has	  
been	   shown	   to	   bind	   directly	   to	   Schwann	   cells	   and	   to	   inhibit	   TNF-­‐α-­‐triggered	  
signalling	  in	  a	  mouse	  model	  of	  nerve	  injury	  (Gaultier	  et	  al.,	  2008a).	  In	  addition,	  sLRP-­‐
1	   induces	   signalling	   in	   macrophages	   with	   subsequent	   activation	   of	   the	   IKK-­‐NF-­‐κB	  
pathway,	  leading	  to	  the	  expression	  of	  regulatory	  cytokines	  (Gorovoy	  et	  al.,	  2010).	  
1.2.3 LRP-­‐2	  or	  Megalin	  
Megalin	   was	   originally	   called	   glycoprotein	   330	   and	   identified	   as	   the	   pathogenic	  
antigen	  of	  Heymann	  nephritis	   (Farquhar	  1982).	  Because	  of	   its	   similarity	  with	  LRP-­‐1	  
and	  the	  presence	  of	  homologous	  binding	  regions,	  Megalin	  was	  associated	  with	  the	  
LDL	  endocytic	   receptor	   family	   (Saito	  et	  al.,	  1994).	   In	   fact,	   like	  LRP-­‐1,	  megalin	  binds	  
and	  internalizes	  serine	  proteinases	  and	  their	  complexes	  with	  serpins,	  including	  pro-­‐
uPA,	   uPA—PAI-­‐1	   and	   tPA—PAI-­‐1.	   Nevertheless,	   unlike	   LRP-­‐1,	   which	   is	   abundantly	  
expressed	  in	  the	  liver,	  megalin	  is	  mainly	  expressed	  in	  the	  kidney,	  where	  it	  is	  involved	  
in	  endocytosis	  and	  metabolism	  of	  several	  glomerular-­‐filtered	  proteins	  and	  vitamin-­‐
protein	  complexes	  in	  the	  proximal	  tube	  (Christensen	  and	  Willnow,	  1999).	  Protein—
vitamin	   complexes	   that	   are	   endocytosed	  by	  megalin	   are	   then	   sorted	   to	   lysosomes	  
where	  the	  proteins	  are	  degraded	  and	  the	  vitamins	  are	  returned	  to	  the	  circulation	  via	  
peritubular	   capillaries.	   Similar	   to	   LRP-­‐1,	   megalin	   seems	   to	   activate	   signaling	  
pathways	  as	  it	  contains	  an	  NPXY	  sequence	  in	  the	  cytoplasmic	  tail	  and	  interacts	  with	  
adaptor	  proteins	  such	  as	  Dab-­‐2	  (Hosaka	  et	  al.,	  2009).	  
	   Many	  of	  the	  biological	  functions	  of	  megalin	  were	  identified	  by	  Leheste	  et	  al.	  
who	  generated	  megalin	  knockout	  mice	   (Leheste	  et	  al.,	   2003;	   Leheste	  et	  al.,	   1999).	  
These	  mice	  die	  of	  pulmonary	  failure	  shortly	  after	  birth,	  indicating	  a	  role	  for	  megalin	  
in	   development.	   In	   addition,	   megalin	   knockout	  mice	   showed	   brain	  malformations	  
and	  vitamin	  D	  deficiency.	  Megalin	  was	   shown	   to	  bind	  and	   internalize	   the	   signaling	  
factor	  BMP-­‐4,	  which	  is	  a	  negative	  regulator	  of	  sonic	  hedgehog.	  Thus,	  sonic	  hedgehog	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activity	   in	  the	  developing	  forebrain	   is	  reduced	   in	  megalin	  knockout	  mice	   leading	  to	  
brain	  deformities,	   such	  as	  holoprosencephaly.	   In	  addition,	   lack	  of	  vitamin	   recovery	  
by	  these	  mice	  led	  to	  greatly	  enhanced	  excretion	  of	  vitamin	  D	  in	  the	  urine.	  Another	  
transgenic	  mouse	  line,	  carrying	  a	  deletion	  of	  megalin	  specifically	  in	  the	  kidney,	  was	  
used	   to	   investigate	   the	   role	   of	   megalin	   in	   vitamin	   homeostasis.	   These	   studies	  
indicated	  that	  as	  well	  as	  vitamin	  D,	  which	  is	  endocytosed	  by	  megalin	  in	  complex	  with	  
the	  vitamin	  D	  binding	  protein,	  vitamin	  A	  and	  vitamin	  B12	  are	  internalized	  by	  megalin	  
in	   complex	  with	   their	   binding	   proteins.	   These	   vitamins	   are	   thus	   reabsorbed	   in	   the	  
kidney,	  through	  a	  megalin-­‐mediated	  mechanism.	  Megalin	  also	  acts	  as	  the	  endocytic	  
receptor	   for	   parathyroid	   hormone	   (PTH)	   and	   thus	   has	   a	   role	   in	   PTH	   homeostasis	  
(Bacic	  et	  al.,	  2003).	  
1.2.4 VLDLR	  
VLDLR	  is	  very	  similar	  to	  LDLR,	  with	  its	  structure	  differing	  from	  that	  of	  LDLR	  only	  by	  an	  
additional	  ligand-­‐binding	  repeat	  at	  the	  N-­‐terminus	  (Sakai	  et	  al.,	  1994).	  Although	  LDLR	  
and	   VLDLR	   show	   such	   similarity,	   the	   two	   genes	   are	   located	   on	   different	  
chromosomes	  (chromosome	  19	  for	  LDLR	  and	  chromosome	  9	  for	  VLDLR)	  (Sakai	  et	  al.,	  
1994),	  and	  their	  tissue	  distribution	  also	  differs,	  with	  VLDLR	  only	  scarcely	  expressed	  in	  
the	   liver,	  where	   LDLR	   is	   highly	   abundant	   (Takahashi	   et	   al.,	   1992).	   VLDLR	   is	  mainly	  
expressed	  in	  muscle,	  heart	  and	  brain	  (Takahashi	  et	  al.,	  1992).	  Two	  different	  forms	  of	  
VLDLR	   are	   produced	   (type	   1-­‐VLDLR	   and	   type-­‐2-­‐VLDLR)	   as	   a	   result	   of	   alternative	  
splicing	   (Iijima	  et	  al.,	  1998).	  VLDLR	  endocytoses	  proteins	   involved	   in	   lipoproprotein	  
metabolism	  such	  as	  apoE	  and	  VLDL	  as	  well	  as	  several	  protease—inhibitor	  complexes	  
including	  protease—anti-­‐thrombin	  III	  and	  protease—PAI-­‐1	  complexes	  (Hussain	  et	  al.,	  
1999).	  In	  contrast	  to	  LDLR,	  VLDLR	  is	  not	  downregulated	  by	  intracellular	  lipoproteins	  
(Sakai	  et	  al.,	  1994;	  Suzuki	  et	  al.,	  1995).	  VLDLR-­‐/-­‐	  mice	  do	  not	  show	  any	  abnormalities	  
in	   lipoprotein	   levels	   in	   plasma,	   although	   their	   adipose	   tissue	   mass	   is	   reduced	  
(Frykman	  et	   al.,	   1995).	   	   The	   reason	   for	   this	  phenotype	   is	  mainly	   that	  VLDLR	   is	   the	  
only	   lipoprotein	   receptor	   for	   VLDL	   triglycerides	   in	   peripheral	   tissues,	  while	   plasma	  
lipoprotein	  levels	  depends	  mainly	  on	  LDLRs	  in	  the	  liver	  (Tacken	  et	  al.,	  2000).	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1.2.5 ApoE	  receptor-­‐2	  
The	   ApoER2	   gene	   is	   differentially	   spliced	   and	   thus	   encodes	   for	   two	   forms	   of	   the	  
same	  protein	  that	  originally	  were	  described	  as	  two	  different	  receptors:	  ApoER2	  and	  
LRP7/8	   (Kim	   et	   al.,	   1996;	   Novak	   et	   al.,	   1996).	   The	   tissue	   expression	   pattern	   of	  
ApoER2	   is	   peculiar,	   as	   it	   is	   present	   only	   in	   brain,	   placenta	   and	   testis,	   unlike	   other	  
LDL-­‐receptor	  family	  members	  that	  have	  a	  much	  broader	  expression	  pattern	  (Nimpf	  
and	   Schneider,	   2000).	  One	   explanation	   of	   this	   unique	   pattern	   of	   expression	   is	   the	  
involvement	  of	  apoER2	   in	   the	   transport	  of	   selenium.	  Selenium	   is	  necessary	   for	   the	  
synthesis	   of	   selenoproteins,	   but	   some	   tissues,	   including	   testis	   and	   brain,	   tolerate	  
selenium	  deficiency	  better	   than	  others	   (Hill	  et	  al.,	  2003).	  The	  mechanism	  by	  which	  
apoER2	   transports	   selenium	   into	   the	   tissue	   has	   been	   recently	   characterized.	   The	  
selenoprotein	   P,	   plasma,	   1	   (Sepp1)	   is	   an	   extracellular	   glycoprotein	   containing	  
multiple	   selenocysteine	   (Sec)	   residues.	  ApoER2	  was	   found	   to	  bind	  and	  endocytose	  
Sepp1	  and	  through	  this	  mechanism	  to	  regulate	  the	  homeostasis	  of	  selenium	  in	  the	  
tissue	   (Kurokawa	  et	  al.,	  2012).	  Reelin	   is	  a	   large	  secreted	  glycoprotein	   that	  binds	   to	  
ApoER2	  and	  VLDLR	   (Hiesberger	  et	  al.,	  1999).	   Following	   ligand	  binding,	   the	  adaptor	  
protein	  Dab1	  associates	  with	  the	  receptor's	  C-­‐terminal	  NPXY	  motifs,	  causing	  Dab1	  to	  
become	   tyrosine	  phosphorylated	  by	  members	  of	   the	   Src-­‐family	   kinases,	   leading	   to	  
transduction	   of	   the	   Reelin	   signal	   downstream	   (Benhayon	   et	   al.,	   2003).	   Reelin	  
signaling	   through	   these	   receptors	   is	   required	   for	   a	   range	   of	   processes	   in	   the	  
developing	   and	   adult	   brain,	   including	   neuronal	   migration	   (Andrade	   et	   al.,	   2007;	  
Hiesberger	   et	   al.,	   1999),	   dendritic	   development	   (Niu	   et	   al.,	   2004),	   and	   synaptic	  
plasticity	  (Beffert	  et	  al.,	  2006;	  Beffert	  et	  al.,	  2005;	  Weeber	  et	  al.,	  2002).	  
1.2.6 LRP-­‐4	  or	  MEGF7	  
MEGF7	  was	   first	   identified	  by	  Nakayama	  and	   colleagues	   in	  1998,	  who	   reported	   its	  
similarity	   to	   some	   members	   of	   the	   LDL	   receptor	   family	   (Nakayama	   et	   al.,	   1998).	  
MEGF7	  is	  also	  known	  as	  LRP-­‐4.	  Its	  size	  and	  structural	  complexity	  are	  in	  between	  that	  
of	  the	  smaller	  LDL-­‐receptors	  (LDLR,	  VLDLR	  and	  ApoER2)	  and	  the	  bigger	  members	  of	  
this	  family	  (LRP-­‐1,	  LRP-­‐1b	  and	  Megalin).	  As	  with	  the	  other	  members,	  MEGF7	  contains	  
one	   NPXY	   motif	   in	   the	   cytoplasmic	   tail	   suggesting	   it	   plays	   a	   role	   in	   signaling	  
transduction	   and	   receptor-­‐mediated	   endocytosis.	   Nevertheless,	   its	   biological	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functions	   are	   not	   yet	   fully	   understood.	  MEGF7	   seems	   to	   play	   a	   pivotal	   role	   in	   the	  
regulation	   of	   essential	   signaling	   pathways	   and	   it	   also	   appears	   to	   be	   involved	   in	  
various	  other	  physiological	  functions	  such	  as	  brain	  development	  (May	  et	  al.,	  2007).	  
Jonson	  et	  al.	   (2005)	  have	  recently	  generated	  a	  MEGF7	  knockout	  mouse	   line,	  which	  
provided	  some	  information	  about	  the	  biological	  functions	  of	  this	  receptor	  (Johnson	  
et	   al.,	   2005).	   	   Homozygous	   knockout	   animals	   show	   fully	   penetrant	   polysyndactyly	  
and	  a	  mild	  and	  incompletely	  penetrant	  form	  of	  craniofacial	  abnormalities,	  which	  are	  
frequently	   associated	  with	   abnormal	   limb	   development	   in	   humans.	   These	   findings	  
suggest	  a	  likely	  role	  for	  MEGF7	  as	  a	  modulator	  of	  the	  signaling	  pathways	  that	  control	  
limb	  development	  in	  the	  embryo.	  
1.2.7 LRP-­‐1b	  
LRP-­‐1b	  is	  approximately	  600	  kDa	  and	  shares	  60	  %	  amino	  acid	  identity	  with	  LRP-­‐1	  (Liu	  
et	   al.,	   2000a).	   Due	   to	   this	   similarity,	   LRP-­‐1b	   also	   binds	   several	   LRP-­‐1	   ligands,	  
including	  RAP,	  uPA,	  tPA,	  PAI-­‐1,	  uPAR,	  Pseudomonas	  exotoxin,	  although	  it	  mediates	  a	  
slower	  rate	  of	  endocytosis	  than	  LRP-­‐1	  (Liu	  et	  al.,	  2001).	  Nevertheless,	  some	  ligands	  
such	  as	   fibrinogen	  seem	  to	  be	  specific	   for	  LRP-­‐1b	  (Haas	  et	  al.,	  2011).	  Unlike	  LRP-­‐1,	  
which	  is	  broadly	  expressed,	  LRP-­‐1b	  has	  a	  restricted	  pattern	  of	  expression	  in	  human	  
tissue.	  It	  is	  reported	  that	  its	  expression	  is	  high	  in	  brain	  and	  thyroid	  gland,	  with	  lower	  
expression	   detected	   in	   skeletal	   muscle	   and	   testis.	   No	   expression	   was	   detected	   in	  
other	  tissues	  including	  heart,	  kidney,	  lung	  and	  placenta	  (Haas	  et	  al.,	  2011).	  Deletion	  
or	  inactivation	  of	  LRP-­‐1b	  has	  been	  correlated	  with	  several	  cancers	  in	  humans	  (Liu	  et	  
al.,	   2000a),	   including	   esophaegeal,	   urothelial,	   head	   and	   neck	   tumors,	   and	   B-­‐cell	  
lymphomas	   (Cengiz	   et	   al.,	   2007;	   Langbein	   et	   al.,	   2002;	   Nakagawa	   et	   al.,	   2006;	  
Rahmatpanah	   et	   al.,	   2006;	   Sonoda	   et	   al.,	   2004).	  More	   recently	   it	   has	   been	   shown	  
that	   its	   inactivation	   by	   epigenetic-­‐	   and	   microRNA-­‐mediated	   mechanisms	   confers	  
cancer	  cells	  with	  an	  increased	  growth	  and	  invasion	  capacity	  (Prazeres	  et	  al.,	  2011).	  In	  
addition,	  when	  activity	  of	  LRP-­‐1b	  is	  restored,	  growth	  and	  invasiveness	  of	  cancer	  cells	  
is	   inhibited	   in	   both	   in	   vitro	   and	   in	   vivo	   experimental	   models,	   with	   a	   decrease	   of	  
MMP-­‐2	  levels	  in	  the	  tumor	  environment	  (Prazeres	  et	  al.,	  2011).	  Deletion	  of	  the	  LRP-­‐
1b	   gene	   is	   lethal	   in	  mice,	   although	  blastocysts	   carrying	   the	   same	  mutation	   can	  be	  
propagated	  normally	  in	  culture.	  Interestingly,	  mice	  that	  express	  a	  truncated	  form	  of	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LRP-­‐1b	  missing	  the	  transmembrane	  and	  cytoplasmic	  domain,	  which	  are	  expected	  to	  
secrete	  the	  entire	  extracellular	  domain	  (ECD)	  of	  LRP-­‐1b,	  are	  viable	  and	  do	  not	  show	  
any	  apparent	  phenotype	  (Dietrich	  et	  al.,	  2010).	  These	  discoveries	  highlight	  the	  role	  
of	   LRP-­‐1b	   in	   development	   and	   its	   potential	   role	   as	   a	   signal	   modulator	   in	   the	  
extracellular	  space.	  
1.2.8 Other	  LRP	  related	  receptors	  
The	   LDL	   receptor	   family	   also	   includes	   additional	  members	   that	   are	  more	   distantly	  
related:	  LRP5	  and	  LRP6	  that	  function	  as	  co-­‐receptors	  in	  the	  Wnt	  canonical	  signaling	  
pathway;	   sorLA/LR11	   which	   plays	   a	   crucial	   role	   in	   trafficking	   APP	   and	   in	   the	  
pathogenesis	   of	   Alzheimer's	   Disease	   (AD);	   and	   LRAD3	   is	   involved	   in	   trafficking	   of	  
APP.	  	  
1.2.8.1 LRP5/6	  
LRP5	  and	  6	  were	  identified	  in	  1998	  and	  found	  to	  share	  high	  homology	  with	  members	  
of	  LDL	  receptor	  family	  (Brown,	  1998;	  Dong	  et	  al.,	  1998).	  However,	  rather	  than	  acting	  
as	  endocytic	   receptors,	   LRP5	  and	  LRP6	  were	   found	   to	  be	  co-­‐receptors	   for	   the	  Wnt	  
canonical	   signaling	  pathway	   (Babij	   et	   al.,	   2003;	   Fujino	  et	  al.,	   2003).	  Both	   LRP5	  and	  
LRP6	   ectodomains	   consist	   of	   four	   repeating	   units	   of	   a	   six-­‐bladed	   β-­‐propeller	  
connected	   to	   an	   EGF-­‐like	   domain,	   followed	   by	   three	   LDLR-­‐type	   A	   repeats.	   Wnt	  
proteins	  bind	  to	  either	  LRP5	  or	  LRP6	  and	  a	   frizzled	  receptor.	  This	  binding	  provokes	  
phosphorylation	   of	   the	   LRP5/6	   cytoplasmic	   tail	  with	   subsequent	   stabilization	   of	   β-­‐
catenin,	  which	  migrates	  into	  the	  nucleus	  and	  induces	  the	  expression	  of	  target	  genes.	  
Both	   LRP5	   and	   LRP6	   play	   a	   role	   in	   development,	  with	   LRP6	   appearing	   to	   be	  more	  
critical	   than	  LRP5.	   In	   fact,	   LRP6	  deletion	   is	   lethal	   in	  mice,	  while	   LRP5-­‐null	  mice	  are	  
fully	  viable,	  but	  show	  a	  high	  degree	  of	  osteoporosis	  (Holmen	  et	  al.,	  2004).	  	  
1.2.8.2 SorLA	  or	  LR11	  
SorLA,	   also	   known	   as	   LR11,	   is	   a	   250	   kDa	   receptor	   belonging	   to	   the	   LDL	   receptor	  
family	   (Jacobsen	  et	  al.,	  1996).	  Similar	   to	  other	  LDL	   receptor	   family	  members	  SorLA	  
binds	   ApoE,	   RAP	   and	   lipoprotein	   lipase.	   However,	   uniquely	   among	   LDLRs,	   SorLA	  
contains	   a	   vacuolar	   protein	   sorting	   10	   protein	   (vps10p)	   domain,	  which	   indicates	   a	  
role	  for	  SorLA	  in	  protein	  trafficking	  (Yamazaki	  et	  al.,	  1996).	  SorLA	  is	  mainly	  expressed	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in	  brain,	  spinal	  cord	  and	  testis.	  Its	  expression	  is	  reduced	  in	  AD	  brains,	  suggesting	  that	  
SorLA	  activity	  is	  linked	  with	  the	  pathogenesis	  of	  AD	  (Scherzer	  et	  al.,	  2004).	  In	  fact,	  in	  
2005	  Andersen	  et	  al.	  reported	  that	  sorLA	  regulates	  processing	  of	  amyloid	  precursor	  
protein.	  The	  overexpression	  of	  sorLA	  in	  neurons	  enhances	  the	  localization	  of	  APP	  in	  
the	  Golgi	  and	  decreases	  it	  on	  the	  cell	  surface,	  thus	  diminishing	  the	  formation	  of	  Aβ.	  
On	  the	  other	  hand,	  ablation	  of	  sorLA	   in	  mice	  provokes	  higher	   levels	  of	  APP	  on	  the	  
cell	  surface	  and	  increases	  production	  of	  Aβ	  (Andersen	  et	  al.,	  2005).	  In	  2006	  Spoelgen	  
and	   colleagues	   reported	   that	   sorLA	   can	   bind	   both	   APP	   and	   BACE	   through	   its	  
cytoplasmic	   tail	   and	   that	   it	   can	   prevent	   interactions	   between	   APP	   and	   BACE	   and	  
therefore	  Aβ	  production	  (Spoelgen	  et	  al.,	  2006).	  
1.2.8.3 LRAD3	  
Very	  little	  is	  known	  about	  LDL	  receptor	  class	  A	  domain	  containing	  3	  (LRAD3)	  which	  is	  
the	  most	  recently	  identified	  member	  of	  the	  LDL	  receptors	  family	  (Ranganathan	  et	  al.,	  
2011b).	   LRAD3	   is	   a	   50	   kDa	   type	   I	   transmembrane	   receptor	   with	   an	   ectodomain	  
containing	   three	  LDLa	  repeats,	  a	   transmembrane	  domain,	  a	  cytoplasmic	  domain	  of	  
151	  amino	  acids,	  which,	  unlike	  most	  other	  members	  of	  the	  LDL	  receptor	  family,	  does	  
not	   contain	   NPXY	   internalization	   sequences.	   However,	   the	   LRAD3	   cytoplasmic	  
domain	   contains	   a	   conserved	   dileucine	   motif	   which	   may	   mediate	   endocytosis	  
(Ranganathan	   et	   al.,	   2011b).	   LRAD3	  expression	  was	   found	   to	   be	  high	   in	   the	  brain,	  
where	  it	  co-­‐localizes	  with	  APP.	  It	  plays	  a	  role	  in	  modulating	  the	  processing	  of	  APP,	  as	  
it	  was	  reported	  that	  coexpression	  of	  LRAD3	  with	  APP	  decreases	  the	   levels	  of	  Aβ	   in	  
the	  medium	  compared	  the	  expression	  of	  only	  APP	  (Ranganathan	  et	  al.,	  2011b).	  
1.3 Heparan	  sulfate	  proteoglycan-­‐mediated	  endocytosis	  
Heparan	   sulfate	   proteoglycans	   (HSPGs)	   are	   glycoproteins	   that	   contain	   covalently	  
attached	   heparan	   sulfate	   chains	   (HS)	   (Sarrazin	   et	   al.,	   2011).	   Heparan	   sulfates	   are	  
glycosaminoglycans	  (GAGs)	  that	  consist	  of	  a	  repeating	  sequence	  of	  the	  disaccharide	  
unit,	   glucuronic	   acid—N-­‐acetylglucosamine,	   and	   differ	   for	   their	   level	   of	   sulfation.	  
There	   are	   four	   groups	   of	   HSPGs	   according	   to	   their	   localization:	   transmembrane	  
HSPGs,	   which	   includes	   the	   syndecan	   family,	   GPI-­‐anchored	   HSPGs,	   which	   includes	  
glypicans,	  and	  secreted	  HSPGs,	  such	  as	  perlecan	  and	  agrin	  (Sarrazin	  et	  al.,	  2011).	  The	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proteoglycan	   serglycin	   falls	   into	   another	   group,	   which	   is	   the	   vesicle-­‐associated	  
HSPGs.	   The	   biosynthesis	   of	   heparan	   sulfate	   proteoglycans	   occurs	   in	   a	   number	   of	  
steps	   and	   involves	   several	   enzymes	   that	   function	   sequentially.	   It	   starts	   with	   the	  
transfer	   of	   xylose	   to	   serine	   residues	   of	   the	   protein	   core	   mediated	   by	  
xylosyltransferase.	   After	   xylose,	   two	  molecules	   of	   galactose	   and	   one	   of	   glucuronic	  
acid	  are	  added	  to	  form	  the	  link	  saccharide	  between	  protein	  and	  HS	  chain.	  After	  the	  
link	   saccharide	   is	   positioned,	   alternate	   N-­‐acetylglucosamine	   units	   and	   glucuronic	  
acid	  units	  are	  added	  to	   the	   link,	  with	   the	  effect	  of	  elongating	   the	  HS	  chain.	  As	   the	  
chain	   polymerizes,	   it	   undergoes	   several	   modifications	   that	   include	   deacetylation,	  
sulfation	   and	   epimerisation.	   Esko	   et	   al.	   (1985)	   created	   a	   mutant	   cell	   line	   not	  
expressing	  HSPGs	   due	   to	   inactivation	   of	   xylosyltransferase	   (Esko	   et	   al.,	   1985).	   The	  
generation	  of	  this	  mutant	  cell	  line	  allowed	  functional	  studies	  that	  have	  shed	  light	  on	  
many	  of	   the	  biological	   functions	  of	  HSPGs.	   To	  date,	  HSPGs	  are	   known	   (i)	   to	  be	   an	  
important	   component	  of	  basal	  membranes,	   (ii)	   to	   function	  as	  extracellular	   storage	  
sites	  for	  cytokines,	  growth	  factors	  and	  chemokines,	  (iii)	  to	  mediate	  cell-­‐cell	  and	  cell-­‐
matrix	   adhesion,	   (iv)	   to	   trigger	   cell	   signaling,	   and	   (v)	   to	   act	   as	   co-­‐receptors	   or	   as	  
independent	  endocytic	  receptors	  (Couchman,	  2010;	  Sarrazin	  et	  al.,	  2011).	  	  	  
1.3.1 HSPGs	  as	  co-­‐receptors	  
HSPGs	   have	   been	   reported	   to	   function	   as	   co-­‐receptors	   to	   the	   LDLR	   family	   for	   the	  
internalization	  of	  a	  number	  of	   ligands.	   It	   is	  postulated	  that	  HSPGs	  may	  accumulate	  
ligands	   in	   certain	   areas	   of	   the	   cell	  membrane	   rendering	   them	  more	   accessible	   for	  
subsequent	  binding	  to	  LDL-­‐	  receptors.	  	  
	   Wang	  et	  al.	  (2004)	  reported	  that	  thrombospondin	  1,	  which	  is	  an	  LRP-­‐1	  ligand,	  
requires	  prior	  high-­‐affinity	  binding	  to	  cell	  surface	  HSPGs	  to	  be	  internalized	  (Wang	  et	  
al.,	   2004).	   Tissue	   factor	   pathway	   inhibitor	   (TFPI)	   is	   an	   important	   regulator	   of	  
coagulation	  by	  inhibiting	  both	  factor	  Xa	  and	  factor	  VIIa,	  two	  crucial	  enzymes	  of	  the	  
coagulation	  cascade.	  TFPI	  is	  internalized	  by	  cells	  through	  a	  mechanism	  that	  involves	  
both	  HSPGs	  and	  LRP-­‐1	  (Schwartz	  and	  Broze,	  1997).	  The	  high	  amount	  of	  HSPGs	  on	  the	  
cell	   surface	   compared	   to	   LRP-­‐1	   suggests	   that	  HSPGs	   serve	   to	  dock	   TFPI	   at	   the	   cell	  
surface	  but	  do	  not	  mediate	  its	  uptake,	  and	  LRP-­‐1	  mediates	  TFPI	  internalization.	  The	  
extracellular	   levels	   of	   coagulation	   factor	   VIII	   are	   also	   regulated	   by	   a	   similar	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mechanism.	  The	  internalization	  of	  factor	  VIII	  is	  blocked	  in	  mutant	  cells	  lacking	  either	  
LRP-­‐1	  or	  HSPGs	  (Sarafanov	  et	  al.,	  2001).	  As	  in	  the	  case	  of	  TFPI,	  firstly	  HSPGs	  mediate	  
the	   binding	   of	   factor	   VIII	   to	   the	   cell	   surface,	   and	   secondly	   LRP-­‐1	   induces	   its	  
endocytosis.	  Several	  other	  proteins	  involved	  in	  blood	  coagulation	  are	  internalized	  in	  
a	  LRP-­‐1-­‐	  and	  heparin-­‐sensitive	  manner,	  including	  uPA	  and	  protease	  nexin-­‐1,(Crisp	  et	  
al.,	  2000).	  Altogether	  these	  studies	  indicate	  the	  LRP-­‐1/HSPGs	  axis	  functions	  as	  a	  key	  
regulator	  of	  blood	  homeostasis.	  	  
	   Kanekyo	   et	   al.	   (2011)	   reported	   that	   another	   LRP-­‐1	   ligand,	   Aβ	   peptide,	   are	  
internalized	   in	   such	   a	   manner	   that	   involves	   HSPGs	   as	   co-­‐receptor.	   Both	   heparin,	  
which	  antagonizes	  cell	  surface	  HSPGs,	  and	  heparinase	  treatment	  blocked	  the	  LRP-­‐1-­‐
dependent	  internalization	  of	  Aβ	  by	  neurons,	  showing	  that	  HSPGs	  and	  LRP-­‐1	  function	  
in	  a	  cooperative	  way	  for	  its	  internalization	  (Kanekiyo	  et	  al.,	  2011).	  	  	  
1.3.2 HSPGs	  as	  independent	  receptors	  
Membrane	   HSPGs	   can	   also	   act	   as	   independent	   receptors,	   although	   the	   precise	  
mechanism	  is	  not	  completely	  understood	  yet.	  Clathrin,	  caveolin	  and	  dynamin	  are	  not	  
involved	  in	  the	  process	  of	  internalization	  through	  HSPGs,	  and	  transmembrane	  HSPGs	  
are	   internalized	   with	   a	   different	   kinetics	   compared	   to	   GPI-­‐anchored	   HSPGs	  
(Yanagishita,	  1992).	  As	  was	  discussed	  in	  Section	  1.2.2.4,	  LRP-­‐1	  plays	  a	  crucial	  role	  in	  
the	  hepatic	  clearance	  of	  chylomicron	  remnants	  from	  plasma.	  Chylomicron	  remnants	  
can	   also	   interact	   with	   HSPGs,	   which	   are	   abundant	   on	   the	   surface	   of	   hepatocytes	  
(Mahley	  and	  Huang,	  2007).	  HSPGs	  can	  either	   function	  as	  co-­‐receptors	   to	  LRP-­‐1	   for	  
the	   clearance	   of	   chylomicron	   remnants,	   or	   they	   can	   directly	   mediate	   the	  
internalization	  of	  remnants.	  Recently,	  Stanford	  et	  al.	  (2009)	  reported	  that	  syndecan-­‐
1	   is	   the	  primary	  heparan	   sulfate	  proteoglycan	   involved	   in	   the	  hepatic	   clearance	  of	  
chylomicrons,	  showing	  that	  Sdc-­‐/-­‐	  mice	  accumulated	  plasma	  triglycerides	  (Stanford	  et	  
al.,	  2009).	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1.4 TIMPs	  
Many	   proteinases	   are	   involved	   in	   the	   degradation	   of	   the	   ECM,	   and	   the	   matrix	  
metalloproteinases	   (MMPs)	   are	   thought	   to	   be	   of	   primary	   importance.	  MMPs,	   also	  
called	  matrixins,	  belong	  to	  the	  metzincin	  superfamily	  of	  zinc-­‐dependent	  proteinases	  
(Nagase	  and	  Woessner,	  1999).	  The	  disintegrin	  and	  metalloproteinases	  (ADAMs)	  and	  
the	   disintegrin	   and	   metalloproteinases	   with	   thrombospondin	   domains	   (ADAMTSs)	  
also	   form	   part	   of	   the	   	   metzincin	   superfamily	   (Apte,	   2009;	   Edwards	   et	   al.,	   2008).	  
While	   MMPs	   and	   ADAMTSs	   mainly	   degrade	   ECM	   components,	   affecting	   the	   cell	  
environment,	   ADAMs	   cleaves	   cell	   surface	   proteins,	   including	   signaling	   receptors,	  
adhesion	  molecules	  and	  pro-­‐cytokines.	  The	  activity	  of	  MMPs,	  ADAMs	  and	  ADAMTSs	  
in	   the	   tissue	   is	   finely	   orchestrated,	   and	   dysregulation	   of	   their	   activities	   leads	   to	  
pathological	   conditions	   associated	  with	   uncontrolled	   ECM	   turnover,	   inflammation,	  
cell	   growth	   and	   migration,	   such	   as	   arthritis,	   cancer,	   and	   cardiovascular	   diseases.	  
Regulation	   of	   MMPs,	   ADAMs	   and	   ADAMTSs	   occurs	   at	   different	   levels,	   including	  
transcriptional	  and	  post-­‐transcriptional	   regulation,	  activation	  of	   inactive	  precursors	  
and	  inhibition	  by	  the	  tissue	  inhibitors	  of	  metalloproteinases	  (TIMPs).	  (Murphy,	  2009;	  
Nagase	   et	   al.,	   2006;	   Werb	   et	   al.,	   1999).	   Consequently,	   TIMPs	   are	   involved	   in	  
maintaining	   tissue	   homeostasis	   by	   controlling	   the	   activity	   of	   these	  
metalloproteinases	   and	   therefore	   TIMPs	   are	   important	   in	   biological	   and	  
physiological	  processes	  including	  embryogenesis,	  development	  and	  wound	  healing.	  
	   The	   first	   member	   of	   the	   TIMP	   family	   was	   discovered	   in	   the	   1970s.	   It	   was	  
found	   in	   different	   tissues	   like	   skin,	   cartilage	   tendon	   and	   serum,	   as	   an	   inhibitor	   of	  
collagenases	   (Bauer	   et	   al.,	   1975;	  Vater	   et	   al.,	   1979;	  Woolley	   et	   al.,	   1975).	   Later,	   it	  
was	   also	   found	   to	   be	   an	   inhibitor	   of	   gelatinases	   and	   stromelysins,	   and	   therefore	  
named	   "tissue	   inhibitor	   of	   metalloproteinases"	   or	   "TIMP"	   (Cawston	   et	   al.,	   1981).	  
Four	  TIMPs	  have	  been	  characterized	  in	  humans.	  All	  of	  them	  present	  some	  common	  
structural	   features	  and	   the	   same	  mechanism	  of	  MMP	   inhibition.	  Nevertheless,	   the	  
four	  TIMPs	  harbor	  some	  properties	  that	  render	  them	  unique	  among	  the	  family.	  	  	  	  
1.4.1 TIMPs:	  common	  features	  
All	   mammalian	   TIMPs	   consist	   of	   two	   distinct	   domains,	   an	   N-­‐terminal	   domain	   of	  
about	  125	  amino	  acid	   residues	  and	  a	  C-­‐terminal	  domain	  of	  about	  65	  residues.	  The	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global	  structure	  of	  each	  domain	  is	  maintained	  by	  three	  disulfide	  bonds	  (Williamson	  
et	  al.,	  1990).	  Recombinant	  forms	  of	  the	  N-­‐terminal	  domains	  of	  TIMPs,	  denominated	  
N-­‐TIMPs,	   have	   stable	   native	   structures	   and	   are	   fully	   active	   as	   inhibitors	   of	  MMPs	  
(Murphy	  et	  al.,	  1991).	  The	  N-­‐terminal	  domains	  consist	  of	  five	  β-­‐strands	  connected	  by	  
loops,	  and	  three	  α-­‐helices,	  one	  at	   the	  N-­‐terminus	  and	  two	  close	   to	   the	  C-­‐terminus	  
forming	  part	  of	  the	  interface	  with	  the	  C-­‐domain	  (Figure	  3)	  (Brew	  and	  Nagase,	  2010).	  	  
	  
	  
Figure	  3,	  Common	  structure	  of	  mammalian	  TIMPs	  
A	   ribbon	   structure	   showing	   the	   common	   features	   of	   mammalian	   TIMPs:	   the	   N-­‐
terminal	  domain	   (blue)	  with	   the	  terminal	   five	  residues	  which	  make	  the	  majority	  of	  
interactions	   with	   metalloproteinases	   (cyan),	   the	   conserved	   disulfide	   bonds	   Cys1-­‐
Cys70	  and	  Cys3-­‐Cys100	  (yellow),	  and	  the	  C-­‐terminal	  domain	  (grey)	  are	  indicated.	  
	  	  
	   Although	   the	   four	   TIMPs	   bind	   tightly	   to	   most	   MMPs,	   some	   differences	   in	  
inhibitory	  properties	  among	  the	  four	  different	  TIMPs	  have	  been	  reported.	  TIMP-­‐1	  is	  
more	   limited	   in	   its	   inhibitory	   spectrum	   than	   the	   other	   three	   TIMPs,	   with	   low	  
affinities	   for	  membrane-­‐type	  MMPs	   (Murphy	  and	  Nagase,	  2008a),	  whereas	  TIMP-­‐2	  
and	  -­‐3	  are	  weaker	  than	  TIMP-­‐1	  in	  inhibiting	  MMP-­‐3	  and	  -­‐7	  (Hamze	  et	  al.,	  2007),	  and	  
TIMP-­‐3	  unlike	  other	  TIMPs,	   is	  able	   to	   inhibit	   several	  members	  of	   the	  ADAMTS	  and	  
ADAM	  metalloproteinase	  families	  (Amour	  et	  al.,	  1998;	  Kashiwagi	  et	  al.,	  2001).	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   Structures	  of	  TIMP-­‐1,	  TIMP-­‐2	  and	  N-­‐TIMP-­‐3	  in	  inhibitory	  complexes	  with	  their	  
target	   metalloproteinases	   have	   been	   determined	   by	   X-­‐ray	   crystallography	  
(Fernandez-­‐Catalan	  et	  al.,	   1998;	  Gomis-­‐Rüth	  et	  al.,	   1997;	  Wisniewska	  et	  al.,	   2008).	  
TIMPs	   appear	   as	   wedge-­‐shaped,	   with	   a	   ridge	   which	   inserts	   into	   the	  
metalloproteinase	  active	  site	  cleft	   in	  such	  a	  manner	   that	   the	  conserved	  N-­‐terminal	  
Cys1	  coordinates	   the	  catalytic	  Zn2+	  of	   the	  metalloproteinases	   (Figure	  4)(Gomis-­‐Rüth	  
et	  al.,	  1997).	  The	  bidentate	  coordination	  of	  the	  metal	  ion	  by	  the	  N-­‐terminal	  α-­‐amino	  
group	  and	  carbonyl	  group	  of	  Cys1	  displaces	  the	  water	  molecules	  needed	  for	  peptide	  
bond	   hydrolysis,	   and	   the	   majority	   of	   the	   interactions	   between	   TIMPs	   and	   a	  
metalloproteinase	   are	  made	   by	   a	   continuous	   ridge	   formed	   by	   the	   N-­‐terminal	   five	  
residues	   (for	   instance	   Cys1-­‐Thr-­‐Cys-­‐Val-­‐Pro5	   in	   TIMP-­‐1)	  which	   are	   highly	   conserved	  
among	  all	  TIMPs,	  and	  the	  loop	  connecting	  the	  β-­‐strands	  C	  and	  D	  (CD	  loop).	  
	  
	   	  
Figure	  4,	  Common	  interactions	  between	  TIMPs	  and	  metalloproteinases	  
The	   conserved	   N-­‐terminal	   Cys1	   (cyan)	   of	   the	   TIMP	   moiety	   (blue)	   coordinates	   the	  
catalytic	  Zn2+	  (red	  sphere),	  which	  is	  bound	  to	  the	  three	  conserved	  histidines	  (yellow)	  
of	  the	  metalloproteinase	  (green).	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1.4.1.1 TIMP-­‐1	  
TIMP-­‐1	  was	  the	  first	  member	  of	  TIMP	  family	  to	  be	  discovered	  and	  purified	  (Bauer	  et	  
al.,	   1975;	   Vater	   et	   al.,	   1979;	  Woolley	   et	   al.,	   1975).	   Compared	   to	   TIMP-­‐3,	   it	   has	   a	  
narrower	  specificity	  against	  the	  different	  groups	  of	  metzincins,	  being	  able	  to	  inhibit	  
MMPs	   and	   only	   ADAM-­‐10	   among	   ADAM	   proteinases,	   but	   with	   a	   relatively	   low	  
affinity	   for	   the	  membrane-­‐type	  1	  matrix	  metalloproteinase	   (MT1-­‐MMP)	  and	  MMP-­‐
19	   (Amour	   et	   al.,	   2000;	   Brew	   and	   Nagase,	   2010).	   TIMP-­‐1	   has	   several	   biological	  
activities	  that	  influence	  cell	  behavior.	  Many	  of	  these	  activities	  are	  dependent	  on	  its	  
metalloproteinase	   inhibitory	   capability,	   but	   others	   are	   independent	   from	   this	  
inhibitory	   function.	   For	   example,	   TIMP-­‐1	   was	   shown	   to	   promote	   cell	   growth	   in	  
various	   cell	   types	   including	   fibroblasts	   (Hayakawa	   et	   al.,	   1992).	   This	   is	   due	   to	   its	  
interaction	  with	  a	  specific	  receptor,	  which	  is	  still	  unknown,	  and	  activation	  of	  MAPK	  
signaling	  pathway	  (Wang	  et	  al.,	  2002).	  TIMP-­‐1	  has	  also	  been	  reported	  to	  have	  anti-­‐
apoptotic	   activity	   (Taube	   et	   al.,	   2006).	   Thus,	   high	   levels	   of	   TIMP-­‐1	   in	   serum	   and	  
expression	   in	   cancer	   are	   associated	   with	   poor	   prognosis	   in	   many	   kinds	   of	   cancer	  
(Kossakowska	   et	   al.,	   1991;	   Nakopoulou	   et	   al.,	   2002).	   The	   anti-­‐apoptotic	   activity	   is	  
mediated	  by	  the	  interaction	  of	  the	  inhibitor	  with	  CD63,	  a	  member	  of	  the	  tetraspanin	  
family	  (Jung	  et	  al.,	  2006).	  The	  TIMP-­‐1—CD63	  complex	  interacts	  with	  integrin	  β1	  and	  
induces	  the	  activation	  of	  survival	  signaling	  through	  focal	  adhesion	  kinase,	  P13K	  and	  
ERK	  (Liu	  et	  al.,	  2003;	  Liu	  et	  al.,	  2005).	  
1.4.1.2 TIMP-­‐2	   	  
TIMP-­‐2	  was	   first	  purified	   from	  the	  cultural	  medium	  of	  human	  melanoma	  cells	  as	  a	  
complex	   of	   proMMP-­‐2—TIMP-­‐2	   (Stetler-­‐Stevenson	   et	   al.,	   1989).	   Besides	   its	  
inhibition	  of	  MMPs,	   the	  protein	   is	  capable	  of	   inhibiting	  angiogenesis	   (Moses	  et	  al.,	  
1990).	   All	   four	  members	   of	   the	   TIMP	   family	   are	   reported	   to	   have	   anti-­‐angiogenic	  
activity,	  which	   is	   linked	   to	   their	   capability	   to	   inhibit	  metalloproteinases.	   However,	  
compared	  to	  other	  TIMPs,	  TIMP-­‐2	   is	  unique	   in	   its	  ability	   to	   inhibit	  endothelial	  cells	  
proliferation	   and	   migration	   in	   a	   manner	   which	   is	   independent	   from	  
metalloproteinase	   inhibition	  and	  possibly	  mediated	  by	  binding	   to	  a	   cell-­‐membrane	  
receptor	   (Murphy	   et	   al.,	   1993a).	   	   As	   with	   TIMP-­‐1,	   TIMP-­‐2	   induces	   cell	   growth.	  
However,	  TIMP-­‐2	  triggers	  a	  different	  signaling	  pathway	  from	  that	  activated	  by	  TIMP-­‐
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1,	   and	   leads	   to	   the	   activation	   of	   the	   protein	   kinase	   A	   (PKA)	   (Wang	   et	   al.,	   2002).	  
Inhibition	   of	   angiogenesis	   may	   be	   due	   to	   TIMP-­‐2	   interaction	   with	   α3β1	   integrin,	  
which	   induces	   tyrosine-­‐kinase	   phosphatase	   activity	   and	   suppresses	   growth	   factor-­‐
induced	  phosphorylation	  pathways	  (Feldman	  et	  al.,	  2004).	  
	   Another	  unique	  property	  of	  TIMP-­‐2	  is	  its	  ability	  to	  mediate	  activation	  of	  pro-­‐
MMP2.	   TIMP-­‐2	   can	   interact	   with	   the	   hemopexin	   domain	   of	   pro-­‐MMP-­‐2	   by	   its	   C-­‐
terminal	  domain.	  A	  molecule	  of	  MT1-­‐MMP	  can	  function	  as	  a	  membrane	  receptor	  for	  
the	  pro-­‐MMP-­‐2—TIMP-­‐2	  complex.	  A	  second	  molecule	  of	  MT1-­‐MMP,	  free	  of	  TIMP-­‐2,	  
homodimerizes	   with	   the	   molecule	   of	   MT1-­‐MMP	   bound	   to	   pro-­‐MMP-­‐2—TIMP-­‐2	  
complex.	   In	   this	   manner,	   the	   free	   MT1-­‐MMP	   which	   is	   in	   close	   proximity	   to	   the	  
trimolecular	   complex	   cleaves	   the	   pro-­‐domain	   from	   pro-­‐MMP-­‐2	   (Strongin	   et	   al.,	  
1995).	  	  
1.4.1.3 TIMP-­‐3	  
TIMP-­‐3	   harbors	   some	   unique	   properties	   among	   TIMPs.	   It	  was	   first	   reported	   as	   an	  
ECM	   binding	   protein	   (Pavloff	   et	   al.,	   1992;	   Staskus	   et	   al.,	   1991;	   Yang	   and	   Hawkes,	  
1992)	  different	  from	  other	  TIMPs	  which	  are	  soluble	  in	  the	  extracellular	  milieu.	  Lee	  et	  
al.	   (2007)	   identified	   the	   ECM-­‐binding	   motif	   in	   TIMP-­‐3	   by	   extensive	   site-­‐directed	  
mutagenesis.	  Mutation	  of	  a	  cluster	  of	   lysine	  and	  arginine	  residues,	   situated	  on	  the	  
opposite	   side	   of	   the	   molecule	   to	   the	   inhibitory	   ridge,	   to	   glutamine	   or	   glutamate	  
residues,	  resulted	  in	  a	  soluble	  TIMP-­‐3.	  This	  cluster	  of	  lysines	  and	  arginines	  is	  specific	  
for	  TIMP-­‐3.	  Furthermore,	  when	  this	  cluster	  of	   lysines	  and	  arginines	  was	   introduced	  
into	  TIMP-­‐1,	  the	  chimera	  inhibitor	  showed	  binding	  to	  the	  ECM	  (Lee	  et	  al.,	  2007).	  	  
	   TIMP-­‐3	   inhibits	   some	  members	   of	   the	  MMP,	   ADAM	   and	   ADAMTS	   families	  
(Amour	   et	   al.,	   1998;	   Kashiwagi	   et	   al.,	   2001;	   Murphy	   et	   al.,	   1991).	   The	   ADAM	  
metalloproteinases	   are	   a	   family	   of	   membrane-­‐bound	   enzymes,	   which	   are	   also	  
referred	   to	   as	   “sheddases”	   for	   their	   ability	   to	   cleave	   extracellular	   portions	   of	  
transmembrane	   proteins,	   releasing	   the	   soluble	   ectodomains	   from	   the	   cell	   surface.	  
TIMP-­‐3	  was	   first	   shown	   to	   inhibit	   ADAM-­‐17,	   also	   called	   the	   tumor	   necrosis	   factor	  
alpha	   (TNF-­‐α)	   converting	   enzyme	   (TACE),	   which	  mediates	   the	   shedding	   of	   soluble	  
TNF-­‐α	   from	   its	  membrane-­‐associated	   precursor	   (Amour	   et	   al.,	   1998).	   It	   also	   sheds	  
others	   receptors	   such	   as	   TNF	   receptors,	   tumor	   growth	   factor	   alpha	   (TGFα)	   and	   L-­‐
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selectin	  (Le	  Gall	  et	  al.,	  2009;	  Wang	  et	  al.,	  2009).	  TIMP-­‐3	  is	  also	  an	  effective	  inhibitor	  
of	  ADAMTS-­‐4	  and	  -­‐5,	  also	  known	  as	  aggrecanase-­‐1	  and	  -­‐2,	  respectively	  (Kashiwagi	  et	  
al.,	  2001).	  The	  inhibition	  of	  TACE	  and	  aggrecanases	  suggest	  a	  leading	  role	  for	  TIMP-­‐3	  
in	  regulating	  inflammatory	  processes	  and	  affecting	  the	  progression	  of	  diseases	  such	  
as	  cancer,	  rheumatoid	  arthritis	  and	  osteoarthritis.	  	  
	   TIMP-­‐3	   shows	   a	   pro-­‐apoptotic	   effect	   on	   several	   cell	   types	   (Ahonen	   et	   al.,	  
1998;	  Baker	  et	  al.,	  1999).	  The	  pro-­‐cell	  death	  function	  of	  TIMP-­‐3	  is	  located	  within	  the	  
N-­‐terminal	   domain	   and	   it	   correlates	   with	   its	  MMP-­‐inhibitory	   activity	   (Bond	   et	   al.,	  
2000).	   Bond	   et	   al.	   (2002)	   showed	   that	   TIMP-­‐3	   is	   involved	   in	   a	   type	   II	   apoptotic	  
pathway	   initiated	  by	  FAS,	  by	  demonstrating	   that	  a	  dominant	  negative	   form	  of	   this	  
death	   receptor	   inhibited	   the	   TIMP-­‐3	   induced	   apoptosis.	   TIMP-­‐3	   pro-­‐apoptotic	  
activity	  results	  from	  its	  ability	  to	  stabilize	  TNF	  receptors	  due	  to	  an	  inhibition	  of	  TACE-­‐
mediated	  shedding	  (Ahonen	  et	  al.,	  2003).	  	  
	   TIMP-­‐3	   is	   also	  a	  potent	   inhibitor	  of	   angiogenesis;	   this	   activity	   is	  dissociated	  
from	  the	  metalloproteinase	  inhibiting	  activity	  and	  it	  is	  due	  to	  direct	  binding	  to	  VEGF	  
receptor	   2	   which	   blocks	   the	   effect	   of	   VEGF	   on	   endothelial	   cells	   (Qi	   et	   al.,	   2003).	  
TIMP-­‐3	   also	   binds	   to	   angiotensin	   II	   type-­‐2	   receptor,	   and	   overexpression	   of	   both	  
TIMP-­‐3	  and	  angiotensin	  II	  type-­‐2	  receptor	  synergistically	  inhibits	  angiogenesis	  (Kang	  
et	  al.,	  2008).	  
1.4.1.4 TIMP-­‐4	  
Among	   four	   TIMPs,	   TIMP-­‐4	   is	   the	   last	   one	   identified	   (Greene	   et	   al.,	   1996).	   The	  
primary	  sequence	  of	  TIMP-­‐4	  is	  51%	  identical	  to	  that	  of	  TIMP-­‐2	  (Olson	  et	  al.,	  1998).	  Its	  
tertiary	   structure	   is	   considered	   to	   be	   stabilized	   by	   six	   disulfide	   bridges,	  which	   is	   a	  
structural	   signature	  of	  TIMPs.	  Despite	   its	   similarity	   to	  TIMP-­‐2	  and	   the	  capability	   to	  
interact	  with	  pro-­‐MMP-­‐2,	  TIMP-­‐4	  does	  not	  induce	  the	  activation	  of	  the	  enzyme	  (Bigg	  
et	   al.,	   2001).	  While	   other	   TIMPs	   are	   expressed	   in	  most	   tissues,	   the	   expression	   of	  
TIMP-­‐4	   is	   largely	   confined	   to	   the	   heart,	   kidney	   and	   brain	   (Koskivirta	   et	   al.,	   2010).	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Table	  3:	  Schematic	  summery	  of	  the	  general	  properties	  of	  the	  four	  TIMPs	  
	  
	  
1.4.2 Biological	  activity	  of	  TIMP-­‐3	  
Studies	   with	   mice	   deficient	   in	   TIMP-­‐3	   have	   suggested	   the	   physiological	   and	  
pathological	   functions	   of	   TIMP-­‐3	   in	   vivo.	   Timp3-­‐null	   mice	   exhibit	   several	  
abnormalities,	   including	   air	   space	   enlargement	   in	   the	   lungs,	   enhanced	   apoptosis	  
during	   mammary	   gland	   involution,	   dilated	   cardiomyopathy,	   abnormal	  
vascularization	   with	   enlarged	   capillaries	   and	   impaired	   bronchiole	   branching	  
morphogenesis	   (Fata	   et	   al.,	   2001;	   Fedak	   et	   al.,	   2004;	   Gill	   et	   al.,	   2003;	   Leco	   et	   al.,	  
2001).	  These	  abnormalities	  are	  due	  to	  enhanced	  matrix	  degradation	  caused	  by	  a	  lack	  
of	  metalloproteinase	  inhibition.	  The	  Timp3-­‐null	  mouse	  has	  additional	  defects	  related	  
to	  excess	  ADAM	  and	  ADAMTS	  activity.	  Timp3-­‐null	  mice	  release	  high	  levels	  of	  TNF-­‐α	  
upon	   challenge	   with	   partial	   hepatectomy,	   due	   to	   excess	   of	   ADAM-­‐17	   activity	  
(Mohammed	   et	   al.,	   2004).	   These	   mice	   show	   signs	   of	   premature	   arthritis	   due	   to	  
increased	  aggrecan	  degradation	  (Sahebjam	  et	  al.,	  2007).	  These	  studies	  indicate	  that	  
TIMP-­‐3	   is	   a	   key	   endogenous	   regulator	   of	   metalloproteinases	   involved	   in	   ECM	  
turnover	  and	  inflammation.	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1.4.3 Regulation	  of	  TIMP-­‐3	  synthesis	  
The	   synthesis	   of	   TIMP-­‐3	   is	   regulated	   transcriptionally,	   which	   includes	   epigenetic	  
regulation.	   More	   recent	   studies	   have	   shown	   that	   it	   is	   also	   regulated	   post-­‐
transcriptionally	  by	  microRNA	  (miRNA).	  	  
Transcriptional	   regulation.	  TGF-­‐β1	   is	   a	  multifunctional	   growth	   factor	   produced	   by	  
different	   cell-­‐types	   such	  as	  monocytes,	  platelets	  and	  chondrocytes.	  This	   factor	   is	  a	  
potent	   inducer	   of	   chondrogenesis	   during	   development	   and	   ECM	   synthesis	   in	  
cartilage.	   It	   has	   been	   shown	   to	   induce	   the	   expression	   of	   TIMP-­‐3	   in	   articular	  
chondrocytes	   (Gunther	  et	  al.,	  1994;	  Su	  et	  al.,	  1996).	  Qureshi	  et	  al.	   (2005)	  reported	  
that	  TGF-­‐β1	  induces	  the	  expression	  of	  TIMP-­‐3	  by	  activating	  the	  ERK-­‐MAPK	  signaling	  
pathway	   leading	   to	   phosphorylation	   of	   the	   Sp-­‐1	   transcription	   factor	   and	   its	  
subsequent	  binding	  to	  the	  TIMP3	  promoter.	  More	  recently,	  Qureshi	  et	  al.	  (2008)	  also	  
reported	  that	  TIMP-­‐3	  expression	  could	  be	  induced	  by	  TGF-­‐β1	  through	  a	  mechanism	  
involving	  Smad-­‐2,	   -­‐3	  and	   -­‐4.	  Oncostatin	  M,	  a	  cytokine	  belonging	   to	   the	   IL-­‐6	   family,	  
can	  also	  induce	  expression	  of	  TIMP-­‐3	  in	  human	  chondrocytes	  by	  activating	  the	  Janus	  
Kinase/STAT	  signaling	  pathway	  (Li	  et	  al.,	  2001).	  	  
	   Epstein-­‐Barr	  virus	  latent	  protein	  1	  (LMP-­‐1)	  is	  a	  viral	  protein	  essential	  for	  the	  
capability	  of	  Epstein-­‐Barr	  virus	   to	  mediate	  growth	  transformation	  of	  B-­‐cells.	  LMP-­‐1	  
was	  shown	  to	  suppress	  TIMP-­‐3	  transcription	  by	  binding	  to	  the	  promoter	  of	  the	  TIMP-­‐
3	  gene,	  thus	  promoting	  metastasis	   in	  EBV-­‐negative	  nasopharyngeal	  carcinoma	  cells	  
(Chang	  et	  al.,	  2008).	  Human	  hepatitis	  B	  virus	  suppresses	  TIMP-­‐3	  expression,	  but	  the	  
molecular	  mechanism	  is	  still	  poorly	  understood	  (Kim	  and	  Kim,	  2004).	  	  
	   Missense	  mutations	  in	  the	  p53	  gene	  inactivate	  its	  growth	  suppressing	  activity	  
and	   are	   observed	   in	   the	  majority	   of	   human	   tumors.	   Thomas	  et	   al.	   (2006)	   showed	  
that	  missense	  mutations	  in	  p53	  create	  a	  mutant	  p53	  that	  gained	  the	  ability	  to	  bind	  
to	   the	   TIMP-­‐3	  promoter	   and	   suppress	   its	   expression.	   Loss	  of	   TIMP-­‐3	  expression	   in	  
cancer	   cells	   could	   lead	   to	   increase	   of	   metalloproteinase	   activity	   and	   therefore	  
increased	  metastatic	  potential.	  	  
Epigenetic	   regulation.	   The	   epigenetic	   regulation	   of	   gene	   expression	   involves	   a	  
number	  of	  mechanisms	  that	  are	  not	  dependent	  on	  gene	  sequence.	  Examples	  of	  such	  
mechanisms	   are	   DNA	   methylation	   and	   histone	   modification.	   DNA	   methylation	  
involves	  the	  addition	  of	  a	  methyl	  group	  to	  cytosines	  or	  adenines.	  DNA	  methylation	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suppresses	  gene	  expression	  by	  affecting	  the	  binding	  of	  transcriptional	  factors	  to	  the	  
gene.	   In	   addition,	   methylated	   DNA	   is	   recognized	   by	   methyl-­‐CpG-­‐binding	   domain	  
proteins,	   which,	   in	   turn,	   recruit	   chromatin	   remodeling	   proteins,	   including	   histone	  
deacetylases.	   Chromatin	   remodeling	   proteins	   modify	   histones	   and	   enhance	   the	  
formation	  of	  compact	  and	  inactive	  chromatin.	  Aberrant	  methylation	  of	  the	  promoter	  
region	   of	   TIMP-­‐3	   gene	   was	   found	   associated	   with	   primary	   cancer	   of	   the	   brain,	  
kidney,	   colon,	  breast,	   etc	   (Bachman	  et	   al.,	   1999).	   This	   epigenetic	   regulation	  of	   the	  
TIMP-­‐3	  gene	  therefore	  participates	  in	  cancer	  progression	  (Eads	  et	  al.,	  2001;	  Rohrs	  et	  
al.,	  2009;	  Ueki	  et	  al.,	  2000).	  
Post-­‐transcriptional	  regulation.	  Post-­‐transcriptional	  regulation	  of	  TIMP-­‐3	  expression	  
has	   been	   reported	   in	   both	   physiological	   processes	   and	   pathological	   conditions.	  
Several	  miRNAs	  have	  been	  found	  to	  bind	  the	  3’-­‐UTR	  of	  the	  TIMP-­‐3	  mRNA	  resulting	  in	  
the	  degradation	  of	   TIMP-­‐3	   transcripts	   and	   its	   gene	   silencing	   (Gabriely	   et	   al.,	   2008;	  
Wang	  et	  al.,	  2010).	  	  
	   miR-­‐21	   is	  one	  of	   the	  most	  expressed	  micro-­‐RNAs	   in	  many	  different	   tumors,	  
including	   glioblastoma,	   and	   its	   expression	   often	   correlates	   with	   tumor	   grade	   and	  
poor	   prognosis	   (Gabriely	   et	   al.,	   2008).	   miR-­‐21	   targets	   TIMP-­‐3	   mRNAs,	   leading	   to	  	  
their	  degradation.	   Its	  ability	  to	  reduce	  TIMP-­‐3	  expression	  promotes	  tumor	   invasion	  
(Gabriely	  et	  al.,	  2008;	  Selaru	  et	  al.,	  2009;	  Song	  et	  al.,	  2010).	  Regulation	  of	  TIMP-­‐3	  by	  
miR-­‐21	  has	  also	  been	  observed	   in	  physiological	  processes,	   including	  wound	  healing	  
(Yang	  et	  al.,	  2011).	  During	  skin	  wound	  healing,	  keratinocytes	  need	  to	  proliferate	  and	  
migrate.	  Both	  keratinocyte	  proliferation	  and	  migration	  are	  favored	  by	  expression	  of	  
miR-­‐21,	  which	  attenuates	  TIMP-­‐3	  expression	  (Yang	  et	  al.,	  2011).	  	  
	   TIMP-­‐3	  mRNA	  is	  a	  validated	  target	  of	  miR-­‐181b	  and	  miR-­‐206	  (Limana	  et	  al.,	  
2011;	  Wang	   et	   al.,	   2010).	  miR-­‐181b	   is	   upregulated	   by	   TGF-­‐β	   and	   its	   expression	   is	  
markedly	   suppressed	   in	   hepatocarcinomas.	   These	   data	   suggest	   that	   TGF-­‐β	   can	  
modulate	   TIMP-­‐3	   expression	   by	   miR-­‐181b	   (Wang	   et	   al.,	   2010).	   miR-­‐206-­‐mediated	  
downregulation	   of	   TIMP-­‐3	   promotes	   cardiac	   regeneration	   of	   chronically	   failing	  
hearts	  (Limana	  et	  al.,	  2011).	  	  
	   miR-­‐221	  and	  miR-­‐222	  can	  downregulate	  the	  expression	  of	  TIMP-­‐3.	  Garofalo	  
et	   al.	   (2009)	   found	   that	   the	   hepatocyte	   growth	   factor/scatter	   factor	   upregulates	  
miR-­‐221	   and	   miR-­‐222	   expression.	   This	   enhances	   tumorigenicity	   of	   lung	   and	   liver	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cancer	   cells	   by	   downregulating	   the	   phosphatase	   and	   tensin	   homolog	   (PTEN)	   and	  
TIMP3	  (Garofalo	  et	  al.,	  2009;	  Song	  et	  al.,	  2007).	  
1.4.4 TIMP-­‐3	  in	  disease	  
Cell-­‐specific	  overexpression	  of	  TIMP-­‐3	  has	  been	  shown	  to	  have	  a	  protective	  role	   in	  
several	   pathologies,	   including	   arthritis,	   cancer	   and	   atherosclerosis.	   Gendron	   et	   al.	  
(2003)	   showed	   that	   TIMP-­‐3	   inhibits	   glycosaminoglycan	   release	   from	   bovine	   nasal	  
and	  porcine	  articular	  cartilage	  explants	  stimulated	  with	  interleukin-­‐1	  alpha	  (IL-­‐1α)	  or	  
retinoic	   acid,	   suggesting	   that	   TIMP-­‐3	   may	   be	   a	   candidate	   agent	   for	   use	   against	  
cartilage	   degradation	   and	   a	   potential	   target	   for	   therapy	   of	   arthritis.	   Intra-­‐articular	  
injection	   of	   TIMP-­‐3	   similarly	   inhibited	   cartilage	   degradation	   in	   a	   rat	  meniscal	   tear	  
model	  (Black	  et	  al.,	  2007).	  	  
	   Baker	  et	  al.	  (1999)	  initially	  showed	  that	  adenoviral-­‐mediated	  overexpression	  
of	   TIMP-­‐3	   in	   different	   cancer	   cell-­‐lines,	   including	   MCF-­‐7,	   HeLa	   and	   HT1080	   cells,	  
inhibited	  cell	  invasion	  by	  blocking	  MMP	  activity	  and	  inducing	  apoptosis	  (Baker	  et	  al.,	  
1999).	   Several	   other	   groups	  have	  also	   investigated	   the	  ability	  of	   TIMP-­‐3	   to	   reduce	  
tumor	  growth	  and	   invasiveness	   in	  vivo.	  Xenografts	  of	  human	  chronic	  myelogenous	  
leukemia	  cells	  were	  less	  invasive	  when	  they	  overexpressed	  TIMP-­‐3	  (Yu	  et	  al.,	  2006).	  
In	   a	   similar	   manner,	   TIMP-­‐3	   overexpression	   blocked	   growth	   and	   invasion	   of	   solid	  
tumors	  (Anania	  et	  al.,	  2011;	  Zhang	  et	  al.,	  2010).	  
	   TIMP-­‐3	   levels	   in	   carotid	   atherosclerotic	   plaques	   are	   reduced,	   particularly	   in	  
regions	   enriched	   with	   monocytes	   and	   macrophages	   (Cardellini	   et	   al.,	   2009).	   A	  
deficiency	   in	   TIMP-­‐3	   leading	   to	   increased	  TACE	  activity	  may	   contribute	   to	   vascular	  
disorders	   by	   increasing	   inflammatory	   mediators,	   such	   as	   TNF-­‐α	   and	   monocyte	  
chemoattractant	  protein-­‐1,	   that	   recruit	  monocytes	  and	  T	   cells	   from	   the	   circulation	  
(Fiorentino	   et	   al.,	   2010).	   The	   protective	   role	   of	   TIMP-­‐3	   in	   atherosclerosis	   was	  
investigated	   by	   Casagrande	   et	   al.	   (2012)	   by	   generation	   of	   a	   mouse	   line	   which	  
overexpresses	  TIMP-­‐3	   in	  the	  macrophages	  via	  the	  macrophage-­‐specific	  gene	  Mac1.	  
They	  were	  protected	  from	  the	  development	  of	  atherosclerotic	  plaques	  when	  these	  
mice	   were	   crossbred	   with	   the	   LDLR	   knockout	   mouse	   (MacT3/LDLR-­‐/-­‐).	  
Atherosclerotic	  plaques	  in	  MacT3/LDLR-­‐/-­‐	  mice	  contained	  increased	  collagen	  content	  
and	   decreased	   necrotic	   core	   formation,	   and	   fewer	   T	   cells	   and	   macrophages	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(Casagrande	  et	  al.,	  2012).	  These	  results	  indicate	  that	  overexpression	  of	  TIMP-­‐3	  may	  
be	  beneficial	  in	  prevention	  of	  plaque	  formation.	  
1.4.5 Metalloproteinases	  inhibited	  by	  TIMP-­‐3	  
1.4.5.1 MMPs	  
The	  human	  genome	  encodes	  23	  MMPs,	  also	  called	  matrixins	  (Nagase	  and	  Woessner,	  
1999).	   All	   of	   the	   matrixins	   are	   multidomain	   zinc	   metalloproteinases,	   which	   share	  
sequence	   homology	   in	   their	   catalytic	   domains	   (Bode	   et	   al.,	   1999).	   They	   are	  
synthesized	   as	   pro-­‐enzymes	   and	   their	   activity	   is	   regulated	   by	   zymogen	   activation.	  
The	   pro-­‐domain	   consists	   of	   three	   α-­‐helices	   connected	   by	   loops.	   All	   the	  matrixins,	  
except	  MMP-­‐23,	  contain	  a	  “cysteine	  switch”	  motif	  PRCGXPD	  in	  the	  pro-­‐domain.	  The	  
thiol	   SH	  group	  of	   the	  cysteine	  coordinates	   the	  catalytic	   zinc.	  Upon	  cleavage	  of	   the	  
prodomain,	  the	  Cys-­‐Zn2+	  coordination	  is	  disrupted	  and	  a	  water	  molecule	  coordinates	  
the	  catalytic	  zinc,	  rendering	  the	  enzyme	  active	  for	  peptide	  hydrolysis	  (Van	  Wart	  and	  
Birkedal-­‐Hansen,	  1990).	  The	  catalytic	  domain	  consists	  of	  one	   five-­‐stranded	  β-­‐sheet	  
and	   3	   α-­‐helices	   and	   connecting	   loops.	   It	   contains	   a	   conserved	   zinc-­‐binding	   motif	  
HEXXHXXGXXH,	  where	   three	  histidine	   residues	   coordinate	   a	   Zn2+	   ion.	   The	   catalytic	  
domain	   also	   contains	   a	   conserved	   methionine,	   which	   forms	   a	   “Met-­‐turn”,	   eight	  
residues	   after	   the	   zinc-­‐binding	  motif.	   The	   “Met-­‐turn”	   forms	   the	  base	  of	   the	   active	  
site	   cleft	   around	   the	   catalytic	   zinc	   (Bode	   et	   al.,	   1999)	   The	   catalytic	   domain	   is	  
connected	   to	   a	   hemopexin	   domain	   by	   a	   linker	   region.	   The	   hemopexin	   domain	   is	  
essential	  for	  collagenases	  to	  perform	  their	  collagenolytic	  activity,	  as	  it	  is	  necessary	  to	  
unwind	  the	  triple	  helical	  structure	  of	  collagen	  and	  render	  the	  collagen	  cleavage	  site	  
accessible	  to	  the	  catalytic	  domain	  (Chung	  et	  al.,	  2004).	  
	   MMPs	   are	   divided	   in	   6	   groups	   based	   on	   their	   domain	   organization	   and	  
substrate	  preferences:	  i)	  collagenases,	  ii)	  gelatinases,	  iii)	  stromelysins,	  iv)	  matrilysins,	  
v)	  membrane-­‐type	  MMPs	  and	  vi)	  other	  MMPs.	  Tissue	  distribution	  and	  representative	  
substrate	  of	  each	  MMPs	  are	  listed	  in	  Table	  4.	  
	   Collagenases	  (MMP-­‐1,	  MMP-­‐8	  and	  MMP-­‐13)	  are	  capable	  of	  cleaving	  fibrillar	  
collagens	   type	   I,	   II	   and	   III	   into	   characteristic	   1/4	  and	  3/4	   fragments.	   They	   can	  also	  
cleave	   other	   ECM	   molecules,	   cytokines,	   chemokines,	   growth	   factors,	   binding	  
proteins	  and	  cell	  adhesion	  molecules	  (Nagase	  et	  al.,	  2006).	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   Gelatinases	   (MMP-­‐2	   and	  MMP-­‐9)	   have	   weak	   or	   no	   activity	   against	   fibrillar	  
collagens	   respectively	   (Aimes	   and	  Quigley,	   1995;	   Patterson	   et	   al.,	   2001).	   They	   can	  
degrade	  denatured	  collagens,	  gelatins	  and	  other	  ECM	  molecules,	  such	  as	  laminin	  and	  
aggrecan	  core	  protein.	  
	   Stromelysins	   (MMP-­‐3,	   MMP-­‐10	   and	   MMP-­‐11)	   share	   the	   same	   domain	  
arrangement	  with	  collagenases,	  although	  they	  do	  not	  cleave	  fibrillar	  collagen.	  MMP-­‐
3	   and	   -­‐10	   function	   as	   activators	   of	   proMMPs	   and	   degrade	   a	   number	   of	   ECM	  
molecules.	  Differently	  from	  MMP-­‐3	  and	  -­‐10,	  MMP-­‐11	  is	  not	  secreted	  as	  an	  inactive	  
proMMP,	  but	   it	   is	   activated	   intracellularly	  by	   furin	   cleavage	   (Pei	  and	  Weiss,	  1995).	  
MMP-­‐11	  shows	  weak	  activity	  towards	  ECM	  molecules	  (Murphy	  et	  al.,	  1993b).	  
	   Matrilysins	   (MMP-­‐7	   and	   MMP-­‐26)	   are	   the	   smallest	   members,	   lacking	   the	  
hemopexin	   domain.	   MMP-­‐7	   is	   mainly	   synthesized	   in	   epithelial	   cells	   (Yu	   and	  
Woessner,	  2000).	  It	  can	  act	  as	  a	  sheddase,	  cleaving	  cell	  surface	  molecules	  including	  
pro-­‐TNF-­‐α,	   Fas-­‐ligand	  and	   syndecan-­‐1	   (Parks	  et	  al.,	   2004).	  MMP-­‐26	   is	  expressed	   in	  
the	   endometrium	   and	   in	   some	   carcinomas,	   and	   it	   cleaves	   several	   ECM	  molecules	  
(Marchenko	  et	  al.,	  2004).	  
	   Membrane-­‐type	   MMPs	   are	   divided	   into	   two	   subgroups:	   the	   type-­‐I	  
transmembrane	   MMPs,	   including	   MMP-­‐14	   (MT1-­‐MMP),	   MMP-­‐15	   (MT2-­‐MMP),	  
MMP-­‐16	   (MT3-­‐MMP)	   and	  MMP-­‐24	   (MT5-­‐MMP),	   and	   the	   GPI-­‐anchored	  members,	  
MMP-­‐17	   (MT4-­‐MMP)	   and	  MMP-­‐25	   (MT6-­‐MMP).	   All	   type-­‐1	   transmembrane	  MMPs	  
can	  activate	  pro-­‐MMP-­‐2	  (English	  et	  al.,	  2001),	  and	  MT1-­‐MMP	  can	  activate	  MMP-­‐13	  
(Knäuper	  et	  al.,	  1996).	  
	   Seven	   members	   of	   the	  MMP	   family	   cannot	   be	   associated	   with	   any	   of	   the	  
above	  groups.	  MMP-­‐12,	  -­‐20	  and	  -­‐27	  share	  a	  similar	  domain	  arrangement.	  MMP-­‐12	  is	  
also	   referred	   to	   as	  metalloelastase	   (Shapiro	   et	   al.,	   1993).	   It	   was	   first	   identified	   in	  
macrophages	   and	   it	   cleaves	   elastin	   and	   other	   ECM	   proteins	   (Shipley	   et	   al.,	   1996).	  
MMP-­‐20	  is	  also	  called	  enamelysin	  and	  it	   is	  tooth-­‐specific	  (Ryu	  et	  al.,	  1999).	  Little	   is	  
known	   about	  mammalian	  MMP-­‐27	   (Yang	   and	  Kurkinen,	   1998).	  MMP-­‐19	   is	   broadly	  
expressed	  in	  human	  tissues	  and	  plays	  a	  role	  in	  tissue	  remodeling	  and	  wound	  healing	  
(Pendas	   et	   al.,	   1997).	   MMP-­‐23	   is	   unique	   as	   it	   lacks	   the	   cysteine-­‐switch	   in	   the	  
prodomain	  and	  the	  hemopexin	  domain	  (Velasco	  et	  al.,	  1999).	  It	  is	  expressed	  mainly	  
Chapter	  1	   	   Introduction	  
	   64	  
in	   testis	   and	   ovary,	   suggesting	   a	   role	   in	   the	   reproductive	   process	   (Velasco	   et	   al.,	  
1999).	   	   MMP-­‐28,	   which	   is	   also	   known	   as	   epilysin,	   degrades	   casein.	   MMP-­‐28	   is	  
expressed	   in	  different	   tissues,	   including	   testis,	  brain,	   intestine	  and	   skin,	   suggesting	  
its	   involvement	   in	   tissue	   homeostasis	   and	   wound	   healing	   (Lohi	   et	   al.,	   2001;	  
Marchenko	  and	  Strongin,	  2001).	  Table	  4	  shows	  a	   list	  of	  all	  MMPs	   identified	  so	   far,	  
their	  substrates	  and	  tissue	  where	  different	  MMPs	  are	  expressed.	  
.	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Table	  4:	  Description	  of	  the	  MMPs,	  their	  tissue	  expression	  and	  their	  substrates	  	  
	  
MMP	   Other	  Names	   Human	  Tissue	  
Expression	  
Substrates	  
	   	   	   	  




collagenase	  1	  	  	  	  	  	  
Most	  tissue	  types	   Type	  I,	  II,	  III,	  X,	  XI	  collagens;	  
fibronectin;	  aggrecan;	  link	  
protein;	  gelatin;	  IGFBP-­‐3;	  IL-­‐
1β	  precursor;	  monocyte	  
chemoatractant	  protein-­‐3;	  
protease	  activated	  receptor	  
1	  
	   	   	   	  
MMP-­‐2	   Gelatinase	  A;	  72-­‐kD	  
gelatinase;	  type	  IV	  
collagenase	  
Skin,	  gingival	  fibroblasts,	  
cartilage	  
Type	  I,	  III,	  IV,	  X,	  XI	  
collagens;	  fibronectin;	  
SPARC;	  aggrecan;	  link	  
protein;	  decorin;	  gelatin;	  
IGFBP-­‐3;	  laminin;	  IL-­‐1β;	  
monocyte	  chemoatractant	  
protein-­‐3;	  big	  endothelin;	  
adrenomedullin;	  stromal	  
cell-­‐derived	  factor	  1α	  
	   	   	   	  
MMP-­‐3	   Stromelysin	  1;	  
transin;	  
proteoglycanase	  




smooth	  muscle	  cells,	  
osteoblasts,	  
keratinocytes	  
Type	  III,	  IV,	  IX,	  X,	  XI	  
collagens;	  fibronectin;	  
SPARC;	  aggrecan;	  perlecan;	  
link	  protein;	  decorin;	  
gelatin;	  plasminogen;	  
IGFBP-­‐3;	  monocyte	  
chemoatractant	  protein-­‐3;	  	  	  
	   	   	   	  
MMP-­‐7	   Matrilysin;	  PUMP-­‐1	   Glandular	  epithelium,	  
mononuclear	  
phagocytes,	  renal	  
mesangial	  cells,	  cartilage	  
Type	  I,	  IV	  collagens;	  
fibronectin;	  SPARC;	  
aggrecan;	  link	  protein;	  
decorin;	  IGFBP-­‐3;	  E-­‐
cadherin;	  Fas	  ligand;	  pro-­‐
TNF-­‐α;	  RANK	  ligand;	  
heparin	  binding	  EGF;	  	  
	   	   	   	  
MMP-­‐8	   Neutrophil	  
collagenase;	  
collagenase	  2	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MMP	   Other	  Names	   Human	  Tissue	  
Expression	  
Substrates	  
	   	   	   	  




T	  cells,	  cartilage,	  various	  
cancers	  
Type	  IV,	  XI	  collagen;	  
aggrecan;	  SPARC;	  link	  
protein;	  decorin;	  galactin-­‐3;	  
gelatin;	  IL-­‐1β	  precursor;	  
precursor	  of	  TGFβ;	  ICAM-­‐1	  
MMP-­‐10	   Stromelysin	  2;	  
transin	  2	  




Type	  III,	  IV	  collagens;	  
fibronectin;	  aggrecan;	  link	  
protein	  
	   	   	   	  




activator	  inhibitor	  2.	  
	   	   	   	  





Type	  I,	  IV	  collagens;	  
fibronectin;	  aggrecan;	  
elastin	  
	   	   	   	  
MMP-­‐13	   Collagenase	  3	   Cartilage,	  breast	  
carcinoma	  




chemoatractant	  protein-­‐3;	  	  
	   	   	   	  





Type	  I,	  II,	  III	  collagens;	  
fibronectin;	  aggrecan;	  
perlecan;	  CD44;	  laminin;	  
MUC1	  
	   	   	   	  
	   	   	   	  






Type	  I	  collagen;	  fibronectin;	  
perlecan;	  laminin;	  tenacin	  C	  	  
	   	   	   	  
MMP-­‐16	   Membrane-­‐type	  3	  
MMP	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MMP	   Other	  Names	   Human	  Tissue	  
Expression	  
Substrates	  
	   	   	   	  

















IGFBP-­‐3;	  COMP;	  laminin	  
	   	   	   	  
MMP-­‐20	   Enamelysin	   Dental	  tissues	   Amelogenin;	  COMP	  
	   	   	   	  
MMP-­‐21	   -­‐	   Kidney,	  lung,	  liver,	  
colon,	  leukocyte,	  
ovary,	  testis,	  placenta,	  
fetal	  brain,	  various	  
cancers	  
α1-­‐anti-­‐trypsin	  
	   	   	   	  
MMP-­‐23	   Cysteine	  array-­‐
MMP	  
Ovary,	  testis,	  prostate,	  
cartilage	  
-­‐	  
	   	   	   	  
MMP-­‐24	   Membrane-­‐type	  5	  
MMP	  
Pancreas,	  kidney,	  





	   	   	   	  






Type	  IV	  collagen;	  
fibronectin;	  fibrin;	  gelatin	  
	   	   	   	  
MMP-­‐26	   Matrilysin	  2;	  
endometase	  
Endometrium,	  kidney,	  




	   	   	   	  
MMP-­‐27	   human	  MMP-­‐22	   B-­‐cells,	  cartilage	   -­‐	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MMP	   Other	  Names	   Human	  Tissue	  
Expression	  
Substrates	  
	   	   	   	  
MMP-­‐28	   Epilysin	   Epidermis,	  heart,	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1.4.5.2 ADAMs	  
A	  disintegrin	  and	  metalloproteinases	   (ADAMs)	  also	  belong	  to	  the	  metzincins	   family	  
of	  zinc-­‐based	  proteinases	  (Murphy,	  2008).	  Twenty-­‐one	  ADAMs	  are	  found	  in	  human,	  
but	   only	   thirteen	  of	   these	   harbor	   the	  metalloproteinases	   signature	  HEXXHXXGXXH	  
sequence	  and	  thus	  have	  proteolytic	  potential.	  Cell	  membrane	  receptors,	  cytokines,	  
growth	  factors	  and	  molecules	  that	  mediate	  cell-­‐cell	  and	  cell-­‐matrix	   interactions	  are	  
among	   the	   physiological	   substrates	   of	   proteolytic	   ADAMs	   (Edwards	   et	   al.,	   2008;	  
Murphy,	   2008).	   Although	   little	   is	   still	   known	   about	   non-­‐proteolytic	   ADAMs,	   their	  
main	  expression	  in	  testis	  and	  a	  number	  of	  knockout	  studies	  suggests	  a	  role	  for	  these	  
proteins	   in	  development	  (Edwards	  et	  al.,	  2008).	  The	  molecular	  structure	  of	  ADAMs	  
consists	  of	  a	  pro-­‐domain,	  catalytic	  domain,	  disintegrin	  domain,	  cysteine-­‐rich	  domain,	  
transmembrane	   domain	   and	   cytoplasmic	   tail.	   ADAMs	   are	   synthesized	   as	   inactive	  
precursors	   and	   their	   activation	   usually	   occurs	   in	   compartments	   of	   the	   trans	   Golgi	  
network	  (TGN)	  through	  cleavage	  by	  a	  furin	  pro-­‐protein	  convertase	  (Lum	  et	  al.,	  1998).	  
The	   cytoplasmic	   tail	   of	   several	   ADAMs	   presents	   binding	   sites	   for	   Src	   homology	   3	  
(SH3)-­‐containing	  proteins.	  The	  SH3	   is	  a	  conserved	  domain	  shared	  by	  many	  adaptor	  
proteins	  and	  tyrosine	  kinases,	   including	  Src	  and	  PI3	  kinase,	  that	  are	   involved	  in	  cell	  
signaling.	   The	   presence	   of	   binding	   sites	   for	   SH3	   containing	   proteins,	   as	   well	   as	   a	  
number	   of	   tyrosine	   and	   serine/threonine	   phosphorylation	   sites,	   suggest	   that	   the	  
cytoplasmic	  tail	  of	  ADAMs	  may	  play	  a	  role	  in	  cell-­‐signaling	  (Murphy,	  2009).	  A	  soluble	  
form,	   generated	   by	   alternative	   splicing,	   has	   been	   reported	   for	   some	   ADAMs,	  
including	  ADAM-­‐12	  and	  ADAM-­‐33	  (Puxeddu	  et	  al.,	  2008;	  Wewer	  et	  al.,	  2006).	  
	   The	  biological	  functions	  of	  ADAMs	  have	  been	  investigated	  by	  the	  generation	  
of	   knockout	  mouse	   lines	   for	   certain	  ADAM	  genes.	  ADAM-­‐1	   and	  ADAM-­‐2	  were	   the	  
first	  two	  members	  of	  the	  family	  to	  be	  identified	  (Primakoff	  et	  al.,	  1987;	  Wolfsberg	  et	  
al.,	   1993).	   Both	   of	   them	   were	   shown	   to	   be	   involved	   in	   sperm-­‐egg	   fusion,	   and	  
knockout	  mice	   for	  Adam1	   and	  Adam2	   show	  male	   infertility	   due	   to	   the	   inability	   of	  
sperm	  to	  migrate	  and	  to	  bind	  the	  egg	  zona	  pellucida,	  respectively	  (Nishimura	  et	  al.,	  
2004;	  Nishimura	  et	  al.,	  2007).	  	  
	   Some	  ADAMs	  are	  well	  studied,	  while	  only	  little	  information	  is	  available	  about	  
the	   others.	   Table	   5	   shows	   a	   list	   of	   all	   ADAMs	   identified	   so	   far,	   their	   pattern	   of	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expression	   and	   their	   substrates.	   Among	   them,	  ADAM-­‐10	   and	  ADAM-­‐17	   are	  widely	  
characterized.	  	  TIMP-­‐1	   inhibits	   ADAM-­‐10,	   TIMP-­‐2	   inhibits	   ADAM-­‐12	   and	   TIMP-­‐3	  
inhibits	  ADAM-­‐10,	  -­‐12,	  -­‐17,	  -­‐28	  and	  -­‐33	  (Brew	  and	  Nagase,	  2010).	  
	   ADAM-­‐10	   plays	   a	   crucial	   role	   in	   Notch	   signaling,	   by	   RIPping	   (Regulation	   of	  
Intramembrane	   Proteolysis)	   the	   intracellular	   domain	   of	   Notch	   (Hartmann	   et	   al.,	  
2002).	  Notch	  is	  a	  transmembrane	  receptor,	  which	  triggers	  cell	  signaling	  events	  that	  
are	   an	   important	  means	   of	   communication	   between	   cells.	   Notch	   signaling	   plays	   a	  
crucial	   role	   in	   embryogenesis,	   development	   and	   cell	   differentiation.	  Notch	   ligands,	  
including	  Delta,	  are	  also	  transmembrane	  proteins	  that	  initiate	  juxtacrine	  signaling	  by	  
interacting	   with	   Notch	   expressed	   by	   the	   receiving	   cell.	   The	   interaction	   between	  
Notch	  and	  Notch	  ligands	  induces	  a	  proteolytic	  cleavage	  that	  releases	  the	  ectodomain	  
of	   the	   receptor.	   There	   is	   strong	   evidence	   that	   ADAM-­‐10	   is	   the	   major	   proteinase	  
involved	   in	   the	   shedding	   of	   Notch,	   although	   other	   ADAMs,	   such	   as	   ADAM-­‐17,	   are	  
also	   known	   to	   be	   involved	   in	   this	   cleavage	   (Hartmann	   et	   al.,	   2002).	   After	   ADAM-­‐
mediated	   ectodomain	   shedding	   of	   Notch,	   a	   γ-­‐secretase	   releases	   the	   Notch	  
intracellular	   domain,	   which	   enters	   the	   nucleus	   and	   modulates	   gene	   expression	  
(Schlondorff	   and	   Blobel,	   1999).	   ADAM-­‐10	   is	   also	   the	   α-­‐secretase	   involved	   in	   the	  
processing	  of	  amyloid	  precursor	  protein	  (APP)	  in	  neurons	  (Kuhn	  et	  al.,	  2010),	  and	  it	  
regulates	  cell	  adhesion	  by	  shedding	  of	  cadherins	  (Murphy,	  2008).	  
	   ADAM-­‐17,	   also	   known	   as	   tumor	   necrosis	   factor	   alpha	   (TNF-­‐α)	   converting	  
enzyme	   (TACE),	   is	   the	  most	  widely	   studied	  member	  of	   the	  ADAM	  family.	   	  TNF-­‐α	   is	  
produced	   as	   a	   transmembrane	   precursor.	   After	   proteolytic	   cleavage	   by	   ADAM-­‐17,	  
TNF-­‐α	   is	   released	   and	   functions	   as	   a	   soluble	   cytokine	   (Black	   et	   al.,	   1997).	   For	   this	  
reason,	   ADAM-­‐17	   plays	   a	   crucial	   role	   in	   inflammation	   and	   other	   processes	   that	  
involve	   TNF-­‐TNF	   receptor-­‐mediated	   signaling.	   ADAM-­‐17	   is	   also	   involved	   in	   the	  
regulation	  of	  epidermic	  growth	  factor	  receptor	  signaling,	  as	  all	   its	  ligands,	  including	  
EGF,	  HB-­‐EGF,	   TGF-­‐β	   and	   amphiregulin	   are	   synthesized	   as	   transmembrane	   proteins	  
which	  require	  ADAM-­‐17-­‐mediated	  shedding	  to	  become	  active	  (Lee	  et	  al.,	  2003).	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Table	  5:	  Description	  of	  the	  ADAMs,	  their	  tissue	  expression	  and	  their	  substrates	  	  
	  
ADAM	   Other	  Names	   Human	  Tissue	  Expression	   Substrates	  
ADAM-­‐1	   	   	   	  
ADAM-­‐2	   fertilin-­‐β;	  PH-­‐30β	   Testis	   -­‐	  
ADAM-­‐7	   EAP1	  	   Epididymis	   -­‐	  
ADAM-­‐8	   MS2,	  CD156a	   granulocytes,	  monocytes	   proTNF-­‐α,	  RANKL,	  IL1RII,	  CHL1,	  
SCF1,	  CD23,	  CD153,	  CX3CL1	  
ADAM-­‐9	   meltrin-­‐γ,	  MDC9	   Most	  tissue	  types	   proHBEGF,	  oxytocinase,	  NGFR,	  
murine	  splice	  variant	  of	  FGFR2	  
ADAM-­‐10	   kuzbanian,	  MADM,	  
SU17	  
Most	  tissue	  types	   proEGF,	  pro-­‐β-­‐cellulin,	  APP,	  
ephrin	  A2	  and	  A5,	  CX3CL1,	  
CXCL16,	  IL6R,	  CD23,	  CD44,	  
FASL,	  Slit,	  L1-­‐CAM,	  NGFR,	  
Notch,	  Delta-­‐like	  1,	  Jagged,	  N-­‐
cadherin,	  E-­‐cadherin,	  VE-­‐
cadherin,	  protocadherin-­‐γ,	  
collagen	  XVII,	  LRP	  	  
ADAM-­‐11	   MDC	   brain	   -­‐	  
ADAM-­‐12	   meltrin-­‐α	   Most	  tissue	  types	   proHBEGF,	  proepiregulin,	  
oxytocinase,	  Delta-­‐like	  1	  
ADAM-­‐15	   metargidin,	  MDC15	   Most	  tissue	  types	   proHBEGF,	  proepiregulin,	  
proamphiregulin,	  CD23,	  E-­‐
cadherin	  
ADAM-­‐17	   TACE	   Most	  tissue	  types	   proTNF-­‐α,	  proTGF-­‐α,	  
proHBEGF,	  proamphiregulin,	  
proneuregulin,	  proNGF,	  TNFRI,	  
TNFRII,	  ERBB4,	  CX3CL1,	  
RANKL,	  IL6R,	  MUC1,	  SCF1	  and	  
2,	  NGFR,	  CSFR,	  Notch,	  CD23,	  
CD30,	  CD40,	  L-­‐selectin,	  LDLR,	  
LRP,	  VCAM1,	  ICAM1,	  APP	  
ADAM-­‐18	   tMDCIII	   Testis	   -­‐	  
ADAM-­‐19	   meltrin-­‐β,	  MADDAM	   Most	  tissue	  types	   RANKL,	  proneuregulin	  
	   	   	   	  
ADAM-­‐20	   -­‐	   Testis	   -­‐	  
ADAM-­‐21	   -­‐	   Testis	   -­‐	  
ADAM-­‐22	   MDC2	   Brain	   -­‐	  
ADAM-­‐23	   MDC3	   Brain	   -­‐	  
ADAM-­‐28	   MDC-­‐L	   Epididymes,	  lung,	  
lymphocytes	  
CD23	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ADAM	   Other	  Names	   Human	  Tissue	  Expression	   Substrates	  
	   	   	   	  
ADAM-­‐29	   -­‐	   Testis	   -­‐	  
ADAM-­‐30	   -­‐	   Testis	   -­‐	  
ADAM-­‐33	   -­‐	   Most	  tissue	  types	   CD23,	  SCF1	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1.4.5.3 ADAMTSs	  
The	   family	  of	  ADAMTSs	   (a	  disintegrin	  and	  metalloproteinase	  with	   thrombospondin	  
motifs)	   are	   closely	   related	   to	   ADAMs,	   but	   they	   do	   not	   have	   a	   transmembrane	  
domain	  and	  are	  therefore	  secreted	  from	  the	  cells.	  Nineteen	  ADAMTSs	  are	  found	  in	  
humans	   (Apte,	   2009).	   All	   of	   these	   are	   translated	   as	   inactive	   pro-­‐enzymes,	   with	  
activation	   that	   involves	   cleavage	   of	   the	   prodomain	   by	   a	   furin-­‐like	   pro-­‐protein	  
convertase.	   The	   structure	   of	   ADAMTSs	   includes	   a	   catalytic	   domain	   which	   shares	  
structural	   similarity	   with	   that	   of	   MMPs,	   and	   ancillary	   domains	   consisting	   of	   a	  
disintegrin-­‐like	  domain,	  a	  central	  thrombospondin	  type-­‐I	  (TS)	  domain,	  a	  cysteine-­‐rich	  
domain,	   a	   spacer	   domain	   and	   a	   variable	   number	   of	   trombospondin	   type-­‐I	   repeats	  
(that	   range	   from	  none	   to	  14).	  Seven	  ADAMTS-­‐like	  proteins	   that	   resemble	  ADAMTS	  
ancillary	  domains	  but	  lack	  metalloproteinase	  domain	  are	  reported	  (Apte,	  2009).	  The	  
ancillary	   domains	   are	   important	   for	   substrate	   specificity	   and	   for	   the	   ability	   of	  
ADAMTSs	  to	  bind	  to	  the	  ECM	  (Porter	  et	  al.,	  2005).	  
	   The	  ADAMTS	  family	  can	  be	  subdivided	   into	   four	  groups	  based	  on	  structural	  
and	  functional	  similarities:	  i)	  proteoglycanases,	  ii)	  procollagen-­‐N-­‐proteinases,	  iii)	  von	  
Willebrand	  factor	  (VWF)-­‐cleaving	  proteinase	  and	  iv)	  other	  ADAMTS	  proteinases	  
	   Proteoglycanases	   (ADAMTS-­‐1,	   -­‐4,	   -­‐5,	   -­‐8,	   -­‐9,	   -­‐15,	  and	   -­‐16)	  are	  able	   to	   cleave	  
the	  core	  proteins	  of	  aggrecan,	  versican	  and/or	  brevican,	  and	  they	  are	  considered	  to	  
play	   a	   role	   in	   ECM	   turnover.	   Among	   them,	   ADAMTS-­‐4	   and	   ADAMTS-­‐5	   have	   the	  
highest	   aggrecanolytic	   activity	   and	   are	   implicated	   in	   the	   pathogenesis	   of	   arthritis	  
(Bondeson	   et	   al.,	   2008).	   ADAMTS-­‐1,	   -­‐4	   and	   -­‐9	   are	   able	   to	   cleave	   versican.	   The	  
expression	   of	   ADAMTS-­‐1	   and	   -­‐4	   is	   high	   in	   atherosclerotic	   lesions,	   the	   former	  
colocalises	   with	   endothelial	   cells	   and	   VSMCs,	   the	   latter	   with	   macrophages	   in	  
atherosclerotic	  lesions	  (Wight	  and	  Merrilees,	  2004).	  ADAMTS-­‐4	  is	  also	  able	  to	  cleave	  
brevican	  (Haddock	  et	  al.,	  2007).	  
	   Procollagen-­‐N-­‐proteinases	   (ADAMTS-­‐2,	   -­‐3,	   and	   -­‐14)	   remove	   N-­‐terminal	  
peptides	  from	  procollagen	  to	  form	  mature	  collagen	  (Porter	  et	  al.,	  2005).	  ADAMTS-­‐2-­‐
null	   mice	   have	   a	   defect	   in	   forming	   type	   I	   collagen	   fibrils	   that	   leads	   to	   the	  
development	  of	  fragile	  skin.	  ADAMTS-­‐3	  and	  -­‐14	  are	  thought	  to	  function	  in	  cartilage	  
and	  tendons,	  respectively	  (Colige	  et	  al.,	  2002;	  Fernandes	  et	  al.,	  2001).	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   The	  VWF-­‐cleaving	  protease	  has	  been	  purified	  and	  cloned	  and	  it	  is	  designated	  
as	   ADAMTS-­‐13	   (Furlan	   et	   al.,	   1996).	   Von	   Willebrand	   factor	   (VWF)	   is	   a	   large	  
multimeric	   glycoprotein	   that	   plays	   a	   crucial	   role	   in	   hemostasis	   (Bonthron	   et	   al.,	  
1986).	  The	  endothelial	  cells	  of	  intact	  vessels	  control	  blood	  fluidity,	  secreting	  several	  
molecules	   that	   prevent	   blood	   clotting	   and	   platelet	   aggregation.	   Following	   vessel	  
injury,	   the	   endothelial	   cells	   stop	   the	   secretion	   of	   coagulation	   and	   aggregation	  
inhibitors	   and	  VWF	  binds	   to	   exposed	   subendothelial	   collagen.	   In	   these	   conditions,	  
the	   inactive	   globular	   conformation	   of	   VWF	   is	   unfolded	   in	   response	   to	   the	   shear	  
forces	   exerted	   by	   the	   flowing	   blood.	   When	   in	   an	   unfolded	   string-­‐like	   active	  
conformation,	   VWF	   is	   able	   to	   bind	   and	   tether	   platelets	   (Sadler,	   1998).	   VWF	  
catabolism	   is	   mainly	   controlled	   by	   ADAMTS-­‐13,	   which	   cleaves	   the	   Tyr1605-­‐Met1606	  
bond	  in	  VWF,	  breaking	  down	  the	  multimers	   into	  smaller	  units,	  which	  are	  degraded	  
by	   other	   proteases	   (Fujikawa	   et	   al.,	   2001).	   In	   humans,	   deficiency	   in	   ADAMTS-­‐13	  
activity	   leads	   to	   a	   pathological	   condition	   of	   the	   blood-­‐coagulation	   system,	   called	  
thrombotic	   thrombocytopenic	   purpura	   (TTP),	  which	   causes	   the	   formation	   of	   small	  
blood	  clots	  throughout	  the	  body	  (Moake,	  2004).	  TTP	  can	  be	  idiopathic	  or	  inherited.	  
The	  idiopathic	  form	  of	  TTP	  is	  an	  autoimmune	  disease	  due	  to	  antibodies	  that	  target	  
and	   inactivate	   ADAMTS-­‐13.	   The	   inherited	   form	   of	   TTP	   is	   also	   known	   as	   Upshaw-­‐
Schülman	  syndrome	  and	  it	  is	  due	  to	  point	  mutations	  in	  the	  ADAMTS13	  gene	  (Levy	  et	  
al.,	  2001).	  
	   There	  are	  a	  number	  of	  ADAMTSs,	  whose	  endogenous	  substrates	  are	  not	  well	  
characterized.	  However,	  ADAMTS-­‐7	  and	  ADAMTS-­‐12	  have	  been	  identified	  to	  cleave	  
the	  cartilage	  oligomeric	  matrix	  protein	  (COMP)	  and	  are	  upregulated	  in	  cartilage	  and	  
synovium	  of	  patients	  with	  rheumatoid	  arthritis,	  suggesting	  a	  role	  for	  these	  enzymes	  
in	  the	  progression	  of	  the	  disease	  (Liu	  et	  al.,	  2006a;	  Liu	  et	  al.,	  2006b).	  ADAMTS-­‐7	  was	  
originally	   identified	   as	   an	   enzyme	   containing	   two	  TS	  domains	   and	  having	   a	   similar	  
domain	   structure	   to	   ADAMTS-­‐5,	   ADAMTS-­‐6,	   and	   ADAMTS-­‐8	   (Hurskainen	   et	   al.,	  
1999).	   A	   longer	   form	   of	   ADAMTS-­‐7,	   called	   ADAMTS-­‐7B,	   was	   then	   isolated	   and	  
believed	   to	   be	   the	   full-­‐length	   version	   of	   the	   enzyme	   (Somerville	   et	   al.,	   2004).	  
ADAMTS-­‐7B	   contains	   six	   additional	   TS	   domains,	   a	  mucin	   domain	   and	   a	   C-­‐terminal	  
PLAC	   (Protease	   and	   LACunin)	   domain.	   ADAMTS-­‐6	   and	   -­‐10	   have	   similar	   primary	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structures,	   suggesting	   also	   their	   activities	   may	   be	   correlated	   (Hurskainen	   et	   al.,	  
1999).	  TIMP-­‐3	   inhibits	  ADAMTS-­‐1,	   -­‐4,	   -­‐5	  and	  weakly	  ADAMTS-­‐2	   (Brew	  and	  Nagase,	  
2010).	  Tissue	  distribution	  and	  substrates	  of	  ADAMTSs	  are	  listed	  in	  Table	  6	  	   	  
Chapter	  1	   	   Introduction	  
	   76	  
Table	  6:	  Description	  of	  the	  ADAMTSs,	  their	  tissue	  expression	  and	  their	  substrates	  	  
	  
ADAMTS	   Other	  Names	   Human	  Tissue	  Expression	   Substrates	  
ADAMTS-­‐1	   Aggrecanase	  3;	  METH-­‐
1	  
Most	  tissue	  types	   Aggrecan;	  versican;	  α2-­‐
macroglobulin	  
	   	   	   	  
ADAMTS-­‐2	   Procollagen	  N-­‐
proproteinase	  
Skin,	  cartilage,	  liver,	  
placenta,	  lung	  
Pro-­‐collagen	  I,	  II,	  and	  III	  N-­‐
propeptides	  
	   	   	   	  
ADAMTS-­‐3	   Procollagen	  N-­‐
proproteinase;	  
KIAA0366	  	  
Skin,	  cartilage,	  placenta,	  
heart,	  brain,	  lung,	  kidney	  
Pro-­‐collagen	  II	  N-­‐propeptides	  
	   	   	   	  
ADAMTS-­‐4	   Aggrecanase	  1;	  ADMP-­‐
1;	  KIAA0688	  
Uterus,	  stomach,	  spinal	  
cord,	  skeletal	  muscle,	  
ovary,	  heart,	  bladder,	  
brain,	  cartilage	  
Aggrecan;	  versican;	  brevican;	  
COMP;	  fibromodulin;	  decorin	  
	   	   	   	  
ADAMTS-­‐5	   Aggrecanase	  2;	  
ADAMTS-­‐11;	  ADMP-­‐2	  
Bladder,	  cervix,	  esophagus,	  
placenta,	  uterus,	  cartilage	  
Aggrecan;	  α2-­‐macroglobulin	  
	   	   	   	  
ADAMTS-­‐6	   -­‐	   Placenta,	  cartilage	   -­‐	  
	   	   	   	  
ADAMTS-­‐7	   -­‐	   Pancreas,	  kidney,	  skeletal	  
muscle,	  liver,	  heart	  
COMP;	  α2-­‐macroglobulin	  
	   	   	   	  
ADAMTS-­‐8	   METH-­‐2	   Brain,	  heart,	  placenta,	  
lung,	  smooth	  muscle,	  
kidney,	  appendix	  
Aggrecan	  
	   	   	   	  
ADAMTS-­‐9	   KIAA1312	   Heart,	  placenta,	  skeletal	  
muscle,	  kidney,	  pancreas,	  
cartilage	  
Aggrecan;	  versican	  
	   	   	   	  
ADAMTS-­‐10	   -­‐	   Cartilage	   -­‐	  
	   	   	   	  





	   	   	   	  
ADAMTS-­‐13	   Von	  Willebrand	  factor-­‐
cleaving	  protease	  
Liver,	  brain,	  prostate,	  
cartilage	  
von	  Willebrand	  factor	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ADAMTS	   Other	  Names	   Human	  Tissue	  Expression	   Substrates	  
ADAMTS-­‐14	   Procollagen	  N-­‐
proproteinase	  
Retina,	  brain,	  lung,	  
placenta,	  prostate,	  skin,	  
cartilage	  
-­‐	  
	   	   	   	  
ADAMTS-­‐15	   -­‐	   Liver,	  kidney,	  cartilage	   Aggrecan	  
	   	   	   	  
ADAMTS-­‐16	   -­‐	   Cartilage,	  brain,	  ovary,	  
fetal	  lung,	  fetal	  kidney	  
Aggrecan	  
	   	   	   	  
ADAMTS-­‐17	   -­‐	   Ovary,	  cartilage,	  fetal	  lung	   -­‐	  
	   	   	   	  
ADAMTS-­‐18	   -­‐	   Endothelium,	  placenta,	  
cartilage,	  fetal	  lung,	  fetal	  
kidney,	  fetal	  brain,	  fetal	  
liver	  
-­‐	  
	   	   	   	  
	   	   	   	  
ADAMTS-­‐19	   -­‐	   Cartilage,	  fetal	  lung	   -­‐	  
	   	   	   	  
	   	   	   	  
ADAMTS-­‐20	   -­‐	   Breast,	  lung,	  testes,	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1.5 Aims	  of	  the	  thesis	  
Troeberg	  et	  al.	  (2008)	  reported	  that	  levels	  of	  TIMP-­‐3	  in	  the	  extracellular	  milieu	  can	  
be	  post-­‐translationally	  regulated	  by	  endocytosis.	  It	  was	  postulated	  that	  this	  process	  
is	   mediated	   by	   LRP-­‐1,	   a	   member	   of	   the	   LDL	   receptor	   family.	   Since	   addition	   of	  
calcium	  pentosan	  polysulfate	  or	  heparin	  to	  chondrocytes	  or	  HTB94	  chondrosarcoma	  
cells	  results	  in	  an	  accumulation	  of	  TIMP-­‐3	  in	  the	  medium,	  it	  was	  suggested	  that	  cell	  
surface	  bound	  heparan	  sulfate	  proteoglycans	  (HSPGs)	  may	  serve	  as	  co-­‐receptors	  for	  
TIMP-­‐3	  endocytosis.	  The	  aim	  of	  this	  study	  is:	  	  
1. To	   elucidate	   TIMP-­‐3	   endocytosis	   in	   more	   details,	   which	   includes	  
determining	   the	   kinetics	   of	   the	   process,	   the	   rate	   of	   endocytosis	   by	  
number	  of	   cell	   lines	  and	   the	  distribution	  of	  endocytosed	  TIMP-­‐3	  among	  
cell	  fractions.	  
2. To	   confirm	   the	   role	   of	   LRP-­‐1	   in	   TIMP-­‐3	   endocytosis	   and	   determine	   the	  
involvement	  of	  other	  LDL	  receptors.	  
3. To	  investigate	  the	  involvement	  of	  LRP-­‐1-­‐independent	  pathways	  in	  TIMP-­‐3	  
endocytosis	  
4. To	   investigate	   the	   role	   of	   heparan	   sulfate	   proteoglycans	   in	   the	  
endocytosis	  of	  TIMP-­‐3.	  	  
5. To	   elucidate	   whether	   TIMP-­‐3	   can	   mediate	   the	   scavenging	   of	   TIMP-­‐3—
MMP	  complexes.	  
	  
To	   pursue	   these	   aims	   I	   set	   up	   a	   method	   to	   purify	   recombinant	   [35S]radiolabeled	  
TIMP-­‐3-­‐FLAG	  from	  the	  conditioned	  medium	  of	  human	  cells,	  and	  I	  optimized	  an	  assay	  
to	  evaluate	   the	   internalization	  of	   [35S]TIMP-­‐3-­‐FLAG	  by	   following	   the	  distribution	  of	  
radioactivity	  among	  cell	  fractions.	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2.1 Reagents	  
2.1.1 Cultured	  cells	  
Human	   chondrosarcoma	   cells	   (HTB94),	   human	   epithelial	   cervical	   cancer	   cells	  
(Michigan	  Cancer	  Foundation	  7),	  human	  breast	  adenocarcinoma	  cell	  line	  (HeLa)	  and	  
human	   acute	  monocytic	   leukemia	   cells	   (THP-­‐1)	   were	   from	   American	   Culture	   Type	  
Collection	  (Manassas,	  VA,	  USA).	  Human	  epithelial	  kidney	  (HEK-­‐293/EBNA)	  cells	  were	  
from	   Invitrogen	   (Paisley,	   UK).	   HEK-­‐293/EBNA	   cells	   transfected	   with	   pCEP4-­‐TIMP-­‐3	  
and	   pCEP4-­‐N-­‐TIMP-­‐3	   constructs	   (Troeberg	   et	   al.,	   2009),	   HEK-­‐293/EBNA	   cells	  
transfected	   with	   pCEP4-­‐ADAMTS4-­‐2	   construct	   (Kashiwagi	   et	   al.,	   2004),	   HEK-­‐
293/EBNA	  cells	  transfected	  with	  pCEP4-­‐ADAMTS5-­‐2	  construct	  (Gendron	  et	  al.,	  2007)	  
and	   HEK-­‐293/EBNA	   cells	   transfected	   with	   pCEP4-­‐MMP-­‐1	   construct	   (Visse	   R.	   and	  
Nagase	   H.,	   unpublished	   data)	   were	   from	   frozen	   cell	   stocks	   prepared	   by	   Dr.	   Linda	  
Troeberg,	   Dr.	   Christi	   Gendron,	   Dr.	   Masahide	   Kashiwagi	   and	   Dr.	   Robert	   Visse,	  
respectively.	   Human	   uterine	   cervical	   fibroblasts	   (HUCF)	   were	   kindly	   provided	   by	  
Professor	  I.	   Ito	  from	  Tokyo	  University	  of	  Pharmacology	  and	  Life	  Science	  (Itoh	  et	  al.,	  
1995).	   Mouse	   embryonic	   fibroblasts	   (MEF-­‐1),	   and	   PEA-­‐13	   (homozygous	   LRP-­‐1	  
deficient)	   cells	  were	  a	  kind	  gift	   from	  Professor	  D.	  Strickland	   from	  the	  University	  of	  
Maryland,	   School	   of	  Medicine,	  Maryland,	   USA	   (Kounnas	   et	   al.,	   1992;	  Willnow	   and	  
Herz,	  1994).	  Syndecan-­‐4-­‐null	  and	  wild-­‐type	  MEF	  cells	  were	  a	  kind	  gift	  from	  Professor	  
J.	   R.	   Couchman	   from	   the	   University	   of	   Copenhagen,	   Denmark.	   CHO-­‐745	   cells,	  
deficient	  in	  both	  chondroitin	  and	  heparan	  sulfate	  proteoglycans,	  and	  control	  CHO-­‐K1	  
cells	  were	  a	  kind	  gift	   from	  Professor	   Jeffrey	  Esko	   from	  University	  of	  California,	  San	  
Diego	  (Esko	  et	  al.,	  1985).	  Porcine	  metacarpophalangeal	  joints	  of	  3-­‐9	  month-­‐old-­‐pigs	  
were	  from	  Fresh	  Tissue	  (London,	  UK)	  and	  were	  used	  within	  24	  hours	  of	  slaughter.	  
2.1.2 Cell	  culture	  reagents	  
Materials	  were	  purchased	   from	   the	   following	   sources:	  Dulbecco’s	  modified	  Eagle’s	  
medium	   (DMEM),	   DMEM	   without	   L-­‐glutamine	   or	   phenol	   red,	   L-­‐glutamine,	   Ham’s	  
F12,	   Roswell	   Park	   Memorial	   Institute	   (RPMI)	   medium,	   penicillin/streptomycin,	  
hygromycin	   B,	   4-­‐(2-­‐hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	   acid	   (HEPES),	  
amphotericin	   B	   and	   trypsin-­‐ethylenediaminetetraacetic	   acid	   (EDTA)	   from	   PAA	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Laboratories	  (Somerset,	  UK);	  fetal	  calf	  serum	  (FCS)	  from	  Gibco	  (Paisley,	  UK);	  DMEM	  
without	   L-­‐glutamine,	   cysteine,	   methionine	   or	   cystine	   from	   MP	   Biomedicals	   (CA,	  
USA).	   Heparin,	   de-­‐sulfated	   heparin,	   chondroitin	   sulfate,	   hyaluronic	   acid,	   sodium	  
chlorate	   and	   collagenase	   from	   Clostridium	   histolyticum	   were	   from	   Sigma-­‐Aldrich	  
(Dorset,	   UK);	   dermatan	   sulfate	   from	   Calbiochem	   (Nottingham,	   UK);	   calcium	  
pentosan	   polysulfate	   from	   Arthropharm	   (Sydney,	   Australia)	   and	   GM6001	   from	  
Elastin	  Products	  Co	  (Owensville,	  Missouri,	  USA);	  Pronase	  E	  from	  BDH	  (Dorset,	  UK).	  	  	  
2.1.3 SDS-­‐PAGE	  and	  Western	  blot	  reagents	  
Materials	   were	   purchased	   from	   the	   following	   sources:	   30%	   (w/v)	   acrylamide/bis-­‐
acrylamide	   from	   Severn	   Biotech	   (Worcestershire,	   UK);	   2-­‐amino-­‐2-­‐methyl-­‐1,3-­‐
propanediol	   (ammediol)	   and	   the	   mouse	   monoclonal	   anti-­‐FLAG	  M2	   antibody	   from	  
Sigma-­‐Aldrich	   Company	   Ltd.	   (Dorset,	   UK);	   PageRuler	   Plus	   Prestained	   Protein	  
Ladder	   for	   SDS-­‐PAGE	   from	   Fermentas	   GmbH	   (St.	   Leon-­‐Rot,	  Germany);	   4-­‐12%	   Tris-­‐
glycine	  polyacrylamide	  gradient	  gels	  and	  polyvinylidene	  difluoride	  (PVDF)	  membrane	  
from	  Invitrogen	  (Paisley,	  UK);	  anti-­‐rabbit	  alkaline	  phosphatase	  (AP)-­‐linked	  antibody,	  
anti-­‐mouse	   AP-­‐linked	   antibody,	   AP	   substrate	   (5-­‐bromo-­‐4-­‐choloro-­‐3-­‐indolyl-­‐1-­‐
phosphate	   and	  nitroblue	   tetrazolium),	   and	  horseradish	  peroxidase	   (HRP)	   substrate	  
from	  Promega	  (Southampton,	  UK);	  anti-­‐rabbit	  HRP-­‐linked	  antibody	  and	  anti-­‐mouse	  
HRP-­‐linked	   antibody	   from	  Dako	   (Ely,	   UK).	   Rabbit	   polyclonal	   anti-­‐TIMP-­‐3	   (ab39184)	  
was	   from	  Abcam	   (Cambridge,	  UK).	  Mouse	  monoclonal	   anti-­‐LRP	  Heavy	  Chain	   (8G1)	  
and	   Light	   Chain	   (5A6)	   were	   from	   Merck	   KGaA	   (Darmstadt,	   Germany).	   Mouse	  
monoclonal	   syndecan-­‐1	   (DL-­‐101)	   and	   syndecan-­‐4	   (5G9)	   were	   from	   Santa	   Cruz	  
Biotechnology	   (Middlesex,	  UK).	  Anti-­‐MMP-­‐1	   antibodies	  were	  prepared	   in	   sheep	  as	  
reported	   (Ito	   and	   Nagase,	   1988).	   HRP-­‐conjugated	   streptavidin	   was	   from	   R&D	  
(Abingdon,	  UK)	  
2.1.4 Protein	  chemistry	  reagents	  
Recombinant	  purified	  His-­‐tagged	  N-­‐TIMP-­‐3	  was	  obtained	  from	  Dr.	  Ngee	  Han	  Lim	  in	  
this	  laboratory	  (Kashiwagi	  et	  al.,	  2001);	  recombinant	  His-­‐tagged	  receptor-­‐associated	  
protein	  (RAP)	  was	  obtained	  from	  Dr.	  Linda	  Troeberg	  in	  this	  laboratory	  (Nielsen	  et	  al.,	  
1995);	   recombinant	   purified	   MMP-­‐1	   catalytic	   domain	   (MMP-­‐1	   ΔC)	   was	   obtained	  
Chapter	  2	   	   Materials	  and	  Methods	  
	   82	  
from	   Dr.	   Robert	   Visse	   in	   this	   laboratory	   (Chung	   et	   al.	   2000).	   FLAG	   peptide	  
(DYKDDDDK)	  was	  purchased	  from	  Advanced	  Biotechnology	  Centre	  (Imperial	  College,	  
London,	  UK).	  	  
2.1.5 Radiochemical	  reagents	  
Pro-­‐Mix™	   L-­‐[35S]	   was	   from	   GE	   Healthcare	   (Buckinghamshire,	   UK)	   and	   Goldstar	  
Multipurpose	  Liquid	  Scintillation	  Cocktail	  was	  from	  Meridian	  (Surrey,	  UK).	  	  
2.1.6 Molecular	  biology	  reagents	  
Materials	   were	   purchased	   from	   the	   following	   sources:	   AffinityScript	   One-­‐Step	   RT-­‐
PCR	  Kit	   from	  Agilent	  Technologies	  UK	  Limited	  (Stockport,	  UK);	  RNeasy	  Mini	  Kit	  and	  
QIAprep	   Spin	   Miniprep	   Kit	   from	   Qiagen	   (Crawley,	   UK);	   Luria-­‐Bertani	   (LB)	   media,	  
Lipofectamine2000™	  and	  Opti-­‐MEM	  medium	  from	  Invitrogen	  (Paisley,	  UK);	  Pfu	  DNA	  
polymerase®	  from	  Amersham	  Biosciences	  UK	  Limited	  (Bucks,	  UK);	  SYBR	  green	  I	  from	  
Molecular	   Probes	   (Cambridge,	   UK);	   siRNAs	   double-­‐stranded	   RNA	   targeting	   human	  
syndecan-­‐1	  (AM12432	  and	  AM142557)	  from	  Ambion	  (Warrington,	  UK).	  	  
2.1.7 Immunofluorescence	  reagents	  
Materials	  were	  purchased	   from	   the	   following	   sources:	   goat	   serum	   from	  Dako	   (Ely,	  
UK);	   Alexa-­‐488	   conjugated-­‐goat	   anti-­‐mouse	   and	   Alexa-­‐568	   conjugated-­‐phalloidin	  
from	  Molecular	  Probes	  (Leiden,	  Netherlands).	  
2.2 Cell	  culture	  
2.2.1 Cell	  line	  culture	  
Cells	  (HEK-­‐293/EBNA,	  HTB94,	  MEF-­‐1,	  PEA-­‐10,	  PEA-­‐13,	  HUCF,	  HeLa,	  MCF-­‐7,	  syndecan-­‐
1-­‐null	   and	   wild-­‐type	   MEFs)	   were	   grown	   in	   DMEM	   supplemented	   with	   100	   U/ml	  
penicillin,	   100	   μg/ml	   streptomycin	   and	   10	  %	   (v/v)	   FCS.	   CHO-­‐K1	   and	   CHO-­‐745	   cells	  
were	   grown	   in	   Ham’s	   F12	   medium	   supplemented	   with	   100	   U/ml	   penicillin,	   100	  
μg/ml	   streptomycin	   and	   10	  %	   (v/v)	   FCS.	   THP-­‐1	   cells	  were	   grown	   in	   RPMI	  medium	  
supplemented	  with	  100	  U/ml	  penicillin,	  100	  μg/ml	  streptomycin	  and	  5	  %	  (v/v)	  FCS.	  
HEK-­‐293/EBNA	  cells	  transfected	  with	  pCEP4-­‐TIMP-­‐3	  and	  pCEP4-­‐N-­‐TIMP-­‐3	  constructs	  
were	   cultured	   in	   DMEM	   supplemented	   with	   100	   U/ml	   penicillin,	   100	   μg/ml	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streptomycin	  and	  10	  %	  (v/v)	  FCS	  with	  the	  addition	  of	  800	  μg/ml	  hygromycin	  B.	  HEK-­‐
293/EBNA	  cells	  transfected	  with	  pCEP4-­‐ADAMTS4-­‐2,	  pCEP4-­‐ADAMTS5-­‐2	  and	  pCEP4-­‐
MMP-­‐1	  constructs	  were	  cultured	  in	  DMEM	  supplemented	  with	  100	  U/ml	  penicillin,	  
100	   μg/ml	   streptomycin	   and	   10	   %	   (v/v)	   FCS	   with	   the	   addition	   of	   100	   μg/ml	  
hygromycin	  B.	  Cells	  were	  passaged	  every	  3-­‐4	  days	  using	  trypsin-­‐EDTA.	  
2.2.2 Primary	  chondrocyte	  isolation	  and	  culture	  
Porcine	   chondrocytes	   were	   isolated	   by	   digesting	   1	   g	   of	   porcine	   articular	   cartilage	  
from	  metacarpophalangeal	  joints	  in	  10	  ml	  of	  DMEM	  with	  10	  %	  FCS	  and	  0.25	  mg/ml	  
bacterial	   collagenase	   (over	   night	   at	   37	   °C	   with	   shaking).	   The	   chondrocytes	   were	  
separated	  from	  undigested	  material	  by	  passing	  through	  a	  cell	   strainer	   into	  a	  50	  ml	  
tube.	  Collected	  cells	  were	  washed	  twice	  and	  cultured	  in	  DMEM	  containing	  100	  U/ml	  
penicillin,	  100	  mg/ml	  streptomycin,	  2	  mg/ml	  amphotericin	  B,	  10	  mM	  HEPES	  and	  10%	  
FCS.	  	  
2.3 SDS-­‐PAGE	  and	  Western	  blots	  
2.3.1 SDS-­‐PAGE	  
SDS-­‐PAGE	  was	  run	  with	  or	  without	  reduction	  of	  samples	  using	  a	  modification	  of	  the	  
ammediol/glycine/HCl	  buffer	  system	  of	  Wyckoff	  et	  al.	   (Wyckoff	  et	  al.,	  1977)	  or	   the	  
Tris-­‐glycine	   buffer	   system	   according	   to	   Laemmli	   (Laemmli,	   1970).	   Polyacrylamide	  
gels	  were	  made	  with	  6-­‐12	  %	  total	  acrylamide,	  depending	  on	  the	  size	  of	  the	  proteins	  
to	  be	  separated.	  Samples	  were	  diluted	  with	  an	  equal	  volume	  of	  2	  x	  sample	  buffer	  [42	  
mM	   ammediol	   or	   0.125	  mM	   Tris-­‐HCl,	   0.01	  %	   (w/v)	   sodium	   azide,	   2	  %	   SDS,	   0.1	  %	  
(w/v)	   bromophenol	   blue,	   50	   %	   (w/v)	   glycerol,	   1	   %	   with	   or	   without	   1	   %	   (v/v)	   β-­‐
mercaptoethanol].	   Typically,	   ammediol	   gels	   were	   run	   at	   200	   V	   for	   45-­‐60	  min	   and	  
Tris-­‐glycine	  gels	  were	  run	  at	  150	  V	  for	  90	  min.	  
2.3.2 Silver	  staining	  
Proteins	  were	   visualized	   in	   SDS-­‐PAGE	   gels	   using	   silver	   staining	   (Shevchenko	   et	   al.,	  
1996).	  Gels	  were	   first	   incubated	  with	   fixing	  solution	   [50	  %	   (v/v)	  methanol	  and	  5	  %	  
(v/v)	   acetic	   acid]	   for	   20	   min	   and	   washed	   for	   10	   min	   with	   50	   %	   (v/v)	   methanol.
	   This	  was	   followed	  by	   2	   10	  min	  washes	   in	   deionised	  water.	  Next,	   gels	  were	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incubated	  with	  sensitizer	  [0.02	  %	  (w/v)	  sodium	  thiosulfate]	  for	  1	  min,	  washed	  twice	  
with	   deionised	   water,	   and	   incubated	   with	   cold	   silver	   reagent	   [0.1	   %	   (w/v)	   silver	  
nitrate]	   for	  60	  min	  at	  4	   °C.	  Following	  this	   incubation,	  gels	  were	  washed	  twice	  with	  
distilled	  water	  prior	  the	  addition	  of	  developer	  [0.04	  %	  (v/v)	  formalin	  and	  2	  %	  (w/v)	  
sodium	  carbonate].	  The	  developing	  reaction	  was	  stopped	  using	  5	  %	  (v/v)	  acetic	  acid	  
when	  protein	  bands	  on	  the	  gels	  were	  clearly	  visualized.	  
2.3.3 Western	  Blotting	  
Proteins	   separated	   by	   SDS-­‐PAGE	   were	   analysed	   by	   Western	   blotting	   using	   Novex	  
Mini-­‐cell	   (Invitrogen)	  or	  Mini-­‐Trans-­‐Blot	   cell	   (BIO-­‐RAD)	   systems.	   The	  proteins	  were	  
transferred	   to	   PVDF	  membranes	   at	   350	  mA	   for	   1	   h	   in	   transfer	   buffer	   [20	  %	   (v/v)	  
methanol,	  12.6	  mM	  Tris,	  96	  mM	  glycine	  and	  0.1	  %	  (w/v)	  SDS].	  Pre-­‐stained	  molecular	  
weight	  markers	  were	  completely	  transferred	   in	  this	  time.	  The	  membrane	  was	  then	  
blocked	  with	   either	   5	  %	   BSA	   in	   TBS	   or	   5	  %	   skimmed	  milk	   in	   TBS	   for	   1	   h	   at	   room	  
temperature.	   In	   general,	   membranes	   were	   incubated	   overnight	   with	   primary	  
antibodies	   (diluted	  depending	  on	   the	  antibody	  used)	   in	  either	  1	  %	  BSA-­‐TBS	  or	  1	  %	  
skimmed	  milk-­‐TBS	   at	   4	   °C.	   The	  membrane	  was	   then	  washed	   three	   times	  with	   TBS	  
containing	  0.1	  %	  Tween	  20.	  After	  washing,	  a	  1:1000	  dilution	  of	  a	  AP-­‐linked	  secondary	  
antibody	  or	  HRP-­‐linked	  secondary	  antibody	  in	  1%	  BSA	  in	  TBS	  or	  1%	  milk	  in	  TBS	  was	  
added	  and	  incubated	  for	  1	  h	  at	  room	  temperature.	  The	  membrane	  was	  subsequently	  
washed	   three	   times	  with	  TBS	  containing	  0.1	  %	  Tween	  20	  and	   then	   incubated	  with	  
either	  the	  AP	  substrate	  until	  bands	  appeared	  or	  the	  HRP	  substrate	  for	  1	  min.	  Protein	  
bands	  developed	  by	  HRP	  were	  detected	  by	  exposure	  to	  photographic	  film.	  
2.3.4 Densitometry	  
Gels	  and	  Western	  blots	  were	  scanned	  using	  a	  BioRad	  GS-­‐710	  imaging	  densitometer.	  
Phoretix	  1D	  software	   (Nonlinear	  Dynamics,	  Newcastle-­‐upon-­‐Tyne,	  UK)	  was	  used	   to	  
quantify	  the	  pixel	  intensity	  of	  the	  protein	  bands.	  Unmodified	  16-­‐bit	  TIFF	  images	  were	  
analysed	  and	  the	  background	  pixel	   intensity	  was	  subtracted	  using	  the	  “rolling	  ball”	  
method.	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2.4 Protein	  Purification	  
2.4.1 Purification	  of	  TIMP-­‐3	  and	  N-­‐TIMP-­‐3	  
Recombinant	   C-­‐terminally	   FLAG-­‐tagged	   TIMP-­‐3	   and	   N-­‐TIMP-­‐3	   were	   purified	  
following	   the	  procedure	  described	  by	   Troeberg	  et	   al.	   (Troeberg	   et	   al.,	   2009).	  HEK-­‐
293/EBNA	   cells	   stably	   transfected	   with	   either	   pCEP4-­‐TIMP-­‐3	   or	   pCEP4-­‐N-­‐TIMP-­‐3	  
construct	  were	  grown	  to	  confluence	   in	   the	  presence	  of	  hygromycin	  B	   (800	  μg/ml).	  
Next,	  the	  cells	  were	  washed	  and	  incubated	  in	  serum-­‐free	  DMEM	  containing	  30	  mM	  
sodium	  chlorate	  (NaClO3).	  The	  conditioned	  medium	  was	  harvested	  after	  4	  days	  and	  
centrifuged	   to	   remove	   cell	   debris	   prior	   to	   being	   applied	   to	   a	   2	  ml	   anti-­‐FLAG	  M2-­‐
agarose	   column	   at	   room	   temperature.	   The	   column	   was	   washed	   with	   10	   column	  
volumes	  of	  1	  M	  NaCl-­‐TNC	  buffer	  [50	  mM	  Tris-­‐HCl	  (pH	  7.5),	  1	  M	  NaCl,	  10	  mM	  CaCl2]	  
to	   remove	   non-­‐specifically	   bound	   proteins.	   The	   column	   was	   then	   washed	   with	   5	  
column	   volumes	   of	   TNC	   buffer	   [50	   mM	   Tris-­‐HCl	   (pH	   7.5),	   150	   mM	   NaCl,	   10	   mM	  
CaCl2].	  The	  proteins	  were	  eluted	  with	  200	  μg/ml	  FLAG	  peptide	  in	  TNC	  buffer	  [50	  mM	  
Tris-­‐HCl	  (pH	  7.5),	  150	  mM	  NaCl,	  10	  mM	  CaCl2]	  and	  fractions	  were	  run	  on	  SDS-­‐PAGE	  
for	  subsequent	  silver	  staining	  and	  Western	  blotting	  with	  anti-­‐FLAG	  primary	  antibody.	  
TIMP-­‐3	  and	  N-­‐TIMP-­‐3	  active	  concentrations	  were	  determined	  by	  titration	  against	  a	  
known	  concentration	  of	  MMP-­‐1	  ΔC,	  using	   the	  Dnp	   (2,4-­‐dinitrophenyl)-­‐Pro-­‐Leu-­‐Gly-­‐
Pro-­‐DL-­‐Amp-­‐D-­‐Lys	  substrate	  (Knight,	  1991).	  
2.4.2 Purification	  of	  ADAMTS4-­‐2,	  ADAMTS5-­‐2	  and	  MMP-­‐1	  
ADAMTS-­‐4	   and	   ADAMTS-­‐5	   are	   multidomain	   metalloproteinases	   with	   a	   similar	  
domain	   arrangement,	   consisting	   of	   a	   prodomain,	   a	   catalytic	   metalloproteinase	  
domain,	  a	  disintegrin	  (Dis)	  domain,	  a	  thrombospondin	  type	  I	  (TS)	  domain,	  a	  cysteine-­‐
rich	   (CysR)	   domain,	   and	   a	   spacer	   (Sp)	   domain.	   In	   addition,	   ADAMTS-­‐5	   contains	   an	  
extra	  TS	  domain	  after	  the	  spacer	  domain	  (Gendron	  et	  al.,	  2007).	  ADAMTS4-­‐2	  is	  a	  C-­‐
terminal	  truncated	  form	  of	  ADAMTS-­‐4	  lacking	  of	  the	  spacer	  domain.	  ADAMTS5-­‐2	  is	  a	  
C-­‐terminal	   truncated	   form	   of	   ADAMTS-­‐5	   lacking	   of	   the	   second	   thrombospondin	  
domain.	  HEK-­‐293/EBNA	  cells	  stably	  transfected	  with	  FLAG-­‐tagged	  pCEP4-­‐ADAMTS4-­‐
2,	   pCEP4-­‐ADAMTS5-­‐2	   and	   pCEP4-­‐proMMP1	   were	   grown	   to	   confluence	   in	   the	  
presence	   of	   hygromycin	   B	   (200	   μg/ml).	   Upon	   reaching	   confluence,	   the	   cells	   were	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washed	   once	   with	   serum-­‐free	   DMEM	   to	   remove	   serum	   and	   then	   incubated	   in	  
serum-­‐free	   DMEM.	   The	   conditioned	   medium	   was	   collected	   after	   4	   days	   and	  
centrifuged	   to	   remove	   cell	   debris.	   The	   conditioned	  medium	  was	  applied	   to	   a	  2	  ml	  
anti-­‐FLAG	   M2-­‐agarose	   column	   at	   4	   °C.	   The	   column	   was	   washed	   with	   10	   column	  
volumes	  of	  1	  M	  NaCl-­‐TNC	  buffer	  [50	  mM	  Tris-­‐HCl	  (pH	  7.5),	  1	  M	  NaCl,	  10	  mM	  CaCl2]	  
to	   remove	   non-­‐specifically	   bound	   proteins.	   The	   column	   was	   then	   washed	   with	   5	  
column	  volumes	  of	   Tris-­‐buffered-­‐saline	   (TBS,	   pH	  7.4).	   The	  protein	  was	  eluted	  with	  
200	   μg/ml	   FLAG	   peptide	   in	   TNC	   [50	  mM	   Tris-­‐HCl	   (pH	   7.5),	   150	  mM	  NaCl,	   10	  mM	  
CaCl2].	  Fractions	  were	  run	  on	  SDS-­‐PAGE	  and	  proteins	  were	  silver	  stained.	  proMMP-­‐1	  
was	   activated	   as	   previously	   described	   (Chung	   et	   al.,	   2000).	   Active	   fractions	   of	  
ADAMTS4-­‐2,	  ADAMTS5-­‐2	  and	  MMP-­‐1	  were	  determined	  by	  titration	  against	  a	  kwown	  
concentration	  of	  recombinant	  N-­‐TIMP-­‐3.	  
2.4.3 Purification	  of	  metabolically	  [35S]labelled	  TIMP-­‐3,	  N-­‐TIMP-­‐3	  and	  
MMP-­‐1	  
[35S]TIMP-­‐3,	  [35S]N-­‐TIMP-­‐3	  and	  [35S]MMP-­‐1	  were	  prepared	  by	  a	  modification	  of	  	  the	  
procedure	   described	   in	   section	   2.4.2.	   HEK-­‐293/EBNA	   cells	   stably	   transfected	   with	  
pCEP4-­‐TIMP-­‐3,	   pCEP4-­‐N-­‐TIMP-­‐3	   or	   pCEP4-­‐MMP1	   construct	   were	   grown	   to	  
confluence	   in	   a	   150	   cm2	   flask,	   washed	   once	   and	   incubated	   in	   serum-­‐free	   DMEM	  
without	   L-­‐glutamine,	   cysteine,	   methionine	   or	   cysteine	   for	   2	   hours	   and	   then	  
incubated	   in	  serum-­‐free	  DMEM	  without	  glutamine,	  cysteine,	  methionine	  or	  cystine	  
containing	   [35S]Met/[35S]Cys	   (25	   μCi/ml	   of	   Pro-­‐Mix™	   L-­‐[35S]).	   Conditioned	   media	  
were	  collected	  after	  4	  days,	  centrifuged	  to	  remove	  cell	  debris,	  and	  applied	  to	  a	  2	  ml	  
anti-­‐FLAG	  M2-­‐agarose	  column.	  The	  resin	  was	  extensively	  washed	  and	  bound	  protein	  
eluted	   with	   200	   μg/ml	   FLAG	   peptide.	   The	   purity	   of	   recombinant	   proteins	   was	  
confirmed	   by	   reducing	   SDS-­‐PAGE	   (Bury	   and	   Roberts,	   1982)	   and	   their	   active	  
concentrations	  determined	  as	  mentioned	  in	  Section	  2.4.2	  and	  2.4.3.	  Gels	  were	  dried	  
and	  exposed	  to	  autoradiographic	  film	  for	  4	  days	  to	  confirm	  that	  the	  purified	  proteins	  
were	  effectively	  radiolabeled.	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2.5 Endocytosis	  assays	  
2.5.1 Western	  Blot	  assay	  to	  follow	  TIMP-­‐3	  clearance	  
Cells	   were	   grown	   to	   confluence	   in	   6-­‐well	   plates.	   After	   washing	   three-­‐times	   with	  
serum-­‐free	  DMEM,	  cells	  were	  incubated	  for	  1	  h	  at	  37	  °C	  with	  DMEM	  containing	  0.1	  
%	   BSA	   with	   or	   without	   GM6001	   (10	   μM),	   RAP	   (500	   nM),	   heparin	   (5-­‐500	   μg/ml),	  
calcium	   pentosan	   polysulfate	   (CaPPS),	   sodium	   pentosan	   polysulfate	   (NaPPS),	  
chondroitin-­‐4-­‐sulfate,	   de-­‐N-­‐sulfated	   heparin	   or	   dermatan	   sulfate	   (all	   at	   50	   or	   200	  
μg/ml).	  Following	  this,	  TIMP-­‐3-­‐FLAG	  (1	  nM)	  was	  added	  and	  incubated	  for	  up	  to	  24	  h	  
in	  a	   final	   volume	  of	  2	  ml.	  After	   incubation,	   the	   conditioned	  medium	  was	   removed	  
and	   the	   protein	  was	   precipitated	  with	   TCA	   at	   the	   final	   concentration	   of	   5	  %	   (v/v)	  
overnight	   at	   4	   °C.	   The	   TCA-­‐soluble	   fraction	  was	   separated	   from	   the	   TCA-­‐insoluble	  
fraction	  by	   centrifugation	  at	   13	  000	   rpm	   for	   15	  min	  at	   4	   °C	   and	   the	  TCA-­‐insoluble	  
fraction	  was	   re-­‐suspended	   in	   30	  μl	   of	   2	   x	   reducing	   sample	  buffer.	   Samples	   (15	  μl)	  
were	  analysed	  by	  SDS-­‐PAGE	  (10	  %	  acrylamide)	  and	  Western	  blotting	  with	  the	  anti-­‐
FLAG-­‐M2	  antibody.	  The	  same	  assay	  was	  used	  to	   investigate	  N-­‐TIMP-­‐3	  clearance	  by	  
HTB94	  cells.	  
2.5.2 Radioactivity-­‐based	  assay	  
Cells	   were	   grown	   to	   confluence	   in	   a	   6-­‐well	   plate.	   After	   washing	   three-­‐times	   with	  
serum-­‐free	  DMEM,	  cells	  were	  incubated	  for	  1	  h	  at	  37	  °C	  with	  DMEM	  containing	  0.1	  
%	  BSA	  with	  or	  without	  GM6001	  (10	  μM),	  heparin,	  NaPPS,	  chondroitin	  sulfate,	  de-­‐N-­‐
sulfated	   heparin	   or	   dermatan	   sulfate	   (all	   at	   200	   μg/ml),	   or	   hyaluronan	   (all	   at	   250	  
μg/ml),	   or	   RAP	   (500	  nM).	  As	   a	   control	   for	   agents	   diluted	   in	  DMSO,	   the	   equivalent	  
dilution	   of	   DMSO	   was	   added	   to	   separate	   wells.	   Following	   this,	   1	   nM	   [35S]TIMP-­‐3	  
(unless	  differently	  stated)	  was	  added	  and	  cultured	  for	  up	  to	  48	  h	  in	  a	  final	  volume	  of	  
2	  ml.	  After	   incubation,	   the	  conditioned	  medium	  was	  removed	  and	  the	  protein	  was	  
precipitated	   with	   TCA	   (5	   %)	   overnight	   at	   4	   °C.	   The	   TCA-­‐soluble	   fraction	   was	  
separated	   from	   the	   TCA-­‐insoluble	   fraction	   by	   centrifugation	   at	   13	   000	   rpm	   for	   15	  
min	  at	  4	  °C.	  The	  cells	  were	  washed	  three-­‐times	  with	  ice-­‐cold	  PBS.	  The	  wash	  fractions	  
were	   transferred	   into	   a	   scintillation	   vial	   and	   counted	   directly.	   The	   cell	   layer	   was	  
incubated	   with	   1M	   NaOH	   for	   1h.	   The	   cell	   suspension	   was	   then	   moved	   into	   a	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scintillation	  vial	  and	  counted.	  TCA-­‐insoluble	  pellet	  was	  dissolved	  in	  1	  M	  NaOH	  (500	  
μl).	  Radioactivities	   in	  each	  fraction	  were	  counted	  using	  a	  HIDEX	  300	  SL	  Scintillation	  
Counter	  (Sheffield,	  UK).	  The	  amount	  of	  radioactivity	  in	  all	  the	  different	  fractions	  was	  
calculated	  as	  percentage	  of	  the	  total	  amount	  of	  radioactivity	  in	  all	  of	  any	  harvested	  
sample.	   The	   percentage	   of	   TCA-­‐soluble	   radioactivity	   in	   the	   preparation	   of	   labeled	  
protein	   prior	   to	   incubation	   with	   cells	   was	   subtracted	   from	   the	   amount	   of	   TCA-­‐
soluble	  radioactivity.	  This	  corrected	  for	  any	  TCA-­‐soluble	  radioactivity	  in	  the	  starting	  
material.	  The	  same	  assay	  was	  used	  to	   investigate	  endocytosis	  of	  [35S]N-­‐TIMP-­‐3	  and	  
[35S]MMP-­‐1.	  In	  these	  assays	  n	  refers	  to	  the	  repetitions	  of	  the	  entire	  experiment.	  The	  
curves	  were	  generated	  by	  fitting	  the	  results	  to	  a	  one-­‐phase	  exponential	  decay.	  	  
2.6 Molecular	  Biology	  
2.6.1 siRNA	  knockdown	  of	  syndecan-­‐1	  in	  HTB94	  cells	  
siRNAs	  [two	  double-­‐stranded	  RNA	  targeting	  syndecan-­‐1	  (AM12432	  and	  AM142557)	  
or	   scrambled]	   were	   transiently	   transfected	   into	   HTB94	   cells	   using	   Lipofectamine	  
2000.	  Throughout	  the	  transfection	  procedure,	  penicillin	  and	  streptomycin	  were	  not	  
added	   to	   the	   medium	   because	   these	   antibiotics	   reduce	   transfection	   efficiency.	  
HTB94	  cells	  were	  seeded	  at	  a	  density	  of	  1-­‐1.5x105	  cells/well	  (6-­‐well	  plate)	  in	  DMEM	  
containing	  10	  %	  FCS.	  Cells	  were	  then	  washed	  and	  incubated	  in	  500	  μl	  of	  Opti-­‐MEM.	  
For	  each	  transfection,	  siRNA	  (10-­‐100	  nM)	  were	  diluted	  in	  serum-­‐free	  Opti-­‐MEM	  to	  a	  
final	  volume	  of	  50	  μl.	  In	  a	  separate	  tube,	  1	  μl	  of	  Lipofectamine	  was	  diluted	  in	  49	  μl	  
serum	  free	  Opti-­‐MEM.	  The	  siRNA	  and	  Lipofectamine	  solutions	  were	  combined	  and	  
incubated	   for	  20	  min	  at	   room	  temperature.	  The	  Lipofectamine-­‐siRNA	  mixture	   (100	  
μl)	   was	   then	   gently	   pipetted	   into	   each	  well	   to	   ensure	   an	   even	   distribution	   of	   the	  
siRNA	   in	   the	   medium.	   After	   3	   h	   the	   medium	   was	   replaced	   with	   2	   ml	   of	   DMEM	  
containing	  10	  %	  FCS	  and	  the	  cells	  were	  grown	  to	  confluence.	  
2.6.2 RNA	  extraction	  and	  quantitative-­‐PCR	  analysis	  of	  syndecan-­‐1	  
knockdown	  
After	   siRNA	   transfection,	   confluent	   HTB94	   cells	   were	   lysated	   and	   RNA	   extracted	  
using	   a	   commercially	   available	   kit	   (RNeasy®	  Mini	   kit,	   Invitrogen),	   according	   to	   the	  
manufacturer’s	   instructions.	   Briefly,	   the	   cells	   were	   lysed	   in	   a	   highly	   denaturing	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detergent-­‐containing	  buffer	  and	   the	   lysates	  were	  directly	  applied	   to	  a	  spin	  column	  
where	   RNA	   was	   specifically	   retained.	   After	   washing	   once	   with	   700	   μl	   of	   washing	  
buffer,	  RNA	  was	  eluted	  using	  50	  μl	  of	  RNAse-­‐free	  water	  and	  samples	  were	  quantified	  
by	   spectrophotometry	   (A	  260	  nm)	  and	   stored	  at	   -­‐80	   °C	  until	   use.	   cDNA	  was	  made	  
from	   total	   cell	   RNA	   using	   the	   affinityScript	   One-­‐Step	   RT-­‐PCR	   Kit,	   according	   to	   the	  
manufacturer’s	   instructions.	  Amplification	  reactions	  were	  performed	   in	  triplicate	   in	  
an	  Applied	  Biosystems	  7500	  Real-­‐Time	  PCR	  System.	  The	  primers	  used	  for	  syndecan	  1	  
(Sdc-­‐1)	   were	   5ʹ′-­‐GCCGCAAATTGTGGCTA-­‐3’	   (forward)	   and	   5ʹ′-­‐
AGCCGGAGAAGTTGTCAGAGTC-­‐3’	  (reverse).	  Primers	  used	  for	  human	  glyceraldehyde	  
3-­‐phosphate	   dehydrogenase	   (GAPDH)	   housekeeping	   gene	   were	   5ʹ′-­‐
GCCCAAAGTCACCGTCAA-­‐3’	   (forward)	   and	   5ʹ′-­‐TCCGAAGAGACCAAAGATCAC-­‐3’	  
(reverse).	  Data	  were	  normalized	  to	  the	  housekeeping	  control	  GAPDH	  and	  these	  are	  
presented	  relative	  to	  control.	  	  
2.7 Immunofluorescence	  
2.7.1 Preparation	  of	  gelatin	  coated	  cover	  slips	  
Glass	  cover	  slips	  (18	  mm	  in	  diameter)	  were	  coated	  with	  5	  mg/ml	  gelatin	  dissolved	  in	  
distilled	  water	  and	  incubated	  for	  15	  min	  at	  room	  temperature.	  	  The	  gelatin	  solution	  
was	   removed	   and	   fixed	   using	   1%	   glutaraldehyde	   in	   TBS	   for	   20	   min	   at	   room	  
temperature.	  Following	  fixation,	  the	  cover	  slips	  were	  incubated	  with	  1	  M	  ammonium	  
chloride	  for	  15	  min	  to	  block	  any	  free	  glutaraldehyde.	  	  One	  cover	  slip	  was	  placed	  into	  
one	  well	  of	  a	  12-­‐well	  plate,	  washed	  twice	  with	  70%	  ethanol	  to	  ensure	  sterility,	  and	  
then	  washed	  thrice	  with	  media	  containing	  10%	  FCS	  before	  the	  cells	  were	  added.	  
2.7.2 Internalization	  of	  TIMP-­‐3	  followed	  by	  immunofluorescence	  
HTB94,	  MEF-­‐1	  and	  PEA-­‐13	  cells	  cultured	  on	  18	  mm	  cover	  glasses	  coated	  with	  gelatin	  
were	  incubated	  at	  37	  °C	  in	  phenol-­‐red	  free	  DMEM	  with	  0.1%	  (v/v)	  FCS	  containing	  1	  
μg/ml	   of	   non-­‐radiolabeled	   recombinant	   FLAG-­‐tagged	   TIMP-­‐3	   in	   the	   presence	   or	  
absence	  of	  heparin	  (200	  mg/ml)	  or	  RAP	  (500	  nM).	  After	  2	  h	  cells	  were	  fixed	  with	  3%	  
paraformaldehyde	  in	  PBS	  for	  10	  min	  and	  blocked	  with	  5%	  (v/v)	  goat	  serum	  and	  3%	  
(w/v)	   bovine	   serum	   albumin	   in	   PBS	   for	   1	   h	   at	   room	   temperature.	   Cells	   were	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permeabilized	  with	  PBS	  containing	  0.1%	  (v/v)	  Triton	  X-­‐100	  and	  then	  incubated	  with	  
anti-­‐FLAG	  M2	   antibody	   (5	   ml/ml)	   at	   room	   temperature	   for	   2	   h.	   Alexa	   Fluor-­‐488–
conjugated	  goat	  anti-­‐mouse	  IgG	  was	  used	  to	  visualize	  the	  antigen	  signal.	  Actin	  was	  
stained	  with	  Alexa	  Fluor-­‐568-­‐conjugated	  phalloidin.	  The	  signals	  were	  analyzed	  using	  
a	  CCD	  camera-­‐equipped	  microscope	  (Nikon	  TE-­‐2000)	  with	  ×60	  objective	  lens.	  	  
2.8 Study	  of	  binding	  of	  TIMP-­‐3	  to	  sLRP-­‐1	  by	  ELISA	  
2.8.1 Purification	  of	  sLRP-­‐1	  from	  plasma	  	  
sLRP-­‐1	  was	  isolated	  from	  fresh-­‐frozen	  human	  plasma	  by	  a	  modification	  of	  previously	  
published	  methods	  (Quinn	  et	  al.,	  1997).	  Plasma	  was	  diluted	  5-­‐fold	  with	  equilibration	  
buffer	   (50	   mM	   citrate,	   pH	   6.0,	   75	   mM	   NaCl,	   0.02	   %	   NaN3)	   supplemented	   with	  
proteinase	   inhibitor	   cocktail	   (P8340,	   Sigma-­‐Aldrich,	   Dorset,	   UK)	   and	   applied	   to	   a	  
MacroPrep	  S	  ion	  exchange	  resin	  (Bio-­‐Rad,	  Hemel	  Hempstead,	  UK)	  equilibrated	  in	  the	  
same	   buffer.	   The	   resin	   was	   extensively	   washed	   in	   equilibration	   buffer	   to	   remove	  
unbound	  material	   and	  bound	  proteins	   then	  eluted	   in	   a	   gradient	   of	   75	   to	   500	  mM	  
NaCl	  in	  equilibration	  buffer	  over	  10	  column	  volumes.	  Eluted	  fractions	  were	  analyzed	  
by	   SDS-­‐PAGE	   with	   silver	   staining	   and	   immunoblotting	   for	   LRP-­‐1	   using	   the	   8G1	  
antibody	  (Abcam,	  Cambridge,	  UK).	  	  	  
2.8.2 ELISA	  detection	  of	  TIMP-­‐3	  binding	  to	  sLRP-­‐1	  	  	  
High-­‐binding	  microtitre	  plates	  (Corning,	  NY,	  USA)	  were	  coated	  with	  0.4	  nmol	  sLRP-­‐1	  
in	  50	  mM	  citrate,	  pH	  6.0,	  75	  mM	  NaCl	  overnight.	  Wells	  were	  blocked	  using	  3	  %	  BSA-­‐
PBS	  (1	  h,	  37	  °C)	  and	  washed	  in	  PBS	  containing	  0.1	  %	  (v/v)	  Tween	  20	  (Sigma-­‐Aldrich,	  
Dorset,	   UK)	   after	   this	   and	   each	   subsequent	   step.	  Wells	  were	   then	   incubated	  with	  
recombinant	  TIMP-­‐3	   in	  blocking	  solution	   (0.15	   -­‐	  20	  nM,	  3	  h,	  37	   °C).	  Bound	  TIMP-­‐3	  
was	  detected	  by	  incubation	  of	  wells	  with	  murine	  M2	  anti-­‐FLAG	  antibody	  (3	  h,	  37	  °C)	  
and	  then	  with	  an	  anti-­‐mouse	  secondary	  antibody	  coupled	  to	  horseradish	  peroxidase	  
(1	   h,	   37	   °C)	   (DAKO,	   Ely,	   UK).	   Hydrolysis	   of	   tetramethylbenzidine	   substrate	   (KPL,	  
Gaithersburg,	  MA,	  USA)	  was	  measured	  at	  450	  nm	  using	  a	  BioTek	  EL-­‐808	  absorbance	  
microplate	  reader	  (BioTek,	  Winooski,	  VT,	  USA).	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3.1 Introduction	  
Our	  laboratory	  has	  recently	  shown	  that	  while	  no	  TIMP-­‐3	  is	  detectable	  in	  the	  medium	  
of	   HTB94	   cells	   in	   culture	   under	   normal	   conditions,	   TIMP-­‐3	   accumulates	   in	   the	  
medium	  when	  heparin	  or	  calcium	  pentosan	  polysulfate	  (CaPPS)	  is	  added	  to	  the	  cells	  
(Troeberg	   et	   al.,	   2008).	   Cytochalasin	   D,	   which	   is	   potent	   inhibitor	   of	   actin	  
polymerization,	  also	   led	  to	  an	  accumulation	  of	  TIMP-­‐3	   in	   the	  medium	  (Troeberg	  et	  
al.,	  2008).	  These	  data	  suggested	  that	  TIMP-­‐3	  can	  be	  rapidly	  internalized	  by	  cells	  after	  
its	  secretion	  and	  that	  heparin	  and	  CaPPS	  interfere	  with	  its	  endocytosis	  leading	  to	  an	  
accumulation	   of	   TIMP-­‐3	   in	   the	   conditioned	   medium.	   Other	   proteinases	   and	  
proteinase—inhibitor	   complexes,	   such	   as	  MMP-­‐13,	  MMP-­‐9—TIMP-­‐1,	   proMMP-­‐2—
TIMP-­‐2	  (Barmina	  et	  al.,	  1999;	  Emonard	  et	  al.,	  2004;	  Hahn-­‐Dantona	  et	  al.,	  2001),	  uPA	  
and	   uPA—uPAI-­‐1(Higazi	   et	   al.,	   1996;	   Kounnas	   et	   al.,	   1993),	   and	   other	   ECM-­‐
associated	  proteins,	  such	  as	  connective	  tissue	  growth	  factor	  (CTGF)	  (Segarini	  et	  al.,	  
2001),	   decorin	   (Brandan	   et	   al.,	   2006)	   and	   fibronectin	   (Salicioni	   et	   al.,	   2002)	   are	  
known	  to	  be	  internalized	  by	  cells	  via	  a	  member	  of	  LDL	  receptor	  superfamily.	  To	  test	  
the	   involvement	   of	   an	   LDL	   receptor	   in	   TIMP-­‐3	   endocytosis,	   Troeberg	   et	   al.	   (2008)	  
treated	   HTB94	   cells	   with	   the	   LDL	   receptor	   superfamily	   antagonist	   RAP,	   and	   they	  
showed	  that	  this	  also	   led	  to	  an	  accumulation	  of	  TIMP-­‐3	   in	  the	  medium,	  suggesting	  
that	  a	  member	  of	  LDL	  receptor	  superfamily	  is	  involved	  in	  TIMP-­‐3	  endocytosis.	  
	   In	  this	  chapter,	  this	  observation	  was	  further	  investigated	  to	  characterize	  the	  
pathways	   involved	   in	   TIMP-­‐3	   endocytosis	   in	  more	   detail.	   Three	   different	  methods	  
were	  used	  to	  study	  TIMP-­‐3	  endocytosis.	  i)	  Western	  blot	  analysis	  was	  used	  to	  follow	  
clearance	  of	  exogenously	  added	  TIMP-­‐3	  from	  conditioned	  medium	  of	  cultured	  cells,	  
ii)	   a	   radioactivity-­‐based	   assay	   was	   used	   to	   investigate	   the	   kinetics	   of	   TIMP-­‐3	  
endocytosis	   and	   iii)	   immunofluorescence	   was	   used	   to	   detect	   the	   presence	   of	  
endocytosed	  TIMP-­‐3	  inside	  cells.	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3.2 Results	  
3.2.1 Monitoring	  TIMP-­‐3	  and	  N-­‐TIMP-­‐3	  disappearance	  from	  the	  
medium	  of	  HTB94	  cells	  by	  Western	  blot	  analysis	  
3.2.1.1 Preparation	  of	  conditioned	  medium	  containing	  recombinant	  FLAG	  
tagged	  TIMP-­‐3	  or	  N-­‐TIMP-­‐3	  
HEK-­‐293/EBNA	   cells	   transfected	  with	   a	   vector	   encoding	   FLAG-­‐tagged	   TIMP-­‐3	  were	  
grown	  to	  confluence	  and	  incubated	  in	  serum-­‐free	  DMEM	  containing	  30	  mM	  sodium	  
chlorate.	  Troeberg	  et	  al.	  (2009)	  showed	  that	  sodium	  chlorate	  (NaClO3),	  which	  inhibits	  
heparan	   sulfate	   proteoglycan	   sulfation,	   prevented	   TIMP-­‐3	   internalization	   and	  
resulted	   in	   accumulation	   of	   soluble	   TIMP-­‐3	   in	   the	  medium	   of	   HEK-­‐293/EBNA	   cells	  
freshly	   transfected	  with	   a	   pCEP-­‐4/TIMP-­‐3-­‐FLAG	   construct.	   Only	   a	   small	   amount	   of	  
TIMP-­‐3	  was	  detected	   in	   the	  conditioned	  medium	  without	  adding	  NaClO3	   (Troeberg	  
et	   al.,	   2009).	   After	   4	   days,	   the	   conditioned	   medium	   (250	   ml)	   was	   collected,	  
centrifuged	  for	  5	  min	  at	  3000	  g	  to	  eliminate	  cell	  debris	  and	  concentrated	  10	  times	  
using	   Vivacell	   250	   filters	   (MWCO	   5000).	   The	   medium	   was	   dialyzed	   using	   Slide-­‐A-­‐
Lyzer	  Dialysis	  Cassettes	  (MWCO	  3500)	  against	  TBS	  to	  remove	  the	  sodium	  chlorate.	  	  
Samples	  were	  taken	  after	  every	  step	  (1	  ml	  or	  100	  µl	  after	  concentration)	  and	  
TCA-­‐precipitated	  (5	  %).	  The	  TCA-­‐insoluble	  pellets	  were	  re-­‐suspended	  in	  30	  μl	  of	  2	  X	  
SDS-­‐PAGE	   buffer	   and	   the	   expression	   of	   TIMP-­‐3	  was	   analysed	   by	  Western	   blotting	  
with	   anti-­‐FLAG	   M2-­‐antibody.	   As	   shown	   in	   Figure	   5,	   TIMP-­‐3	   was	   detected	   in	   the	  
conditioned	  medium.	   Conditioned	  medium	   containing	   FLAG	   tagged	   N-­‐TIMP-­‐3	   was	  
made	  in	  the	  same	  manner	  (data	  not	  shown).	   Inhibitory	  activity	  of	  both	  TIMP-­‐3	  and	  
N-­‐TIMP-­‐3	  was	  confirmed	  by	  titration	  against	  MMP-­‐1	  ΔC.	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Figure	  5,	  Western	  blot	  of	  conditioned	  medium	  containing	  TIMP-­‐3-­‐FLAG	  
Conditioned	  medium	  from	  HEK-­‐293/EBNA	  cells	  transfected	  with	  pCEP4/TIMP-­‐3-­‐FLAG	  
was	   harvested	   after	   4	   days	   of	   culture	   in	   serum-­‐free	   DMEM	  with	   30	   mM	   NaClO3,	  
concentrated	   and	   dialyzed	   against	   TBS.	   Samples	   of	   conditioned	   medium	   (1	   ml),	  
concentrated	  medium	  (100	  μl),	  dialysis	  buffer	  (1	  ml)	  and	  concentrated	  and	  dialyzed	  
medium	  (100	  μl)	  were	  precipitated	  with	  TCA	  (5	  %)	  and	  analysed	  by	  Western	  blotting	  
using	  the	  anti-­‐FLAG	  M2-­‐antibody.	  	  	  
3.2.1.2 Time	  course	  of	  TIMP-­‐3	  disappearance	  from	  the	  medium	  of	  HTB94	  
cells	  	  
To	   investigate	  whether	   TIMP-­‐3	   could	   be	   endocytosed	   by	  HTB94	   cells,	   the	   TIMP-­‐3-­‐
FLAG	   containing	   medium,	   concentrated	   and	   dialyzed	   (prepared	   as	   described	   in	  
Section	   3.2.1.1),	   was	   added	   to	   HTB94	   cells	   and	   the	   amount	   of	   recombinant	   FLAG	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tagged	  TIMP-­‐3	  remaining	  in	  the	  medium	  of	  HTB94	  cells	  over	  24	  h	  was	  examined	  by	  
Western	  blotting.	  	  
	   HTB94	   cells	   were	   grown	   to	   confluence	   in	   DMEM	   10	   %	   FCS,	   and	   then	  
incubated	   in	   DMEM	   0.1	   %	   FCS	   supplemented	  with	   100	   μl	   of	   FLAG-­‐tagged	   TIMP-­‐3	  
containing	  medium.	  Cells	  were	  cultured	  for	  up	  to	  24	  h	  and	  the	  conditioned	  medium	  
was	  harvested	  at	  the	  time	  points	  indicated,	  and	  concentrated	  by	  TCA	  precipitation.	  
Equal	  volumes	  of	  all	  samples	  were	  analysed	  by	  Western	  blotting	  using	  the	  anti-­‐FLAG-­‐
M2	  antibody	  as	  described	  in	  Section	  3.2.1.1.	  
Figure	   6	   shows	   that	   the	   amount	   of	   TIMP-­‐3	   in	   the	   medium	   of	   HTB94	   cells	  
reduced	  over	  a	  24	  h	  time	  period.	  To	  determine	  the	  half-­‐life	  of	  TIMP-­‐3	  disappearance	  
from	   the	  medium	  of	  HTB94	   cells,	   the	  pixel	   volume	  of	   each	  band	   in	   Figure	  6A	  was	  
quantified	  using	  Phoretix	  software.	  A	  graph	  of	  pixel	  volume	  of	  TIMP-­‐3	  in	  the	  medium	  
against	  time	  is	  shown	  in	  Figure	  6B.	  The	  t½	  of	  TIMP-­‐3	  disappearance	  from	  the	  medium	  
was	  about	  6	  h.	  TIMP-­‐3	  could	  not	  be	  detected	  in	  either	  the	  wash	  fractions	  or	  within	  
the	  cells	  (results	  not	  shown).	  	  
 
Figure	  6,	  TIMP-­‐3	  disappearance	  from	  the	  medium	  of	  HTB94	  cells	  	  
A.	  Conditioned	  medium	  containing	  TIMP-­‐3	  was	  added	  to	  HTB94	  cells,	  harvested	  at	  
indicated	   hours	   and	   precipitated	  with	   TCA	   (5	  %).	   TCA-­‐insoluble	   fractions	  were	   re-­‐
suspended	  in	  2	  X	  SDS-­‐PAGE	  buffer	  and	  analysed	  by	  Western	  blotting	  using	  the	  anti-­‐
FLAG-­‐M2	   antibody.	  B.	   The	   pixel	   volume	   of	   each	   band	   from	   the	  Western	   blot	  was	  
quantified	   using	   Phoretix	   software.	   The	   curve	   was	   generated	   by	   fitting	   to	   a	   one-­‐
phase	  exponential	  decay.	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3.2.1.3 Time	  course	  of	  N-­‐TIMP-­‐3	  disappearance	  from	  the	  medium	  of	  HTB94	  
cells	  	  	  
The	   same	   procedure	   was	   used	   to	   determine	   whether	   N-­‐TIMP-­‐3	   could	   also	   be	  
endocytosed.	  HTB94	  cells	  were	  grown	  to	  confluence,	  then	  washed	  and	  incubated	  in	  
N-­‐TIMP-­‐3-­‐containing	   conditioned	   medium.	   Conditioned	   medium	   was	   harvested	   at	  
the	  time	  points	   indicated	  and	  treated	  as	  previously	  described	   in	  Section	  3.2.1.2	  for	  
TIMP-­‐3.	  Figure	  7A	  shows	  that	  the	  amount	  of	  N-­‐TIMP-­‐3	  in	  the	  medium	  of	  HTB94	  cells	  
reduced	  over	  a	  24	  h	  time	  period.	  Graphs	  of	  pixel	  volume	  of	  N-­‐TIMP-­‐3	  in	  the	  medium	  
against	   time	   are	   shown	   in	   Figure	   7B.	   The	   t½	   of	   N-­‐TIMP-­‐3	   disappearance	   from	   the	  
medium	  was	  about	  6	  h.	  As	  for	  TIMP-­‐3,	  N-­‐TIMP-­‐3	  could	  not	  be	  detected	  in	  either	  the	  
wash	  fractions	  or	  within	  the	  cells	  (data	  not	  shown).	  
 
 
Figure	  7,	  N-­‐TIMP-­‐3	  disappearance	  from	  the	  medium	  of	  HTB94	  cells	  	  
A.	  Conditioned	  medium	  containing	  N-­‐TIMP-­‐3	  was	  added	  to	  HTB94	  cells,	  harvested	  at	  
the	   time	  points	   indicated	   and	  precipitated	  with	   TCA	   (5	  %).	   TCA-­‐insoluble	   fractions	  
were	  re-­‐suspended	  in	  2	  X	  SDS-­‐PAGE	  buffer	  and	  analyzed	  by	  Western	  blotting	  using	  
the	  anti-­‐FLAG-­‐M2	  antibody.	  B.	  The	  pixel	  volume	  of	  each	  band	  corresponding	  at	  the	  
amount	   of	   N-­‐TIMP-­‐3	   remaining	   in	   the	  medium	   at	   each	   time	  was	   quantified	   using	  
Phoretix	   software.	   The	   curve	  was	   generated	   by	   fitting	   to	   a	   one-­‐phase	   exponential	  
decay.	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3.2.1.4 The	  effect	  of	  GAGs	  on	  TIMP-­‐3	  disappearance	  from	  the	  medium	  of	  
HTB94	  cells	  	  
Troeberg	   et	   al.	   (2008)	   showed	   that	   heparin	   and	   CaPPS	   induced	   accumulation	   of	  
TIMP-­‐3	  in	  the	  conditioned	  media	  of	  cultured	  HTB94	  cells.	  To	  determine	  if	  GAGs	  other	  
that	  heparin	  and	  CaPPS	  could	  protect	  against	  TIMP-­‐3	  depletion,	   cells	  were	   treated	  
with	  other	  GAGs,	  including	  de-­‐N-­‐sulfated	  heparin,	  dermatan	  sulfate	  and	  chondroitin-­‐
4-­‐sulfate	   (at	  50	  μg/ml	  and	  200	  μg/ml)	   for	  1	  h	  prior	   to	   the	  addition	  of	   conditioned	  
medium	  containing	  TIMP-­‐3.	  After	  8	  h,	  the	  medium	  was	  precipitated	  with	  TCA	  (5	  %)	  
and	  analysed	  by	  Western	  blotting	  with	  the	  anti-­‐FLAG-­‐M2	  antibody.	  Only	  heparin	  and	  
CaPPS	   increased	   the	  amount	  of	   intact	  TIMP-­‐3	   remaining	   in	   the	  medium,	   the	  other	  
GAGs	  tested	  did	  not	  show	  similar	  effects	  (Figure	  8A	  and	  B).	  
	  
Chapter	  3	   	   TIMP-­‐3	  internalization	  by	  different	  cell	  types	  
	   98	  
 
Figure	  8,	  The	  effect	  of	  GAGs	  on	  TIMP-­‐3	  disappearance	  from	  the	  medium	  of	  HTB94	  
cells.	  	  
HTB94	   cells	   were	   incubated	   with	   or	   without	   de-­‐N-­‐sulfated	   heparin,	   dermatan	  
sulfate,	  chondroitin	  sulfate,	  calcium	  pentosan	  polysulfate	  or	  heparin	  (50	  μg/ml	  and	  
200	  μg/ml)	  for	  1	  h	  prior	  to	  addition	  of	  conditioned	  medium	  containing	  TIMP-­‐3.	  After	  
8	  h,	  the	  conditioned	  medium	  was	  harvested	  and	  precipitated	  with	  TCA	  (5	  %).	  A.	  Each	  
sample	  was	  analysed	  by	  Western	  blotting	  using	  anti-­‐FLAG-­‐M2	  antibody.	  B.	  The	  pixel	  
volume	  of	  each	  TIMP-­‐3	  band	  was	  quantifiied	  using	  Phoretix	  software.	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3.2.1.5 The	   effect	   of	   RAP	   on	   TIMP-­‐3	   disappearance	   from	   the	   medium	   of	  
HTB94	  cells	  	  
To	  determine	  whether	   a	  member	  of	   the	   LDL	   family	   of	   receptors	  mediated	   TIMP-­‐3	  
endocytosis,	   cells	   were	   treated	   with	   the	   LDL	   receptor	   family	   antagonist	   RAP	   (500	  
nM)	  for	  1	  h	  prior	  to	  the	  addition	  of	  conditioned	  medium	  containing	  TIMP-­‐3.	  Media	  
were	  harvested	  at	   the	   indicated	  time	  points	  and	  precipitated	  with	  TCA	   (5	  %).	  TCA-­‐
insoluble	   fractions	   were	   analysed	   by	   Western	   blotting	   with	   the	   anti-­‐FLAG-­‐M2	  
antibody.	  Figure	  9	  shows	  that	  RAP	  protected	  against	  TIMP-­‐3	  disappearance	  from	  the	  
medium	   at	   8	   h.	   This	   is	   in	   agreement	   with	   previous	   findings	   in	   our	   laboratory	  
(Troeberg	  et	  al.,	  2008).	  
 
Figure	  9,	  Effect	  of	  RAP	  on	  TIMP-­‐3	  disappearance	  from	  the	  medium	  	  
HTB94	  cells	  were	  incubated	  with	  or	  without	  RAP	  (500	  nM)	  for	  1	  h	  prior	  to	  addition	  of	  
conditioned	  medium	  containing	  TIMP-­‐3.	  At	  0,	  5	  and	  8	  h	  the	  conditioned	  medium	  was	  
harvested	   and	   precipitated	   with	   TCA.	   A.	   Each	   sample	   was	   analysed	   by	   Western	  
blotting	  using	  anti-­‐FLAG-­‐M2	  antibody.	  B.	  The	  pixel	  volume	  of	  each	  TIMP-­‐3	  band	  was	  
quantified	  using	  Phoretix	  software.	  
	  
3.2.2 Monitoring	  TIMP-­‐3	  endocytosis	  using	  a	  radioactivity-­‐based	  assay	  
While	  Western	  blotting	  analysis	  was	  a	  useful	  initial	  tool	  to	  investigate	  disappearance	  
of	   TIMP-­‐3	   from	   the	   medium,	   this	   technique	   was	   not	   sufficient	   to	   detect	   TIMP-­‐3	  
within	   the	   cells.	   We	   thus	   established	   a	   more	   sensitive-­‐quantitative	   radioactivity	  
based	  assay	  to	  investigate	  TIMP-­‐3	  endocytosis.	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3.2.2.1 Purification	  of	  [35S]Met/[35S]Cys-­‐labeled	  TIMP-­‐3	  and	  N-­‐TIMP-­‐3	  	  
HEK-­‐293/EBNA	   cells	   stably	   transfected	   with	   FLAG-­‐tagged	   TIMP-­‐3	   were	   grown	   to	  
confluence,	  and	  metabolically	  labeled	  with	  [35S]Met/[35S]Cys	  by	  incubation	  for	  4	  days	  
in	   serum-­‐free	   DMEM	   without	   cysteine,	   methionine	   or	   cystine,	   containing	  
[35S]Met/[35S]Cys	  (25	  μCi/ml).	  Sodium	  chlorate	  (30	  mM)	  was	  added	  to	  ensure	  TIMP-­‐3	  
accumulation	  in	  the	  medium	  (section	  2.4.1).	  	  
[35S]TIMP-­‐3	   and	   [35S]N-­‐TIMP-­‐3	  were	   purified	   from	   the	   conditioned	  medium	  
using	   anti-­‐FLAG	   M2	   affinity	   chromatography	   and	   FLAG	   peptide	   elution	   (section	  
2.4.1).	  Aliquots	  of	   each	   sample	  were	   analysed	  by	   SDS-­‐PAGE	  and	   silver	   staining.	  As	  
the	   silver	   stain	   in	   Figure	   10	   shows,	   elution	   1	   contained	   two	   protein	   bands	   at	   a	  
molecular	  weight	  of	   approximately	  21	   kDa	  and	  24	   kDa,	   corresponding	   to	   the	  non-­‐
glycosylated	   and	   glycosylated	   forms	   of	   TIMP-­‐3	   (Pavloff	   et	   al.,	   1992).	   Similarly,	  
exposure	  to	  autoradiographic	   film	   indicated	  that	  the	  protein	  was	   labeled	  with	  [35S]	  
and	   that	   there	   were	   no	   other	   radioactive	   contaminants	   in	   the	   preparation.	   The	  
purified	  protein	  was	  verified	  to	  be	  TIMP-­‐3-­‐FLAG	  by	  Western	  blot	  analysis	  with	  anti-­‐
FLAG	  M2	  antibody.	  The	  same	  procedure	  was	  used	  to	  purify	  [35S]N-­‐TIMP-­‐3	  (data	  not	  
shown).	  Active	  concentrations	  of	  [35S]TIMP-­‐3	  were	  determined	  by	  titration	  against	  a	  
known	  concentration	  of	  MMP-­‐1	  ΔC.	  Briefly,	  MMP-­‐1	  ΔC	  activity	  can	  be	  measured	   in	  
vitro	  by	  following	  the	  hydrolysis	  of	  a	  cleavable	  fluorogenic	  substrate.	  50	  μl	  of	  40	  nM	  
MMP-­‐1	  ΔC	  were	   incubated	  with	   serial	  dilutions	  of	   the	   [35S]TIMP-­‐3	  preparation	   (50	  
μl)	   for	   1	   h	   at	   37	   °C	   to	   allow	   formation	   of	   stable	   1:1	   [35S]TIMP-­‐3—MMP-­‐1	   ΔC	  
complexes.	   Then,	   100	   μl	   of	   Dnp	   (2,4-­‐dinitrophenyl)-­‐Pro-­‐Leu-­‐Gly-­‐Pro-­‐DL-­‐Amp-­‐D-­‐Lys	  
substrate	   (3	  μM)	  were	  added.	  The	  amount	  of	  MMP-­‐1	  ΔC	   that	   remains	  uninhibited	  
after	  incubation	  cleaves	  the	  fluoregenic	  substrate	  and	  TIMP-­‐3	  concentration	  can	  be	  
determined	  from	  the	  maximum	  dilution	  (lowest	  concentration	  of	  TIMP-­‐3)	  that	  gives	  
a	   complete	   inhibition	  of	  MMP-­‐1	  ΔC.	  The	  dilution	   factor	  of	   [35S]TIMP-­‐3	  preparation	  
(X-­‐axis)	  was	  plotted	  against	  the	  MMP-­‐1	  ΔC	  activity	  as	  row	  fluorescence	  units	  (Y-­‐axis).	  
The	   X-­‐intercept	   gives	   the	   dilution	   of	   TIMP-­‐3	   preparation	   required	   to	   completely	  
inhibit	   MMP-­‐1	   ΔC.	   Figure	   10D	   shows	   that	   the	   X-­‐intercept	   was	   about	   0.150,	   thus	  
elution	  1	  contained	  about	  40	  nM/0.150=	  266	  nM	  [35S]TIMP-­‐3.	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Figure	  10,	  Purification	  of	  [35S]TIMP-­‐3-­‐FLAG 
A.	   HEK-­‐293/EBNA	   cells	   transfected	   with	   TIMP-­‐3-­‐FLAG	   were	   metabolically	   labeled	  
with	   [35S]Met/[35S]Cys	   for	   4	   days.	   The	   resulting	   conditioned	   medium	   (20	   ml)	   was	  
loaded	  onto	  an	  anti-­‐FLAG	  M2-­‐agarose	  column	  (2	  ml).	  After	  washing	  with	  1	  M	  NaCl	  in	  
TBS	  buffer	  (20	  ml)	  and	  TBS	  (20	  ml),	  the	  bound	  material	  was	  eluted	  with	  200	  μg/ml	  
FLAG	  peptide	   in	   TBS	   in	   3	  ml	   fractions.	  A.	   Aliquots	  were	   analysed	   by	   SDS-­‐PAGE	   (1.	  
starting	  material,	  2.	  unbound	  material,	  3.	  NaCl	  wash-­‐1,	  4.	  NaCl	  wash-­‐2,	  5.	  TBS	  wash-­‐
1,	   6.	   TBS	   wash-­‐2,	   7.	   elution-­‐1,	   8.	   elution-­‐2,	   9.	   elution-­‐3)	   and	   silver	   staining.	   B.	  
Western	  blot	  of	  [35S]TIMP-­‐3	  using	  anti-­‐FLAG	  M2-­‐antibody.	  C.	  The	  gel	  was	  dried	  and	  
exposed	  to	  autoradiographic	  film	  overnight.	  D.	  Titration	  of	  MMP-­‐1	  ΔC	  with	  dilutions	  
of	  [35S]TIMP-­‐3	  preparation.	  
3.2.2.2 Kinetics	  of	  [35S]TIMP-­‐3	  internalization	  by	  HTB94	  cells	  	  
2	  ml	  of	  1	  nM	  [35S]TIMP-­‐3	  were	  added	  to	  1	  x	  106	  cells/well	  HTB94	  cells	  at	  37	  °C	  and	  
the	   distribution	   of	   radioactivity	   in	   various	   cell	   fractions	   analyzed	   over	   24	   h.	   The	  
amount	  of	  TCA-­‐insoluble	  radioactivity	  in	  the	  conditioned	  medium	  decreased	  over	  24	  
h,	   indicating	  that	  the	  amount	  of	   intact	  TIMP-­‐3	  was	  decreased.	  The	  amount	  of	  TCA-­‐
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soluble	   radioactivity	   increased,	   indicating	   that	   [35S]TIMP-­‐3	   was	   degraded	   (Figure	  
11A).	  Radioactivity	  was	  also	  detected	  in	  the	  cell-­‐associated	  fraction.	  It	  increased	  over	  
the	   first	   2	   h	   and	   then	   reached	   a	   constant	   level	   .	   Treatment	   of	   the	   cell	   layer	  with	  
pronase	  indicated	  that	  about	  half	  of	  cell-­‐associated	  [35S]TIMP-­‐3	  was	  detected	  on	  the	  
cell	   surface	   (Figure	  11B).	  Taken	  together,	   these	  data	   thus	   indicate	   that	   [35S]TIMP-­‐3	  
bound	  to	  the	  cell-­‐surface,	  was	  internalized	  and	  degraded	  by	  the	  cells,	  with	  fragments	  
released	  back	  into	  the	  medium.	  
	  
Figure	  11,	  Time	  course	  of	  [35S]TIMP-­‐3	  internalization	  by	  HTB94	  cells	  
A.	   [35S]TIMP-­‐3	   (1	   nM)	   was	   added	   to	   HTB94	   cells.	   After	   the	   indicated	   times,	  
conditioned	   media	   were	   treated	   with	   5	   %	   TCA	   and	   centrifuged	   to	   separate	   TCA-­‐
soluble	  (●)	  radioactivity,	  that	  represents	  [35S	  TIMP-­‐3	  fragments,	  from	  TCA-­‐insoluble	  
material	  (■),	  that	  represents	  intact	  [35S	  TIMP-­‐3.	  Cell-­‐associated	  radioactivity	  (p)	  was	  
solubilized	   in	   NaOH.	   Radioactivity	   present	   in	   the	   different	   fractions	   was	   counted	  
(n=3).	  B.	   Cells	  were	   released	   from	   the	   culture	   dish	  with	   pronase	   (10	  min,	   on	   ice),	  
then	   centrifuged	   to	   separate	   pronase-­‐sensitive	   fraction	   (surface-­‐bound, ●)	   from	  
pronase-­‐resistant	  fraction	  (intracellular,	  ■)	  (n=3).	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3.2.2.3 Concentration-­‐dependent	  endocytosis	  of	  [35S]TIMP-­‐3	  
To	   investigate	  the	  concentration-­‐dependence	  of	  TIMP-­‐3	  clearance,	   [35S]TIMP-­‐3	  was	  
added	  at	  a	  range	  of	  concentrations	  (0.5	  -­‐	  5	  nM)	  and	  the	  medium	  was	  harvested	  at	  
various	  time	  points.	  The	  TCA-­‐insoluble	  fraction	  remaining	  at	  each	  concentration	  was	  
expressed	   as	   %	   of	   the	   total	   counts	   for	   any	   time-­‐point,	   normalized	   against	   the	  
fraction	  at	  0	  h	  and	  plotted	  against	   time	  of	   incubation	   (Figure	  12A).	  At	  each	  of	   the	  
concentrations	  tested,	  [35S]	  TIMP-­‐3	  disappeared	  from	  the	  medium	  at	  a	  similar	  rate.	  
The	   TCA-­‐soluble	   fraction	   also	   increased	   in	   the	  medium	   and	   all	   the	   concentrations	  
tested	  increased	  at	  the	  same	  rate	  (Figure	  12B).	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Figure	  12,	  Concentration-­‐dependent	  [35S]TIMP-­‐3	  clearance	  by	  HTB94	  cells	  
HTB94	  cells	  were	   incubated	   for	  1	  h	  at	  37	   °C,	   then	   [35S]	  TIMP-­‐3	   (0.5	  nM,	  1	  nM,	  2.5	  
nM,	  5	  nM)	  was	  added.	  At	   the	   time	  points	   indicated,	   the	   conditioned	  medium	  was	  
removed	  and	   the	  TCA-­‐soluble	  and	  TCA-­‐insoluble	   fractions	  were	  harvested.	  A.	   TCA-­‐
insoluble	  fraction.	  B.	  TCA-­‐insoluble	  fraction	  (%)	  C.	  TCA-­‐soluble	  fraction	  (%).	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3.2.2.4 Kinetics	  of	  [35S]N-­‐TIMP-­‐3	  internalization	  by	  HTB94	  cells	  
To	   investigate	   whether	   the	   N-­‐terminal	   inhibitory	   domain	   of	   TIMP-­‐3	   is	   also	  
internalized,	   a	   time	   course	   experiment	   was	   performed,	   as	   described	   in	   section	  
3.2.2.2.	  HTB94	  cells	  were	  plated	  at	  a	  density	  of	  1x106	  cells/well	  and	  grown	  overnight	  
before	  incubation	  with	  DMEM	  containing	  0.1	  %	  FCS	  supplemented	  with	  1	  nM	  [35S]N-­‐
TIMP-­‐3.	  The	  radioactivity	  in	  the	  TCA-­‐insoluble,	  -­‐soluble	  and	  cell-­‐associated	  fractions	  
were	  measured	  as	  described	  in	  Section	  3.2.2.2.	  As	  shown	  in	  Figure	  13,	  [35S]N-­‐TIMP-­‐3	  
seems	  to	  be	  cleared	   in	  a	  similar	  manner	  as	  [35S]TIMP-­‐3,	  with	  similar	   initial	  kinetics,	  
but	  the	  rate	  of	  internalization	  and	  degradation	  was	  reduced	  after	  5	  h.	  	  
	  
	  
Figure	  13,	  Time	  course	  of	  [35S]N-­‐TIMP-­‐3	  internalization	  by	  HTB94	  cells	  
[35S]N-­‐TIMP-­‐3	   (1	   nM)	   was	   added	   to	   HTB94	   cells.	   After	   the	   indicated	   times,	  
conditioned	   media	   were	   treated	   with	   5	   %	   TCA	   and	   centrifuged	   to	   separate	   TCA-­‐
soluble	  (●)	  radioactivity	  from	  TCA-­‐insoluble	  material	  (■).	  Cell-­‐associated	  radioactivity	  
(p)	   was	   solublised	   in	   NaOH.	   Radioactivity	   present	   in	   the	   different	   fractions	   was	  
counted	  (n=3).	  Data	  for	  TIMP-­‐3	  (black	  lines)	  are	  from	  Figure	  11.	  
	  
3.2.2.5 Endocyosis	  of	  [35S]TIMP-­‐3	  at	  4	  °C	  and	  in	  Dynasore	  pre-­‐treated	  HTB94	  
cells	  
To	  confirm	  that	  the	  decrease	  of	  radioactivity	  in	  the	  TCA-­‐insoluble	  fraction	  is	  due	  to	  
endocytosis	   rather	   than	   to	   non-­‐specific	   binding	   of	   [35S]TIMP-­‐3	   to	   cell	   or	   plate,	   an	  
experiment	  was	  performed	  at	  4	   °C.	  HTB94	  cells	  were	  seeded	   in	  a	  6-­‐well	  plate	  at	  a	  
density	   of	   1x106	   cells,	   rested	   overnight	   and	   washed	   three-­‐times	   in	   serum-­‐free	  
DMEM	  before	  incubation	  at	  4	  °C	  in	  DMEM	  containing	  0.1	  %	  FCS	  for	  30	  min.	  HTB94	  
cells	  were	  then	  incubated	  with	  [35S]TIMP-­‐3	  (1	  nM)	  at	  4	  °C.	  As	  shown	  in	  Figure	  14A,	  at	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4	   °C	   radioactivity	   in	   the	   TCA-­‐insoluble	   fraction	   slightly	   decreased	   over	   6	   h	   and	  
degradation	   of	   [35S]TIMP-­‐3	  was	   not	   observed	   (radioactivity	   in	   TCA-­‐soluble	   fraction	  
did	  not	  increase).	  Radioactivity	  in	  the	  cell-­‐associated	  fraction	  increased	  over	  the	  first	  
2	   h	   and	   then	   remained	   constant.	   These	   data	   suggested	   that	   [35S]TIMP-­‐3	   was	   not	  
endocytosed	  at	  4	  °C	  but	  that	  it	  still	  bound	  to	  the	  cell	  surface.	  	  
Dynasore	  is	  a	  cell-­‐permeable	  inhibitor	  of	  dynamin,	  a	  large	  GTPase	  responsible	  
for	  the	  scission	  of	  newly	  formed	  vesicles	  at	  the	  plasma	  membrane,	  and	  as	  such	  it	  is	  
an	   inhibitor	   of	   dynamin-­‐dependent	   endocytosis.	   Well-­‐characterised	   clathrin-­‐	   and	  
caveolin-­‐mediated	   pathways	   require	   dynamin	   and	   as	   a	   result	   are	   inhibited	   by	  
Dynasore.	   Nevertheless,	   growing	   numbers	   of	   molecules	   are	   reported	   to	   be	  
internalized	   in	   a	   dynamin-­‐independent	   manner,	   such	   as	   GPI-­‐	   anchored	   proteins	  
(Mayor	   and	   Pagano,	   2007),	   major	   histocompatibility	   complex	   I	   (Radhakrishna	   and	  
Donaldson,	  1997)	  and	  various	  bacterial	  toxins	  and	  viruses	  (Sandvig	  et	  al.,	  2008).	  To	  
address	   the	   question	   of	   whether	   inhibition	   of	   dynamin	   could	   also	   affect	   TIMP-­‐3	  
endocytosis,	  HTB94	   cells	  were	   seeded	   in	   a	   6-­‐well	   plate	   at	   a	  density	  of	   1x106	   cells,	  
rested	   overnight	   and	   washed	   three-­‐times	   in	   serum-­‐free	   DMEM	   before	   incubation	  
with	  80	  µM	  Dynasore	  in	  DMEM	  0.1	  %	  FCS.	  After	  30	  min,	  1	  nM	  [35S]TIMP-­‐3	  was	  added	  
to	   the	  cells	  and	  samples	  harvested	  over	  6	  h.	  Figure	  14B	  shows	   that	   in	  presence	  of	  
Dynasore,	   radioactivity	   in	   the	   TCA-­‐insoluble	   fraction	   slightly	   decreased	   and	  
radioactivity	   associated	   with	   cells	   increased,	   indicating	   that	   [35S]TIMP-­‐3	   bound	   to	  
cells.	   Radioactivity	   associated	  with	   the	   TCA-­‐soluble	   fraction	   also	   slightly	   increased,	  
suggesting	   that	   a	   dynamin-­‐independent	   endocytic	   pathway	   is	   involved	   in	   the	  
internalization	  of	  TIMP-­‐3.	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Figure	  14,	  Inhibition	  of	  [35S]TIMP-­‐3	  endocytosis	  at	  4°	  C	  and	  in	  presence	  of	  Dynasore	  
A.	   HTB94	   cells	   were	   seeded	   in	   a	   6-­‐well	   plate	   at	   a	   density	   of	   1x106	   cells,	   rested	  
overnight	  and	  washed	  three-­‐times	  in	  serum-­‐free	  DMEM.	  Then,	  cells	  were	  incubated	  
at	  4	  °C	  in	  DMEM	  containing	  0.1	  %	  FCS.	  After	  30	  min,	  1	  nM	  [35S]	  TIMP-­‐3	  was	  added.	  At	  
the	  time	  points	  indicated,	  the	  conditioned	  medium	  was	  harvested	  and	  radioactivity	  
in	  TCA-­‐insoluble	  (■),	  TCA-­‐soluble	  (●)	  and	  cell-­‐associated	  (p)	  fractions	  was	  measured	  
(n=3).	  
B.	   HTB94	   cells	   were	   seeded	   in	   a	   6-­‐well	   plate	   at	   a	   density	   of	   1x106	   cells,	   rested	  
overnight	  and	  washed	  three-­‐times	  in	  serum-­‐free	  DMEM.	  Cells	  were	  incubated	  with	  
80	  µM	  Dynasore	  at	  37	  oC	   in	  DMEM	  containing	  0.1	  %	  FCS.	  After	  30	  min,	  1	  nM	  [35S]	  
TIMP-­‐3	   was	   added.	   At	   the	   time	   points	   indicated,	   the	   conditioned	   medium	   was	  
harvested	  and	  radioactivity	  in	  TCA-­‐insoluble	  (■),	  TCA-­‐soluble	  (●)	  and	  cell-­‐associated	  
(p)	  fractions	  was	  measured	  (n=2).	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3.2.2.6 Effect	  of	  GAGs	  on	  [35S]TIMP-­‐3	  endocytosis	  
3.2.2.6.1 Highly	  sulfated	  GAGs	  inhibited	  [35S]TIMP-­‐3	  endocytosis	  
The	  effect	  of	  GAGs	  on	  TIMP-­‐3	  clearance	  was	  previously	  investigated	  by	  Western	  blot	  
analysis	  (Figure	  8).	  Here	  the	  inhibitory	  effect	  of	  GAGs	  on	  [35S]TIMP-­‐3	  is	  investigated	  
further.	  HTB94	  cells	  were	  seeded	  in	  a	  6-­‐well	  plate	  at	  a	  density	  of	  1x106	  cells,	  rested	  
overnight	  and	  washed	  three-­‐times	   in	  serum-­‐free	  DMEM	  before	   incubation	  at	  37	  °C	  
in	  DMEM	  containing	  0.1	  %	  FCS	  and	  heparin	  or	  sodium	  pentosan	  polysulfate	  (NaPPS)	  
or	  de-­‐sulfated	  heparin	  or	  chondroitin	  sulfate	  or	  dermatan	  sulfate	  or	  hyaluronic	  acid	  
(all	  at	  200	  µg/ml)	  for	  1	  h.	  HTB94	  cells	  were	  then	  incubated	  with	  [35S]TIMP-­‐3	  (1	  nM).	  
Media	   were	   harvested	   after	   24	   h	   and	   TCA	   precipitated	   as	   described	   before.	   TCA-­‐
insoluble	  fractions	  were	  transferred	  into	  scintillation	  vials	  and	  counted.	  	  
Figure	   15	   shows	   that	   heparin	   inhibited	   the	   decrease	   in	   TCA-­‐insoluble	  
radioactivity	  after	  24	  h,	  NaPPS	  similarly	  inhibited	  [35S]TIMP-­‐3	  endocytosis,	  while	  de-­‐
sulfated	   heparin,	   dermatan	   sulfate,	   chondroitin	   sulfate	   and	   hyaluronic	   acid	   had	  
minimal	  effects	  on	  TIMP-­‐3	  endocytosis.	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Figure	  15,	  Effect	  of	  different	  GAGs	  on	  [35S]TIMP-­‐3	  endocytosis	  
HTB94	  cells	  were	  seeded	  in	  a	  6-­‐well	  plate	  at	  a	  density	  of	  1x106	  cells,	  rested	  overnight	  
and	   washed	   three-­‐times	   in	   serum-­‐free	   DMEM	   before	   incubation	   with	   indicated	  
GAGs	  (200	  µg/ml)	  for	  1	  h	  at	  37	  °C	  prior	  adding	  1	  nM	  [35S]TIMP-­‐3.	  After	  24	  h	  media	  
were	   harvested	   and	   TCA-­‐precipitated.	   Radioactivity	   associated	   with	   TCA-­‐insoluble	  
fractions	  was	  measured	  (n=2).	  
	  
3.2.2.6.2 The	  effect	  of	  heparin	  on	  [35S]TIMP-­‐3	  endocytosis	  
To	   understand	   the	  mechanism	   of	   heparin	   inhibition,	   a	   time	   course	   of	   [35S]TIMP-­‐3	  
internalization	  by	  HTB94	  cells	   in	  the	  presence	  of	  heparin	  was	  performed.	  Figure	  16	  
shows	   that	   the	   decrease	   in	   TCA-­‐insoluble	   [35S]TIMP-­‐3	   is	   inhibited	   by	   heparin	  
compared	  to	  untreated	  control.	  Also,	  the	  appearance	  of	  radioactivity	  in	  TCA-­‐soluble	  
and	   cell-­‐associated	   fractions	   was	   inhibited	   compared	   to	   control.	   Heparin	   also	  
blocked	   the	   internalization	  of	   [35S]N-­‐TIMP-­‐3	   in	   a	   similar	  manner	   (data	  not	   shown),	  
suggesting	   that	   in	   both	   cases	   heparin	   interfered	   with	   TIMP-­‐3	   binding	   to	   the	   cell	  
surface	  and	  subsequent	  endocytosis.	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Figure	  16,	  Effect	  of	  heparin	  on	  [35S]TIMP-­‐3	  endocytosis.	  	  
HTB94	  were	  incubated	  at	  37	  °C	  with	  heparin	  (200	  μg/ml).	  After	  1	  h,	  1	  nM	  [35S]TIMP-­‐3	  
was	  added.	  The	  conditioned	  medium	  was	  harvested	  at	  different	  time	  points	  over	  24	  
h	  and	  TCA-­‐precipitated.	  Radioactivity	   in	  TCA-­‐insoluble	  (■),	  TCA-­‐soluble	  (●)	  and	  cell-­‐
associated	  (p)	  fractions	  was	  measured	  and	  compared	  to	  that	  of	  samples	  non-­‐treated	  	  
with	  heparin	  (black	  symbols	  and	  lines)	  (n=3).	  
	  
3.2.2.7 RAP	  inhibits	  [35S]TIMP-­‐3	  endocytosis	  
We	  showed	  that	  RAP	  inhibited	  endocytosis	  using	  Western	  blot	  (section	  3.2.1.5).	  We	  
therefore	  investigated	  whether	  it	  also	  inhibits	  the	  endocytosis	  of	  [35S]TIMP-­‐3.	  HTB94	  
cells	  were	  incubated	  with	  RAP	  (500	  nM)	  for	  1	  h	  at	  37	  °C	  and	  then	  [35S]TIMP-­‐3	  (1	  nM)	  
was	  added.	  Fractions	  were	  harvested	  at	  various	  time	  points	  as	  previously	  described.	  
Figure	  17	  shows	   that	  RAP	   inhibited	   the	  decrease	  of	  TCA-­‐insoluble	   [35S]TIMP-­‐3,	  and	  
inhibited	   the	  appearance	  of	   TCA-­‐soluble	  and	   cell-­‐associated	   fractions	   compared	   to	  
the	   controls.	   These	   results	   suggest	   that	   an	   LRP-­‐dependent	   pathway	   is	   involved	   in	  
TIMP-­‐3	  endocytosis.	  RAP	  was,	  however,	  less	  effective	  at	  blocking	  TIMP-­‐3	  endocytosis	  
than	   heparin	   (Figure	   16),	   suggesting	   that	   LRP-­‐independent	   pathways	  may	   also	   be	  
involved	   TIMP-­‐3	   endocytosis.	   RAP	   inhibited	   [35S]N-­‐TIMP-­‐3	   endocytosis	   in	   a	   similar	  
manner	  (not	  shown).	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Figure	  17,	  Effect	  of	  RAP	  on	  [35S]TIMP-­‐3	  endocytosis	  by	  HTB94	  cells	  	  
HTB94	  cells	  were	  incubated	  at	  37	  °C	  in	  DMEM	  containing	  0.1	  %	  FCS	  and	  RAP	  500	  nM.	  
After	  1	  h,	  [35S]TIMP-­‐3	  	  (1	  nM)	  was	  added,	  and	  the	  conditioned	  medium	  was	  removed	  
at	   different	   time	   points	   and	   TCA-­‐precipitated.	   Radioactivity	   in	   TCA-­‐insoluble	   (■),	  
TCA-­‐soluble	   (●)	   and	   cell-­‐associated	   (p)	   fractions	   was	   measured	   and	   compared	   to	  
that	  of	  samples	  non-­‐treated	  with	  RAP	  (black	  symbols	  and	  lines)	  (n=3).	  
	  
3.2.3 Visualisation	   of	   TIMP-­‐3	   endocytosis	   by	   immunofluorescent	  
microscopy	  
To	  visualize	  TIMP-­‐3	  internalized	  by	  cells,	  HTB94	  cells	  were	  cultured	  on	  18	  mm	  cover	  
glasses	  coated	  with	  gelatin.	  1	  μg/ml	  of	  non-­‐radiolabeled	   recombinant	  FLAG-­‐tagged	  
TIMP-­‐3	  was	  added	  to	  cells	  either	  alone	  or	  in	  combination	  with	  heparin	  (200	  μg/ml)	  
or	  RAP	  (500	  nM)	  in	  phenol-­‐red	  free	  DMEM	  with	  0.1	  %	  FCS.	  Cell-­‐associated	  TIMP-­‐3-­‐
FLAG	  was	  visualized	  with	  anti-­‐FLAG	  M2	  antibody	  (5	  μg/ml)	  at	  RT	  for	  2	  h.	  Actin	  was	  
stained	  with	  Alexa	  Fluor-­‐568-­‐conjugated	  phalloidin.	  	  
An	   intense	   and	   punctate	   staining	   was	   observed	   inside	   cells	   supplemented	  
with	   TIMP-­‐3-­‐FLAG	   (Figure	   18).	   In	   the	   presence	   of	   heparin,	   the	   staining	   was	  
completely	  abolished,	  and	  in	  the	  presence	  of	  RAP	  the	  labeling	  was	  strongly	  reduced	  
but	  not	  completely	  abolished.	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Figure	  18,	  Detection	  of	  TIMP-­‐3-­‐FLAG	  within	  HTB94	  cells	  
HTB94	  cells	  were	  incubated	  at	  37	  °C	  with	  1	  μg/ml	  of	  FLAG-­‐tagged	  TIMP-­‐3	  for	  2	  h	  in	  
the	   presence	   or	   absence	   of	   heparin	   (200	   μg/ml)	   or	   RAP	   (500	   nM)	   and	   then	  
permeabilised	  and	  immunostained	  for	  the	  presence	  of	  TIMP-­‐3-­‐FLAG	  inside	  the	  cells	  
using	   an	   M2	   anti-­‐FLAG	   antibody	   and	   an	   Alexa	   468-­‐labelled	   secondary	   antibody	  
(green	  channel).	  The	  cytoskeleton	  was	  visualized	  using	  Alexa	  568-­‐labelled	  phalloidin	  
(red	  channel).	  Control	  samples	  were	  not	  supplemented	  with	  TIMP-­‐3-­‐FLAG.	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3.2.4 Internalization	  of	  [35S]TIMP-­‐3	  by	  different	  cell	  types	  
We	  investigated	  whether	  TIMP-­‐3	  endocytosis	  was	  a	  general	  phenomenon	  occurring	  
in	  other	   cell-­‐types	  different	   from	  HTB94	   cells.	   Primary	   chondrocytes	  were	   isolated	  
from	   pig	   cartilage,	   as	   described	   in	   Section	   2.2.2,	   and	   then	   incubated	   with	   1	   nM	  
[35S]TIMP-­‐3	  at	  37	   °C.	  The	  distribution	  of	   radioactivity	   in	  different	  cell-­‐fractions	  was	  
analysed	   over	   24	   h.	   The	   amount	   of	   TCA-­‐insoluble	   radioactivity	   in	   the	   conditioned	  
medium	   decreased	   over	   24	   h,	   and	   radioactivity	   in	   the	   TCA-­‐soluble	   and	   cell-­‐
associated	  fractions	  increased	  (Figure	  19B)	  showing	  kinetics	  of	  internalization	  similar	  
to	  that	  of	  HTB94	  cells	  (Figure	  19A).	  [35S]TIMP-­‐3	  (1	  nM)	  incubated	  with	  human	  uterine	  
cervical	   fibroblasts	   (HUCF)	  was	   internalized	   and	   degraded	   as	  well	   as	   chondrocytes	  
(Figure	  19C).	  THP-­‐1	  cells	   (human	  acute	  monocytic	   leukemya)	   supplemented	  with	  1	  
nM	   [35S]TIMP-­‐3	   showed	   a	   slower	   internalization	   of	   the	   inhibitor	   compared	   to	  
chondrocytes	  and	  fibroblasts,	  but	  internalization	  still	  occurred	  (Figure	  19D).	  	  
Clearance	   of	   TIMP-­‐3	   by	   carcinoma	   cell	   lines	   showed	   a	   distinct	   profile.	  
Incubation	  of	  [35S]TIMP-­‐3	  with	  both	  MCF-­‐7	  cells	  (human	  breast	  adenocarcinoma	  cell	  
line)	   and	   HeLa	   (human	   epithelial	   cervical	   cancer)	   cells	   resulted	   in	   a	   similar	  
radioactivity	   distribution	   among	   cell-­‐fractions	   over	   24	   h.	   The	   amount	   of	   TCA-­‐
insoluble	   radioactivity	   in	   the	   conditioned	   medium	   decreased	   over	   time;	   but	  
surprisingly	  the	  amount	  of	  radioactivity	  in	  the	  TCA-­‐soluble	  fraction	  did	  not	  increase	  
over	  24	  h	  and	  a	  high	  amount	  of	  radioactivity	  was	  found	  associated	  with	  cells.	  These	  
data	   suggest	   that	   TIMP-­‐3	   binds	   to	   the	   Hela	   and	   MCF-­‐7	   cell-­‐surface,	   but	   it	   is	   not	  
internalized	  nor	  degraded	  and	  released	  back	  in	  the	  medium	  (Figure	  19E	  and	  F).	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Figure	  19,	  Internalization	  of	  TIMP-­‐3	  by	  different	  cell-­‐types	  
1	  nM	  [35S]TIMP-­‐3	  was	  added	  to	  different	  cell-­‐lines	  and	  TCA-­‐insoluble	  (■),	  TCA-­‐soluble	  
(●)	  and	  cell-­‐associated	  (p)	  radioactivity	  analysed	  at	  various	  times	  over	  24	  h	  (n=2).	  
	  
3.3 Discussion	  
Troeberg	   et	   al.	   (2008)	   showed	   that	   TIMP-­‐3	   accumulated	   in	   the	  medium	   of	   HTB94	  
cells	   or	   pig	   articular	   chondrocytes	   in	   culture	   when	   cells	   were	   treated	   with	   highly	  
sulfated	  GAGs	   such	  as	  heparin	  or	  CaPPS.	   The	   fact	   that	   cytochalasin	  D,	  which	   is	   an	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inhibitor	  of	  actin	  polymerization	  and	  as	  such	  an	  inhibitor	  of	  endocytic	  processes,	  also	  
led	   to	  accumulation	  of	  TIMP-­‐3	   in	   the	  medium,	  prompted	  Troeberg	   et	  al.	   (2008)	   to	  
postulate	   that	   TIMP-­‐3	   was	   rapidly	   internalized	   by	   cells	   after	   secretion.	   It	   was	  
postulated	   that	   this	  process	   is	  mediated	  by	  a	  member	  of	   the	   LDL	   receptor-­‐related	  
protein	   (LRP)	   family	   as	   the	   LRP	   ligand	   antagonist,	   RAP,	   caused	   an	   accumulation	  of	  
TIMP-­‐3	  in	  the	  medium	  of	  treated	  cells.	  Furthermore,	  it	  was	  also	  suggested	  that	  cell	  
surface	   heparan	   sulfate	   proteoglycans	   (HSPGs)	   may	   be	   also	   involved	   in	   TIMP-­‐3	  
endocytosis,	  since	  addition	  of	  CaPPS	  or	  heparin	  resulted	  in	  an	  accumulation	  of	  TIMP-­‐
3	  in	  the	  medium,	  	  
In	   this	   chapter,	   I	   confirmed	   that	   TIMP-­‐3	   is	   internalized	   by	   HTB94	   cells	  
confirmed	  by	  following	  the	  clearance	  of	  exogenously	  added	  recombinant	  TIMP-­‐3	  by	  
Western	   blotting	   and	   by	   detecting	   endocytosed	   TIMP-­‐3	   within	   cells	   by	  
immunofluorescence	  microscopy.	  Using	  a	  radioactivity-­‐based	  assay,	  I	  followed	  TIMP-­‐
3	   internalization	  over	   time,	  and	   showed	   that	  TIMP-­‐3	   is	   internalized	  by	  HTB94	  cells	  
and	   degraded	   into	   fragments,	   which	   were	   released	   back	   into	   the	   medium.	   This	  
method	  was	  proven	  to	  be	  useful	  to	  study	  the	  kinetics	  of	  TIMP-­‐3	  internalization.	  The	  
inhibitor	  was	  endocytosed	  with	  a	   rate	   that	   is	  not	  constant	  but	  changed	  over	  24	  h,	  
being	   faster	   at	   earlier	   time	   points	   and	   slower	   at	   later	   time	   points.	   Exogenously	  
added	  TIMP-­‐3	  was	  not	  completely	  internalized	  by	  cells	  over	  24	  h,	  with	  about	  50	  %	  of	  
the	  starting	  material	  remaining	  in	  the	  medium	  at	  24	  h.	  N-­‐TIMP-­‐3	  was	  internalized	  in	  
a	   similar	   manner	   to	   full	   length	   TIMP-­‐3,	   suggesting	   that	   the	   N-­‐terminal	   domain	  
contains	   the	   minimal	   residues	   required	   for	   internalization.	   TIMP-­‐3	   internalization	  
reached	  a	  plateau	  after	  about	  10	  h;	  only	  a	  very	  small	  amount	  of	  TIMP-­‐3	  was	  taken	  
up	   after	   10	   h.	   This	   plateauing	   phenomenon	  will	   be	   investigated	   in	  more	   detail	   in	  
chapter	  5.	  	  
Highly	   sulfated	  GAGs	   blocked	   the	   endocytosis	   of	   TIMP-­‐3,	  while	   de-­‐sulfated	  
heparin,	   dermatan	   sulfate,	   chondroitin	   sulfate	   and	   hyaluronic	   acid	   did	   not.	   We	  
hypothesized	  that	  highly	  sulfated	  GAGs	  could	  directly	  bind	  to	  the	  TIMP-­‐3	  molecule,	  
interfering	  with	  TIMP-­‐3	  binding	  to	  the	  cell	  surface	  HSPGs,	  which	  have	  been	  reported	  
to	   act	   as	   co-­‐receptors	   for	   the	   internalization	   of	   some	   LRP	   ligands	   such	   as	   TSP,	  
lipoprotein	   lipase	   and	   Aβ	   peptide	   (Chappell	   et	   al.,	   1993;	   Kanekiyo	   et	   al.,	   2011;	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Mikhailenko	  et	   al.,	   1995).	   The	   role	  of	  HSPGs	   in	   TIMP-­‐3	  endocytosis	  will	   be	   further	  
investigated	  in	  Chapter	  4.	  
RAP	   inhibits	   binding	   and	   uptake	   of	   all	   the	   ligands	   of	   all	   the	   LDL	   receptor	  
family	  members	  (Bu,	  1998).	  LRP-­‐1	  contains	  four	  ligand-­‐binding	  regions,	  with	  regions	  
II	  and	  IV	  being	  the	  major	  binding	  site	  for	  LRP-­‐1	  ligands.	  RAP	  is	  able	  to	  bind	  regions	  II,	  
III	  and	  IV	  (Migliorini	  et	  al.,	  2003).	  We	  speculate	  that	  similarly	  to	  other	  LRP-­‐1	  ligands,	  
TIMP-­‐3	   binds	   to	   regions	   II	   and	   IV.	   	  When	   RAP	  was	   added	   to	   HTB94	   cells,	   TIMP-­‐3	  
endocytosis	  was	   strongly	   inhibited,	   but	   not	   completely.	   These	   data	   suggest	   that	   a	  
member	  of	  the	  LDL	  receptor	  family	   is	   involved	   in	  the	   internalization	  of	  TIMP-­‐3	  and	  
the	  possibility	  that	  an	  LRP-­‐independent	  mechanism	  is	  also	  involved.	  	  
The	  members	  of	  the	  LDLR	  family	  bind	  and	  internalize	  ligands	  with	  a	  clathrin-­‐
dependent	   mechanism	   (Brown	   and	   Goldstein,	   1979;	   Chen	   et	   al.,	   1990).	   While	  
cytochalasin	   D	   and	   low	   temperature	   completely	   blocked	   TIMP-­‐3	   endocytosis,	  
Dynasore,	  an	   inhibitor	  of	  all	  dynamin-­‐dependent	  endocytic	  pathways,	  only	  partially	  
inhibited	   TIMP-­‐3	   endocytosis,	   suggesting	   that	   a	   dynamin-­‐independent	   pathway	  
might	  be	  also	  involved.	  	  
Porcine	   articular	   chondrocytes	   internalized	   TIMP-­‐3	   with	   similar	   kinetics	   to	  
HTB94	  cells,	  showing	  that	  endocytosis	  might	  be	  an	  important	  regulatory	  mechanism	  
to	   control	   TIMP-­‐3	   concentration	   in	   cartilage.	   TIMP-­‐3	   endocytosis	   is	   a	   general	  
phenomenon,	   as	   many	   different	   cell-­‐types,	   including	   human	   fibroblasts,	   murine	  
embryo	  fibroblasts,	  human	  monocytes,	  COS-­‐7	  cells	  and	  others,	  effectively	  internalize	  
TIMP-­‐3.	   Interestingly,	   among	   all	   the	   tested	   cell-­‐types,	   only	   two	   types	   of	   cell	   lines	  
(HeLa	   and	  MCF-­‐7	   cells)	   failed	   to	   internalize	   TIMP-­‐3;	   these	   are	   both	   carcinoma	   cell	  
lines.	   In	   these	   cell-­‐lines	   TIMP-­‐3	   binds	   to	   the	   cell-­‐surface	   without	   being	   taken	   up	  
inside.	  It	  was	  reported	  that	  LDLR	  and	  VLDLR	  expression	  was	  downregulated	  in	  MCF-­‐
7,	   HeLa	   and	   Hep-­‐G2	   cells	   at	   both	  message	   and	   protein	   levels	   (Shen	   et	   al.,	   2011).	  
Overexpression	   of	   midkine	   and	   its	   premature	   interaction	   with	   LRP-­‐1	   in	   the	   Golgi	  
leads	  the	  receptor	  to	  proteosomal	  degradation	  and	  interruption	  of	  its	  maturation	  in	  
human	   colorectal	   carcinomas,	   resulting	   in	   a	   decrease	   in	   the	   number	   of	   mature	  
receptors	  on	  the	  cell	  surface	  (Sakamoto	  et	  al.,	  2011).	  The	  decrease	  of	  mature	  LRP-­‐1	  
on	  the	  cell	  surface	  might	  explain	  the	  lack	  of	  TIMP-­‐3	  endocytosis	  by	  these	  cell	   lines.	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Hypoxia	  stimulates	  LRP-­‐1	  expression	  through	  hypoxia-­‐inducible	   factor-­‐1α	   in	  human	  
vascular	   smooth	  muscle	   cells	   (Castellano	   et	   al.,	   2011)	   and	  mouse	   embryonic	   stem	  
cells	  (Lee	  et	  al.,	  2011).	  It	  will	  be	  investigated	  whether	  the	  hypoxic	  condition	  induces	  
LRP-­‐1	   expression	   in	   carcinoma	   cells	   and	   rescues	   TIMP-­‐3	   endocytosis,	   which	   may	  
allow	   carcinoma	   cells	   to	   escape	   from	   an	   oncosuppressor	   effect	   of	   TIMP-­‐3	   (Cruz-­‐
Munoz	  et	  al.,	  2006a).	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4.1 Introduction	  
As	  shown	  in	  Chapter	  3,	  receptor-­‐associated	  protein	  (RAP),	  which	  is	  an	  antagonist	  of	  
all	   members	   of	   the	   LDL	   receptor	   superfamily,	   reduced	   TIMP-­‐3	   internalization	   by	  
HTB94	  cells.	  These	  data	  prompted	  us	  to	  postulate	  that	  a	  member	  of	  the	  LRP	  family	  
of	   receptors	   plays	   a	   key	   role	   in	   the	   endocytosis	   of	   TIMP-­‐3.	   As	   already	  mentioned,	  
many	  proteinases	  and	  proteinases—inhibitor	  complexes	  are	  endocytosed	  by	  LRP-­‐1,	  a	  
scavenging	  receptor	  member	  of	  the	  LDL	  receptors.	  In	  this	  chapter,	  LRP-­‐1-­‐null	  mouse	  
embryonic	  fibroblasts	  (PEA-­‐13	  cells)	  (Kounnas	  et	  al.,	  1992)	  were	  used	  to	  investigate	  
whether	   or	   not	   LRP-­‐1	   is	   the	  member	   of	   the	   LDL	   receptor	   superfamily	   involved	   in	  
TIMP-­‐3	   endocytosis.	   PEA-­‐13	   cells	   and	   their	   wild-­‐type	   counterparts	   (MEF-­‐1	   cells)	  
represent	  a	  perfect	  tool	  to	  study	  LRP-­‐1-­‐mediated	  endocytosis	  as	  they	  have	  been	  well	  
characterised	   and	   used	   to	   investigate	   the	   LRP-­‐1-­‐mediated	   endocytosis	   of	   several	  
ligands	  (Willnow	  and	  Herz,	  1994).	  	  
Although	  RAP	  reduced	  TIMP-­‐3	  endocytosis	  by	  HTB94	  cells,	  some	  endocytosis	  
still	  occurred	  in	  the	  presence	  of	  RAP,	  indicating	  that	  TIMP-­‐3	  is	  internalized	  by	  an	  LRP-­‐
independent	  mechanism.	  Many	  ligands	  that	  are	  internalized	  by	  LDLRs	  also	  undergo	  
LRP-­‐independent	   internalization,	   which	   is	   mediated	   by	   HSPGs	   in	   several	   cases	  
(Mahley	   and	   Huang,	   2007).	   Highly	   sulfated	   GAGs,	   such	   as	   heparin	   and	   CaPPS	  
completely	   blocked	   TIMP-­‐3	   endocytosis.	   These	   discoveries	   led	   me	   to	   further	  
investigate	   the	   involvement	   of	   HSPGs	   in	   TIMP-­‐3	   endocytosis.	   Esko	   et	   al.	   (1985)	  
generated	   Chinese	   hamster	   ovary	   cell	   mutants	   (CHO-­‐745)	   defective	   in	   the	  
biosynthesis	   of	   glycosaminoglycans	   by	   genetic	   disruption	   of	   the	   enzyme	   xylosyl-­‐
transferase,	  which	  is	  responsible	  for	  the	  initiation	  of	  chondroitin	  sulfate	  and	  heparan	  
sulfate	   biosynthesis	   (Esko	   et	   al.,	   1985).	   In	   this	   chapter,	   the	   involvement	   of	   HSPGs	  
was	   assessed	  by	   testing	   the	   ability	   of	   CHO-­‐745	   to	   internalize	   TIMP-­‐3	   compared	   to	  
that	  of	  their	  wild-­‐type	  counterparts	  (CHO-­‐K1).	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4.2 Endocytosis	  of	  [35S]TIMP-­‐3	  by	  LRP-­‐1-­‐deficient	  PEA-­‐13	  cells	  
and	  the	  wild-­‐type	  MEF-­‐1	  cells	  
4.2.1 Endocytosis	  of	  [35S]TIMP-­‐3	  is	  inhibited	  in	  PEA-­‐13	  cells	  
To	   further	   investigate	   the	   role	   of	   LRP-­‐1	   in	   TIMP-­‐3	   endocytosis,	   [35S]TIMP-­‐3	  
endocytosis	   by	   wild-­‐type	   mouse	   embryonic	   fibroblasts	   (MEF-­‐1)	   and	   by	   LRP-­‐1-­‐
deficient	  mouse	  embryonic	  fibroblasts	  (PEA-­‐13)	  were	  compared.	  As	  shown	  in	  Figure	  
20,	   the	   decrease	   in	   TCA-­‐insoluble	   radioactivity	   and	   the	   increase	   in	   TCA-­‐soluble	  
radioactivity	   were	   less	   by	   PEA-­‐13	   (Figure	   20B)	   cells	   compared	   to	   either	   HTB94	  
(Figure	  20C)	  or	  MEF-­‐1	  cells	  (Figure	  20A),	  suggesting	  that	  LRP-­‐1	  contributes	  to	  TIMP-­‐3	  
endocytosis.	   However,	   cell-­‐associated	   [35S]TIMP-­‐3	   was	   only	   slightly	   decreased	   in	  
PEA-­‐13	  cells	   compared	   to	  MEF-­‐1	  cells,	   indicating	   that	   [35S]TIMP-­‐3	  can	  bind	   the	  cell	  
surface	  even	   in	  absence	  of	  LRP-­‐1.	  The	  slow	  internalization	  of	   [35S]TIMP-­‐3	  by	  LRP-­‐1-­‐
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Figure	  20,	  Time	  course	  of	  [35S]TIMP-­‐3	  clearance	  by	  MEF-­‐1	  and	  PEA-­‐13	  cells	  
MEF-­‐1	  and	  PEA-­‐13	  cells	  were	  incubated	  at	  37	  °C	  in	  DMEM	  containing	  0.1	  %	  FCS	  and	  1	  
nM	  [35S]TIMP-­‐3.	  At	  the	  time	  points	  indicated,	  the	  conditioned	  medium	  was	  removed	  
and	   cell-­‐associated,	   TCA-­‐soluble	   and	   TCA-­‐insoluble	   fractions	   were	   harvested	   as	  
described	  before	  (n=3).	  A.	  Graph	  of	  [35S]TIMP-­‐3	  endocytosis	  in	  MEF-­‐1	  cells.	  B.	  Graph	  
of	   [35S]TIMP-­‐3	   endocytosis	   in	   PEA-­‐13	   cells.	  C.	   Graph	   of	   [35S]TIMP-­‐3	   endocytosis	   in	  
HTB94	  cells	  (from	  chapter	  3).	  
4.2.2 Immunofluorescence	  analysis	  also	  indicates	  LRP-­‐1	  involvement	  	  
MEF-­‐1	  and	  PEA-­‐13	  cells	  were	  incubated	  with	  40	  nM	  FLAG-­‐tagged	  TIMP-­‐3	  for	  2	  h	  at	  
37	   °C.	   After	   fixation,	   labeling	   of	   the	   permeabilized	   cells	   with	   an	   anti-­‐FLAG	  
monoclonal	  antibody	  detected	  with	  an	  Alexa-­‐488	  secondary	  antibody	  showed	  green	  
fluorescence.	   Immunolocalization	   of	   TIMP-­‐3-­‐FLAG	   was	   greatly	   reduced	   in	   PEA-­‐13	  
cells	   No	   staining	   was	   observed	   inside	   cells	   not	   incubated	   with	   TIMP-­‐3-­‐FLAG,	  
indicating	  that	  the	  signal	  was	  specific	  (Figure	  21).	  These	  results	  indicate	  that	  TIMP-­‐3-­‐
FLAG	  is	  internalized	  through	  LRP-­‐1.	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Figure	   21,	   Internalization	   of	   TIMP-­‐3	   by	   PEA-­‐13	   cells	   and	  MEF-­‐1	   cells	   detected	   by	  
confocal	  microscopy	  
MEF-­‐1	  and	  PEA-­‐13	  cells	  were	  incubated	  at	  37	  °C	  with	  40	  nM	  of	  FLAG-­‐tagged	  TIMP-­‐3	  
for	  2	  h	  and	  then	  permeabilsed	  and	  immunostained	  for	  the	  presence	  of	  TIMP-­‐3-­‐FLAG	  
inside	  the	  cells.	  Control	  samples	  were	  not	  supplemented	  with	  TIMP-­‐3-­‐FLAG	  
4.2.3 Effects	  of	  heparin	  and	  RAP	  on	  [35S]TIMP-­‐3	  endocytosis	  by	  MEF-­‐1	  
cells	  and	  PEA-­‐13	  cells	  
MEF-­‐1	   cells	   and	   PEA-­‐13	   cells	  were	   preincubated	  with	   heparin	   (200	   μg/ml)	   for	   1	   h	  
before	   addition	   of	   1	   nM	   [35S]TIMP-­‐3.	   In	   both	   MEF-­‐1	   and	   PEA-­‐13	   cells,	   heparin	  
inhibited	  the	  decrease	  in	  TCA-­‐insoluble	  radioactivity	  as	  well	  as	  the	  increase	  in	  TCA-­‐
soluble	  and	  cell-­‐associated	  radioactivity.	  Heparin	  inhibited	  endocytosis	  of	  [35S]TIMP-­‐
3	  by	  PEA-­‐13	  cells	  as	  effectively	  as	  that	  by	  HTB94	  or	  MEF-­‐1	  cells.	  This	   indicates	  that	  
heparin	   is	   an	   effective	   inhibitor	   of	   both	   LRP-­‐1-­‐dependent	   and	   LRP-­‐1-­‐independent	  
internalization	  (Figure	  22A	  and	  Figure	  22B).	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   MEF-­‐1	   cells	   and	  PEA-­‐13	  cells	  were	   then	   incubated	  with	  500	  nM	  RAP	   for	  30	  
min	   before	   addition	   of	   [35S]TIMP-­‐3	   (1	   nM).	   As	   shown	   in	   Figure	   22C	   shows,	   RAP	  
reduced	   the	   uptake	   of	   the	   TCA-­‐insoluble	   [35S]TIMP-­‐3	   by	   MEF-­‐1	   cells	   and	   the	  
radioactivity	   in	   the	   TCA-­‐soluble	   fraction.	   Cell-­‐associated	   [35S]TIMP-­‐3	   was	   slightly	  
higher	  in	  RAP-­‐treated	  cells.	  The	  kinetics	  of	  [35S]TIMP-­‐3	  internalization	  by	  RAP-­‐treated	  
MEF-­‐1	  cells	  was	  very	  similar	  to	  that	  by	  PEA-­‐13	  cells.	  The	  slower	  rate	  of	  [35S]TIMP-­‐3	  
internalization	  in	  RAP-­‐treated	  MEF-­‐1	  and	  PEA-­‐13	  suggests	  that	  LRP-­‐1	  plays	  a	  key	  role	  
in	   [35S]TIMP-­‐3	  endocytosis,	   but	   also	   that	   an	   LRP-­‐1-­‐independent	  endocytic	  pathway	  
occurs	   in	   these	   cells.	   RAP-­‐treated	   PEA-­‐13	   cells	   internalized	   [35S]TIMP-­‐3	   with	   the	  
same	  kinetics	  as	  non-­‐RAP-­‐treated	  PEA-­‐13	  cells	  (Figure	  22D),	  confirming	  that	  an	  LRP-­‐
1-­‐independent	   and	   RAP-­‐insensitive	   pathway	   is	   also	   involved	   in	   [35S]TIMP-­‐3	  
internalization.	  
	  
	  Figure	  22,	  Effects	  of	  heparin	  and	  RAP	  on	  TIMP-­‐3	  internalization	  by	  MEF-­‐1	  and	  PEA-­‐
13	  cells.	  	  
[35S]TIMP-­‐3	   (1	   nM)	  was	   added	   to	  MEF-­‐1	  or	  PEA-­‐13.	   TCA-­‐soluble	   (●),	   TCA-­‐insoluble	  
(■)	   and	   cell-­‐associated	   (p)	   radioactivity	   analysed	   at	   various	   times	   (n=3).	   A.	  
Internalization	   of	   [35S]TIMP-­‐3	   by	   MEF-­‐1	   cells	   in	   the	   presence	   (red	   symbols)	   and	  
absence	  (black	  symbols)	  of	  200	  μg/ml	  of	  heparin.	  B.	  Internalization	  of	  [35]TIMP-­‐3	  by	  
PEA-­‐13	  cells	  in	  the	  presence	  (red	  symbols)	  and	  absence	  (black	  symbols)	  of	  200	  μg/ml	  
of	   heparin.	   C.	   Internalization	   of	   [35S]TIMP-­‐3	   by	   MEF-­‐1	   cells	   in	   the	   presence	   (red	  
symbols)	   and	   absence	   (black	   symbols)	   of	   500	   nM	   RAP.	   D.	   Internalization	   of	  
[35S]TIMP-­‐3	  by	  PEA-­‐13	  cells	  in	  the	  (red	  symbols)	  and	  absence	  (black	  symbols)	  of	  500	  
nM	  RAP.	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4.2.4 Absence	   of	   LRP-­‐1	   does	   not	   affect	   TIMP-­‐3	   surface	   binding,	   but	  
decreases	  TIMP-­‐3	  internalization	  and	  degradation	  
Previous	   experiments	   suggested	   that	   the	   absence	   of	   LRP-­‐1	   in	   PEA-­‐13	   cells	   did	   not	  
affect	  TIMP-­‐3	  binding	  to	  the	  cell.	  Radioactivity	  in	  the	  cell-­‐associated	  fraction	  of	  PEA-­‐
13	   cells	   was	   very	   similar	   as	   that	   of	   MEF-­‐1	   cells	   at	   the	   time	   points	   analyzed.	   To	  
confirm	  these	  data,	  a	  surface-­‐binding	  experiment	  was	  performed	  at	  4	  °C.	  MEF-­‐1	  and	  
PEA-­‐13	  cells	  were	  grown	   to	   confluence	   in	  a	  6-­‐well	  plate,	   then	  washed	   three-­‐times	  
and	   incubated	   in	   ice	   cold	  DMEM	  with	   0.1	  %	   FCS	   for	   30	  min.	  Next,	   1	  ml	   of	   40	   nM	  
[35S]TIMP-­‐3	   in	   ice	   cold	   TBS	  was	   added	   to	   cells	   and	   [35S]TIMP-­‐3	   allowed	   to	   bind	   to	  
cells	  for	  2	  hours	  at	  4	  °C.	  To	  assess	  cell	  binding	  at	  4	  °C,	  cells	  were	  washed	  twice	  in	  TBS	  
and	   collected	   with	   1	   ml	   of	   1M	   NaOH	   for	   scintillation	   counting.	   To	   assess	  
internalization	   of	   surface	   bound	   [35S]TIMP-­‐3,	   other	   cells	   were	   washed	   in	   TBS	   and	  
incubated	   in	  pre-­‐warmed	  DMEM	  with	  0.1	  %	  FCS	   for	  2	  h	  at	  37	   °C.	  After	  2	  h,	  media	  
were	  harvested	  and	  TCA-­‐precipitated	  as	  described	  previously.	   The	   cell	   layers	  were	  
treated	  with	  0.1	  %	  pronase	  solution	  on	  ice	  for	  10	  min	  to	  release	  surface	  ligands	  and	  
detach	  cells	  from	  the	  plate.	  Cells	  were	  separated	  from	  the	  pronase-­‐sensitive	  fraction	  
by	   centrifugation	   and	   collected	   with	   1	   ml	   of	   1M	   NaOH.	   Radioactivity	   in	   the	   TCA-­‐
insoluble	   fraction	   (intact	   TIMP-­‐3	   in	   the	   medium),	   TCA-­‐soluble	   fraction	   (degraded	  
TIMP-­‐3	   in	   the	   medium),	   surface-­‐bound	   fraction	   (pronase-­‐sensitive	   counts	   of	   cell	  
fraction)	   and	   cell-­‐associated	   fraction	   (pronase-­‐resistent	   counts	   of	   cell	   fraction)	  
fraction	   was	   measured.	   Figure	   23A	   shows	   that	   a	   similar	   amount	   of	   [35S]TIMP-­‐3	  
bound	   to	   MEF-­‐1	   and	   PEA-­‐13	   cells	   at	   4	   °C,	   indicating	   that	   TIMP-­‐3	   binds	   to	   a	   cell	  
surface	  molecule	  other	   than	   LRP-­‐1.	  After	   2	   h	   incubation	  with	  DMEM	  0.1	  %	   FCS	   at	  
37	   °C,	   both	   MEF-­‐1	   and	   PEA-­‐13	   cells	   internalized	   [35S]TIMP-­‐3	   as	   shown	   by	   the	  
decrease	   of	   radioactivity	   in	   their	   surface-­‐bound	   fractions	   and	   by	   the	   presence	   of	  
intracellular	   radioactivity	   and	   degradation	   products.	   Once	   again,	   [35S]TIMP-­‐3	  
internalization	   by	   MEF-­‐1	   cells	   was	   higher	   compared	   to	   that	   by	   PEA-­‐13	   cells,	  
indicating	   that	   LRP-­‐1	  plays	   a	   key	   role	   in	   TIMP-­‐3	   internalization,	   but	   that	   an	   LRP-­‐1-­‐
mediated	  pathway	  is	  not	  the	  only	  one	  involved.	  Interestingly,	  some	  intact	  [35S]TIMP-­‐
3	  molecules	  were	  released	  back	  into	  the	  media	  during	  the	  incubation	  at	  37	  °C,	  as	  we	  
could	  detect	  radioactivity	  in	  the	  TCA-­‐insoluble	  fractions.	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A	   time	  course	  of	   surface-­‐bound	   [35S]TIMP-­‐3	   internalization	  and	  degradation	  
by	  MEF-­‐1	  and	  PEA-­‐13	  was	  performed.	  MEF-­‐1	  and	  PEA-­‐13	  cells	  were	  first	   incubated	  
with	  40	  nM	  [35S]TIMP-­‐3	  	  at	  4	  °C	  for	  2	  h	  to	  allow	  surface	  binding.	  After	  washing,	  cells	  
were	   further	   incubated	  with	   fresh	   DMEM	  0.1	  %	   FCS	   pre-­‐warmed	   at	   37	   °C.	   At	   the	  
indicated	  time	  points,	  degraded	  [35S]TIMP-­‐3	  was	  measured.	  Degradation	  of	  surface-­‐
bound	  [35S]TIMP-­‐3	  	  by	  MEF-­‐1	  was	  higher	  than	  that	  by	  PEA-­‐13	  cells	  over	  5	  h	  (Figure	  
23B).	  	  	  
	  
	  
Figure	  23,	  [35S]TIMP-­‐3	  surface-­‐binding	  to	  MEF-­‐1	  and	  PEA-­‐13	  cells	  
A.	   MEF-­‐1	   (solid	   bars)	   and	   PEA-­‐13	   (open	   bars)	   cells	   were	   incubated	   with	   40	   nM	  
[35S]TIMP-­‐3	   at	   4	   °C	   for	   2	   h	   to	   allow	   surface	   binding.	   After	  washing,	   some	   cultures	  
were	   directly	   lysed	   to	   quantify	   cell-­‐associated	   radioactivity.	   Alternatively,	   dishes	  
were	   reincubated	   with	   fresh	  medium	   pre-­‐warmed	   at	   37	   °C.	   Surface-­‐bound	   ligand	  
(pronase-­‐sensitive	   radioactivity),	   intracellular	   (pronase-­‐resistant),	   degraded	   (TCA-­‐
soluble	   counts	   in	   the	   medium)	   and	   intact-­‐released	   (TCA-­‐insoluble	   counts	   in	   the	  
medium)	   [35S]TIMP-­‐3	   	   were	   measured	   after	   2	   h	   at	   37	   °C.	   Surface	   binding	   of	  
[35S]TIMP-­‐3	  to	  MEF-­‐1	  and	  PEA-­‐13	  cells	  is	  similar,	  but	  endocytosis	  and	  degradation	  of	  
[35S]TIMP-­‐3	  by	  PEA-­‐13	  cells	  is	  lower	  than	  by	  MEF-­‐1	  cells.	  This	  result	  is	  representative	  
of	  two	  separate	  experiments.	  
B.	  MEF-­‐1	  and	  PEA-­‐13	  cells	  were	  first	  incubated	  with	  40	  nM	  [35S]TIMP-­‐3	  	  at	  4	  °C	  for	  2	  
h	   to	   allow	   surface	   binding.	   After	  washing,	   cells	  were	   further	   incubated	  with	   fresh	  
DMEM	  0.1	  %	  FCS	  pre-­‐warmed	  at	  37	  °C.	  At	  the	  indicated	  times,	  degraded	  [35S]TIMP-­‐3	  
(TCA-­‐soluble	  counts	  in	  the	  medium)	  was	  measured.	  This	  experiment	  was	  performed	  
twice	  with	  similar	  results.	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4.3 Investigation	  of	  HSPGs	  as	  potential	   receptors	   involved	   in	  
the	  LRP-­‐1-­‐independent	  pathway	  
4.3.1 Internalization	  of	  [35S]TIMP-­‐3	  by	  syndecan-­‐4-­‐deficient	  cells	  
Echtemeyer	  et	  al.	  (2009)	  showed	  that	  syndecan-­‐4	  is	  overexpressed	  in	  chondrocytes	  
in	   osteoarthritis,	   and	   postulated	   that	   this	   leads	   to	   the	   increase	   in	   activity	   of	  
ADAMTS-­‐5	   observed	   both	   in	   vitro	   and	   in	   vivo,	   leading	   to	   the	   appearance	   of	   an	  
osteoarthritic	   phenotype	   in	   animal	   models	   (Echtermeyer	   et	   al.,	   2009).	   They	  
postulated	  that	  the	  increase	  of	  ADAMTS-­‐5	  activity	   is	  due	  to	  cell-­‐signalling	  triggered	  
by	  syndecan-­‐4.	  	  
We	  investigated	  whether	  syndecan-­‐4	  has	  a	  role	  in	  the	  endocytosis	  of	  TIMP-­‐3	  
by	  using	   the	   radioactivity-­‐based	  assay	  of	   [35S]TIMP-­‐3	  endocytosis	  using	   syndecan-­‐4	  
deficient	   mouse	   embryonic	   fibroblasts.	   Both	   syndecan-­‐4-­‐deficient	   and	   wild-­‐type	  
MEFs	  clearly	  internalized	  [35S]TIMP-­‐3,	  as	  radioactivity	  in	  TCA-­‐insoluble	  fractions	  went	  
down	   over	   24	   h,	   and	   radioactivity	   in	   cell-­‐associated	   and	   TCA-­‐soluble	   fractions	  
increased	  with	  a	  similar	  kinetics	  (Figure	  24).	  These	  data	  suggested	  that	  syndecan-­‐4	  is	  
not	  involved	  in	  TIMP-­‐3	  internalization.	  
	  
Figure	  24,	  TIMP-­‐3	  endocytosis	  by	  Syndecan-­‐4-­‐deficient	  and	  -­‐wild-­‐type	  MEFs	  
Syndecan-­‐4-­‐deficient	   and	   wild-­‐type	   MEFs	   were	   incubated	   at	   37	   °C	   in	   DMEM	  
containing	   0.1	   %	   FCS	   and	   1	   nM	   [35S]TIMP-­‐3.	   At	   the	   time	   points	   indicated,	   the	  
conditioned	   medium	   was	   removed	   and	   cell-­‐associated,	   TCA-­‐soluble	   and	   TCA-­‐
insoluble	   fractions	   were	   harvested	   as	   described	   before.	   The	   graph	   shows	   a	   time	  
course	  of	  [35S]TIMP-­‐3	  endocytosis	  by	  wild-­‐type	  MEFs	  (black	  symbols)	  and	  syndecan-­‐
4-­‐deficient	  MEFs	  (red	  symbols)	  (n=2).	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4.3.2 Internalization	  of	  [35S]TIMP-­‐3	  by	  syndecan-­‐1	  silenced	  HTB94	  cells	  
Other	   ligands	  of	  LDLR	  family,	  such	  as	  triglyceride-­‐rich	   lipoproteins	  and	  ApoE-­‐VLDLs,	  
can	   be	   also	   internalized	   in	   an	   LRP-­‐independent	  manner	   via	   syndecan-­‐1,	   through	   a	  
process	  which	   is	   clathrin-­‐independent	   and	  heparin-­‐sensitive	   (Stanford	  et	   al.,	   2009;	  
Wilsie	   et	   al.,	   2006).	   I	   hypothesized	   that	   this	   could	   also	   be	   the	   case	   for	   TIMP-­‐3.	   I	  
therefore	  silenced	  Sdc-­‐1	  in	  HTB94	  cells	  and	  tested	  whether	  the	  lack	  of	  Sdc-­‐1	  has	  an	  
effect	  on	  TIMP-­‐3	  internalization.	  
4.3.2.1 siRNA	  silencing	  of	  Sdc-­‐1	  
To	  silence	  Sdc-­‐1	   in	  HTB94	  cells,	  two	  Sdc-­‐1	  small	   interfering	  RNA	  (siRNA)	  specific	  for	  
human	  Sdc-­‐1	   gene	  were	  purchased	   from	  Ambion	   (catalog	  no.	   12432	  and	  142557).	  
These	   two	   siRNAs	  have	  been	   shown	   to	   inhibit	   Sdc-­‐1	  mRNA	   for	  more	   than	  90	  %	   in	  
different	  cell	   lines,	  such	  as	  PC3,	  LNCaP	  and	  EJ-­‐1	  cells	  (Hu	  et	  al.,	  2010;	  Ogawa	  et	  al.,	  
2007).	   To	   establish	   the	   conditions	   for	   Sdc-­‐1	   knockdown,	   HTB94	   cells	   were	  
transfected	   overnight	   in	   a	   6-­‐well	   plate	  with	   scrambled	   siRNA,	   Sdc-­‐1	   siRNA	   12432,	  
Sdc-­‐1	   siRNA	   142557	   or	   a	   combination	   of	   both	   targeting	   siRNAs,	   all	   at	   10-­‐100	   nM.	  
Lipofectamine	  2000	  was	  used	  for	  the	  transfection	  as	  described	  in	  Section	  2.6.1.	  Cells	  
were	   harvested	   after	   24	   h	   and	   48	   h	   in	   culture,	   total	   RNA	   was	   extracted	   using	   a	  
RNeasy®	  Mini	   kit	   (Invitrogen)	   and	   a	  q-­‐PCR	   to	   assess	  Sdc-­‐1	   expression	   compared	   to	  
the	   housekeeping	   gene	   GAPDH	   was	   performed.	   Figure	   25	   shows	   that	   Sdc-­‐1	  
expression	   was	   reduced	   by	   about	   70	   %	   compared	   to	   scrambled	   siRNA	   24	   h	   after	  
transfection	  with	  10	  nM	  siRNA	  12432,	  by	  about	  80	  %	  with	  10	  nM	  siRNA	  142557	  and	  
by	  more	  than	  80	  %	  with	  a	  combination	  of	  Sdc-­‐1	  siRNAs	  12432	  and	  142557.	  The	  same	  
percentage	   of	   silencing	  was	  maintained	   48	   h	   after	   transfection.	  When	   the	   siRNAs	  
concentration	  was	   increased	   to	  50	  nM,	  a	  slightly	  higher	  knockdown	  of	  about	  90	  %	  
was	   obtained	   24	   h	   after	   transfection	   with	   siRNA	   12432,	   siRNA	   142557	   and	   a	  
combination	  of	  both	  siRNAs.	  48	  h	  after	  transfection	  with	  Sdc-­‐1	  targeting	  siRNAs,	  Sdc-­‐
1	  expression	  drops	  down	  by	  >	  90	  %.	  Transfection	  with	  either	  100	  nM	  	  siRNA	  12432	  or	  
siRNA	  142557	  or	  a	  combination	  of	  the	  two,	  led	  to	  a	  decrease	  of	  Sdc-­‐1	  expression	  of	  
more	   than	   90	   %	   compared	   to	   transfection	   with	   a	   scrambled	   siRNA,	   which	   was	  
maintained	  between	  24	  and	  48	  h.	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Figure	  25,	  Sdc-­‐1	  knockdown	  in	  HTB94	  cells	  
For	   transfection,	   either	   10	   or	   50	   or	   100	   nM	   of	   either	   siRNA	   12432,	   142557	   or	   a	  
combination	   of	   both,	   was	   added	   to	   1-­‐1.5	   x	   105	   HTB94	   cells	   in	   6-­‐well	   plate	   using	  
Lipofectamine	   2000.	   Control	   cells	   were	   transfected	   with	   scrambled	   siRNA.	   At	   4	   h	  
after	   transfection,	   each	   well	   was	   supplemented	   with	   3	   ml	   of	   complete	   growth	  
medium;	   at	   24	   h	   and	   48	   h	   after	   transfection,	   the	   cells	  were	   harvested,	   total	   RNA	  
extracted	   and	   expression	   of	   Sdc-­‐1	   evaluated	   in	   comparison	   with	   GAPDH	  
housekeeping	  gene.	  Percentage	  of	  Sdc-­‐1	  expression	  after	  transfection	  with	  10	  or	  50	  
or	  100	  nM	  siRNAs	  at	  24	  h	  and	  48	  h	   is	  shown.	  Two	  siRNAs	  specific	  for	  human	  Sdc-­‐1	  
were	  designed	  by	  Ambion;	  each	  and	  a	  combination	  of	  them	  silence	  Sdc-­‐1	  expression	  
by	  80	  %	  -­‐	  90	  %.	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4.3.2.2 Internalization	  of	  [35S]TIMP-­‐3	  by	  Sdc-­‐1	  silenced	  HTB94	  cells	  
A	  combination	  of	  12432	  and	  142557	  siRNAs	   (50	  nM)	  was	  used	   to	  silence	  Sdc-­‐1,	  as	  
these	  conditions	  resulted	  in	  a	  knockdown	  of	  Sdc-­‐1	  expression	  of	  more	  than	  90	  %.	  A	  
time	  course	  of	  [35S]TIMP-­‐3	  endocytosis	  was	  started	  24	  h	  after	  Sdc-­‐1	  targeting	  siRNAs	  
transfection.	  As	   shown	   in	   Figure	  26A,	  HTB94	   cells	   transfected	  with	  Sdc-­‐1	   targeting	  
siRNAs	   internalized	   [35S]TIMP-­‐3	   in	   a	   similar	   manner	   to	   HTB94	   transfected	   with	  
scrambled	   siRNAs.	   In	   both	   cases,	   radioactivity	   in	   the	   TCA-­‐insoluble	   fraction	  
decreased	  similarly,	  and	  radioactivity	  in	  the	  TCA-­‐soluble	  fraction	  and	  associated	  with	  
cells	  increased	  at	  the	  same	  rate.	  Non-­‐transfected	  HTB94	  cells	  thus	  showed	  the	  same	  
kinetics	   of	   internalization	   as	   HTB94	   cells	   transfected	   with	   Sdc-­‐1	   targeting	   siRNAs	  
(Figure	   26B).	   These	   data	   indicate	   that	   syndecan-­‐1	   is	   not	   involved	   in	   the	  
internalization	  of	  TIMP-­‐3.	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Figure	  26,	  The	  effect	  of	  Sdc-­‐1	  silencing	  on	  TIMP-­‐3	  internalization	  by	  HTB94	  cells	  
HTB94	   cells	   were	   transfected	   with	   a	   combination	   of	   two	   Sdc-­‐1	   targeting	   50	   nM	  
siRNAs	   from	   Ambion:	   12432	   and	   142557.	   24	   h	   after	   transfection	   cells	   were	  
incubated	   at	   37	   °C	   in	   DMEM	   containing	   0.1	   %	   FCS	   and	   1	   nM	   [35S]TIMP-­‐3	   and	  
[35S]TIMP-­‐3	   endocytosis	   monitored.	   At	   the	   indicated	   time	   points,	   media	   were	  
collected	  and	  TCA	  precipitated,	  and	  cells	  harvested.	  Radioactivity	  in	  TCA-­‐insoluble,	  -­‐
soluble	   and	   cell-­‐associated	   fractions	   was	   measured.	   A.	   Kinetics	   of	   [35S]TIMP-­‐3	  
internalization	  by	  HTB94	  cells	  transfected	  with	  Sdc-­‐1	  targeting	  siRNAs	  (black	  symbols	  
and	   lines)	   and	   with	   scrambled	   siRNAs	   (red	   symbols	   and	   lines).	   B.	   Kinetics	   of	  
[35S]TIMP-­‐3	  internalization	  by	  non-­‐transfected	  control	  HTB94	  cells	  (red	  symbols	  and	  
lines)	  and	  transfected	  with	  Sdc-­‐1	  targeting	  siRNAs	  (black	  symbols	  and	  lines).	  
	  
4.3.3 Internalization	  of	  [35S]TIMP-­‐3	  by	  CHO-­‐745	  and	  wild-­‐type	  CHO-­‐K1	  
Four	  distinct	  syndecan	  proteins	  are	  known	  in	  mammals.	  There	  is	  some	  evidence	  that	  
when	  a	  certain	  syndecan	  protein	   is	   lacking,	   its	  activity	  may	  be	  compensated	  for	  by	  
other	   syndecans,	   other	   transmembrane	   proteoglycans,	   or	   even	   members	   of	   the	  
glypican	   family	   (Couchman,	   2010).	   Both	   syndecan-­‐4-­‐null	   cells	   and	   Sdc-­‐1-­‐silenced	  
HTB94	  cells	   internalized	  TIMP-­‐3	  as	  well	  as	   their	  wild-­‐type	  counterparts.	  To	  exclude	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that	   compensation	   among	   HSPGs	   could	   occur	   for	   TIMP-­‐3	   endocytosis,	   non-­‐HSPG-­‐
expressing	  CHO-­‐745	  and	  wild-­‐type	  CHO-­‐K1	  cells	  were	  chosen	  as	  a	  model	  system	  to	  
test	  TIMP-­‐3	  internalization.	  	  
	   CHO-­‐745	  cells	  are	  deficient	  in	  xylosyl	  transferase,	  the	  enzyme	  which	  initiates	  
heparan	   sulfate	   biosynthesis	   by	   catalyzing	   the	   attachment	   of	   xylose	   to	   a	   serine	  
residue	  of	  a	  core	  protein	  (Esko	  et	  al.,	  1985).	  As	  a	  result,	  CHO-­‐745	  cells	  are	  deficient	  
in	  both	  CS-­‐	  and	  HS-­‐	  proteoglycans.	  CHO-­‐K1	  and	  CHO-­‐745	  cells	  were	  incubated	  with	  1	  
nM	  [35S]TIMP-­‐3	  at	  37	  °C	  for	  24	  h.	  Radioactivity	  in	  the	  TCA-­‐insoluble	  fractions	  of	  both	  
CHO-­‐KI	   and	   CHO-­‐745	   decreased	   over	   24	   h,	   and	   cell-­‐associated	   and	   TCA-­‐soluble	  
radioactivity	   increased,	   suggesting	   that	   both	   cell-­‐types	   internalize,	   degrade	   and	  
release	   fragments	  of	   [35S]TIMP-­‐3	   (Figure	  27A	  and	  B).	  The	  kinetics	  of	   internalization	  
by	  CHO-­‐KI	   and	  CHO-­‐745	  were	  very	   similar	   (Figure	  27C),	   indicating	   that	   cell-­‐surface	  
CS-­‐	   and	  HS-­‐	   proteoglycans	   are	   not	   required	   for	   TIMP-­‐3	   endocytosis.	   Nevertheless,	  
the	   decrease	   in	   TCA-­‐insoluble	   radioactivity	   was	   slightly	   reduced	   in	   CHO-­‐745	  
compared	  to	  CHO-­‐K1	  cells,	  and	  the	  cell-­‐associated	  radioactivity	  was	  slightly	  higher.	  
These	   data	   indicate	   that	   TIMP-­‐3	  might	   bind	   to	   HSPGs	   on	   the	   cell	   surface,	   but	   its	  
endocytosis	  is	  not	  significantly	  different	  in	  absence	  or	  presence	  of	  HSPGs.	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Figure	  27,	  Internalization	  of	  TIMP-­‐3	  by	  CHO-­‐KI	  and	  CHO-­‐745	  cells	  
CHO-­‐KI	  and	  CHO-­‐745	  cells	  were	   incubated	  at	  37	   °C	   in	  DMEM	  containing	  0.1	  %	  FCS	  
and	   1	   nM	   [35S]TIMP-­‐3.	   At	   the	   time	   points	   indicated,	   the	   conditioned	  medium	  was	  
removed	   and	   cell-­‐associated,	   TCA-­‐soluble	   and	   TCA-­‐insoluble	   fractions	   were	  
harvested	  as	  described	  before.	  A.	  Time	  course	  of	  [35S]TIMP-­‐3	  endocytosis	  by	  CHO-­‐KI.	  
B.	  Time	  course	  of	  [35S]TIMP-­‐3	  endocytosis	  by	  CHO-­‐745.	  C.	  Superimposed	  kinetics	  of	  
[35S]TIMP-­‐3	   internalization	   by	   CHO-­‐KI	   (black	   symbols	   and	   lines)	   and	   CHO-­‐745	   (red	  
symbols	  and	  lines)	  cells	  (n=3).	  	  
	  
4.3.3.1 Effects	   of	   heparin	   and	   RAP	   on	   [35S]TIMP-­‐3	   endocytosis	   by	   CHO-­‐KI	  
and	  CHO-­‐745	  cells	  
CHO-­‐KI	   and	   CHO-­‐745	   cells	   were	   preincubated	   with	   heparin	   (200	   μg/ml)	   for	   1	   h	  
before	  addition	  of	  [35S]TIMP-­‐3.	   In	  both	  cell	  types,	  heparin	  inhibited	  the	  decrease	  in	  
TCA-­‐insoluble	   radioactivity	  as	  well	  as	   the	   increase	   in	  TCA-­‐soluble	   radioactivity	  over	  
24	  h	  (Figure	  28A	  and	  B).	  Heparin	  inhibited	  endocytosis	  by	  both	  CHO-­‐KI	  and	  CHO-­‐745,	  
showing	  that	  heparin	  inhibition	  of	  TIMP-­‐3	  endocytosis	  is	  not	  related	  to	  the	  presence	  
of	  GAGs	  on	  the	  cell	  surface.	  
CHO-­‐KI	   and	   CHO-­‐745	   cells	   were	   incubated	   with	   RAP	   (500	   nM)	   for	   30	   min	  
before	   addition	   of	   [35S]TIMP-­‐3	   (1	   nM).	   Figure	   28C	   and	   Figure	   28D	   show	   that	   RAP	  
reduced	   the	  uptake	  of	   the	   TCA-­‐insoluble	   [35S]TIMP-­‐3	  by	   both	   cell	   types,	   indicating	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that	  TIMP-­‐3	  is	  internalized	  in	  a	  LRP-­‐dependent	  manner	  also	  by	  these	  cells.	  Kinetics	  of	  
[35S]TIMP-­‐3	  internalization	  by	  RAP	  treated	  CHO-­‐KI	  and	  CHO-­‐745	  cells	  was	  very	  similar	  
suggesting	   that	   the	   LRP-­‐1-­‐dependent	   pathway	   is	   the	   main	   mechanism	   of	   TIMP-­‐3	  
internalization	  and	  that	  the	  LRP-­‐1-­‐independent	  mechanism	  is	  not	  mediated	  by	  cell-­‐
surface	  HSPGs.	  
	  
Figure	  28,	  [35S]TIMP-­‐3	  endocytosis	  by	  CHO-­‐KI	  and	  -­‐745	  cells	  in	  presence	  of	  heparin	  
or	  RAP	  
[35S]TIMP-­‐3	  (1	  nM)	  was	  added	  to	  CHO-­‐KI	  or	  CHO-­‐745	  cells,	  and	  TCA-­‐soluble	  (●),	  TCA-­‐
insoluble	   (■)	   and	   cell-­‐associated	   (p)	   radioactivity	   analysed	   at	   various	   times.	   A.	  
Internalization	  of	  [35S]TIMP-­‐3	  by	  CHO-­‐KI	  cells	  in	  the	  presence	  (red	  symbols	  and	  lines)	  
and	  absence	  (black	  symbols	  and	  lines)	  of	  200	  μg/ml	  of	  heparin.	  B.	  Internalization	  of	  
[35S]TIMP-­‐3	  by	  CHO-­‐745	   cells	   in	   the	  presence	   (red	   symbols	   and	   lines)	   and	  absence	  
(black	  symbols	  and	  lines)	  of	  200	  μg/ml	  of	  heparin.	  C.	  Internalization	  of	  [35S]TIMP-­‐3	  by	  
CHO-­‐KI	  cells	  in	  the	  presence	  (red	  symbols	  and	  lines)	  and	  absence	  (black	  symbols	  and	  
lines)	  of	  500	  nM	  RAP.	  D.	   Internalization	  of	  [35S]TIMP-­‐3	  by	  CHO-­‐745	  cells	   in	  the	  (red	  
symbols	  and	  lines)	  and	  absence	  (black	  symbols	  and	  lines)	  of	  500	  nM	  RAP.	  
	  
4.3.3.2 The	  effect	  of	  sodium	  chlorate	  on	  [35S]TIMP-­‐3	  endocytosis	  
To	  understand	  the	  role	  of	  highly	  sulfated	  GAGs	   in	  TIMP-­‐3	  endocytosis,	  HTB94	  cells	  
were	   pre-­‐treated	   with	   30	   mM	   sodium	   chlorate,	   which	   prevents	   GAG	   sulfation	  
(Baeuerle	  and	  Huttner,	  1986),	  for	  24	  h	  prior	  incubation	  with	  1	  nM	  [35S]TIMP-­‐3.	  Figure	  
29	  shows	  that	  radioactivity	  in	  the	  TCA-­‐insoluble	  fraction	  of	  sodium	  chlorate	  treated	  
samples	  decreased	  indistinguishable	  from	  that	  of	  non-­‐treated	  samples;	  radioactivity	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associated	   with	   cells	   and	   TCA-­‐soluble	   fraction	   of	   treated	   samples	   increased	   in	   a	  
similar	  manner	  as	   that	  of	  non-­‐treated	  control	  samples,	  suggesting	  that	  sulfation	  of	  
GAGs	  is	  not	  essential	  for	  [35S]TIMP-­‐3	  endocytosis.	  
	  
Figure	  29,	  The	  effect	  of	  sodium	  chlorate	  on	  [35S]TIMP-­‐3	  endocytosis.	  
HTB94	  were	  pre-­‐treated	  with	  30	  mM	  sodium	  chlorate	  for	  24	  h	  at	  37	  °C	  prior	  adding	  
[35S]TIMP-­‐3	  	  (1	  nM).	  The	  conditioned	  medium	  was	  collected	  at	  indicated	  time	  points	  
and	   harvested	   as	   described	   before.	   TCA-­‐insoluble	   [35S]TIMP-­‐3	   clearance	   is	   not	  
affected	  by	  sodium	  chlorate	  (■)	  compared	  to	  untreated	  control	   (■).	  Appearance	  of	  
[35S]TIMP-­‐3	   TCA-­‐soluble	   and	   cell-­‐associated	   fractions	   (●	   and	   p,	   respectively)	  
increase	  in	  a	  similar	  manner	  to	  controls	  (●	  and	  p)	  (n=2).	  
	  
4.4 Discussion	  
As	  discussed	   in	   the	  Chapter	  3,	  RAP	   treated	  HTB94	   cells	   internalized	  TIMP-­‐3	  with	  a	  
slower	  rate	  compared	  to	  non-­‐treated	  controls,	  suggesting	  that	  members	  of	  the	  LDL	  
receptor	  superfamily	  play	  a	  key	  role	  in	  TIMP-­‐3	  endocytosis,	  but	  that	  an	  LDL	  receptor-­‐
independent	  pathway	  also	  occurs.	   I	   investigated	  which	  member	  of	   the	  LDLR	  family	  
was	   involved	   in	   TIMP-­‐3	   internalization.	  Many	   proteinases,	   proteinase	   inhibitors	   or	  
molecules	  that	  play	  a	  role	  in	  the	  ECM	  turnover,	  are	  internalized	  by	  cells	  via	  LRP-­‐1.	  I	  
postulated	  that	   it	  could	  also	  be	  the	  case	  for	  TIMP-­‐3,	  and	  therefore	   I	   tested	  TIMP-­‐3	  
endocytosis	  by	  LRP-­‐1-­‐null	  mouse	  embryonic	  fibroblasts	  (PEA-­‐13).	  TIMP-­‐3	  binding	  to	  
the	   cell	   surface	   of	   MEF-­‐1	   and	   PEA-­‐13	   was	   comparable,	   but	   internalization	   and	  
degradation	   of	   TIMP-­‐3	   by	   PEA-­‐13	   cells	  was	   approximately	   half	   as	  much	   as	   that	   in	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MEF-­‐1	  cells.	  These	  data	  confirmed	  our	  hypothesis	  that	  TIMP-­‐3	  could	  be	  endocytosed	  
via	   LRP-­‐1,	   and	   that	   another	   as	   yet	   uncharacterized	   internalization	   pathway	   is	   also	  
involved.	   RAP-­‐treated	   PEA-­‐13	   cells	   internalized	   TIMP-­‐3	   with	   the	   same	   kinetics	   as	  
non-­‐treated	   controls,	   indicating	   that	   LRP-­‐1	   is	   the	   only	   member	   of	   LDLR	   family	  
involved	  in	  this	  process.	  	  
Heparin	   completely	   blocked	   TIMP-­‐3	   endocytosis	   either	   in	   presence	   or	   in	  
absence	  of	   LRP-­‐1.	   I	  postulated	   that	  an	  HSPG	  might	  be	   the	  primary	  binding	   site	   for	  
TIMP-­‐3	   and	   that	   it	   may	   function	   as	   a	   co-­‐receptor	   for	   the	   LRP-­‐1-­‐mediated	  
endocytosis,	  as	   it	  occurs	  for	  other	  LRP-­‐1	  ligands	  (Chappell	  et	  al.,	  1993;	  Mikhailenko	  
et	  al.,	  1995).	  	  In	  the	  absence	  of	  LRP-­‐1,	  HSPG	  might	  directly	  mediate	  internalization	  as	  
has	   been	   shown	   for	   the	   Aβ	   peptide	   (Kanekiyo	   et	   al.,	   2011).	   Members	   of	   the	  
syndecan	   family	   were	   thought	   to	   be	   possible	   candidates	   for	   their	   high	   degree	   of	  
sulfation	   and	   for	   their	   involvement	   in	   the	   endocytosis	   of	   LRP	   ligands	   either	   as	   co-­‐
receptors	   or	   proper	   receptors	   (Stanford	   et	   al.,	   2009;	   Wilsie	   et	   al.,	   2006).	   It	   was	  
shown	  that	  syndecan-­‐4-­‐null	  mice	  are	  protected	  from	  osteoarthritis	   in	  experimental	  
models	  (Echtermeyer	  et	  al.,	  2009).	  We	  hypothesized	  that	  if	  syndecan-­‐4	  was	  involved	  
in	  TIMP-­‐3	  internalization,	  then	  TIMP-­‐3	  levels	  would	  be	  increased	  in	  syndecan-­‐4-­‐null	  
mice,	  which	  may	  explain	  their	  resistance	  to	  osteoarthritis.	  Surprisingly,	  syndecan-­‐4-­‐
null	  cells	  internalized	  TIMP-­‐3	  as	  well	  as	  wild-­‐type	  cells.	  Similar	  results	  were	  obtained	  
testing	   TIMP-­‐3	   internalization	   by	   syndecan-­‐1-­‐silenced	   cells.	   Redundancy	   among	  
members	  of	  the	  syndecan	  family	  can	  occur	  and	  syndecans	  can	  compensate	  for	  each	  
other	   (Couchman,	   2010).	   To	   exclude	   this	   possibility	   in	   our	   studies,	   we	   tested	   the	  
internalization	  of	  TIMP-­‐3	  in	  CHO-­‐745	  cells,	  which	  are	  defective	  in	  the	  biosynthesis	  of	  
glycosaminoglycans	  as	   they	   lack	  xylosyl-­‐transferase	   (Esko	  et	  al.,	  1985).	  TIMP-­‐3	  was	  
effectively	   internalized	  by	  CHO-­‐745	   cells,	  with	   similar	   kinetics	   to	  wild-­‐type	  CHO-­‐K1	  
cells,	  implying	  that	  HSPGs	  are	  not	  involved	  in	  TIMP-­‐3	  endocytosis.	  Sodium	  chlorate	  is	  
known	   to	   be	   an	   in	   vitro	   inhibitor	   of	   ATP–sulfurylase,	   the	   first	   enzyme	   in	   the	  
biosynthesis	   of	   3'-­‐phosphoadenosine	   5'-­‐phosphosulfate,	   the	   high-­‐energy	   sulphate	  
donor	   in	   biological	   reactions	   inhibits	   the	   sulfation	   (Baeuerle	   and	   Huttner,	   1986).	  
Treatment	   of	   various	   cell	   cultures	   with	   sodium	   chlorate	   resulted	   in	   inhibition	   of	  
proteoglycan	   sulfation	   (Baeuerle	   and	   Huttner,	   1986).	   Sodium	   chlorate-­‐treated	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HTB94	   cells	   internalized	   TIMP-­‐3	   as	  well	   as	   non-­‐treated	   controls,	   further	   indicating	  
that	   HSPGs	   are	   not	   involved	   in	   internalization	   of	   TIMP.	   RAP	   effectively	   reduced	  
internalization	   in	   both	   CHO-­‐745	   and	   CHO-­‐K1	   cells,	   suggesting	   that	   the	   LRP-­‐1-­‐
mediated	  pathway	  of	  TIMP-­‐3	  endocytosis	   is	  also	  active	   in	   these	  cells.	  Heparin	  also	  
completely	  blocked	  TIMP-­‐3	  endocytosis	  by	  CHO-­‐745	  cells,	  indicating	  that	  heparin	  did	  
not	   protect	   TIMP-­‐3	   from	   endocytosis	   by	   preventing	   its	   binding	   to	   HSPGs.	   Highly	  
sulfated	  GAGs	  may	  block	  TIMP-­‐3	  binding	  to	  LRP-­‐1	  either	  directly	  binding	  to	  TIMP-­‐3	  
or	  binding	  to	  a	  receptor.	  Some	  other	  molecules	  on	  the	  cell	  surface	  which	  have	  been	  
shown	   binding	   TIMP-­‐3	   may	   be	   possible	   candidates	   for	   its	   LRP-­‐independent	  
internalization.	  TIMP-­‐3	  may	  bind	  to	  membrane-­‐associated	  metalloproteinases	   (MT-­‐
MMPs	   or	   ADAMs),	   but,	   as	   it	   will	   be	   shown	   in	   Chapter	   6,	   the	   presence	   of	   the	  
metalloproteinases	   inhibitor	   GM6001	   did	   not	   block	   TIMP-­‐3	   binding	   to	   the	   cell	  
surface,	  therefore	  this	  possibility	  is	  unlikely.	  TIMP-­‐3	  has	  been	  shown	  to	  interact	  with	  
VEGFR-­‐2	   (Qi	   et	   al.,	   2003).	   VEGFR-­‐2	   is	   internalized	   by	   a	   clathrin-­‐dependent	  
mechanism	   upon	   binding	   of	   its	   ligand	   VEGF	   (Lampugnani	   et	   al.,	   2006),	   thus	   this	  
receptor	  may	   be	   the	   TIMP-­‐3	   binding	   partner	   that	  mediates	   its	   LRP-­‐1-­‐independent	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5.1 Introduction	  
I	   observed	   that	   the	   rate	   of	   TIMP-­‐3	   endocytosis	   by	   different	   cell	   types	  was	   initially	  
fast,	  but	  that	  it	  then	  gradually	  decreased	  over	  time	  and	  became	  minimal	  around	  10	  h	  
after	   addition	   of	   the	   inhibitor	   to	   the	   cells.	   In	   this	   chapter,	   I	   investigated	   possible	  
causes	  of	  this	  “plateau”	  in	  TIMP-­‐3	  internalization.	  
Firstly,	   I	   examined	  whether	   the	   decreased	   rate	   of	   TIMP-­‐3	   endocytosis	   was	  
due	   to	   TIMP-­‐3-­‐induced	   apoptosis	   of	   the	   cells.	   It	   is	   well	   established	   that	   TIMP-­‐3	  
induces	   apoptosis	   in	   a	   variety	   of	   cell	   types,	   primarily	   through	   its	   ability	   to	   inhibit	  
metalloproteinase-­‐mediated	   shedding	   of	   death	   receptors,	   such	   as	   tumor	   necrosis	  
factor	   receptor-­‐1	   (TNFRI),	   FAS	   receptor,	   and	  TNF-­‐related	   apoptosis	   inducing	   ligand	  
receptor-­‐1	   (TRAIL-­‐R1)	   (Ahonen	  et	  al.,	  2003;	  Bond	  et	  al.,	  2002).	   	   Inhibition	  of	  death	  
receptors	  shedding	  by	  TIMP-­‐3	  results	  in	  an	  increased	  stabilization	  of	  these	  receptors	  
on	  the	  cell	  surface,	  and	  a	  higher	  cell	  responsiveness	  to	  apoptosis	  induced	  by	  TNF-­‐α,	  
anti-­‐Fas-­‐antibodies	  or	  TRAIL.	  Secondly,	  I	  investigated	  whether	  the	  decrease	  in	  TIMP-­‐
3	   endocytosis	  was	   caused	   by	   shedding	   of	   LRP-­‐1	   from	   the	   surface	   of	   endocytosing	  
cells.	   Several	   studies	   indicate	   that	   LRP-­‐1	   can	   undergo	   proteolytic	   shedding.	   For	  
example,	  a	  truncated,	  soluble	  form	  of	  LRP-­‐1	  is	  found	  in	  human	  plasma	  (Quinn	  et	  al.,	  
1997)	  and	  in	  the	  conditioned	  medium	  of	  HT1080	  cultured	  cells	  (Selvais	  et	  al.,	  2011).	  
Different	   metalloproteinases,	   such	   as	   ADAM-­‐10,	   ADAM-­‐12,	   BACE	   and	   TACE,	   have	  
been	  shown	  to	  cleave	  the	  ectodomain	  of	  LRP-­‐1	  in	  vitro	  (Liu	  et	  al.,	  2009;	  Selvais	  et	  al.,	  
2009;	  von	  Arnim	  et	  al.,	  2005).	  The	  released	  LRP-­‐1	  ectodomain,	  or	  so	  called	  soluble	  
LRP-­‐1	   (sLRP-­‐1),	  maintains	   its	   ligand-­‐binding	   ability	   (Quinn	   et	   al.,	   1997).	   sLRP-­‐1	   can	  
also	   be	   further	   proteolytically	   fragmentated	   by	  MT1-­‐MMP	   (Rozanov	   et	   al.,	   2004).	  
Both	  shedding	  and	  further	  degradation	  modulate	  the	  amount	  of	  functional	  LRP-­‐1	  on	  
the	   cell-­‐membrane,	   and	   consequently	   modulate	   the	   scavenging	   of	   LRP-­‐1	   ligands,	  
such	  as	  MMP-­‐2	  and	  MMP-­‐9	  (Selvais	  et	  al.,	  2009).	  
5.2 Results	  
5.2.1 [35S]TIMP-­‐3	  does	  not	  impair	  cell	  viability	  
Ahonen	  et	  al.	  (2003)	  showed	  that	  TIMP-­‐3	  induced	  apoptosis	   in	  melanoma	  cell	   lines	  
at	  concentrations	  above	  25-­‐50	  nM	  (Ahonen	  et	  al.,	  2003),	  whereas,	  previous	  work	  in	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our	   laboratory	   found	   that	   N-­‐TIMP-­‐3	   did	   not	   induce	   apoptosis	   in	   porcine	  
chondrocytes	   even	   at	   the	   concentration	   of	   1	   μM	   (Gendron	   et	   al.,	   2003).	   We	  
investigated	   whether	   [35S]TIMP-­‐3	   could	   impair	   viability	   of	   HTB94	   cells,	   since	   such	  
event	   may	   lead	   to	   a	   decrease	   in	   [35S]TIMP-­‐3	   internalization.	   For	   this	   purpose	   we	  
used	   the	  MTT	   (3-­‐(4,5-­‐Dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐diphenyltetrazolium	  bromide)	  assay.	  
The	  MTT	  is	  a	  yellow	  tetrazole	  that	  is	  reduced	  to	  purple	  formazan	  in	  living	  cells.	  The	  
absorbance	  of	  this	  purple	  product	  can	  be	  then	  quantified	  by	  measuring	  at	  a	  certain	  
wavelength	  using	  a	  spectrophotometer.	  	  
	   	   HTB94	   cells	   were	   incubated	   with	   or	   without	   1	   nM	   [35S]TIMP-­‐3	   in	   DMEM	  
containing	   0.1	   %	   FCS.	   Cells	   fixed	   in	   3	   %	   PFA	   in	   PBS	   (10	  min,	   RT)	   were	   used	   as	   a	  
negative	  control.	  At	  the	  indicated	  time	  points,	  the	  medium	  was	  replaced	  with	  phenol	  
red-­‐free	   DMEM	   containing	   0.5	   mg/ml	   MTT	   reagent	   (10	   min,	   37	   °C).	   Then,	   the	  
reaction	  was	  stopped	  by	  addition	  of	  10	  %	  SDS	  in	  10	  mM	  HCl	  (over	  night,	  37	  °C)	  and	  
absorbance	  at	  574	  nm	  measured.	  Figure	  30	   shows	   that	   [35S]TIMP-­‐3	   (1	  nM)	  had	  no	  
detectable	  effect	  on	  cell	  viability	  over	  24	  h.	  	  
	  
Figure	  30,	  MTT	  assay	  of	  [35S]TIMP-­‐3	  treated	  HTB94	  cells	  
HTB94	   cells	   were	   incubated	  with	   (●)	   or	   without	   (■)	   [35S]TIMP-­‐3	   (1	   nM)	   in	   DMEM	  
containing	   0.1	   %	   FCS	   (0-­‐24	   h).	   At	   the	   indicated	   period	   of	   time,	   the	   medium	   was	  
replaced	  with	  MTT	  reagent	   in	  phenol	  red-­‐free	  DMEM	  (10	  min,	  37	  °C).	  The	  reaction	  
was	   stopped	   by	   addition	   of	   10	   %	   SDS	   in	   10	   mM	   HCl	   and	   absorbance	   at	   574	   nm	  
determined.	  HTB94	  cells	  fixed	  in	  3	  %	  PFA	  in	  PBS	  (10	  min,	  RT)	  were	  used	  as	  negative	  
control	  (p)	  (n=3).	  
Chapter	  5	   	   Investigation	  of	  plateau	  in	  TIMP-­‐3	  internalization	  
	   140	  
5.2.2 	  Pre-­‐treatment	   of	   HTB94	   cells	   with	   TIMP-­‐3	   has	   no	   effect	   on	  
subsequent	  [35S]TIMP-­‐3	  endocytosis	  
To	   test	   whether	   the	   decrease	   in	   TIMP-­‐3	   endocytosis	   was	   due	   to	   a	   decrease	   in	  
availability	   of	   endocytic	   receptors	   on	   the	   cell	   surface,	   HTB94	   cells	  were	   incubated	  
with	   or	   without	   non-­‐radioactive	   TIMP-­‐3	   (1	   nM)	   for	   24	   h,	   before	   the	   addition	   of	  
[35S]TIMP-­‐3	  (1nM).	  As	  shown	  in	  Figure	  31,	  the	  decrease	  in	  TCA-­‐insoluble	  radioactivity	  
and	  the	  increase	  in	  TCA-­‐soluble	  and	  cell-­‐associated	  radioactivity	  of	  cells	  pre-­‐treated	  
with	   TIMP-­‐3	   was	   similar	   to	   that	   of	   non-­‐treated	   cells,	   indicating	   that	   the	   pre-­‐




Figure	   31,	   The	   effect	   of	   non-­‐radioactive	   TIMP-­‐3	   pre-­‐treatment	   on	   [35S]TIMP-­‐3	  
internalization	  by	  HTB94	  cells.	  
HTB94	  cells	  were	  pre-­‐treated	  with	  TIMP-­‐3	  (1	  nM)	  (red	  symbols	  and	  lines)	  or	  serum-­‐
free	  DMEM	  (black	   symbols	  and	   lines)	   for	  24	  h.	  Both	   conditioned	  media	  were	   then	  
replaced	  with	  [35S]TIMP-­‐3	  (1	  nM)	  in	  DMEM	  0.1	  %	  FCS	  (24	  h,	  37	  °C)	  and	  TCA-­‐soluble	  
(●,●),	   TCA-­‐insoluble	   (■,■)	   and	   cell-­‐associated	   (p,p)	   radioactivity	   was	   analysed	   at	  
various	  periods	  of	  time.	  This	  experiment	  was	  performed	  twice	  with	  similar	  results.	  
	  
5.2.3 TIMP-­‐3	  remnants	  are	  protected	  from	  internalization	  
I	  analyzed	  whether	  [35S]TIMP-­‐3	  remaining	  in	  the	  medium	  after	  24	  h	  incubation	  with	  
HTB94	  cells	  (referred	  to	  as	  [35S]TIMP-­‐3	  remnants)	  could	  be	  internalized	  by	  fresh	  cells.	  
[35S]TIMP-­‐3	  (1	  nM)	  was	  incubated	  with	  HTB94	  cells	  for	  24	  h.	  At	  the	  indicated	  time,	  a	  
portion	   of	   conditioned	   media	   was	   harvested	   and	   the	   distribution	   of	   radioactivity	  
between	   TCA-­‐insoluble,	   TCA-­‐soluble	   and	   cell-­‐associated	   fraction	   were	   analyzed.	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After	   24	   h,	   the	   rest	   of	   conditioned	   medium	   was	   harvested	   as	   the	   [35S]TIMP-­‐3	  
remnants,	   which	   were	   transferred	   to	   fresh	   HTB94	   cells,	   and	   their	   endocytosis	  
monitored	   over	   the	   subsequent	   24	   h.	   As	   shown	   in	   Figure	   32A,	   [35S]TIMP-­‐3	   was	  
rapidly	  endocytosed	  by	  HTB94	  cells	  initially,	  but	  the	  rate	  of	  endocytosis	  was	  greatly	  
reduced	  after	  10	  h.	  When	  the	  [35S]TIMP-­‐3	  remnants	  were	  transferred	  to	  fresh	  HTB94	  
cells,	   no	   further	   endocytosis	   was	   detectable	   (Figure	   32B).	   The	   decrease	   in	   TCA-­‐
insoluble	   radioactivity	   and	   the	   increase	   in	   TCA-­‐soluble	   radioactivity	  were	  minimal,	  
with	   the	   distribution	   of	   radioactivity	   in	   these	   samples	   remaining	   constant.	   These	  
data	   suggest	   that	   [35S]TIMP-­‐3	   remnants	   had	   become	   resistant	   to	   endocytosis	   by	  
HTB94	  cells.	  [35S]TIMP-­‐3	  binding	  to	  the	  cells	  was	  detectable	  but	  the	  amount	  of	  this	  
binding	  was	  greatly	  reduced	  compared	  to	  the	  freshly	  added	  [35S]TIMP-­‐3,	  suggesting	  
that	  the	  ability	  of	  [35S]TIMP-­‐3	  remnants	  to	  bind	  to	  the	  cell	  surface	  was	  also	  impaired.	  	  
	  
	  
Figure	  32,	  Endocytosis	  of	  [35S]TIMP-­‐3	  remnants	  by	  fresh	  HTB94	  cells	  
HTB94	  cells	  were	  incubated	  with	  [35S]TIMP-­‐3	  (1	  nM)	  in	  DMEM	  containing	  0.1	  %	  FCS	  
at	  37	  °C,	  and	  [35S]TIMP-­‐3	  endocytosis	  monitored	  over	  24	  h.	  After	  24	  h,	  conditioned	  
media	   containing	   [35S]TIMP-­‐3	   remnants	   were	   collected	   and	   transferred	   to	   fresh	  
HTB94	  cells.	  At	  the	  indicated	  time	  points,	  the	  conditioned	  medium	  was	  collected	  and	  
TCA-­‐precipitated,	   and	   cells	   harvested.	   Radioactivity	   in	   the	   TCA-­‐insoluble	   (■),	   TCA-­‐
soluble	   (●)	   and	   cell-­‐associated	   (p)	   fractions	   was	   measured.	   This	   result	   is	  
representative	  of	  two	  separate	  experiments.	  
	  
5.2.4 TIMP-­‐3	  remnants	  inhibit	  ADAMTS-­‐4	  
HTB94	  cells	  were	  incubated	  with	  10	  nM	  TIMP-­‐3	  in	  DMEM	  containing	  0.1	  %	  FCS.	  After	  
24	  or	  48	  h	   incubation,	  TIMP-­‐3	   remnants	  were	  harvested	  and	   incubated	  with	  1	  nM	  
ADAMTS-­‐4	  (1	  h,	  37	  °C)	  to	  test	  their	  inhibitory	  activity.	  Figure	  33	  shows	  that	  at	  0	  h,	  10	  
nM	  TIMP-­‐3	   in	  DMEM	   containing	   0.1	  %	   FCS	   completely	   inhibited	   1	   nM	  ADAMTS-­‐4,	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compared	  to	  plain	  conditioned	  medium	  taken	  as	  a	  negative	  control.	  The	  activity	  of	  
ADAMTS-­‐4	  was	  inhibited	  less	  by	  TIMP-­‐3	  containing	  medium	  harvested	  after	  24	  and	  
48	   h,	   but	   these	   conditioned	   media	   still	   inhibited	   ADAMTS-­‐4	   activity	   effectively	  
compared	  to	  control	  conditioned	  media	  which	  were	  not	  supplemented	  with	  TIMP-­‐3.	  
These	  data	  indicate	  that	  TIMP-­‐3	  remnants	  retained	  their	  ability	  to	  inhibit	  ADAMTS-­‐4,	  
indicating	   that	   their	   overall	   structure	   had	   been	   maintained.	   The	   lower	   inhibitory	  
activity	  of	  TIMP-­‐3	  remnants	  at	  48	  h	  and	  24	  h	  compared	  to	  that	  at	  0	  h	  is	  in	  line	  with	  
the	  internalization	  kinetics	  of	  TIMP-­‐3	  that	  is	  shown	  in	  Section	  3.2.2.2	  
	  
Figure	  33,	  Inhibitory	  activity	  of	  TIMP-­‐3-­‐remnants	  
HTB94	   cells	  were	   incubated	  with	   TIMP-­‐3	   (10	   nM)	   in	   DMEM	   containing	   0.1	  %	   FCS.	  
After	  0,	  24	  and	  48	  h,	  the	  medium	  was	  collected	  and	  inhibition	  of	  ADAMTS-­‐4	  (1	  nM)	  
by	   residual	   [35S]TIMP-­‐3	  analyzed.	  Conditioned	  medium	   (100	  μl)	  was	   incubated	   (1h,	  
37	   °C)	   with	   ADAMTS-­‐4	   (1nM)	   and	   its	   residual	   activity	   was	   measured	   against	   a	  
fluorescent	   peptide	   as	   row	   fluorescence	  units	   (18h,	   37	   °C)	   (Troeberg	   et	   al.,	   2009).	  
This	  result	  is	  representative	  of	  two	  separate	  experiments.	  
	  
5.2.5 [35S]TIMP-­‐3	  remnants	  are	  not	  truncated	  nor	  degraded	  
HTB94	   cells	   in	   6-­‐well	   plate	   were	   incubated	   with	   [35S]TIMP-­‐3	   (1	   nM)	   in	   DMEM	  
containing	  0.1	  %	  FCS.	  Cells	  were	  cultured	  up	   to	  24	  h	  and	   the	  conditioned	  medium	  
was	  harvested	  at	  the	  time	  points	   indicated	  and	  TCA-­‐precipitated.	  Equal	  volumes	  of	  
all	  samples	  were	  analysed	  by	  reducing	  SDS-­‐PAGE	  and	  subsequent	  autoradiography.	  
Figure	   34	   shows	   the	   decreased	   intensity	   of	   [35S]TIMP-­‐3	   band	  over	   time,	   indicating	  
that	   [35S]TIMP-­‐3	   was	   endocytosed	   by	   the	   cells.	   It	   is	   also	   notable	   that	   [35S]TIMP-­‐3	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remained	  in	  the	  medium	  (remnants)	  exhibited	  essentially	  the	  same	  molecular	  weight	  
from	  the	  original	  [35S]TIMP-­‐3.	  [35S]TIMP-­‐3	  remnants	  ran	  as	  a	  single	  band	  on	  reducing	  
SDS-­‐PAGE,	   indicating	   that	   [35S]TIMP-­‐3	  was	   not	   degraded	   during	   incubation	   on	   the	  
cells.	  	  
	  
Figure	  34,	  Autoradiographic	  analysis	  of	  [35S]TIMP-­‐3	  after	  exposure	  to	  HTB94	  cells	  	  
	  [35S]TIMP-­‐3	  (1	  nM)	  was	  added	  to	  HTB94	  cells,	  and	  media	  harvested	  at	  the	  indicated	  
time	   points	   and	   precipitated	   with	   TCA	   (5	   %).	   TCA-­‐insoluble	   fractions	   were	   re-­‐
suspended	   in	   2	   X	   reducing	   SDS-­‐PAGE	   buffer	   and	   analysed	   by	   SDS-­‐PAGE	   and	  
autoradiography.	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5.2.6 Incubation	  of	  [35S]TIMP-­‐3	  with	  conditioned	  medium	  from	  HTB94	  
cells	  impairs	  its	  internalization	  
Since	  	  [35S]TIMP-­‐3	  remained	  in	  the	  medium	  of	  HTB94	  cells	  after	  a	  24	  h	  incubation	  did	  
not	   show	   any	   apparent	   changes	   in	   its	   molecular	   weight,	   I	   hypothesized	   that	  
[35S]TIMP-­‐3	  may	  bind	  to	  a	  protein	  released	  by	  HTB94	  cells	  and	  that	  such	  complexes	  
are	  resistant	  to	  endocytosis.	  To	  test	  this	  hypothesis,	  HTB94	  cells	  were	  incubated	  with	  
DMEM	  containing	  0.1	  %	  FCS	   for	  24	  h	  at	  37	   °C.	  Then,	   the	  conditioned	  medium	  was	  
collected,	   incubated	  with	  1	  nM	  [35S]TIMP-­‐3	  (overnight,	  RT)	  and	  transferred	  to	  fresh	  
confluent	  HTB94	  cells	  in	  a	  6-­‐well	  plate.	  As	  a	  control,	  1	  nM	  [35S]TIMP-­‐3	  incubated	  with	  
DMEM	  containing	  0.1	  %	  FCS	  was	  added	  to	  HTB94	  cells.	  At	  the	  indicated	  time	  points,	  
the	  distribution	  of	  radioactivity	  in	  the	  TCA-­‐insoluble,	  TCA-­‐soluble	  and	  cell-­‐associated	  
fractions	  was	   analysed.	   As	   shown	   in	   Figure	   35,	   pre-­‐incubation	   of	   [35S]TIMP-­‐3	  with	  
HTB94	   conditioned	   medium	   greatly	   reduced	   endocytosis	   of	   the	   protein.	   The	  
decrease	  in	  TCA-­‐insoluble	  was	  minimal,	  and	  the	  increase	  in	  the	  TCA-­‐soluble	  and	  cell-­‐
associated	  fractions	  was	  also	  lower	  compared	  to	  that	  of	  [35S]TIMP-­‐3	  incubated	  with	  
DMEM.	   These	   data	   suggest	   that	   HTB94	   cells	   release	   molecules	   that	   inhibit	   the	  
endocytosis	  of	  [35S]TIMP-­‐3.	  	  
	  
Figure	   35,	   The	   effect	   of	   HTB94	   cell-­‐conditioned	   medium	   on	   [35S]TIMP-­‐3	  
internalization	  
[35S]TIMP-­‐3	   (1	   nM)	  was	   incubated	  with	   either	   DMEM	   containing	   0.1	   %	   FCS	   (black	  
lines	   and	   symbols)	   or	   the	   conditioned	   medium	   from	   HTB94	   cells	   (red	   lines	   and	  
symbols)	   overnight	   at	   room	   temperature.	   After	   24	   h,	   these	   [35S]TIMP-­‐3-­‐containing	  
media	   were	   transferred	   to	   fresh	   HTB94	   cells	   and	   the	   amount	   of	   TCA-­‐soluble	   (●),	  
TCA-­‐insoluble	   (■)	   and	   cell-­‐associated	   (p)	   radioactivity	   quantified	   at	   various	   time	  
points.	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5.2.7 [35S]TIMP-­‐3	  remnants	  from	  LRP-­‐1-­‐deficient	  cells	  are	  endocytosed	  
by	  fresh	  LRP-­‐1	  wild-­‐type	  cells	  
As	   LRP-­‐1	   has	   been	   shown	   to	   undergo	   proteolytic	   shedding	   (Quinn	   et	   al.,	   1997;	  
Selvais	   et	   al.,	   2011),	   we	   investigated	   whether	   shed	   LRP-­‐1	   (sLRP-­‐1)	   could	   bind	   to	  
TIMP-­‐3	   and	   interfere	  with	   its	   endocytosis.	   [35S]TIMP-­‐3	   (1	   nM)	  was	   incubated	  with	  
either	  MEF-­‐1	  or	  PEA-­‐13	  cells	  in	  DMEM	  containing	  0.1	  %	  FCS.	  After	  24	  h,	  conditioned	  
media	   containing	   [35S]TIMP-­‐3	   remnants	   were	   collected	   from	   both	   cell	   types	   and	  
transferred	  to	  fresh	  MEF-­‐1	  cells.	  	  
As	  shown	  in	  Figure	  36A,	  remnants	  from	  MEF-­‐1	  cells	  were	  not	  endocytosed	  by	  
fresh	  MEF-­‐1	  cells,	  similar	  to	  the	  results	  we	  obtained	  in	  HTB94	  cells	   (see	  Figure	  32).	  
Radioactivity	  in	  the	  TCA-­‐soluble	  fraction	  remained	  constant	  over	  24	  h,	  indicating	  that	  
no	  detectable	  endocytosis	  and	  degradation	  of	  [35S]TIMP-­‐3	  occurred.	  Radioactivity	  in	  
the	  TCA-­‐insoluble	  fraction	  decreased	  slightly,	  and	  radioactivity	  in	  the	  cell-­‐associated	  
fraction	   increased	   slightly,	   indicating	   that	   some	  of	   [35S]TIMP-­‐3	   remnants	   bound	   to	  
the	  cell	  surface	  and	  ECM.	  
However,	   [35S]TIMP-­‐3	   remnants	   from	   PEA-­‐13	   cells	   were	   effectively	  
internalized	   by	   fresh	   MEF-­‐1	   cells	   (Figure	   36B).	   Radioactivity	   in	   the	   TCA-­‐insoluble	  
fraction	   decreased	   and	   radioactivity	   in	   TCA-­‐soluble	   and	   cell-­‐associated	   fractions	  
increased	  over	  24	  h.	  	  
Since	  incubation	  of	  [35S]TIMP-­‐3	  on	  wild-­‐type	  cells,	  but	  not	  on	  LRP-­‐1-­‐deficient	  
cells,	   rendered	   [35S]TIMP-­‐3	   resistant	   to	   endocytosis,	   we	   reasoned	   that	   shed	   LRP-­‐1	  
may	  bind	  to	  TIMP-­‐3	  and	  inhibit	  its	  endocytosis.	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Figure	  36,	   [35S]TIMP-­‐3	   remnants	   from	  PEA-­‐13	  but	  not	   those	   from	  MEF-­‐1	  cells	  are	  
endocytosed	  by	  fresh	  MEF-­‐1	  cells	  
[35S]TIMP-­‐3	  (1	  nM	  in	  DMEM	  with	  0.1	  %	  FCS)	  was	  incubated	  with	  either	  wild-­‐type	  (A)	  
or	   LRP-­‐1-­‐deficient	   PEA-­‐13	   MEFs	   (B).	   After	   24	   h,	   conditioned	   media	   containing	  
residual	  [35S]TIMP-­‐3	  was	  transferred	  to	  fresh	  wild-­‐type	  cells	  and	  the	  amount	  of	  TCA-­‐
soluble	   (●),	   TCA-­‐insoluble	   (■)	   and	   cell-­‐associated	   (p)	   radioactivity	   quantified	   at	  
various	  time	  points.	  This	  experiment	  was	  repeated	  twice	  with	  similar	  results.	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5.2.8 sLRP-­‐1	  accumulates	  in	  the	  medium	  of	  HTB94	  cells	  
To	  test	  whether	  sLRP-­‐1	  was	  released	  from	  the	  HTB94	  cell	  surface	  and	  accumulated	  in	  
the	   conditioned	   medium,	   confluent	   HTB94	   cells	   were	   incubated	   with	   DMEM	  
containing	  0.1	  %	  FCS,	  in	  the	  absence	  or	  presence	  of	  1	  nM	  TIMP-­‐3	  (37	  °C).	  Cells	  were	  
cultured	   for	   up	   to	   26	  h	   and	   conditioned	  media	  were	  harvested	   at	   the	   time	  points	  
indicated	  and	  TCA-­‐precipitated.	  Pellets	  were	  re-­‐suspended	  in	  2X	  non-­‐reducing	  SDS-­‐
PAGE	  buffer	  and	  analysed	  by	  Western	  blot	  using	  an	  anti-­‐LRP-­‐1	  antibody.	  Figure	  37	  
shows	   that	   bands	   corresponding	   to	   LRP-­‐1	   accumulated	   in	   the	  medium	   over	   time,	  
either	  in	  the	  absence	  or	  presence	  of	  1	  nM	  TIMP-­‐3.	  This	  indicates	  that	  LRP-­‐1	  was	  shed	  
from	   HTB94	   cells	   and	   its	   soluble	   ectodomain	   accumulated	   in	   the	   conditioned	  
medium.	  Shedding	  was	  not	  affected	  by	  addition	  of	  1	  nM	  TIMP-­‐3.	  
	  
	  
Figure	  37,	  Accumulation	  of	  sLRP-­‐1	  in	  the	  medium	  of	  HTB94	  cells	  
HTB94	  cells	  were	  incubated	  with	  DMEM	  0.1	  %	  FCS	  (26	  h,	  37	  °C)	  either	  in	  the	  absence	  
or	   presence	   of	   1	   nM	   TIMP-­‐3.	   Conditioned	  media	  were	   harvested	   at	   the	   indicated	  
time	  points,	  precipitated	  with	  TCA	  (5	  %)	  and	  analysed	  by	  Western	  blot	  using	  an	  anti-­‐
LRP-­‐1	  antibody.	  This	  result	  is	  representative	  of	  two	  separate	  experiments.	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5.2.9 Co-­‐immunoprecipitation	  of	  sLRP-­‐1	  with	  TIMP-­‐3	  
We	   investigated	  whether	   complexes	   of	   TIMP-­‐3	   and	   sLRP-­‐1	   could	   be	   isolated	   from	  
the	   conditioned	   medium	   of	   HTB94	   cells.	   Conditioned	   medium	   from	   HTB94	   was	  
incubated	  with	  TIMP-­‐3-­‐FLAG	  (1	  nM,	  18	  h,	  RT)	  and	  applied	  to	  an	  M2	  anti-­‐FLAG	  M2-­‐
agarose	  resin.	  Conditioned	  medium	  not	  incubated	  with	  TIMP-­‐3	  FLAG	  was	  used	  as	  a	  
control.	   The	   column	   was	   washed	   with	   10	   volumes	   of	   TNC	   buffer,	   and	   then	  
sequentially	  eluted	  with	  TNC	  buffer	  containing	  1	  M	  NaCl	  (2	  X	  0.5	  ml)	  and	  then	  200	  
μg/ml	  FLAG	  peptide	   (2	  X	  0.5	  ml).	  Eluted	  samples	  were	  precipitated	  with	  TCA	  (5	  %)	  
and	  pellets	  re-­‐suspended	  in	  SDS-­‐PAGE	  buffer	  and	  analysed	  by	  Western	  blotting	  using	  
an	   anti-­‐FLAG	   M2	   and	   an	   anti-­‐LRP-­‐1	   antibodies.	   As	   shown	   in	   Figure	   38,	  
immunoblotting	   of	   the	   eluted	   material	   indicated	   that	   sLRP-­‐1	   eluted	   with	   TIMP-­‐3,	  
indicating	  that	  they	  are	  present	  as	  a	  complex	  in	  the	  HTB94	  medium.	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Figure	  38,	  Co-­‐Immunoprecipitation	  of	  sLRP-­‐1	  with	  TIMP-­‐3-­‐FLAG	  
Conditioned	  medium	   from	  HTB94	  cells	  was	   incubated	  with	  FLAG-­‐tagged	  TIMP-­‐3	   (1	  
nM,	  18	  h,	  RT)	  and	  then	  applied	  to	  an	  M2	  anti-­‐FLAG	  affinity	  resin	  (1	  ml)	  equilibrated	  
in	   TNC.	   The	   resin	   was	   extensively	   washed	   with	   TNC	   and	   then	   sequentially	   eluted	  
with	  TNC	  containing	  1	  M	  NaCl	  (2	  x	  0.5	  ml,	  E1	  and	  E2)	  and	  200	  µg/ml	  FLAG	  peptide	  (2	  
x	  0.5	  ml,	  E3	  and	  E4).	  Samples	  were	  analyzed	  by	  immunoblotting	  using	  anti-­‐LRP-­‐1	  and	  
anti-­‐FLAG	  antibodies.	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In	  a	  second	  experiment,	  TIMP-­‐3	  incubated	  with	  HTB94	  conditioned	  medium	  
was	   similarly	   applied	   to	   an	  M2	   anti-­‐FLAG	   affinity	   resin,	   and	  bound	  materials	  were	  
then	  eluted	  with	  TNC	  buffer	  containing	  200	  μg/ml	  FLAG	  peptide	  (4	  X	  0.5	  ml).	  Elution	  
samples	  were	  precipitated	  with	  TCA	  (5	  %)	  and	  then	  subjected	  to	  SDS-­‐PAGE	  analysis	  
by	  silver	  staining.	  As	  shown	  in	  Figure	  39,	  a	  band	  with	  the	  molecular	  weight	  of	  sLRP-­‐1	  
was	  detected	   in	  E1,	   the	   first	   fraction	  eluted	  with	   the	  FLAG	  peptide.	  This	  band	  was	  
excised	   and	   analysed	  by	  mass	   spectrometry	  by	  Dr	   Jan	   Enghild	   at	   the	  University	   of	  
Aarhus,	  Denmark.	  This	  analysis	  confirmed	  that	  the	  detected	  band	  was	  LRP-­‐1.	  	  
	  
	  
Figure	  39,	  Silver	  stain	  of	  co-­‐immunoprecipitation	  of	  sLRP-­‐1	  with	  TIMP-­‐3-­‐FLAG	  
Conditioned	  medium	   from	  HTB94	  cells	  was	   incubated	  with	  FLAG-­‐tagged	  TIMP-­‐3	   (1	  
nM,	  18	  h,	  RT)	  and	  then	  applied	  to	  M2	  anti-­‐FLAG	  affinity	  resin	  (1	  ml)	  equilibrated	  in	  
TNC.	  The	  resin	  was	  washed	  with	  TBS	  and	  then	  with	  TNC	  containing	  1	  M	  NaCl	  (10	  x	  2	  
ml).	  Samples	  were	  taken	  throughout	  the	  washing	  (W1,	  W2,	  W3	  and	  W4).	  Finally,	  the	  
column	  was	  eluted	  with	  TNC	  containing	  FLAG	  peptide	  (4	  x	  0.5	  ml,	  E1,	  E2,	  E3	  and	  E4).	  
Samples	  were	  analysed	  silver	  staining.	  The	  detected	  band	  with	  the	  correct	  molecular	  
weight	  was	  analysed	  by	  mass-­‐spectrometry	  which	  confirmed	  that	  it	  was	  LRP-­‐1.	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5.3 Discussion	  
When	   exogenous	   TIMP-­‐3	   was	   added	   to	   a	   variety	   of	   cell	   types,	   it	   was	   rapidly	  
endocytosed	   in	   the	   first	   5	   hours	   after	   addition,	   but	   after	   that	   the	   rate	   of	   its	  
endocytosis	   gradually	   decreased	   and	   only	   a	   minimal	   amount	   of	   TIMP-­‐3	   was	  
endocytosed	   by	   10	   h	   after	   addition.	   In	   this	   chapter,	   I	   investigated	   a	   possible	  
mechanism	  for	  this	  decreased	  TIMP-­‐3	  endocytosis.	  
TIMP-­‐3	   induces	   apoptosis	   in	   melanoma	   cells	   at	   25-­‐50	   nM	   (Ahonen	   et	   al.,	  
2003),	   nevertheless,	   TIMP-­‐3	   does	   not	   cause	   it	   in	   porcine	   chondrocyte	   at	  
concentrations	  up	  to	  1	  μM	  (Gendron	  et	  al.,	  2003).	  While	  the	  concentration	  of	  TIMP-­‐3	  
used	   in	   the	   endocytosis	   assays	   (1nM)	  was	  much	   lower	   than	   that	   shown	   to	   induce	  
apoptosis	   in	  melanoma	  cells,	   I	  examined	  the	  possibility	  that	  decreased	  endocytosis	  
was	  due	  to	  cell	  death.	  Treatment	  of	  HTB94	  cells	  with	  1	  nM	  TIMP-­‐3	  had	  no	  effect	  on	  
viability	  over	  24	  h,	   indicating	  that	  the	  plateauing	  out	  the	  endocytic	  was	  not	  due	  to	  
apoptosis	  induced	  by	  TIMP-­‐3.	  
Reduced	  endocytosis	  due	  to	  a	  decrease	  in	  active	  receptors	  on	  the	  cell	  surface	  
was	   also	   considered.	   LRP-­‐1	   is	   a	   scavenging	   receptor	   that	   binds	   over	   30	   different	  
ligands	  and	  delivers	  them	  to	   lysosomes	  for	  degradation	  (Lillis	  et	  al.,	  2005).	  LRP-­‐1	   is	  
constitutively	  endocytosed	  from	  the	  membrane	  and	  recycled	  back	  to	  the	  cell	  surface	  
(van	   Kerkhof	   et	   al.,	   2005).	   To	   test	   the	   possibility	   that	   the	   decrease	   in	   TIMP-­‐3	  
endocytosis	  was	  due	  to	  a	  decrease	  in	  the	  amount	  of	  cell	  surface	  LRP-­‐1,	  HTB94	  cells	  
were	  pre-­‐treated	  with	  non-­‐radioactive	  TIMP-­‐3	  for	  24	  h.	  Then,	  [35S]TIMP-­‐3	  was	  added	  
and	   its	   endocytosis	   monitored.	   Such	   pre-­‐treatment	   of	   cells	   had	   no	   effect	   on	  
endocytosis	  of	   [35S]TIMP-­‐3,	   indicating	  that	  the	  decrease	   in	   internalization	  rate	  over	  
time	   is	   not	   due	   to	   slowing	   down	   recycling	   of	   LRP-­‐1	   receptors	   on	   the	   cell	   surface.	  
However,	   I	   found	   that	   TIMP-­‐3	   remaining	   in	   the	   conditioned	   medium	   (TIMP-­‐3	  
remnants)	  was	  not	  internalized	  by	  fresh	  HTB94	  cells.	  I	  considered	  that	  TIMP-­‐3	  might	  
have	   undergone	   chemical	   modifications	   during	   its	   incubation	   with	   cells	   which	  
rendered	  it	  resistant	  to	  internalization.	  However,	  TIMP-­‐3	  remnants	  were	  still	  active	  
against	   ADAMTS-­‐4	   after	   48	   h	   of	   incubation	   with	   HTB94	   cells,	   and	   they	   appeared	  
indistinguishable	   from	   purified	   recombinant	   TIMP-­‐3	   on	   autoradiography	   after	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reducing	   SDS-­‐PAGE.	   These	   data	   suggested	   that	   TIMP-­‐3	   remnants	   resistance	   to	  
endocytosis	  was	  not	  due	  structural	  modification	  of	  TIMP-­‐3.	  	  
It	  has	  been	  reported	  that	  LRP-­‐1	  is	  shed	  by	  MT1-­‐MMP	  and	  ADAMs	  (Quinn	  et	  
al.,	  1997;	  Rozanov	  et	  al.,	  2004).	  Intact	  soluble	  LRP-­‐1	  (namely	  sLRP-­‐1)	  has	  been	  shown	  
to	  accumulate	  in	  human	  plasma	  (Quinn	  et	  al.,	  1997)	  and	  has	  been	  identified	  at	  the	  
blood-­‐brain	   barrier	   in	   ischemia	   (Polavarapu	   et	   al.,	   2007).	   I	   investigated	   whether	  
sLRP-­‐1	   accumulated	   in	   the	   medium	   after	   shedding	   and	   whether	   sLRP-­‐1	   could	  
interact	   with	   TIMP-­‐3	   and	   prevent	   its	   internalization.	  We	   verified	   that	   HTB94	   cells	  
constitutively	  shed	  LRP-­‐1,	  and	  that	  sLRP-­‐1	  accumulates	  in	  the	  medium	  over	  time	  in	  a	  
TIMP-­‐3-­‐independent	   manner.	   Incubation	   of	   TIMP-­‐3	   with	   the	   conditioned	   medium	  
from	   HTB94	   cells	   impaired	   endocytosis	   of	   the	   inhibitor.	   To	   further	   investigate	  
whether	  LRP-­‐1	  played	  a	  role	  in	  this	  reduction	  in	  endocytosis,	  TIMP-­‐3	  was	  incubated	  
with	   LRP-­‐1-­‐null	  mouse	   fibroblasts	   and	  with	   the	  wild-­‐type	   fibroblasts	   for	   24	   h	   and	  
remnants	   from	   both	   cell	   types	   transferred	   to	   fresh	   LRP-­‐1-­‐positive	   wild-­‐type	   cells.	  
Only	  TIMP-­‐3	  remnants	  collected	  from	  LRP-­‐1-­‐null	  cells	  were	  internalized,	  while	  TIMP-­‐
3	   remnants	   from	   LRP-­‐1	   wild-­‐type	   cells	   were	   not	   internalized	   by	   fresh	   mouse	  
fibroblasts,	   suggesting	   that	   sLRP-­‐1	   interacts	   with	   TIMP-­‐3	   and	   blocks	   endocytosis.	  
Using	   co-­‐immunoprecipitation	   and	  mass	   spectrometry	   analysis,	  we	   confirmed	   that	  
sLRP-­‐1	  was	  complexed	  with	  TIMP-­‐3	  in	  the	  medium	  of	  HTB94	  cells.	  	  
Shedding	  of	  LRP-­‐1	  has	  been	  shown	  to	  modulate	  extracellular	  matrix	  turnover.	  
For	  example,	  LRP	  shedding	  regulates	  the	  internalization	  of	  MMP-­‐2	  and	  MMP-­‐9	  in	  a	  
“loss	   of	   function”	  manner.	   Cyclic	   elimination	   of	   the	   endometrium	   functional	   layer	  
through	   menstrual	   bleeding	   is	   due	   to	   intense	   tissue	   breakdown	   by	   MMP-­‐2	   and	  
MMP-­‐9	   (Selvais	   et	   al.,	   2009),	   which	   follows	   the	   fall	   of	   estrogen	   and	   progesterone	  
that	  occurs	  in	  the	  absence	  of	  pregnancy.	  Selvais	  et	  al.	  (2009)	  showed	  that	  the	  fall	  of	  
estrogen	   and	   progesterone	   increases	   mRNA	   level	   of	   ADAM-­‐12	   in	   human	  
endometrium,	  and	  ADAM-­‐12	   is	  an	  LRP-­‐1	  sheddase.	  During	   the	   fall	  of	  estrogen	  and	  
progesterone,	  LRP-­‐1	  is	  shed	  by	  ADAM-­‐12	  and	  the	  clearance	  of	  MMP-­‐2	  and	  MMP-­‐9	  is	  
blocked,	   although	   LRP-­‐1	  mRNA	  expression	   remains	   constant	   throughout	   the	   cycle.	  
More	   recently,	   Selvais	   and	   colleagues	   reported	   that	   metalloproteinase-­‐dependent	  
shedding	   of	   LRP-­‐1	   can	   be	   impaired	   by	   overloading	   fibroblastoid	  HT1080	   cells	  with	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cholesterol	   (Selvais	   et	   al.,	   2011).	   It	   is	   proposed	   that	   cholesterol	   could	   increase	  
compartmentalization	  between	  LRP-­‐1	  and	  its	  sheddases	   in	  distinct	  areas	  within	  the	  
cell	  membrane	  and	  reduces	  shedding	  events.	  	  
LRP-­‐1	  plays	  a	  key	  role	  in	  Aβ	  peptide	  clearance	  from	  the	  brain	  (Shibata	  et	  al.,	  
2000).	  sLRP-­‐1	   is	   found	   in	  human	  brain	  tissue,	   in	   the	  cerebral	  spinal	   fluid	  and	  other	  
tissues	  such	  as	  human	  plasma	  and	  placenta	  (Liu	  et	  al.,	  2009).	  Levels	  of	  sLRP-­‐1	  in	  the	  
cerebral	   spinal	   fluid	   increase	   with	   age	   and	   LRP-­‐1	   shedding	   is	   induced	   by	   the	   Aβ	  
peptide.	  These	  evidences	  suggest	   that	  LRP-­‐1	  shedding	  during	  age	  might	  contribute	  
to	  the	  pathogenesis	  of	  Alzheimer	  Disease.	  
In	  this	  chapter,	   I	  have	  demonstrated	  that	  LRP-­‐1	  shedding	  may	  also	  regulate	  
extracellular	  matrix	   turnover	   in	   a	   different	  manner.	   sLRP-­‐1	   released	   from	   the	   cell	  
surface	  can	  interact	  with	  TIMP-­‐3	  in	  the	  extracellular	  milieu	  preventing	  it	  from	  being	  
internalized.	   Importantly,	   the	   TIMP-­‐3—sLRP-­‐1	   complex	   retains	   the	  
metalloproteinase	   inhibitory	   activity	   of	   TIMP-­‐3.	   Therefore,	   shed	   LRP-­‐1	   can	   protect	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6.1 Introduction	  
LRP-­‐1	  can	  modulate	  ECM	  turnover	  and	  consequently	  cell	  behavior,	  by	  regulating	  the	  
clearance	   of	   different	   classes	   of	   proteinases	   and	   their	   endogenous	   inhibitors,	  
including	   metzincins	   and	   TIMPs,	   and	   serine	   proteases	   and	   serpins.	   Among	   the	  
metzincins,	  MMP-­‐13	  was	  the	  first	  member	  that	  was	  reported	  to	  be	   internalized	  by	  
LRP-­‐1	   (Barmina	   et	   al.,	   1999).	   ProMMP-­‐2,	   through	   its	   hemopexin	   domain,	   interacts	  
with	  the	  C-­‐terminal	  domain	  of	  TIMP-­‐2,	  thus	  forming	  a	  proMMP-­‐2—TIMP-­‐2	  complex.	  
This	   complex	   is	   also	   endocytosed	  by	   LRP-­‐1	   (Emonard	   et	   al.,	   2004).	   Emonard	  et	   al.	  
(2004)	   reported	   that	  both	  proMMP-­‐2	  and	  TIMP-­‐2	  harbor	  binding	  determinants	   for	  
LRP-­‐1	   recognition	  and	   therefore	   they	  can	  also	  be	   internalized	  by	   this	   receptor	   in	  a	  
free	  form.	  Hahn-­‐Dantona	  et	  al.	  (2001)	  showed	  that	  MMP-­‐9	  interacts	  with	  LRP-­‐1	  and	  
that	   it	   can	   be	   internalized	   alone	   or	   in	   complex	   with	   TIMP-­‐1.	   However,	   differently	  
from	   TIMP-­‐2,	   TIMP-­‐1	   does	   not	   bind	   to	   LRP-­‐1,	   thus	   it	   can	   be	   endocytosed	   by	   the	  
receptor	  only	  when	  in	  complex	  with	  the	  enzyme.	  
	   Analogous	  examples	  can	  also	  be	  found	  among	  serine	  proteases	  and	  serpins.	  
uPA	  is	  synthesized	  as	  an	  inactive	  zymogen	  precursor,	  pro-­‐uPA,	  which	  is	  activated	  by	  
plasmin	  (Dano	  et	  al.,	  1985).	  Both	  pro-­‐uPA	  and	  uPA	  bind	  with	  high	  affinity	  to	  the	  cell	  
surface	   receptor	   uPAR.	   uPAR	   can	   mediate	   the	   slow	   internalization	   of	   uPA	   in	   a	  
clathrin-­‐	   and	   dynamin-­‐independent	   manner,	   by	   a	   mechanism	   which	   shares	   many	  
features	  with	  macropinocytosis	  (Cortese	  et	  al.,	  2008).	  Nykjaer	  et	  al.	  (1992)	  reported	  
that	   when	   uPA	   is	   in	   a	   complex	   with	   its	   specific	   inhibitor	   PAI-­‐1,	   uPA	   endocytosis	  
occurs	   at	   a	   higher	   rate	   (Nykjaer	   et	   al.,	   1992b).	   They	   showed	   that	   the	   uPA—PAI-­‐1	  
complex	   interacts	   with	   uPAR	   at	   the	   cell	   surface,	   recruiting	   LRP-­‐1,	   which	  mediates	  
internalization	  of	  the	  complex.	  PAI-­‐1	  also	  increased	  the	  rate	  of	  tPA	  endocytosis.	  
In	  this	  chapter,	  I	  investigated	  endocytosis	  of	  TIMP-­‐3	  in	  complex	  with	  various	  
MMPs	  and	  ADAMTSs.	  The	  aim	  of	  these	  experiments	  is	  to	  determine	  whether	  TIMP-­‐3	  
can	  be	   internalized	  only	   in	  a	   free	   form	  or	  also	   in	  complex	  with	   its	   target	  enzymes,	  
and	   also	   to	   determine	  whether	   TIMP-­‐3	   can	   promote	   the	   endocytosis	   of	   its	   target	  
enzymes	  in	  a	  similar	  way	  to	  that	  reported	  for	  PAI-­‐1.	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6.2 TIMP-­‐3	  is	  internalized	  in	  a	  free	  form	  
Cultured	  HTB94	  cells	  release	  a	  variety	  of	  metalloproteinases,	  and	  we	  considered	  that	  
[35S]TIMP-­‐3	  may	  be	  endocytosed	  in	  complex	  with	  these	  enzymes.	  To	  investigate	  this	  
possibility,	  we	   examined	   endocytosis	   of	   [35S]TIMP-­‐3	   in	   the	   presence	   of	   the	   broad-­‐
spectrum	   metalloproteinase	   inhibitor	   GM6001,	   which	   would	   block	   interaction	   of	  
[35S]TIMP-­‐3	  	  with	  such	  metalloproteinases	  released	  by	  HTB94	  cells.	  
HTB94	  cells	  were	  plated	  at	  a	  density	  of	  1x106	  cells/well	  and	  grown	  overnight	  
before	   incubation	   with	   DMEM	   containing	   0.1	   %	   FCS	   supplemented	   with	   10	   μM	  
GM6001	   for	   1	   h	   at	   37	   °C.	   Next,	   1	   nM	   [35S]TIMP-­‐3	   was	   added	   and	   radioactivity	  
distribution	   among	   the	   TCA-­‐insoluble,	   TCA-­‐soluble	   and	   cell-­‐associated	   fractions	  
monitored	  over	  24	  h.	  TCA-­‐insoluble	  [35S]TIMP-­‐3	  decreased	  both	  in	  the	  presence	  and	  
in	   the	   absence	   of	   GM6001	   with	   similar	   kinetics,	   and	   the	   TCA-­‐soluble	   and	   cell-­‐
associated	   radioactivity	   also	   followed	   similar	   kinetics	   (Figure	   40).	   These	   results	  
suggest	   that	   TIMP-­‐3	   can	   be	   internalized	   in	   a	   free	   form	   by	   HTB94	   cells,	   without	  
formation	  of	  a	  complex	  with	  metalloproteinases.	  
	  
Figure	  40,	  Effect	  of	  GM6001	  on	  [35S]TIMP-­‐3	  internalization	  
[35S]TIMP-­‐3	   (1	   nM)	   was	   added	   to	   HTB94	   cells	   (0	   to	   24	   h)	   in	   the	   absence	   (black	  
symbols	   and	   lines)	   or	   presence	   (red	   symbols	   and	   lines)	   of	   10	   μM	   GM6001,	   and	  
radioactivity	   in	   the	   cell-­‐associated,	   and	   TCA-­‐soluble	   and	   TCA-­‐insoluble	   fractions	   of	  
the	  conditioned	  media	  quantified	  by	  scintillation	  counting	  (n=3).	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6.2.1 TIMP-­‐3	  binds	  directly	  to	  LRP-­‐1	  
To	  confirm	  that	  TIMP-­‐3	  could	  directly	  bind	  to	  LRP-­‐1,	  I	  measured	  binding	  of	  TIMP-­‐3	  to	  
immobilized	   sLRP-­‐1	   purified	   from	  plasma	  by	   ELISA.	  As	   shown	   in	   Figure	   41,	   TIMP-­‐3	  
bound	  readily	  to	  LRP-­‐1,	  compared	  to	  control	  wells.	  Heparin	  is	  reported	  to	  antagonize	  
the	  binding	  of	  different	  LRP-­‐1	  ligands	  to	  LRP-­‐1,	  including	  lipoprotein	  lipase	  (Williams	  
et	  al.,	  1994),	  α2M	  (Arandjelovic	  et	  al.,	  2005),	  and	  PAI-­‐1	  (Stefansson	  et	  al.,	  1998).	  To	  
test	  whether	   or	   not	   this	  was	   also	   the	   case	   for	   TIMP-­‐3,	   I	   incubated	   TIMP-­‐3	   (0.1-­‐20	  
nM)	  with	  100	  μg/ml	  heparin	  before	  adding	  it	  to	  the	  sLRP-­‐1	  coated	  wells.	  Upon	  pre-­‐
incubation	  with	  heparin,	  binding	  of	  TIMP-­‐3	  to	  LRP-­‐1	  was	  completely	  abolished.	  
	  
	  
Figure	  41,	  Interaction	  of	  TIMP-­‐3	  with	  sLRP-­‐1	  measured	  by	  ELISA	  
Shed	   LRP-­‐1	   purified	   from	   human	   plasma	   was	   coated	   onto	   microtitre	   plates	   and	  
binding	  of	  TIMP-­‐3	  (0.1	  –	  20	  nM)	   in	  the	  absence	  (●)	  and	  presence	  (■)	  of	  100	  μg/ml	  
heparin	   was	   measured	   using	   an	   M2	   anti-­‐FLAG	   antibody	   and	   a	   HRP-­‐conjugated	  
secondary	  antibody.	  Control	  wells	  (▲)	  were	  not	  coated	  with	  sLRP.	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6.3 Effect	   of	   complex	   formation	   with	   prototypic	   metzincins	  
on	  TIMP-­‐3	  endocytosis	  	  
6.3.1 Formation	   of	   a	   complex	   with	   ADAMTS4-­‐2	   or	   ADAMTS5-­‐2	   does	  
not	  affect	  TIMP-­‐3	  endocytosis	  
ADAMTS4-­‐2	   is	   a	   C-­‐terminal	   spacer	   domain	   truncated	   form	   of	   ADAMTS-­‐4,	   and	  
ADAMTS5-­‐2	   is	   a	   truncated	   form	   of	   ADAMTS-­‐5	   that	   lacks	   of	   the	   C-­‐terminal	   TS-­‐2	  
domain	   (Gendron	   et	   al.,	   2007;	   Kashiwagi	   et	   al.,	   2004).	   To	   investigate	   whether	  
formation	   of	   a	   complex	   with	   these	   proteinases	   had	   an	   effect	   on	   TIMP-­‐3	  
internalization,	   [35S]TIMP-­‐3—ADAMTS4-­‐2	   or	   [35S]TIMP-­‐3—ADAMTS5-­‐2	   complexes	  
were	  made	   in	   vitro	   by	   incubating	   10	   nM	   ADAMTS4-­‐2	   or	   ADAMTS5-­‐2	   with	   10	   nM	  
[35S]TIMP-­‐3	   for	   1	   h	   at	   37	   °C.	   Either	   [35S]TIMP-­‐3—ADAMTS4-­‐2	   or	   [35S]TIMP-­‐3—
ADAMTS5-­‐2	  was	  added	  to	  HTB94	  cells	  plated	  in	  a	  6-­‐well	  plate	   in	  DMEM	  containing	  
0.1	   %	   FCS,	   and	   the	   distribution	   of	   radioactivity	   among	   the	   cell	   fractions	   was	  
monitored	   over	   24	   h.	   The	   decrease	   in	   TCA-­‐insoluble	   radioactivity	   of	   [35S]TIMP-­‐3—
ADAMTS4-­‐2	   or	   [35S]TIMP-­‐3—ADAMTS5-­‐2	   wells	   was	   similar	   to	   that	   of	   [35S]TIMP-­‐3	  
alone	  (Figure	  42).	  These	  data	  suggest	  that	  the	  formation	  of	  a	  complex	  with	  ADAMTS-­‐
4	  or	  ADAMTS-­‐5	  has	  no	  effect	  on	  the	  rate	  of	  [35S]TIMP-­‐3	  endocytosis.	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Figure	  42,	  Internalization	  of	  [35S]TIMP-­‐3—ADAMTS4-­‐2	  and	  [35S]TIMP-­‐3—ADAMTS5-­‐
2	  complexes	  
[35S]TIMP-­‐3	  (10	  nM)	  was	  incubated	  in	  vitro	  with	  ADAMTS4-­‐2	  or	  ADAMTS5-­‐2(10	  nM,	  1	  
h,	  37	  °C)	  and	  either	  [35S]TIMP-­‐3—ADAMTS4-­‐2	  or	  [35S]TIMP-­‐3—ADAMTS5-­‐2	  complex	  
added	   to	   HTB94	   cells.	   At	   the	   indicated	   time	   points,	   the	   conditioned	  medium	  was	  
harvested	   and	   precipitated	   with	   TCA	   (5	   %).	   Radioactivity	   in	   the	   TCA-­‐insoluble	  
fraction	   of	   [35S]TIMP-­‐3—ADAMTS4-­‐2	   (red	   symbols)	   or	   [35S]TIMP-­‐3—ADAMTS5-­‐2	  
(blue	   symbols)	  was	  measured	   and	   compared	   to	   that	   of	   [35S]TIMP-­‐3	   supplemented	  
controls	  (open	  symbols,	  dotted	  line)	  (n=3).	  
	  
6.3.2 Formation	  of	  TIMP-­‐3—MMP-­‐1	  complexes	  does	  not	  affect	  TIMP-­‐3	  
endocytosis	  
To	   investigate	   whether	   complex	   formation	   with	   MMP-­‐1	   had	   an	   effect	   on	   TIMP-­‐3	  
endocytosis,	   [35S]TIMP-­‐3—MMP-­‐1	  complex	  was	  generated	   in	  vitro	  by	   incubating	  10	  
nM	   of	   MMP-­‐1	   with	   10	   nM	   [35S]TIMP-­‐3	   for	   1	   h	   at	   37	   °C.	   Mantuano	   et	   al.	   (2008)	  
reported	  that	  MMP-­‐9	  interacts	  with	  LRP-­‐1	  by	   its	  hemopexin	  domain.	  Thus,	  we	  also	  
made	  a	  complex	  of	  [35S]TIMP-­‐3	  with	  the	  catalytic	  domain	  of	  MMP-­‐1	  (MMP-­‐1	  ΔC),	  in	  
a	  similar	  manner	  as	  for	  full	   length	  MMP-­‐1,	  to	  evaluate	  the	  effect	  of	  the	  hemopexin	  
domain	   of	   MMP-­‐1	   in	   this	   process.	   Either	   [35S]TIMP-­‐3—MMP-­‐1	   or	   [35S]TIMP-­‐3—
MMP-­‐1	   ΔC	   complex	   was	   added	   to	   HTB94	   cells	   and	   radioactivity	   in	   TCA-­‐insoluble	  
fraction	   followed	   over	   24	   h.	   The	   decrease	   in	   TCA-­‐insoluble	   radioactivity	   in	   cells	  
treated	  with	  [35S]TIMP-­‐3—MMP-­‐1	  or	  [35S]TIMP-­‐3—MMP-­‐1	  ΔC	  complex	  had	  the	  same	  
kinetics	  as	  that	  of	  [35S]TIMP-­‐3,	  suggesting	  that	  the	  formation	  of	  a	  complex	  between	  
TIMP-­‐3	  and	  MMP-­‐1	  does	  not	  affect	  TIMP-­‐3	  internalization,	  and	  that	  the	  hemopexin	  
domain	  of	  MMP-­‐1	  does	  not	  alter	  this	  process.	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Figure	   43,	   Effect	   of	   a	   MMP-­‐1	   and	   MMP-­‐1ΔC	   complex	   formation	   on	   [35S]TIMP-­‐3	  
endocytosis	  
[35S]TIMP-­‐3	  (10	  nM)	  was	  complexed	  in	  vitro	  with	  MMP-­‐1	  or	  MMP-­‐1	  ΔC	  (10	  nM,	  1	  h,	  
37	   °C)	   prior	   to	   being	   added	   to	   HTB94	   cells.	   At	   the	   indicated	   time	   points,	   the	  
conditioned	   medium	   was	   harvested	   and	   precipitated	   with	   TCA	   (5	   %),	   and	  
radioactivity	  in	  the	  TCA-­‐insoluble	  fraction	  of	  [35S]TIMP-­‐3—MMP-­‐1	  treated	  cells	  (red	  
symbols)	  and	  [35S]TIMP-­‐3—MMP-­‐1	  ΔC	  treated	  cells	  (blue	  symbols)	  was	  compared	  to	  
that	  of	  [35S]TIMP-­‐3	  treated	  cells	  (open	  symbols	  and	  dotted	  lines)	  (n=3).	  
	  
6.3.3 MMP-­‐1	  is	  internalized	  in	  complex	  with	  TIMP-­‐3	  
Our	   laboratory	   has	   recently	   shown	   that	   ADAMTS-­‐5	   and	   ADAMTS-­‐4	   can	   be	  
internalized	   by	   LRP-­‐1	   independently	   from	   TIMP-­‐3.	   Both	   enzymes	   have	   the	   LRP-­‐1	  
binding	   determinants	   and	  we	   found	   that	   they	   directly	   interact	  with	   LRP-­‐1	   in	   vitro	  
(Yamamoto	   et	   al.,	   submitted;	   Owen	   and	   Nagase,	   unpublished	   observations).	   I	  
investigated	   whether	   MMP-­‐1	   itself	   could	   be	   endocytosed.	   HTB94	   cells	   were	  
incubated	  with	  10	  nM	  [35S]MMP-­‐1	  at	  37	  °C	  for	  24	  h,	  and	  at	  the	  indicated	  time	  points,	  
medium	  was	  harvested	  and	  precipitated	  with	  TCA	  (5	  %).	  Radioactivity	  present	  in	  the	  
cell	   fractions	   was	   measured.	   As	   shown	   in	   Figure	   44A,	   TCA-­‐insoluble	   radioactivity	  
decreased	  and	  TCA-­‐soluble	  and	  cell-­‐associated	  radioactivity	  increased	  over	  24	  h,	  but	  
with	  a	  slower	  kinetics	  compared	  to	  that	  of	  TIMP-­‐3.	  This	  data	  suggest	  that	  although	  
[35S]MMP-­‐1	  is	  internalized	  by	  HTB94	  cells,	  the	  mechanism	  of	  internalization	  may	  be	  
different	  from	  that	  of	  TIMP-­‐3.	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When	  [35S]MMP-­‐1	  was	  in	  a	  [35S]MMP-­‐1—TIMP-­‐3	  complex,	  its	  internalization	  
showed	  similar	  kinetics	  as	  that	  of	  TIMP-­‐3	  alone	  (Figure	  44B).	  To	  investigate	  whether	  
MMP-­‐1	  can	  be	   internalized	   in	  a	   free	   form	  not	  complexed	  with	  TIMP-­‐3,	   I	   incubated	  
[35S]MMP-­‐1	  with	  HTB94	  cells	  at	  37	  °C	  for	  24	  h	  in	  the	  presence	  of	  10	  	  μM	  GM6001,	  to	  
inhibit	   binding	   of	   [35S]MMP-­‐1	   with	   endogenous	   TIMP-­‐3.	   In	   these	   conditions,	  
radioactivity	   in	   the	  TCA-­‐insoluble	   fraction	  minimally	  decreased,	  and	  radioactivity	   in	  
the	   TCA-­‐soluble	   and	   cell-­‐associated	   fractions	   also	   minimally	   increased	   over	   24	   h,	  
suggesting	   that	  MMP-­‐1	  can	  be	   internalized	  only	  efficiently	   in	  complex	  with	  TIMP-­‐3	  
and	  not	  as	  a	  free	  enzyme	  (Figure	  44C).	  
	  
Figure	   44,	  MMP-­‐1	   is	  minimally	   internalized	   by	   HTB94	   cells,	   but	   it	   is	   taken	   up	   in	  
complex	  with	  TIMP-­‐3	  
10	  nM	  [35S]MMP-­‐1	  was	  added	  to	  HTB94	  cells	  in	  a	  6-­‐well	  plate	  either	  alone	  (A)	  or	  in	  
complex	  with	   TIMP-­‐3	   (B)	   or	   in	   the	  presence	  of	  GM6001	   (C).	   At	   the	   indicated	   time	  
points,	   the	   medium	   was	   harvested	   and	   precipitated	   with	   TCA	   (5	   %),	   and	   cells	  
collected	  with	  1	  ml	  of	  NaOH	   (1	  N).	  Radioactivity	   in	  TCA-­‐insoluble,	   TCA-­‐soluble	  and	  
cell-­‐associated	   fractions	  was	  measured	   (this	   result	   is	   representative	   of	   2	   separate	  
experiments).	   D,	   Comparison	   of	   the	   radioactivity	   decrease	   in	   the	   TCA-­‐insoluble	  
fraction	   of	   [35S]MMP-­‐1	   treated	   cells,	   [35S]MMP-­‐1—TIMP-­‐3	   treated	   cells	   and	  
[35S]MMP-­‐1	  treated	  cells	  in	  the	  presence	  of	  GM6001.	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6.3.4 MMP-­‐1	  does	  not	  interact	  with	  LRP-­‐1	  
To	   investigate	  whether	  MMP-­‐1	  can	  directly	  bind	  to	  LRP-­‐1	  or	  only	  when	   in	  complex	  
with	  TIMP-­‐3,	  an	  ELISA	  was	  performed.	  MMP-­‐1-­‐FLAG	  (0.1-­‐40	  nM)	  was	  added	  to	  sLRP-­‐
1	   purified	   from	   plasma,	   which	   was	   previously	   immobilized	   onto	   microtitre	   wells.	  
Binding	  was	  measured	  by	  an	  M2	  anti-­‐FLAG	  primary	  antibody	  and	  an	  HRP-­‐conjugated	  
anti-­‐mouse	   secondary	   antibody.	   TIMP-­‐3-­‐FLAG	   (0.1-­‐40	   nM)	   was	   added	   to	   control	  
wells	  and	  binding	  measured	  in	  a	  similar	  manner.	  Compared	  to	  TIMP-­‐3,	  which	  clearly	  
bound	  to	  sLRP-­‐1,	  MMP-­‐1	  did	  not	  show	  any	  binding	  to	  the	  receptor	  (Figure	  45).	  
	  
Figure	  45,	  MMP-­‐1	  does	  not	  bind	  to	  LRP-­‐1.	  
Shed	   LRP-­‐1	   purified	   from	   human	   plasma	   was	   coated	   onto	   microtitre	   plates	   and	  
binding	  of	  TIMP-­‐3-­‐FLAG	  (0.1	  –	  20	  nM)	  (▲)	  and	  MMP-­‐1-­‐FLAG	  (0.1	  –	  20	  nM)	  (●)	  was	  
measured	   using	   an	   M2	   anti-­‐FLAG	   antibody	   and	   an	   HRP-­‐conjugate	   secondary	  
antibody.	  	  
6.3.5 TIMP-­‐3	  bridges	  MMP-­‐1	  to	  LRP-­‐1	  
In	   section	   6.3.3	   I	   showed	   that	   MMP-­‐1	   internalization	   by	   HTB94	   cells	   is	   increased	  
upon	   formation	  of	   a	   complex	  with	  TIMP-­‐3.	   To	  demonstrate	   that	   this	   is	   due	   to	   the	  
TIMP-­‐3	   capability	   of	   mediating	   the	   interaction	   between	   MMP-­‐1	   and	   LRP-­‐1,	   I	  
measured	  the	  binding	  of	  MMP-­‐1	  to	  immobilized	  sLRP-­‐1	  in	  the	  presence	  and	  absence	  
of	   TIMP-­‐3.	   Two	   different	   approaches	   were	   used.	   TIMP-­‐3-­‐FLAG	   (40	   nM)	   was	  
immobilized	  onto	  sLRP-­‐1	  coated	  microtitre	  plates.	  Then,	  either	  (i)	  biotinylated	  MMP-­‐
1	   (E200A)	   (0.1-­‐40	   nM)	  was	   added	   to	  wells	   and	   binding	   detected	   by	   incubation	   of	  
wells	  with	  HRP-­‐conjugated	  streptavidin	  (Figure	  46A),	  or	  (ii)	  MMP-­‐1-­‐FLAG	  (0.1-­‐40	  nM)	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was	   added	   and	   binding	   detected	   with	   an	   anti-­‐MMP-­‐1	   antibody	   and	   then	   with	   an	  
anti-­‐sheep	   secondary	   antibody	   conjugated	   with	   HRP	   (Figure	   46B).	   In	   both	   cases,	  
MMP-­‐1	  bound	  to	  sLRP-­‐1	  only	  in	  the	  presence	  of	  TIMP-­‐3,	  suggesting	  that	  the	  inhibitor	  
can	  bridge	  enzyme	  and	  receptor	  and	  mediate	  the	  LRP-­‐1-­‐dependent	  internalization	  of	  
MMP-­‐1.	  
	  
Figure	  46,	  TIMP-­‐3	  mediates	  binding	  of	  MMP-­‐1	  to	  LRP-­‐1.	  
Shed	  LRP-­‐1	  was	  coated	  onto	  microtitre	  plates	  and	  incubated	  with	  TIMP-­‐3-­‐FLAG	  (40	  
nM)	  at	  37	  °C	  for	  2h.	  Then,	  (A)	  biotinylated	  MMP-­‐1	  E200A	  (0.1	  –	  40	  nM)	  was	  added	  to	  
sLRP-­‐1	   coated	   wells	   and	   binding	   detected	   by	   HRP-­‐conjugated	   streptavidin	   (■).	  
Control	  wells	  were	   either	   not	   incubated	  with	   TIMP-­‐3-­‐FLAG	   (●)	   or	   not	   coated	  with	  
sLRP-­‐1	  and	  incubated	  with	  TIMP-­‐3	  (▲).	  Alternatively,	  (B)	  FLAG-­‐tagged	  MMP-­‐1	  (0.1	  –	  
40	  nM)	  was	  added	  to	  sLRP-­‐1	  coated	  wells	  and	  binding	  detected	  by	  an	  anti-­‐MMP-­‐1	  
and	   anti-­‐sheep	   HRP-­‐conjugated	   antibody	   (■).	   Control	   wells	   were	   either	   not	  
incubated	  with	  TIMP-­‐3-­‐FLAG	  (●)	  or	  not	  coated	  with	  sLRP-­‐1	  and	  incubated	  with	  TIMP-­‐
3	  (▲).	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6.4 Effect	  of	  other	  MMPs	  on	  TIMP-­‐3	  endocytosis	  
To	  test	  whether	  TIMP-­‐3	  could	  also	  be	  endocytosed	  in	  complex	  with	  classes	  of	  MMPs	  
other	   than	   collagenases,	   such	   as	   stromelysins	   and	   membrane-­‐type	  
metalloproteinases,	   a	   complex	   of	   [35S]TIMP-­‐3	  with	   the	   catalytic	   domain	   of	  MMP-­‐3	  
and	  MMP-­‐14	  was	  made	  in	  vitro.	  10	  nM	  of	  MMP-­‐3	  ΔC	  or	  MMP-­‐14	  ΔC	  was	  incubated	  
with	   [35S]TIMP-­‐3	   (10	   nM)	   for	   1	   h	   at	   37	   °C.	   Resultant	   [35S]TIMP-­‐3—MMP-­‐3	   ΔC	   or	  
[35S]TIMP-­‐3—MMP-­‐14	   ΔC	   complex	   was	   added	   to	   HTB94	   cells	   in	   a	   6-­‐well	   plate	   in	  
DMEM	   containing	   0.1	   %	   FCS,	   and	   radioactivity	   in	   the	   TCA-­‐insoluble	   fraction	   was	  
monitored	   over	   24	   h.	   As	   shown	   in	   Figure	   47,	   in	   both	   cases,	   the	   TCA-­‐insoluble	  
radioactivity	   of	   [35S]TIMP-­‐3-­‐enzyme	   samples	   decreased	   with	   similar	   kinetics	   as	  
[35S]TIMP-­‐3	   alone,	   indicating	   that	   the	   formation	   of	   a	   complex	   with	   these	  
metalloproteinases	  does	  not	  affect	  TIMP-­‐3	  endocytosis.	  
	  
Figure	  47,	  Effect	  of	  MMP-­‐3	  ΔC	  or	  MMP-­‐14	  ΔC	  on	  [35S]TIMP-­‐3	  endocytosis	  
10	  nM	  [35S]TIMP-­‐3	  was	  incubated	  with	  MMP-­‐3	  ΔC	  (red	  symbols)	  or	  MMP-­‐14	  ΔC	  (blue	  
symbols)	  (10	  nM,	  1	  h,	  37	  °C),	  and	  the	  complex	  then	  added	  to	  HTB94	  cells	  for	  up	  to	  24	  
h.	   At	   the	   indicated	   time	   points,	   the	   conditioned	   medium	   was	   harvested,	   and	  
radioactivity	   in	   the	   TCA-­‐insoluble	   fraction	   compared	   to	   that	   of	   [35S]TIMP-­‐3	   alone	  
(open	  symbols,	  dotted	  line),	  data	  for	  [35S]TIMP-­‐3	  are	  from	  Figure	  43)	  
	  
6.5 Discussion	  
As	   discussed	   in	   the	   Introduction,	   LRP-­‐1	   can	   mediate	   the	   cellular	   uptake	   of	  
metalloproteinases	   and	   TIMPs,	   thus	   regulating	   their	   levels	   in	   the	   tissue	   and	  
controlling	  biological	  processes,	  including	  cell	  migration.	  MMP-­‐2,	  MMP-­‐9	  and	  MMP-­‐
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13	  contain	  binding	  determinants	  for	  LRP-­‐1,	  therefore	  they	  can	  interact	  directly	  with	  
the	  receptor.	  It	  is	  reported	  that	  MMP-­‐2	  and	  MMP-­‐9	  can	  also	  be	  internalized	  by	  LRP-­‐1	  
when	  in	  complex	  with	  their	  endogenous	   inhibitor	  TIMP-­‐2	  and	  TIMP-­‐1,	  respectively.	  
Interestingly,	   while	   TIMP-­‐2	   also	   harbors	   a	   binding	   site	   for	   LRP-­‐1	   and	   it	   can	   be	  
internalized	  without	  MMP-­‐2,	  TIMP-­‐1	  does	  not	  bind	  to	  LRP-­‐1	  when	  in	  a	  free	  form	  and	  
it	   can	   be	   taken	   up	   only	   in	   complex	   with	   MMP-­‐9.	   In	   this	   chapter,	   I	   investigated	  
whether	  TIMP-­‐3	  can	  be	  internalized	  in	  a	  free	  form	  and/or	  in	  a	  complex	  with	  its	  target	  
metalloproteinases.	   To	   answer	   this	   question,	   I	   firstly	   used	   the	   hydroxamate-­‐based	  
inhibitor	  of	  metalloproteinases,	  GM6001,	  which	  did	  not	  inhibit	  the	  internalization	  of	  
TIMP-­‐3	   indicating	   that	   TIMP-­‐3	   does	   not	   require	   formation	   of	   a	   complex	   with	  
secreted	  metalloproteinases	   to	   be	   internalized.	   Secondly,	   I	   confirmed	   that	   TIMP-­‐3	  
harbors	  the	  binding	  determinants	  for	  LRP-­‐1	  by	  detecting	  direct	  binding	  of	  TIMP-­‐3	  to	  
LRP-­‐1	   in	  vitro.	  These	  results	  suggested	  that	  TIMP-­‐3	  endocytosis	   is	  a	  way	  to	  control	  
levels	   of	   this	   inhibitor	   in	   the	   extracellular	   environment.	   Therefore,	   TIMP-­‐3	  
endocytosis	  may	   protect	   tissues	   from	   accumulation	   of	   an	   excess	   of	   free	   inhibitor,	  
which	  may	   be	   detrimental	   as	   it	   induces	   cellular	   apoptosis.	   On	   the	   other	   hand,	   in	  
response	   to	   specific	   stimuli,	   the	   cell	   can	   increase	   levels	   of	   TIMP-­‐3	   in	   the	   tissue	  by	  
blocking	   its	   endocytosis.	   The	   activation	   of	   sheddases	   that	   cleave	   LRP-­‐1	   may	   be	   a	  
potential	   mechanism	   for	   reducing	   endocytosis.	   Tissue	   levels	   of	   TIMP-­‐3	   may	   be	  
regulated	   by	   controlling	   the	   cycle	   of	   secretion/endocytosis	   of	   the	   inhibitor.	   This	  
process,	  which	  would	  be	  energetically	   expensive	   for	   the	   cell,	  may	  be	  explained	  by	  
the	  fact	  that	  it	  enables	  cells	  to	  respond	  more	  rapidly	  to	  specific	  stimuli,	  rather	  than	  
synthesizing	  TIMP-­‐3	  de	  novo.	  	  	  	  
As	  discussed	  in	  the	  Chapter	  5,	  highly	  sulfated	  GAGs	  inhibit	  the	  internalization	  
of	  TIMP-­‐3	  and	  this	  is	  not	  due	  to	  the	  involvement	  of	  HSPGs	  or	  CSPGs	  in	  the	  endocytic	  
machinery.	   Several	   LRP-­‐1	   ligands,	   including	   ApoE	   (Lalazar	   et	   al.,	   1988),	   RAP	  
(Migliorini	  et	  al.,	  2003),	  lipoprotein	  lipase	  (Williams	  et	  al.,	  1994),	  PAI-­‐1	  (Rodenburg	  et	  
al.,	   1998;	   Stefansson	   et	   al.,	   1998)	   and	   α2-­‐macroglobulin—protease	   complexes	  
(Arandjelovic	  et	  al.,	  2005;	  Dolmer	  and	  Gettins,	  2006)	  are	   reported	   to	   interact	  with	  
the	   receptor	   through	   clusters	   of	   positively	   charged	   arginine	   and	   lysine	   residues.	  
Heparin	  has	  been	   shown	   to	  directly	   inhibit	   interaction	  of	   some	  of	   these	   ligands	   to	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LRP-­‐1.	   In	   this	  chapter,	   I	   verified	   that	  heparin	  could	  also	  block	   the	  direct	  binding	  of	  
TIMP-­‐3	  to	  LRP-­‐1,	  shedding	  light	  on	  the	  mechanism	  underlying	  the	  inhibition	  of	  TIMP-­‐
3	  endocytosis	  by	  highly	  sulfated	  GAGs.	  Lee	  et	  al.	   identified	  a	  cluster	  of	   lysines	  and	  
arginines	   residues	   involved	   in	   TIMP-­‐3	   binding	   to	   the	   ECM	   (Lee	   et	   al.,	   2007).	   I	  
speculate	   that	   the	   determinants	   for	   LRP-­‐1	   binding	   are	   located	   in	   this	   cluster	   of	  
positively	   charged	   residues	   on	   the	   TIMP-­‐3	  molecule,	   overlapping	  with	   the	   binding	  
site	  for	  GAGs.	  Our	  laboratory	  plans	  to	  determine	  which	  of	  these	  individual	  residues	  
is	  involved	  in	  the	  TIMP-­‐3-­‐LRP-­‐1	  interaction	  by	  site-­‐directed	  mutagenesis.	  	  
It	   is	   reported	   that	   tPA	   and	   uPA	   are	   endocytosed	   by	   LRP-­‐1	   only	   when	   in	  
complex	  with	   PAI-­‐1.	   PAI-­‐1	   interacts	   directly	  with	   LRP-­‐1,	   forming	   a	   bridge	   between	  
the	   receptor	   and	   these	   proteases.	   Thus,	   I	   investigated	   whether	   TIMP-­‐3	   could	  
mediate	   the	   LRP-­‐1-­‐dependent	   uptake	   of	   metalloproteinases	   that	   do	   not	   directly	  
interact	  with	  the	  receptor.	  Differently	  from	  ADAMTS-­‐4	  and	  -­‐5,	  which	  are	  two	  LRP-­‐1	  
ligands	   (Yamamoto	   et	   al.;	   Owen	   and	   Nagase,	   unpublished	   obsarvations),	   MMP-­‐1	  
showed	  no	  affinity	   for	   LRP-­‐1	   in	  vitro.	  However,	  when	  MMP-­‐1	  was	   in	  complex	  with	  
TIMP-­‐3,	   it	   was	   internalized	   with	   similar	   kinetics	   to	   the	   free	   inhibitor.	   TIMP-­‐3	   was	  
shown	   to	  bridge	  binding	  of	   the	  enzyme	   to	  LRP-­‐1	  and	   to	  mediate	   its	   scavenging	  by	  
cells.	  In	  this	  manner,	  TIMP-­‐3	  not	  only	  inactivates	  its	  target	  metalloproteinases	  in	  the	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7.1 LRP-­‐1	  is	  the	  major	  receptor	  for	  TIMP-­‐3	  endocytosis	  
Studies	  in	  Timp3-­‐/-­‐	  mice	  have	  reported	  the	  crucial	  role	  of	  this	  inhibitor	  in	  maintaining	  
tissue	  homeostasis	  by	   regulating	   the	  activity	  of	  several	  metalloproteinases	   (Fata	  et	  
al.,	  2001;	  Fedak	  et	  al.,	  2004;	  Mohammed	  et	  al.,	  2004;	  Sahebjam	  et	  al.,	  2007).	  TIMP-­‐3	  
has	   a	   protective	   role	   in	   pathological	   conditions	   characterized	   by	   enhanced	   ECM	  
degradation,	   inflammation,	   cell	   growth	   and	   migration,	   including	   arthritis,	  
atherosclerosis	  and	  cancer	  (Ahonen	  et	  al.,	  1998;	  Baker	  et	  al.,	  1999;	  Cardellini	  et	  al.,	  
2009;	   Casagrande	   et	   al.,	   2012;	   Cruz-­‐Munoz	   et	   al.,	   2006a;	   Gendron	   et	   al.,	   2003).	  
Therefore,	   there	   is	   an	   increasing	   interest	   in	   understanding	   the	   mechanisms	   that	  
regulate	   levels	   of	   TIMP-­‐3	   in	   the	   tissue.	   TIMP-­‐3	   expression	   can	   be	   regulated	   at	  
different	   levels	   by	   different	   factors:	   (i)	   transcriptionally,	   by	   cytokines	   and	   growth	  
factors,	   including	  TGF-­‐β	  and	  oncostatin	  M	  (Li	  et	  al.,	  2001;	  Qureshi	  et	  al.,	  2005);	   (ii)	  
post-­‐transcriptionally,	  due	  to	   the	  action	  of	  a	  number	  of	  micro	  RNAs	   including	  miR-­‐
21,	  miR-­‐221,	  miR-­‐222,	  miR181b	  and	  miR206	   (Gabriely	   et	   al.,	   2008;	  Garofalo	  et	   al.,	  
2009;	   Limana	   et	   al.,	   2011;	   Song	   et	   al.,	   2010;	   Wang	   et	   al.,	   2010);	   and	   (iii)	  
epigenetically	   by	   histone	   deacetylases	   and	   promoter	   methylation	   (Anania	   et	   al.,	  
2011;	  Cardellini	  et	  al.,	  2009).	  Furthermore,	  my	  study	  has	  revealed	  a	  new	  mechanism	  
for	  regulating	  levels	  of	  TIMP-­‐3	  in	  the	  extracellular	  space.	  	  
	   In	  2008,	  Troeberg	  et	  al.	  reported	  the	  first	  evidence	  that	  TIMP-­‐3	  levels	  in	  the	  
extracellular	  space	  can	  be	  post-­‐translationally	  regulated	  by	  endocytosis,	  with	  TIMP-­‐3	  
accumulating	   in	   the	   conditioned	   medium	   of	   chondrocytes	   and	   chondrosarcoma	  
HTB94	   cells	   in	   the	   presence	   of	   RAP.	   I	   investigated	   the	   mechanism	   of	   TIMP-­‐3	  
endocytosis	  using	  three	  different	  approaches:	  immunoblotting,	  confocal	  microscopy	  
and	   purified	   [35S]radiolabeled	   TIMP-­‐3.	   By	   following	   the	   distribution	   of	   purified	  
[35S]radiolabeled	   TIMP-­‐3	   among	   cell	   fractions	   after	   its	   exogenous	   addition	   to	  
cultured	   cells,	   I	   could	   investigate	   the	   kinetics	   of	   TIMP-­‐3	   endocytosis.	   This	  
methodology	  also	  allowed	  me	  to	  discover	  that	  TIMP-­‐3	  is	  degraded	  by	  cells	  after	   its	  
endocytosis,	   with	   fragments	   released	   into	   the	   conditioned	  medium.	   I	   investigated	  
the	  kinetics	  of	  endocytosis	  and	  degradation	  of	  [35S]TIMP-­‐3	  by	  LRP-­‐1-­‐deficient	  PEA-­‐13	  
mouse	   fibroblasts.	   These	   cells	   represent	   a	  widely	  used	  model	   for	   investigating	   the	  
involvement	  of	  LRP-­‐1	   in	  diverse	  cell	  processes,	   including	  endocytosis	  and	  signalling	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(Willnow	  and	  Herz,	  1994).	  TIMP-­‐3	  endocytosis	  was	  clearly	  reduced	  in	  LRP-­‐1-­‐deficient	  
PEA-­‐13	   cells	   compared	   to	   wild-­‐type	   cells,	   indicating	   that	   LRP-­‐1	   is	   the	   major	  
component	   of	   TIMP-­‐3	   endocytic	   machinery.	   RAP	   did	   not	   further	   decrease	   the	  
residual	  internalization	  of	  the	  TIMP-­‐3	  by	  PEA-­‐13	  cells,	  indicating	  that	  among	  the	  LDL	  
receptor	  family,	  LRP-­‐1	  is	  the	  only	  one	  involved	  in	  this	  process.	  
7.2 The	  LRP-­‐1/sLRP-­‐1	  ratio	  regulates	  levels	  of	  TIMP-­‐3	  in	  the	  
tissue	  
I	  compared	  the	  kinetics	  of	  TIMP-­‐3	  endocytosis	  by	  a	  number	  of	  cell	   types,	   including	  
chondrosarcoma	  cells,	  porcine	  articular	  chondrocytes,	  fibroblasts	  and	  monocyte-­‐like	  
THP-­‐1	  cells.	  In	  all	  cases,	  the	  rate	  of	  TIMP-­‐3	  endocytosis	  was	  not	  constant	  over	  time.	  
TIMP-­‐3	  endocytosis	  was	   initially	   rapid,	   then	  slowing	  down	   to	   reach	  a	  plateau	  after	  
around	   10	   h,	   after	   which	   only	   a	   minimal	   amount	   of	   TIMP-­‐3	   was	   internalized.	   I	  
investigated	  the	  causes	  of	  this	  decrease	   in	  endocytosis	  and	  demonstrated	  that	   it	   is	  
due	   to	   the	   interaction	   of	   TIMP-­‐3	   with	   a	   soluble	   form	   of	   LRP-­‐1,	   generated	   by	  
proteolytic	  shedding	  of	  the	  transmembrane	  receptor.	  Shedding	  is	  an	  important	  way	  
of	   regulating	   concentrations	   of	   LRP-­‐1	   on	   the	   cell	   surface.	   A	   number	   of	   sheddases	  
have	  been	  reported	  to	  release	  the	  ectodomain	  of	  LRP-­‐1,	  including	  ADAM-­‐10,	  ADAM-­‐
12,	   ADAM-­‐17	   and	   BACE	   (Gorovoy	   et	   al.,	   2010;	   Liu	   et	   al.,	   2009;	   Polavarapu	   et	   al.,	  
2007;	  Rozanov	  et	  al.,	  2004;	  Selvais	  et	  al.,	  2009;	  von	  Arnim	  et	  al.,	  2005).	  LRP-­‐1	  is	  shed	  
by	  cleavage	  in	  the	  β-­‐chain,	  which	  induces	  the	  release	  of	  the	  α-­‐chain	  and	  part	  of	  the	  
β-­‐chain.	   MT1-­‐MMP	   was	   also	   reported	   to	   cleave	   LRP-­‐1,	   but,	   differently	   from	   the	  
mentioned	  sheddases	  that	  generate	  a	  soluble	  form	  of	  the	  entire	  LRP-­‐1	  ectodomain,	  
it	  provokes	  a	  fragmentation	  of	  the	  receptor	  (Rozanov	  et	  al.	  2004).	  The	  specific	  sites	  
at	  which	  these	  enzymes	  cleave	  have	  not	  yet	  been	  identified.	  	  
	   A	   number	   of	   stimuli	   are	   reported	   to	   induce	   LRP-­‐1	   shedding,	   and	   different	  
stimuli	   can	   activate	   different	   sheddases	   in	   a	   cell-­‐specific	   manner.	   Generally,	  
inflammation	   seems	   to	   regulate	   this	   process.	   Increased	   levels	   of	   sLRP-­‐1	   are	  
detectable	   in	   the	   plasma	   of	   patients	   with	   rheumatoid	   arthritis,	   systemic	   lupus	  
erythematous	  (Gorovoy	  et	  al.,	  2010)	  and	  liver	  disease	  (Quinn	  et	  al.,	  1997).	  Molecules	  
involved	  in	  inflammation,	  such	  as	  interferon	  γ	  and	  LPS	  stimulate	  LRP-­‐1	  shedding	  by	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ADAM-­‐17	   (Gorovoy	  et	  al.,	  2010).	   sLRP-­‐1	   itself	   is	  a	  mediator	  of	   inflammation,	  being	  
able	  to	  activate	  the	  IΚΚ-­‐NF-­‐κB	  patway	  through	  its	  N-­‐terminus	  (Gorovoy	  et	  al.,	  2010).	  
Cholesterol	  depletion	  has	  also	  been	  found	  to	  stimulate	  LRP-­‐1	  shedding	  by	  MT1-­‐MMP	  
and	   ADAM-­‐12	   (Selvais	   et	   al.,	   2011).	   I	   observed	   the	   accumulation	   of	   sLRP-­‐1	   in	   the	  
conditioned	  medium	  of	  HTB94	  cells	  in	  the	  absence	  of	  any	  pro-­‐inflammatory	  stimuli.	  
Since	   a	   number	   of	   the	   proposed	   LRP-­‐1	   ‘sheddases’	   are	   metalloproteinases,	  
production	   of	   sLRP-­‐1	   should	   be	   inhibited	   by	   metalloproteinase	   inhibitors	   such	   as	  
TIMP-­‐3	   and	   GM6001.	   However,	   the	   concentration	   of	   [35S]TIMP-­‐3	   that	   we	   used	   in	  
endocytosis	   assays	   (1	   nM)	   is	   an	   order	   of	   magnitude	   lower	   than	   the	   TIMP-­‐3	  
concentration	   previously	   shown	   to	   inhibit	   MT1-­‐MMP	   and	   ADAM12-­‐mediated	  
shedding	   (Selvais	   et	   al.,	   2011).	  GM6001	  has	  been	   shown	   to	   inhibit	   LRP-­‐1	   shedding	  
(Gorovoy	   et	   al.,	   2010;	  Wygrecka	   et	   al.,	   2011),	   but	  we	   found	   that	  GM6001	   had	   no	  
effect	   on	   the	   rate	   of	   [35S]TIMP-­‐3	   endocytosis	   by	   HTB94	   cells.	   This	   suggests	   that	   a	  
GM6001-­‐insensitive	   sheddase	   may	   mediate	   LRP-­‐1	   shedding	   in	   HTB94	   cells.	   More	  
interestingly,	   some	   preliminary	   experiments	   that	   I	   performed	   recently	   show	   that	  
TIMP-­‐3	  itself	  can	  induce	  LRP-­‐1	  shedding	  in	  a	  concentration-­‐dependent	  manner,	  with	  
the	  generation	  of	  two	  fragments	  of	  150	  kDa	  and	  250	  kDa.	  Sheddases	  responsible	  for	  
LRP-­‐1	  constitutive	  shedding	  in	  HTB94	  cells	  and	  the	  mechanisms	  underlying	  TIMP-­‐3-­‐
induced	  shedding	  of	  LRP-­‐1	  are	  currently	  under	  investigation	  in	  our	  laboratory.	  
	   Shedding	   of	   LRP-­‐1	   has	   numerous	   consequences.	   Firstly,	   it	   can	   reduce	  
endocytosis	  of	  LRP-­‐1	  ligands	  in	  a	  loss-­‐of-­‐function	  manner	  by	  reducing	  the	  number	  of	  
endocytic	   receptors	   on	   the	   cell	   surface	   (Rozanov	   et	   al.,	   2004;	   Selvais	   et	   al.,	   2011;	  
Wygrecka	  et	   al.,	   2011).	   Secondly,	   sLRP-­‐1	   can	  bind	   to	   and	   inhibit	   endocytosis	  of	   its	  
ligands,	   as	   has	   been	   reported	   for	   tPA,	   MMP-­‐2	   and	   MMP-­‐9	   (Quinn	   et	   al.,	   1997;	  
Wygrecka	   et	   al.,	   2011).	   By	   antagonizing	   LRP-­‐1-­‐mediate	   endocytosis,	   sLRP-­‐1	   can	  
increase	  the	  half-­‐life	  of	  TIMP-­‐3	  in	  the	  extracellular	  space.	  More	  importantly,	  I	  found	  
that	  the	  TIMP-­‐3-­‐sLRP-­‐1	  complex	  is	  still	  able	  to	  inhibit	  metalloproteinases,	  therefore	  
the	  ratio	  between	  cell	  surface	  LRP-­‐1	  and	  sLRP-­‐1	  is	  an	  important	  factor	  that	  regulates	  
the	  bioavailability	  of	  TIMP-­‐3	  to	  inhibit	  metalloproteinases	  in	  the	  extracellular	  space,	  
thus	  controlling	  ECM	  proteolysis	  and	  proteolysis	  of	  cell	  surface	  molecules.	  	  
	   Heparin	   has	   been	   shown	   to	   directly	   inhibit	   interaction	   of	   other	   ligands,	  
including	   factor	   IXa	   (Neels	  et	  al.,	  2000),	  apolipoproteins	   (Nilsson	  et	  al.,	  2007),	  C4b-­‐
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binding	  protein	  (Westein	  et	  al.,	  2002)	  and	  PAI-­‐1	  (Nykjaer	  et	  al.,	  1992b),	  with	  LRP-­‐1.	  
In	  the	  case	  of	  PAI-­‐1,	  the	  heparin-­‐binding	  and	  LRP-­‐binding	  regions	  have	  been	  found	  to	  
overlap	  (Horn	  et	  al.,	  1998;	  Stefansson	  et	  al.,	  1998).	  Binding	  of	  proteins	  to	  heparin	  is	  
commonly	  mediated	  by	  clusters	  of	  positively	  charged	  residues	  (Gandhi	  and	  Mancera,	  
2008).	  Similarly,	  binding	  of	  protein	  ligands	  to	  LRP	  and	  related	  LDL	  receptors	  is	  often	  
mediated	   by	   positive	   residues,	   as	   has	   been	   demonstrated	   for	   RAP	   (Fisher	   et	   al.,	  
2006;	   van	   den	   Biggelaar	   et	   al.,	   2011),	   α2M	   (Arandjelovic	   et	   al.,	   2005),	   PAI-­‐1	  
(Rodenburg	  et	  al.,	  1998;	   Jensen	  et	  al.,	  2009;	  Skeldal	  et	  al.,	  2006),	  apolipoprotein	  E	  
(Lalazar	  et	  al.,	  1988),	  lipoprotein	  lipase	  (Williams	  et	  al.,	  1994)	  and	  factor	  VIII	  (Meems	  
et	   al.,	   2011).	   In	   the	   case	   of	   RAP,	   crystallography	   and	   mutagenesis	   studies	   have	  
confirmed	   that	   K256	   and	   K270	   mediate	   binding	   to	   acidic	   pockets	   in	   the	   ligand	  
binding	  motifs	  of	  the	  receptor	  (Fisher	  et	  al.,	  2006;	  van	  den	  Biggelaar	  et	  al.,	  2011).	  I	  
found	   that	   heparin	   blocks	   the	   direct	   binding	   of	   TIMP-­‐3	   to	   sLRP-­‐1	   purified	   from	  
plasma.	   This	   suggests	   that,	   as	   in	   the	   case	   of	   PAI-­‐1,	   the	   heparin-­‐binding	   and	   LRP-­‐
binding	   sites	   of	   TIMP-­‐3	  may	   overlap.	   The	   crystal	   structure	   of	   full-­‐length	   TIMP-­‐3	   is	  
currently	  unavailable,	  but	  the	  protein	   is	  predicted	  to	  contain	  an	  extended	  patch	  of	  
basic	   residues,	   located	   on	   the	   opposite	   face	   of	   the	   protein	   to	   the	   inhibitory	   ridge	  
that	   interacts	   with	   metalloproteinases.	   Mutagenesis	   indicates	   that	   this	   region	  
mediates	  binding	  to	  the	  extracellular	  matrix	  and	  to	  sulfated	  proteoglycans	  (Lee	  et	  al.,	  
2007).	  Residues	  in	  this	  region	  may	  also	  mediate	  binding	  to	  LRP.	  Binding	  of	  TIMP-­‐3	  to	  
sLRP-­‐1,	   which	   inhibits	   the	   TIMP-­‐3	   uptake	   by	   competing	   with	   the	   endocytic	  
transmembrane	   LRP-­‐1,	   may	   also	   prevent	   TIMP-­‐3	   from	   binding	   to	   the	   ECM.	  
Therefore,	  sLRP-­‐1	  can	  regulate	  the	  bioavailability	  of	  TIMP-­‐3	  in	  the	  extracellular	  space	  
by	  increasing	  its	  half-­‐life	  and	  by	  competing	  for	  binding	  of	  TIMP-­‐3	  to	  the	  ECM.	  
7.3 LRP-­‐1-­‐independent	  endocytosis	  of	  TIMP-­‐3	  
In	   addition	   to	   the	   LRP-­‐1-­‐mediated	   pathway,	   I	   observed	   an	   LRP-­‐1-­‐independent	  
endocytosis	  of	  TIMP-­‐3	  in	  PEA-­‐13	  cells	  and	  RAP-­‐treated	  HTB94,	  MEFs	  and	  CHO	  cells.	  
Although	  this	  is	  a	  slower	  process	  compared	  to	  the	  LRP-­‐1-­‐mediated	  endocytosis,	  it	  is	  
also	  likely	  to	  be	  receptor-­‐mediated.	  Endocytosis	  of	  TIMP-­‐3	  in	  all	  tested	  cell	  types	  was	  
almost	  completely	  inhibited	  by	  heparin,	  which	  is	  known	  to	  antagonize	  the	  binding	  of	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proteins	   to	  HSPGs	   and	   CSPGs.	   I	   hypothesized	   that	  members	   of	   these	   two	   families	  
could	   be	   involved	   in	   the	   LRP-­‐1-­‐independent	   pathway.	   In	   agreement	   with	   this	  
hypothesis,	   HSPGs	   have	   been	   demonstrated	   to	   mediate	   endocytosis	   of	   ligands	  
including	   lipoproteins	   (Stanford	   et	   al.,	   2009),	   and	   endocytosis	  mediated	   by	   HSPGs	  
does	  not	  require	  dynamin,	  as	  it	  was	  the	  case	  for	  the	  LRP-­‐1-­‐independent	  endocytosis	  
of	   TIMP-­‐3.	   Alternatively,	   HSPG	   might	   act	   as	   co-­‐receptors	   of	   LRP-­‐1-­‐mediated	  
endocytosis,	   concentrating	   ligands	   on	   the	   cell	   surface	   for	   the	   subsequent	   LRP-­‐1-­‐
mediated	   internalization.	   A	   similar	   endocytic	   mechanism	   was	   proposed	   for	  
thrombospondin	  1	  (Wang	  et	  al.,	  2004),	  tissue	  factor	  pathway	  inhibitor	  (Schwartz	  and	  
Broze,	   1997),	   amyloid-­‐β	   (Kanekiyo	   et	   al.,	   2011)	   and	   factor	   VIII	   (Sarafanov	   et	   al.,	  
2001).	  Based	  on	   these	   reports	   I	  hypothesized	   that	  TIMP-­‐3	  could	  be	   internalized	  by	  
two	  different	  pathways:	  i)	  TIMP-­‐3	  initially	  binds	  to	  an	  HSPG	  on	  the	  cell	  surface	  that	  
functions	   as	   a	   co-­‐receptor	   and	   transfers	   the	   inhibitor	   to	   LRP-­‐1	   for	   subsequent	  
endocytosis;	   or	   ii)	   TIMP-­‐3	   binds	   to	   an	   HSPG	   which	   itself	   mediates	   the	   inhibitor	  
endocytosis.	   However,	   I	   found	   that	   TIMP-­‐3	   endocytosis	   was	   not	   affected	   in	  
xylosyltransferase-­‐deficient	   CHO-­‐745	   cells,	   indicating	   that	   sulfated	   cell	   surface	  
proteoglycans	   are	   not	   required	   for	   TIMP-­‐3	   endocytosis.	   In	   line	   with	   this	   finding,	  
TIMP-­‐3	   endocytosis	   was	   also	   unimpaired	   in	   sodium	   chlorate	   treated	   cells,	   and	   in	  
syndecan-­‐4-­‐null	  and	  syndecan-­‐1-­‐silenced	  cells.	  I	  therefore	  conclude	  that	  cell	  surface	  
HSPG	   or	   CSPG	   do	   not	   mediate	   the	   LRP-­‐1-­‐independent	   pathway	   of	   TIMP-­‐3	  
endocytosis.	   The	   receptor	   that	   mediates	   the	   LRP-­‐1-­‐independent	   endocytosis	   of	  
TIMP-­‐3	   is	   yet	   to	   be	   identified.	   Members	   belonging	   to	   the	   macrophage	   mannose	  
receptor	   protein	   family	   may	   be	   possible	   candidates	   as	   they	   have	   been	   shown	   to	  
internalize	  some	  LRP-­‐1	  ligands	  and	  play	  a	  crucial	  role	  in	  ECM	  turnover.	  For	  instance,	  
urokinase	   plasminogen	   activator	   receptor-­‐associated	   protein/endocytic	   recycling	  
protein	   Endo180	   is	   expressed	   in	   chondrocytes	   and	   fibroblasts	   and	   is	   involved	   in	  
collagen	   internalization	   (Engelholm	   et	   al.,	   2003;	   Kjoller	   et	   al.,	   2004),	   and	   the	  
macrophage	  mannose	  receptor	  mediates	  internalization	  of	  ADAMTS-­‐13	  by	  dendritic	  
cells	  (Sorvillo	  et	  al.,	  2012).	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Figure	  48.	  Model	  for	  TIMP-­‐3	  endocytosis.	  
	  
7.4 LRP-­‐1:	  a	  master	  regulator	  of	  ECM	  turnover	  
I	  investigated	  what	  the	  biological	  significance	  of	  TIMP-­‐3	  endocytosis	  is,	  whether	  it	  is	  
a	  means	  to	  scavenge	   inactive	  metalloproteinases	   in	  TIMP-­‐3—enzyme	  complexes	  or	  
whether	   it	   is	   a	   mechanism	   to	   control	   levels	   of	   free	   inhibitor	   in	   the	   tissue.	   The	  
internalization	  of	  TIMP-­‐3	  was	  not	  altered	   in	   the	  presence	  of	   the	  metalloproteinase	  
inhibitor	   GM6001,	   which	   prevents	   TIMP-­‐3	   from	   forming	   a	   complex	   with	  
metalloproteinases.	  This	  suggests	  that	  TIMP-­‐3	  can	  be	  internalized	  in	  a	  free	  form	  and	  
that	   its	   endocytosis	   is	   a	   mechanism	   to	   control	   levels	   of	   this	   physiological	   and	  
pathologically	   important	   inhibitor	   in	   the	   extracellular	   space.	   TIMP-­‐3	   has	   been	  
reported	  to	  induce	  apoptosis	  by	  stabilizing	  death	  receptors;	  therefore	  accumulation	  
of	  TIMP-­‐3	  in	  the	  extracellular	  space	  may	  be	  detrimental	  for	  the	  cell	   (Ahonen	  et	  al.,	  
2003;	  Baker	  et	  al.,	  1999).	  
	   I	   found	  that	  TIMP-­‐3	  can	  be	   internalized	   in	  complex	  with	  metalloproteinases	  
without	   any	   significant	   change	   in	   kinetics	   compared	   to	   free	   TIMP-­‐3.	   As	   discussed	  
above,	  a	  patch	  of	  positive	  residues	  that	  may	  drive	  the	  binding	  of	  TIMP-­‐3	  to	  LRP-­‐1	  is	  
located	   in	   the	   opposite	   face	   to	   the	   inhibitory	   ridge.	   I	   hypothesize	   that	   the	   LRP-­‐1	  
binding	  determinants	  on	   the	  TIMP-­‐3	  molecule	  are	  not	  sterically	   shielded	  when	  the	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inhibitor	   is	   in	   complex	  with	  metalloproteinases.	   As	   shown	   for	  MMP-­‐2,	   -­‐9,	   -­‐13	   and	  
ADAMTS-­‐4	  and	  -­‐5,	  some	  metalloproteinases	  harbor	  LRP-­‐1	  binding	  determinants	  and	  
they	   can	   be	   internalized	   by	   LRP-­‐1	   independently	   from	   binding	   to	   TIMP-­‐3	   or	   other	  
TIMPs	   (Barmina	  et	  al.,	  1999;	  Emonard	  et	  al.,	  2004;	  Hahn-­‐Dantona	  et	  al.,	  2001).	  On	  
the	   other	   hand,	   I	   found	   that	   MMP-­‐1	   does	   not	   have	   affinity	   for	   LRP-­‐1	   and	   it	   is	  
minimally	  endocytosed	  by	  cells.	  When	  in	  complex	  with	  TIMP-­‐3,	  the	  internalization	  of	  
MMP-­‐1	   occurs	   at	   a	   higher	   rate,	   suggesting	   that	   TIMP-­‐3	   can	   bridge	   binding	   of	   the	  
enzyme	   to	   LRP-­‐1.	   Other	   classes	   of	   MMPs	   (eg.	   stromelysins	   and	   membrane-­‐type	  
MMPs)	  are	  also	  internalized	  in	  complex	  with	  TIMP-­‐3,	  indicating	  that	  the	  inhibitor	  can	  
generally	   mediate	   the	   scavenging	   of	   metalloproteinases.	   Scavenging	   of	   inhibited	  
metalloproteinases	  may	  have	  some	  biological	  consequences.	  Firstly,	   it	  may	  prevent	  
accumulation	   of	   inactive	   enzymes	   in	   the	   ECM	   that	   may	   compete	   with	   other	  
molecules	   for	   specific	   binding	   sites	   in	   the	   ECM,	   including	   proteoglycans.	   Secondly,	  
binding	   of	   TIMP-­‐3—metalloproteinase	   complexes	   to	   LRP-­‐1	   could	   activate	   cell-­‐
signalling	  and	  modulate	  gene	  expression.	   In	  agreement	  with	   this	  hypothesis,	   it	  has	  
been	  reported	  that	  MMP-­‐9	  activates	  ERK1/2	  and	  Akt	  in	  Schwann	  cells	  upon	  binding	  
to	  LRP-­‐1,	  and	  that	  LRP-­‐1	  activates	  ERK1/2	  and	  inhibits	  JNK	  in	  cancer	  cells,	  promoting	  
their	  migration	  (Langlois	  et	  al.,	  2010;	  Mantuano	  et	  al.,	  2008).	  
	   The	   capability	   of	   LRP-­‐1	   to	   internalize	   metalloproteinases	   and	  
metalloproteinase	   inhibitors,	   controlling	   their	   levels	   in	   the	   extracellular	   space,	  
renders	  it	  a	  master	  regulator	  of	  the	  ECM.	  Altered	  levels	  of	  this	  receptor	  on	  the	  cell	  
surface	   affect	   the	   cell	   environment	   and	   can	   lead	   to	   pathological	   conditions.	   For	  
example,	  low	  levels	  of	  LRP-­‐1	  in	  chondrocytes	  are	  associated	  with	  OA	  (Yamamoto	  et	  
al.,	   2012).	   Interestingly,	   despite	   our	   finding	   that	   the	   presence	   of	   RAP	   induces	  
accumulation	   of	   TIMP-­‐3	   in	   the	   conditioned	   medium	   of	   cultured	   porcine	   articular	  
chondrocytes,	   the	  addition	  of	  RAP	   to	  porcine	  articular	   cartilage	  explants	  promotes	  
cartilage	  degradation,	  primarily	  due	  to	  an	  increase	  in	  ADAMTS-­‐5	  activity	  (Yamamoto	  
et	  al.,	  2012).	  Silencing	  of	  LRP-­‐1	   in	  carcinoma	  cells	  enhances	  pericellular	  proteolysis	  
(Dedieu	   et	   al.,	   2008).	   Interestingly,	   overexpression	   of	   LRP-­‐1	   also	   increases	  
pericellular	   proteolysis	   in	   human	   glioblastoma	   cells,	   by	   inducing	   the	   expression	   of	  
MMP-­‐2	  and	  MMP-­‐9	  via	  ERK	  signalling	  (Song	  et	  al.,	  2009).	  These	  examples	  show	  the	  
importance	  of	  LRP-­‐1	  in	  controlling	  proteolysis	  in	  the	  ECM	  both	  in	  terms	  of	  increasing	  
Chapter	  7	   	   Concluding	  remarks	  and	  future	  prospects	  
	   175	  
net	   proteolysis,	   and	   decreasing	   net	   proteolysis.	   Due	   to	   the	   high	   number	   of	  
heterogeneous	  LRP-­‐1	  ligands,	  ranging	  from	  metalloproteinases	  to	  growth	  factors,	   it	  
is	   impossible	   to	   connect	   lack	   of	   LRP-­‐1	   activity	  with	   an	   effect	   of	   only	   one	   of	   these	  
ligands.	  Furthermore,	  LRP-­‐1-­‐induced	  cell	  signalling	  may	  affect	  the	  cell	  environment,	  
and	  inactivation	  of	  the	  receptor	  would	  also	  inactivate	  the	  LRP-­‐1-­‐mediated	  responses.	  
More	  than	  forty	  LRP-­‐1	  ligands	  have	  been	  identified	  so	  far	  and	  many	  of	  them	  lead	  to	  
opposite	  biological	  effects,	  such	  as	  proteinases	  and	  their	  endogenous	  inhibitors.	  The	  
mechanism	   how	   LRP-­‐1	   induces	   a	   specific	   cell	   response	   by	   internalizing	   opposing	  
effectors	   and	   how	   levels	   of	   these	   effectors	   are	   interconnected	   is	   not	   well	  
understood	  yet	  and	  represents	  fascinating	  research	  for	  the	  future.	  	  	  	  	  
7.5 Concluding	  remarks	  
TIMP-­‐3	  has	  been	  shown	  to	  have	  protective	  effects	  in	  a	  number	  of	  diseases:	  (i)	  TIMP-­‐
3	   inhibits	   cartilage	   degradation	   in	   both	   in	   vitro	   and	   in	   an	   in	   vivo	   model	   of	  
osteoarthritis.	   (ii)	  TIMP-­‐3	  overexpression	   in	  cancer	  cells	   is	  protective	  against	  tumor	  
growth	  and	  invasion,	  and	  (iii)	  TIMP-­‐3	  overexpression	  in	  macrophages	  decreases	  the	  
incidence	   of	   vascular	   diseases	   in	   an	   atherogenic	   mouse	   model.	   Therefore,	  
understanding	   how	   levels	   of	   TIMP-­‐3	   are	   regulated	   in	   the	   tissue	   may	   lead	   to	  
therapeutic	   targets	   for	   these	  diseases.	  TIMP-­‐3	   levels	   in	   the	  ECM,	  and	   therefore	   its	  
metalloproteinase	   inhibitory	  activity,	  have	  been	  shown	  to	  be	  regulated	  at	  different	  
levels.	   TIMP-­‐3	   expression	   can	   be	  modulated	   by	   epigenetic	  mechanisms,	   cytokines,	  
growth	  factors	  and	  micro-­‐RNAs.	  Recently,	  work	  from	  our	  laboratory	  has	  shown	  that	  
TIMP-­‐3	  levels	  in	  the	  ECM	  can	  also	  be	  post-­‐translationally	  regulated	  by	  endocytosis.	  
	   In	  this	  thesis,	  I	  found	  that	  the	  endocytic	  receptor	  LRP-­‐1	  is	  the	  major	  regulator	  
of	   TIMP-­‐3	   levels	   in	   the	   tissue.	   The	   shed	   form	  of	   LRP-­‐1	   also	   interacts	  with	   TIMP-­‐3,	  
preventing	   it	   from	  binding	   cell	   surface	   LRP-­‐1,	   thus	   increasing	   the	   bioavailability	   of	  
the	   inhibitor	   in	   the	   extracellular	   space.	  When	   TIMP-­‐3	   is	   bound	   to	   sLRP-­‐1,	   it	   is	   still	  
capable	  of	  inhibiting	  proteinases,	  therefore	  the	  equilibrium	  between	  sLRP-­‐1	  and	  cell-­‐
surface	   LRP-­‐1	   is	   crucial	   in	   controlling	   ECM	  proteolysis	   in	   the	   tissue.	   This	   discovery	  
may	   be	   used	   in	   development	   of	   novel	   therapies	   for	   those	   pathologies	   associated	  
with	  enhanced	  ECM	  degradation.	  A	  current	  study	  in	  our	  laboratory	  aims	  to	  generate	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a	   TIMP-­‐3	  mutant	   that	   does	   not	   interact	  with	   LRP-­‐1	   and	   to	   test	   this	  mutant	   for	   its	  
capability	   to	   inhibit	   cartilage	   breakdown	   in	   models	   of	   OA.	   In	   addition,	   we	   have	  
planned	   to	   evaluate	   the	   effects	   of	   overexpression	   of	   sLRP-­‐1	   in	   different	   biological	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MMPsWe investigated whether the afﬁnity of tissue inhibitor of metalloproteinases (TIMP)-3 for adamalysins with
thrombospondin motifs (ADAMTS)-4 and ADAMTS-5 is affected by the non-catalytic ancillary domains of the
enzymes. For this purpose, we ﬁrst established a novel method of purifying recombinant FLAG-tagged TIMP-
3 and its inhibitory N-terminal domain (N-TIMP-3) by treating transfected HEK293 cells with sodium
chlorate to prevent heparan sulfate proteoglycan-mediated TIMP-3 internalization. TIMP-3 and N-TIMP-3
afﬁnity for selected matrix metalloproteinases and forms of ADAMTS-4 and -5 lacking sequential C-terminal
domains was determined. TIMP-3 and N-TIMP-3 displayed similar afﬁnity for various matrix metallopro-
teinases as has been previously reported for E. coli-expressed N-TIMP-3. ADAMTS-4 and -5 were inhibited
more strongly by N-TIMP-3 than by full-length TIMP-3. The C-terminal domains of the enzymes enhanced
interaction with N-TIMP-3 and to a lesser extent with the full-length inhibitor. For example, N-TIMP-3 had
7.5-fold better Ki value for full-length ADAMTS-5 than for the catalytic and disintegrin domain alone. We
propose that the C-terminal domains of the enzymes affect the structure around the active site, favouring
interaction with TIMP-3.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
In addition to their catalytic domains, proteolytic enzymes often
have non-catalytic ancillary domains that modulate interaction of the
enzyme with substrates or inhibitors. Indeed, almost all members
of the metzincin family of metalloproteinases have such ancillary
domains, and they have been shown to mediate recognition and
cleavage of numerous substrates. For example, the hemopexin domain
of matrix metalloproteinase 1 (MMP-1) is required for cleavage of
collagen (Clark and Cawston, 1989). Among the related adamalysins
with thrombospondin motifs (ADAMTSs), the C-terminal domains of
ADAMTS-4 and ADAMTS-5 have been shown to promote aggrecan
cleavage (Kashiwagi et al., 2004; Gendron et al., 2007; Fushimi et al.,
2008), the C-terminal spacer domain of ADAMTS13 promotes cleavagealysin with thrombospondin
disintegrin; LRP, low-density
proteinase;N-TIMP,N-terminal
spacer; TACE, tumour necrosis
etalloproteinase; TS, thrombos-
x: +44 020 8383 4994.
).
ll rights reserved.of von Willebrand factor (Gao et al., 2008) and C-terminal domains of
ADAMTS-2 modulate processing of the N-terminal propeptide of pro-
collagen (Colige et al., 2005). These ancillary domains have also
been shown to modulate interaction of some metzincins with the
endogenous tissue inhibitors of metalloproteinases (TIMPs). For
example, the MMP-2 hemopexin domain interacts strongly with
TIMP-2 (Murphy et al., 1992; Butler et al., 1999; Morgunova et al.,
2002). While the MMPs are inhibited by all four of the mammalian
TIMPs, most adamalysins and ADAMTSs are inhibited only by TIMP-3.
Compared to theMMPs, the adamalysins and ADAMTSs have a greater
number and diversity of C-terminal ancillary domains and the role of
these in modulating interactions with TIMP-3 is largely unknown, as a
lack of sensitive substrates has hampered in-depth kinetic analysis.
Good substrates are available for ADAM17, or tumour necrosis factor-
α converting enzyme (TACE) and the C-terminal domains of this
enzyme have been shown to reduce the afﬁnity of the enzyme for both
full-length TIMP-3 and N-TIMP-3 by 10-fold (Lee et al., 2002).
ADAMTS-4 and -5 cleave the cartilagematrix proteoglycan aggrecan
at various sites, releasing the chondroitin and keratan sulfate-bearing
region of themolecule from the tissue. This is an early and crucial step in
the development of osteoarthritis as it reduces the ability of the tissue to
resist compressive loads. Both enzymes are readily proteolyzed to
smaller isoforms, which have altered proteolytic activity (Gao et al.,
2004). Here we investigate TIMP-3 inhibition of the isoforms, with an
464 L. Troeberg et al. / Matrix Biology 28 (2009) 463–469aim tounderstandingwhether, as in the caseof ADAM17, theC-terminal
ancillary domains of the enzymes regulate TIMP-3 binding to the active
site. To do this, we developed a novel method of purifying sufﬁcient
soluble full-length TIMP-3 and its inhibitory N-terminal domain (N-
TIMP-3) for kinetic analysis.
N-TIMP-3 can be successfully expressed in Escherichia coli and
refolded in vitro (Kashiwagi et al., 2001), but we have not been able to
refold full-length TIMP-3 using this system. Unlike the other TIMPs,
TIMP-3 binds tightly to the extracellular matrix and is not readily
soluble (Lee et al., 2007; Yu et al., 2000). It is thus difﬁcult to re-
combinantly express TIMP-3 in mammalian cells, and to date full-
length TIMP-3 has only been recombinantly produced in NSO mouse
myeloma cells, which do not produce an extracellular matrix (Apte
et al., 1995). Here we describe successful puriﬁcation of full-length
TIMP-3 and N-TIMP-3 recombinantly expressed in human embryonic
kidney HEK293 cells. Recently developed synthetic ﬂuorescent
quenched substrates allowed us to determine the inhibition constants
of both TIMP-3 and N-TIMP-3 for various forms of ADAMTS-4 and
ADAMTS-5.2. Results
2.1. Puriﬁcation of recombinant TIMP-3 and N-TIMP-3
This study describes a novel method of purifying soluble full-length
TIMP-3. No TIMP-3 is observed in the conditioned medium of
transfected HEK293 cells, and we have previously shown that TIMP-3
is rapidly endocytosed after secretion from the cell by a scavenger
endocytic receptor of the low-density lipoprotein receptor-related
protein (LRP) family (Troeberg et al., 2008). TIMP-3 accumulates in the
conditioned medium if this endocytic pathway is blocked, for example
by the addition of receptor-associated protein (RAP), an inhibitor of
LRP-mediated endocytosis (Troeberg et al., 2008). Heparin also causes
an accumulation of TIMP-3, indicating that a heparan sulfate proteogly-
can co-receptor is possibly required for LRP-mediated endocytosis as
has been reported for other LRP ligands (Godyna et al., 1995; Sarafanov
et al., 2001). However, heparin binds to TIMP-3 tightly and puriﬁcation
of TIMP-3 from heparin-treated cells proved difﬁcult. To keep
recombinantly expressed TIMP-3 in themedium,we treated transfected
cells with sodium chlorate (NaClO3), which blocks sulfation of
cell surface glycosaminoglycans (Baeuerle and Huttner, 1986; Safaiyan
et al., 1999). This resulted in the accumulation of FLAG-tagged TIMP-3
and N-TIMP-3 in the conditioned medium of transfected cells. Both
proteins were puriﬁed from the conditioned medium by anti-FLAG
afﬁnity chromatography (Fig. 1A). As previously reported for full-
length ADAMTS-4 (Kashiwagi et al., 2004), substantial processing of the
C-terminal FLAG-tag occurred, reducing the yield to approximately
50 μg of puriﬁed protein per litre of conditioned medium. Both TIMP-3
andN-TIMP-3 expressed inHEK293were conﬁrmed tohave the expected
N-terminal sequence 1CTCSPSHPQD and to react with a polyclonal anti-
TIMP-3 antibody (Fig 1B). Titration against a known concentration of
MMP-1 showed all preparations of TIMP-3 to be 100% active.
TIMP-3 contains a single N-glycosylation site in its C-terminal
domain (Apte et al., 1995) and various possible O-glycosylation sites.
Various cell types have been shown to express both a 27 kDa
glycosylated and a 24 kDa non-glycosylated form (Apte et al., 1995;
Fabunmi et al., 1996; Langton et al., 1998). Transfected HEK293 cells
also synthesized both glycosylated and non-glycosylated forms, but
only the glycosylated form remained after puriﬁcation, with the non-
glycosylated form possibly lost due to increased “stickiness”. Indeed,
we obtained lower yields when we treated cells with tunicamycin to
obtain only the non-N-glycosylated form. N-TIMP-3 was expressed
primarily as a non-glycosylated form, with a lower amount of a higher
molecular mass glycosylated form present. Since N-TIMP-3 contains
no N-glycosylation sites, this possibly reﬂects O-glycosylation.2.2. Ki(app) of TIMP-3 and N-TIMP-3 for selected MMPs
We compared the inhibitory activity of our mammalian-expressed
TIMP-3 and N-TIMP-3 with the previously characterized E. coli-
expressed N-TIMP-3 with a C-terminal His-tag (Kashiwagi et al.,
2001). Ki(app) values determined in the current study for E. coli-
expressed N-TIMP-3 agreed well with previously published values for
this protein (Kashiwagi et al., 2001). Although we determined a 6-fold
lower Ki(app) value for N-TIMP-3 inhibition of the catalytic domain of
MMP-3 (MMP-3cat), our results agree with that found in the previous
study that N-TIMP-3 is a weaker inhibitor of MMP-3cat than of the
catalytic domain of MMP-1 (MMP-1cat) or MMP-2 (Table 1).
We found that mammalian-expressed N-TIMP-3 had essentially
identical inhibitory properties to the E. coli-expressed N-TIMP-3,
being a strong inhibitor of MMP-1cat and MMP-2, and a 10-fold
weaker inhibitor of MMP-3cat.
MMP-1cat was equally well inhibited by N-TIMP-3 and full-length
TIMP-3. MMP-3cat, however, was more strongly inhibited by full-length
TIMP-3 than by N-TIMP-3, implying that the C-terminal domain of the
inhibitor contributes tobinding. TheMMP-2catalytic domain (MMP-2cat)
was equally well inhibited by N-TIMP-3 and full-length TIMP-3, but the
full-length enzymewasmore strongly inhibitedby the full-lengthTIMP-3
than by N-TIMP-3. This indicates that the C-terminal domain of TIMP-3
interacts with the C-terminal hemopexin domain of MMP-2.
2.3. Ki of TIMP-3 and N-TIMP-3 for ADAMTS-4 and ADAMTS-5
We analyzed TIMP-3 and N-TIMP-3 inhibition of various isoforms
(Fig. 2) of ADAMTS-4 and -5 lacking C-terminal ancillary domains.
Fig. 3 shows representative data for four enzyme isoforms ﬁtted to the
tight-binding equation (Bieth, 1995). All isoforms of ADAMTS-4 and
-5 were effectively inhibited by TIMP-3 and N-TIMP-3, with Ki values
in the sub-nanomolar range. All ADAMTS-5 isoforms were inhibited
more strongly by N-TIMP-3 than by full-length TIMP-3 (Table 2). The
C-terminal domains of ADAMTS-5 enhanced inhibition by N-TIMP-3,
with full-length ADAMTS-5 (ADAMTS5-1) having a 7.5-fold better Ki
value than ADAMTS5-5, which consists of the catalytic and disintegrin
domain. The C-terminal domains of the enzyme had a similar, although
less marked, effect on association with the full-length inhibitor. The
C-terminal domains of ADAMTS-4 also had a similar effect on asso-
ciation with full-length and N-TIMP-3 (Table 2).
Glycosylation had little effect on TIMP-3 or N-TIMP-3 inhibition of
ADAMT5-2 or ADAMTS4-2 (Table 3).
The isolated catalytic domains of ADAMTS-4 and -5 (ADAMTS4-5
and ADAMTS5-6) had only minimal activity on natural substrates and
the synthetic substrates used, so their inhibition by TIMP-3 could not
be analyzed by enzyme inhibition kinetics.
3. Discussion
Here we report a novel method to generate recombinant TIMP-3
protein by treating transfectedHEK293 cellswith sodiumchlorate. Our
initial attempts to express TIMP-3 in HEK293 or HTB94 chondrosar-
coma cells were hampered by the observation that, although these
cells transcribe a considerable amount of TIMP-3 mRNA, no TIMP-3
accumulates in the conditionedmedium.Wehave previously reported
that TIMP-3 is normally internalized but accumulates inmedium in the
presence of an antagonist of the LRP endocytic receptor or heparin
(Troeberg et al., 2008). We thus treated cells with sodium chlorate,
which blocks sulfation of cell surface glycosaminoglycans (Baeuerle
andHuttner, 1986; Safaiyan et al., 1999) and observed accumulation of
soluble TIMP-3 in the medium. TIMP-3 has previously been puriﬁed
from the conditioned medium of transfected NSO mouse myeloma
cells (Apte et al., 1995), which appear to lack this endocytic pathway.
Our transfected cells showed no signs of TIMP-3-induced apoptosis
(Bond et al., 2000) in the absence of sodium chlorate, but exhibited
Fig. 1. Puriﬁcation of TIMP-3 and N-TIMP-3. FLAG-tagged glycosylated human TIMP-3 and N-TIMP-3 were expressed by treating transfected HEK293 with 30 mM sodium chlorate
in serum-free DMEM and puriﬁed from the conditioned medium by FLAG afﬁnity chromatography and cation exchange chromatography. A. Silver-stained 10% polyacrylamide
SDS-PAGE gel of TIMP-3 (100 ng) and N-TIMP-3 (100 ng). B. Immuoblot of 12% polyacrylamide SDS-PAGE gel of TIMP-3 (100 ng) and N-TIMP-3 (100 ng) stained using a
polyclonal rabbit anti-TIMP-3 antibody.
465L. Troeberg et al. / Matrix Biology 28 (2009) 463–469increased cell death once chloratewas added and TIMP-3 accumulated
in the medium.
Our values for TIMP-3 inhibition of ADAMTS-5 (Ki=0.1–1.2 nM,
Table 2) are in agreement with the previously reported value of
0.66 nM (Kashiwagi et al., 2001). Our Ki values for TIMP-3 inhibition of
ADAMTS-4 (Ki=0.1–0.7 nM) are also in agreementwith that reported
by Kashiwagi et al. (2001), although higher values of 4–8 nM have
been reported in other studies (Hashimoto et al., 2001; Wayne et al.,
2007).
C-terminal domains distal to the disintegrin domain are required
for ADAMTS-4 and -5 activity on aggrecan and various other protein
substrates, but these domains had little effect on hydrolysis of the
synthetic substrates used in this study (data not shown). The isolated
catalytic domains of ADAMTS-4 and -5 had negligible activity on these
synthetic substrates. To date, the catalytic domain alone has not been
shown to effectively cleave protein substrates such as aggrecan,
suggesting that the disintegrin domain may be part of the minimal
catalytic unit. This view is supported by the crystal structures of
ADAMTS-4 and -5, which show that the disintegrin domain is locatedTable 1













MMP-1cat 1.2 0.8±0.4 0.9±0.6 1. 1±0.6
MMP-2 4.3 1.3±0.5 0.9±0.3 b0.1
MMP-2cat ND 0.8±0.1 1.0±0.3 0.9±0.3
MMP-3cat 66.9 11.1±5.0 9.1±3.3 1.0±0.4
a Ki(app) given as mean±standard deviation (n=4–6).close to the catalytic domain and may act as an extension of the
catalytic cleft (Mosyak et al., 2008).
The inhibitorymachinery of TIMPs is contained in their N-terminal
domains, and inmost cases, the C-terminal domains of bothMMPs and
TIMPs have aminimal effect on complex formation (Brew et al., 2000).
There are some notable exceptions to this, in which interactions other
than binding of the N-terminal TIMP domain to the catalytic domain of
the enzyme contribute substantially to the overall binding energy. In
particular, the C-terminal domains of TIMP-2, TIMP-3 and TIMP-4 bind
strongly to the MMP-2 hemopexin domain (Butler et al., 1999; Lee
et al., 2001; Morgunova et al., 2002; Murphy et al., 1992; Troeberg
et al., 2002) and the C-terminal domain of TIMP-1 binds to the
hemopexin domain of MMP-9 (Bodden et al., 1994).
While the C-terminal domains of MMPs either have little effect or
strengthen binding to TIMPs, the C-terminal domains of ADAM17
weaken interactionwith both full-length TIMP-3 and N-TIMP-3 by 10-
fold (Lee et al., 2002). Also, the ADAM17 catalytic domain interacts
more strongly with the prodomain than the enzyme with disintegrin
and cysteine-rich domains attached to the catalytic domain (Milla et
al., 1999). Lee et al. (2002) postulated that the C-terminal domains of
the enzyme may sterically hinder access to the catalytic site. The
spatial orientation of the ADAM17 C-terminal domains is not known,
as crystal structures are only available for the catalytic domain in
complex with either a hydroxamate inhibitor or N-TIMP-3 (Maskos et
al., 1998; Wisniewska et al., 2008). However, for the related snake
venom metalloproteinases, called vascular apoptosis-inducing pro-
teins (VAPs), crystal structures are available showing the catalytic,
disintegrin and cysteine-rich domains (Igarashi et al., 2007; Igarashi
et al., 2006; Takeda, 2008). These structures support Lee et al.'s (2002)
proposal that the C-terminal domains of ADAM17 may sterically
hinder TIMP-3 access to the active site as the C-terminal VAP domains
Fig. 2. ADAMTS-4 and ADAMTS-5 isoforms analyzed. Each isoform has a FLAG-tag at its C-terminus and was puriﬁed from the conditioned medium of transfected HEK293 cells by
FLAG afﬁnity chromatography. Dis, disintegrin domain; TS, thrombospondin domain; CysR, cysteine-rich domain; Sp, spacer domain.
466 L. Troeberg et al. / Matrix Biology 28 (2009) 463–469adopt a C-shaped conformation, with the concave surface of the
cysteine-rich domain being located near to and facing the catalytic
domain (Igarashi et al., 2007). Additionally, there is a “hinge” region
between the catalytic and disintegrin domains and the 6 available VAP
structures indicate ﬂexibility in the orientation of the catalytic domain
relative to the C-terminal domains.
In contrast to ADAM17, we found that the ADAMTS-4 and -5
C-terminal domains increase association with N-TIMP-3 by 5–7-fold
(Table 2). The C-terminal domains also increase association with full-
length TIMP-3, albeit to a lesser extent (Ki for ADAMTS-4 and -5 improves
2-fold). This is in agreement with the report of Wayne et al. (2007). In
particular, our data suggest that the TS domains of ADAMTS-4 and -5
are involved in interaction with TIMP-3. Deletion of the C-terminal
TS domain of ADAMTS-5 increases Ki for N-TIMP-3 by 3-fold. FurtherFig. 3. Inhibition of ADAMTS-4 and ADAMTS-5 by TIMP-3 and N-TIMP-3. ADAMTS5-1 (A, 0.5
3 (○) for 1 h at 37 °C and residual activity against Abz-TESE~SRGAIY-Dpa-KK determined (18
respectively for ADAMTS5-1, and 1.89±0.06 nM and 1.35±0.04 nM respectively for ADA
0.25–10 nM TIMP-3 (●) or N-TIMP-3 (○) for 1 h at 37 °C and residual activity against FA
had Ki(app) values of 0.39±0.03 nM and 0.19±0.04 nM respectively for ADAMTS4-1, an
given are the standard errors on the ﬁt of the data to the tight-binding equation (Eq. (deletion of the Sp and CysR domains has minimal effect on Ki, but
deletion of the ﬁrst TS domain results in a further increase in Ki for N-
TIMP-3. Ki values for ADAMTS-4 deletionmutants show the same result,
with deletion of the TS domain increasing Ki for N-TIMP-3 by 6-fold,
while deletion of the Sp and CysR domains had little effect. Interestingly,
the TS domains have also been shown to play a role in substrate re-
cognition and cleavage (Tortorella et al., 2000; Fushimi et al., 2008).
The domain architecture of the full-length ADAMTSs is not known,
as three-dimensional structures are only available for the catalytic and
disintegrin domains of ADAMTS-1, -4 and -5 (Gerhardt et al., 2007;
Mosyak et al., 2008; Shieh et al., 2008). Although the ADAMTS and
VAP disintegrin domains share sequence homology, it is not possible
to extrapolate to the ADAMTSs from the available VAP structures as
their domain arrangements are dissimilar and may adopt a differentnM) and ADAMTS5-5 (B, 0.5 nM)were incubated with 0.5–5 nM TIMP-3 (●) or N-TIMP-
h, 37°C). TIMP-3 and N-TIMP-3 had Ki(app) values of 0.70±0.04 nM and 0.14±0.02 nM
MTS5-5. ADAMTS4-1 (C, 0.5 nM) and ADAMTS4-4 (D, 0.5 nM) were incubated with
M-AE~LQGRPISIAK-TAMRA (1 μM) determined (18 h, 37 °C). TIMP-3 and N-TIMP-3
d 0.38±0.04 nM and 0.55±0.05 nM respectively for ADAMTS4-4. The error values
2)) (Bieth, 1995).
Table 2
Ki values (nM)a for mammalian-expressed TIMP-3 and N-TIMP-3 inhibition of
ADAMTS-4 and ADAMTS-5.
N-TIMP-3 TIMP-3 N-TIMP-3 TIMP-3
ADAMTS5-1 0.13±0.06 0.63±0.17
ADAMTS5-2 0.35±0.03 0.72±0.17 ADAMTS4-1 0.13±0.06 0.22±0.15
ADAMTS5-3 0.29±0.08 1.00±0.39 ADAMTS4-2 0.18±0.02 0.22±0.07
ADAMTS5-4 0.40±0.18 1.13±0.37 ADAMTS4-3 0.10±0.01 0.40±0.07
ADAMTS5-5 1.01±0.45 1.17±0.33 ADAMTS4-4 0.64±0.15 0.51±0.21
a Ki values given as mean±standard deviation (n=4–6).
467L. Troeberg et al. / Matrix Biology 28 (2009) 463–469orientation relative to the catalytic domain (Gerhardt et al., 2007;
Takeda, 2008). The crystal structures of the catalytic and disintegrin
domains of ADAMTS-4 with and without a low molecular weight
inhibitor determined byMosyak et al. (2008) indicated an ‘open’ and a
‘closed’ form, respectively. In the latter form, the residues Asp328 and
Thr329 in the so-called S2Vloop of 322CGXXXCDTL330 are around the
catalytic zinc and the side chain of Asp328 chelates the Zn2+ ion and
that of Thr329 ﬁlls the space at the mouth of the S1Vpocket. Thus, the
S2V loop remains as an auto-inhibitor unless structural re-arrange-
ments occur around this region and disrupt the interaction between
Asp328 and the Zn2+ ion. However, as proposed by Mosyak et al.
(2008), the active open form and the inactive closed formmay exist in
equilibrium. Full-length ADAMTS-4 and ADAMTS-5 are highly active
against a natural substrate, aggrecan, but deletion of the C-terminal
non-catalytic domains of the enzymes greatly reduces their activity
(Kashiwagi et al., 2004; Gendron et al., 2007; Fushimi et al., 2008).
This suggests that these domains alone or substrate binding to
these non-catalytic domains may shift the equilibrium to the more
open form. Our data support this possibility, since the presence of the
C-terminal domains enhances associationwith N-TIMP-3. Also, agents
that interact with the ADAMTS C-terminal domains, such as calcium
pentosan polysulfate and aggrecan, improve afﬁnity for TIMP-3
(Troeberg et al., 2008; Wayne et al., 2007).
It is unclear why the C-terminal domains favour association with N-
TIMP-3 more than with full-length TIMP-3. Given that N-TIMP-3 is a
slightly better inhibitor of full-length ADAMTS-4 and -5 than full-length
TIMP-3 (Table 2), steric clashes may occur between the C-terminal
domain of TIMP-3 and the ADAMTS non-catalytic domains. Alterna-
tively, a surface available in N-TIMP-3 but not full-length TIMP-3 may
enhance interaction with the non-catalytic domains of the enzyme,
which in turn, could increase the afﬁnity of binding to the active site.
Interestingly, N-TIMP-4 is also a better inhibitor of ADAM17 than full-
length TIMP-4 (Lee et al., 2005). The opposite is true for ADAM10,
which is not inhibited by N-TIMP-1 or N-TIMP-3, but is effectively
inhibited by full-length TIMP-1 and TIMP-3 (Rapti et al., 2008). The
ADAMs and the ADAMTSs analyzed to date thus vary considerably in
their afﬁnity for N-TIMP-3 relative to full-length TIMP-3, possibly
reﬂecting conformational diversity of their C-terminal domains.
Structural studies of the complex formed between full-length
ADAMTS-4 or -5 and TIMP-3 are necessary to obtain further informa-
tion on these molecular interactions.Table 3
Effect of glycosylation on TIMP-3 and N-TIMP-3 inhibition of ADAMTS4-2 and
ADAMTS5-2.
N-TIMP-3 Kia TIMP-3 Kia
Glycosylatedb Non-glycosylatedc Glycosylatedb Non-glycosylatedd
ADAMTS5-2 0.35±0.03 0.32±0.12 0.72±0.17 1.37±0.4
ADAMTS4-2 0.18±0.02 0.79±0.02 0.22±0.07 0.20±0.08
a Ki values (nM) are expressed as mean±standard deviation (n=4).
b Glycosylated TIMP-3 and N-TIMP-3 were expressed in HEK293 cells.
c Non-glycosylated N-TIMP-3 was expressed in E. coli.
d Non-glycosylated TIMP-3 was expressed in HEK293 cells treated with 5 μg/ml
tunicamycin.4. Experimental procedures
4.1. Preparation of TIMP-3 and N-TIMP-3 from HEK293
Recombinant humanC-terminally FLAG-taggedTIMP-3 andN-TIMP-3
were expressed using pCEP4-based expression vectors (Invitrogen,
Paisley, UK) constructed by the PCR method. The TIMP-3 expression
vector was constructed using the sense primer 5′-CTCGAGTCCC-
TTTTTTTTCCACAGGAGCTCGCCGCCACCATGACCCCTTGGCTCGGGCT-
CATCGTGCTC-3′ containing an XhoI site (underlined), Kozak consensus
sequence (in italics) and TIMP-3N-terminal sequence, and the anti-sense
primer 5′-CTCGAGCTACTTATCGTCGTCATCCTTGTAATCGGGGTCTGTGG-
CATTGATGATGCTTTTATCCGG-3′ containing an XhoI site (underlined),
FLAG epitope (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-stop) (in italics) and
the C-terminal sequence of TIMP-3, with a TIMP-3 vector kindly provided
by Prof M. Seiki (University of Tokyo, Japan) as a template. The N-TIMP-3
(residues 1–121, from 1CTCSPS to HLGCN121) vector was constructed
using the same sense primer and the anti-sense primer 5′-CTCGAGC-
TACTTATCGTCGTCATCCTTGTAATCGTTACAACCCAGGTGATACCGATAGTT-
CAGCC-3′ containing an XhoI site (underlined), FLAG epitope (in italics)
and theC-terminal sequence ofN-TIMP3. PCR fragmentswere ligated into
pCEP4 at the XhoI site.
Human embryonic kidney HEK293 cells were transfected with the
expression plasmids by lipofection with FuGENE6 (Roche Applied
Science, Basel, Switzerland) and transfected cells selected by treatment
with 800 μg/ml hygromycin B (PAA Laboratories GmbH, Pasching,
Austria) over 3 weeks. Transfected cell lines were maintained
under standard cell culture conditions in Dulbecco's modiﬁed Eagle's
medium (DMEM) containing 10% (v/v) fetal calf serum, penicillin
(100units/ml), streptomycin (100units/ml), 250 μg/ml G418 (PAA
Laboratories GmbH, Pasching, Austria) and 800 μg/ml hygromycin B.
For expression of recombinant FLAG-tagged TIMP-3 and N-TIMP-3,
transfected cells were treated with 30 mM sodium chlorate (NaClO3,
Sigma-Aldrich, Dorset, UK) in serum-free DMEM. Non-glycosylated
full-length human TIMP-3 was prepared by treating transfected
HEK293 cells with 5 μg/ml tunicamycin in addition to sodium chlorate.
In all cases, medium was changed every 2 days to reduce TIMP-3-
induced apoptosis (Bond et al., 2000). Conditioned media (0.5–1 l)
were centrifuged to remove cell debris and applied to a column of anti-
FLAG M2-agarose (1.5 ml, Sigma-Aldrich, Dorset, UK). The column was
washed with 50 mM Tris–HCl, pH 7.5, 1 M NaCl, 10 mM CaCl2, 0.05%
Brij-35, 0.02% NaN3. Bound proteins were eluted with 200 µg/ml FLAG
peptide (Sigma-Aldrich, Dorset, UK) in TNC buffer (50 mMTris–HCl, pH
7.5, 150 mM NaCl, 10 mM CaCl2, 0.05% Brij-35 and 0.02% NaN3). To
remove the FLAG peptide, the eluate was applied to a Macro-Prep 25 S
resin (400 μl, BioRad, Hemel Hempstead, UK) equilibrated in TNC
buffer. Recombinant protein was eluted with 50 mM Tris–HCl, pH 7.5,
1 M NaCl, 10 mM CaCl2, 0.05% Brij-35 and 0.02% NaN3. Finally, the
buffer was exchanged for TNC buffer using a PD-10 desalting column
(GE Healthcare, Bucks, UK).
The purity of recombinant TIMP-3 andN-TIMP-3was conﬁrmed by
reducing SDS-PAGE (Bury, 1981) and their active concentrations
determined by titration with known concentrations of the catalytic
domain of MMP-1. The identity of the puriﬁed proteins was conﬁrmed
using a commercial rabbit polyclonal antibody (AbCam, Cambridge,
UK, catalogue number ab39184) and M2 anti-FLAG antibody (Sigma-
Aldrich, Dorset, UK).
N-terminal analysis was carried out on TIMP-3 and N-TIMP-3
prepared from HEK293. Samples were denatured in SDS sample buffer
at 80 °C in the presence of 50 mM dithiothreitol. SDS-PAGE was
performed on a 10% gel (10 cm×10 cm×0.15 cm) according to Bury
(1981). The gel was electroblotted to Immobilon-P membrane (Milli-
pore) in 10 mM CAPS 10% methanol pH 11 (Matsudaira, 1987) and
stained forproteinusingCoomassie Brilliant Blue. Bands of interestwere
excised and placed directly onto a Polybrene-treated glass ﬁlter.
Samples were analyzed by automated Edman degradation using an
468 L. Troeberg et al. / Matrix Biology 28 (2009) 463–469Applied Biosystems Procise 494HT sequencer with on-line phenylthio-
hydantoin HPLC analysis. The instruments were operated according to
the manufacturers' instructions.
4.2. Preparation of E. coli-expressed N-TIMP-3, ADAMTSs and MMPs
The N-terminal domain of human TIMP-3 with C-terminal His-tag
was expressed in E. coli, puriﬁed and folded in vitro (Kashiwagi et al.,
2001). Human ADAMTS-4 and ADAMTS-5 deletion mutants (Fig. 2)
were expressed and puriﬁed as previously described (Fushimi et al.,
2008). The catalytic domains of humanMMP-1 (MMP-1cat) andMMP-3
(MMP-3cat) were prepared as described (Chung et al., 2000; Suzuki
et al., 1998).HumanproMMP-2and thepro-formof theMMP-2 catalytic
domain (proMMP-2ΔC, lacking hemopexin-domain residues 466 to
660) were expressed in HEK293 cells using pCEP4-based expression
vectors. The proMMP-2ΔC expression plasmid was constructed from
the proMMP-2/pCEP4 plasmid by PCR mutagenesis using the sense
primer 5′-CAGTACATCAAGTGTATCATATGCCAAGTCCGCCCC-3′ and the
anti-sense primer 5′-GCCAAGGTCAATAAGCTTTCATCACCCATAGAGCTC-
3′. The resulting PCR product was digested with KpnI and HindIII and
ligated into similarly cut pCEP4. Both vectors were transfected
into HEK293 cells and transfected cells selected by treatment with
1000 μg/ml hygromycin B as described for TIMP-3 above. Recombinant
proMMP-2 and proMMP-2cat were puriﬁed from the conditioned
mediumby gelatin afﬁnity chromatography and gel ﬁltration chromato-
graphy (Itoh et al., 1995). Active forms of the enzymeswere prepared by
treatment with 1 mM 4-aminophenylmercuric acetate (ICN Biochem-
icals, Solon, OH, USA) for 60 min at 37 °C, after which the buffer was
exchanged for TNC buffer using a PD-10 desalting column (GE Health-
care, Bucks, UK). Active concentrations of all enzymes were determined
by titration against a known concentration of E. coli-expressedN-TIMP-3
(for ADAMTS-4 and -5) or TIMP-1 (for MMPs).
4.3. Measurement of inhibition constant, Ki
All enzyme assays were conducted in TNC buffer (50 mM Tris–HCl,
pH 7.5, 150 mM NaCl, 10 mM CaCl2, 0.05% Brij-35 and 0.02% NaN3) at
37 °C, using a Gemini microplate spectroﬂuorometer (Molecular
Devices, Sunnyvale, CA, USA).
The activity of ADAMTS-4 was monitored using the ﬂuorescent
peptide substrate carboxyﬂuorescein-Ala-Glu~Leu-Asn-Gly-Arg-Pro-
Ile-Ser-Ile-Ala-Lys-N,N,N’,N’-tetramethyl-6-carboxyrhodamine
(FAM-AE~LQGRPISIAK-TAMRA) at a ﬁnal concentration of 0.5 μM with
an excitation wavelength of 485 nm and an emission wavelength of
538 nm (495 nm cut-off) (Wayne et al., 2007).
The activity of ADAMTS-5 was monitored using the ﬂuorescent
peptide substrate ortho-aminobenzoyl-Thr-Glu-Ser-Glu~Ser-Arg-Gly-
Ala-Ile-Tyr-(N-3-[2,4-dinitrophenyl]-L-2,3-diaminopropionyl)-Lys-
Lys-NH2 [Abz-TESE~SRGAIY-Dpa-KK] (kindly provided by Dr. Andrew
Parker, AstraZeneca, Macclesﬁeld, UK). This peptide is based on the
ADAMTS-4 cleavage site in rat brevican (Nakamura et al., 2000;
Matthews et al., 2000). ADAMTS-5 has been predicted to also cleave at
this site (Nakada et al., 2005) and we found that recombinant
ADAMTS-5 cleaved this substrate more readily than ADAMTS-4 in
vitro. The substrate was used at a ﬁnal concentration of 20 μMwith an
excitation wavelength of 300 nm and an emission wavelength of
430 nm (420 nm cut-off). Substrate hydrolysis by 0.5 nM ADAMTS-5
was conﬁrmed to be linear for 18 h at 37 °C.
Activities of MMP-1 and MMP-2 were measured using the ﬂuo-
rescent quenched peptide substrate (7-methoxycoumarin-4-yl)
acetyl-Pro-Leu-Gly-Leu-(N-3-[2,4-dinitrophenyl]-L-2,3-diaminopro-
pionyl)-Ala-Arg-NH2 (Mca-PLGL-Dpa-AR) at 1.5 μM ﬁnal concentra-
tion (Knight et al., 1992). Activity of MMP-3cat was measured using
the ﬂuorescent quenched substrate NFF-3, Mca-Arg-Pro-Lys-Pro-Val-
Glu-Nva-Trp-Arg-Lys(2,4-dinitrophenyl)-NH2 at 1.5 μM ﬁnal concen-
tration (Nagase et al., 1994).Ki values of TIMP-3 for various isoforms of ADAMTS-4 and
ADAMTS-5 were determined under equilibrium kinetic conditions
(Bieth, 1995). Final enzyme concentrations for Ki determinations
were as follows: ADAMTS-4 and -5 were used at 0.5 nM, MMP-1,
MMP-1cat and MMP-3cat were used at 1 nM, and MMP-2 and MMP-
2cat were used at 0.125 nM. Enzymes were pre-incubated (1 h, 37 °C)
with TIMP-3 (0.5–100 nM ﬁnal concentration) and equilibrium rate of
substrate hydrolysis (vs) determined (18 h, 37 °C). Prism software
(GraphPad, La Jolla, CA, USA) was used to ﬁt the data to the tight-









where vo is equilibrium rate of substrate hydrolysis in the absence of
inhibitor, Eo is the total enzyme concentration, Io is the total inhibitor
concentration and Ki(app) is the apparent inhibition constant.
To determine Ki from Ki(app), the Km of the enzymes for the
substrates used must be known (Bieth, 1995). Wayne et al. (2007)
determined a Km value of 15 μM for ADAMTS-4 cleavage of FAM-
AE~LQGRPISIAK-TAMRA, which we used at 0.5 μM. We determined a
Km value of 76 μM for ADAMTS-5 cleavage of Abz-TESE~SRGAIY-Dpa-






where Ki is the inhibition constant, [S] is the initial substrate con-
centration and Km is the Michaelis constant for the substrate used.
Therefore, Ki(app) was divided by 1.033 to determine Ki for ADAMTS-4,
and by 1.26 to determine Ki for ADAMTS-5.
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ABSTRACT Aggrecan is a major matrix component
of articular cartilage, and its degradation is a crucial
event in the development of osteoarthritis (OA). Ada-
malysin-like metalloproteinase with thrombospondin
motifs 5 (ADAMTS-5) is a major aggrecan-degrading
enzyme in cartilage, but there is no clear correlation
between ADAMTS-5 mRNA levels and OA progression.
Here, we report that post-translational endocytosis of
ADAMTS-5 by chondrocytes regulates its extracellular
activity. We found 2- to 3-fold reduced aggrecanase
activity when ADAMTS-5 was incubated with live por-
cine cartilage, resulting from its rapid endocytic clear-
ance. Studies using receptor-associated protein (RAP),
a ligand-binding antagonist for the low-density lipopro-
tein receptor-related proteins (LRPs), and siRNA-medi-
ated gene silencing revealed that the receptor respon-
sible for ADAMTS-5 clearance is LRP-1. Domain-
deletion mutagenesis of ADAMTS-5 identified that the
noncatalytic first thrombospondin and spacer domains
mediate its endocytosis. The addition of RAP to porcine
cartilage explants in culture increased the basal level of
aggrecan degradation, as well as ADAMTS-5-induced
aggrecan degradation. Notably, LRP-1-mediated en-
docytosis of ADAMTS-5 is impaired in chondrocytes
of OA cartilage, with 90% reduction in protein
levels of LRP-1 without changes in its mRNA levels.
Thus, LRP-1 dictates physiological and pathological
catabolism of aggrecan in cartilage as a key modula-
tor of the extracellular activity of ADAMTS-5.—
Yamamoto, K., Troeberg, L., Scilabra, S. D., Pelosi,
M., Murphy, C. L., Strickland, D. K., Nagase, H.
LRP-1-mediated endocytosis regulates extracellular
activity of ADAMTS-5 in articular cartilage. FASEB J.
27, 000–000 (2013). www.fasebj.org
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Articular cartilage consists of a sparse population
of chondrocytes in an abundant extracellular matrix
(ECM), whose major components are collagen fibrils
and aggrecan proteoglycans (1). Collagen fibrils,
mainly type II collagen, form a meshwork and provide
the tissue with tensile strength. Aggrecan, present as
large aggregated complexes interacting with hyaluro-
nan and link proteins, forms a hydrated gel within the
collagen meshwork and gives cartilage its ability to
withstand mechanical compression. Chondrocytes, the
only cell type present in articular cartilage, regulate
tissue homeostasis by balancing the synthesis and deg-
radation of the ECM macromolecules. A disruption in
this balance results in the cartilage destruction seen in
rheumatoid arthritis and osteoarthritis (OA), largely
due to elevated proteolytic enzyme activities (2, 3).
Because the presence of aggrecan prevents collagenoly-
sis by collagenases of the matrix metalloproteinase
(MMP) family, aggrecan loss is considered to be a
crucial early event in the development of arthritis,
particularly OA (4, 5).
The proteinases responsible for aggrecan degrada-
tion are MMPs and aggrecanases; the latter being
members of the adamalysin with thrombospondin
motifs (ADAMTS) family (3). Aggrecanases were
defined by their ability to cleave the Glu373-Ala374
bond of the aggrecan core protein (6, 7). Elevated
aggrecanase-generated aggrecan fragments were
found in synovial fluids of patients with OA and
inflammatory joint disease (8, 9). These fragments
were also detected in normal synovial fluid and
serum of animals (7), suggesting that aggrecanases
function in both physiological and pathological ca-
tabolism of aggrecan.
The ADAMTSs are multidomain metalloproteinases
consisting of a metalloproteinase domain, a disintegrin
1 Correspondence: Matrix Biology Section, Kennedy Institute
of Rheumatology, Nuffield Department of Orthopaedics, Rheu-
matology andMusculoskeletal Sciences, University of Oxford, 65




Abbreviations: -CD, -cyclodextrin; ADAM, adamalysin;
ADAMTS, adamalysin-like metalloproteinase with thrombos-
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ECM, extracellular matrix; EEA1, early endosome antigen 1;
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domain, a thrombospondin (TS) domain, a cysteine-
rich (CysR) domain, a spacer (Sp) domain and a
number of additional TS domains (10). Among the
ADAMTSs that have aggrecanase activity, ADAMTS-4
and ADAMTS-5 have been considered as the major
aggrecanases involved in cartilage matrix turnover be-
cause of their effective aggrecanase activity in vitro (11,
12). The expression of ADAMTS-4 at mRNA and pro-
tein levels correlate with the progression of OA in
humans (13). In contrast, ADAMTS-5-null mice, but
not ADAMTS-4-null mice, showed protection of their
cartilage from destruction when challenged in an OA
model induced by surgically induced joint destabiliza-
tion (14, 15) or antigen-induced arthritis (16), indicat-
ing that ADAMTS-5 plays a key role in aggrecan degra-
dation, at least in mice. ADAMTS-5 is 30 times more
active on aggrecan than ADAMTS-4 (12). Nevertheless,
mRNA levels for ADAMTS-5 in OA cartilage are not
significantly elevated compared to that in normal car-
tilage (13, 17, 18). Treatment of human chondrocytes
with the proinflammatory cytokine interleukin-1 (IL-1)
increased ADAMTS-4 mRNA levels (17), but the levels
of ADAMTS-5 mRNA were reported to be inconsistent
and do not correlate with degradation of aggrecan in
cartilage (see ref 19 for review). This led us to postulate
that the aggrecanase activity of ADAMTS-5 in cartilage
may be regulated at the protein level, and changes at
the mRNA level may not be the major factor controlling
its aggrecanase activity. The aggrecanase activity of
ADAMTS-5 is inhibited by tissue inhibitor of metallo-
proteinases 3 (TIMP-3), which is expressed in cartilage
(20). Furthermore, processing of the C-terminal ancil-
lary domain of ADAMTS-5 reduces the aggrecanase
activity (21).
Biochemical characterization of ADAMTS-5 has
been carried out in vitro using purified monomeric
aggrecan as a substrate. These studies do not reflect
the complexity of the cartilage matrix where numer-
ous minor ECM components, such as fibromodulin;
decorin; biglycan; cartilage oligomeric matrix pro-
tein; type VI, IX, and XI collagens; matrillins; and
cell surface proteoglycans assemble together with
type II collagen fibrils and aggrecan (1). Further-
more, ADAMTS-5 binds to the negatively charged cell
surface and ECM molecules (21), and sulfated poly-
saccharides, such as heparan sulfate, may regulate
the aggrecanase activity of ADAMTS-5 (20). There-
fore, we tested aggrecanase activity of ADAMTS-5 in
the context of the cartilage matrix using dissected
porcine articular cartilage, which presents a substrate
close to physiological conditions. We confirmed that
ADAMTS-5 has a greater aggrecan-degrading activity
than ADAMTS-4, MMP-1, or MMP-13, and we found
that the aggrecanase activity of ADAMTS-5 was much
lower when live cartilage was used as a substrate. This
was due to a rapid endocytic clearance and degrada-
tion of ADAMTS-5 by chondrocytes, which is me-
diated by low-density lipoprotein receptor-related
protein (LRP)-1, but this endocytic pathway is dys-




The sources of materials used were as follows: dimethylmeth-
ylene blue (DMMB), dynasore, -cyclodextrin (-CD), poly-
myxin B, and the anti-FLAG M2 mouse monoclonal antibody
from Sigma-Aldrich (Dorset, UK); the anti-early endosome
antigen 1 (EEA1) rabbit polyclonal antibody, and the anti-
LRP-1 mouse monoclonal antibodies 5A6 and 8G1 from
Abcam (Cambridge, UK) and Calbiochem (San Diego, CA,
USA); the anti-actin antibody from Santa Cruz Biotechnology
(Santa Cruz, CA, USA); the anti-tubulin antibody from Cell
Signaling (Danvers, MA, USA); and BC-3 mouse monoclonal
antibody that recognizes the N-terminal 374ARGSV generated
by aggrecanase cleavage of aggrecan core protein from Ab-
cam. The anti-human ADAMTS-5 catalytic domain rabbit
polyclonal antibody was raised in rabbits and characterized
(21). Recombinant human ADAMTS-5 and its domain-dele-
tion mutants, ADAMTS-4 lacking the Sp domain, MMP-1, and
MMP-13, were prepared as described previously (11, 21, 22).
Recombinant human IL-1 was kindly provided by Prof. J.
Saklatvala (Kennedy Institute of Rheumatology, London,
UK). All other reagents used were of the highest analytical
grade available.
Expression and purification of human receptor-associated
protein (RAP)
Recombinant human C-terminally His-tagged RAP was ex-
pressed in Escherichia coli using a pET3a-based expression
vector (Novagen/EMD Biosciences, Madison, WI, USA). The
human RAP cDNA was isolated by polymerase chain reaction
(PCR) using cDNA from HT1080 cells as a template with the
sense primer 5=-TGGCATATGTACTCGCGGGAGAAGAAC-
CAGCCCAAGCCGTCCCCGAAACGC-3= containing an NdeI
site (underscored) and RAP N-terminal sequence and the
antisense primer 5=-CCAGGATCCCTAATGGTGATGGTGAT-
GGTGGAGTTCGTTGTGCCGAGCTCT-3= containing a BamHI
site (underscored), a 6-histidine tag (in italics) and the
C-terminal sequence of RAP. PCR fragments were ligated into
CloneJET cloning vector (Fermentas, Glen Burnie, MD,
USA), digested with NdeI and BamHI, and ligated into simi-
larly cut pET3a. The sequence was confirmed by DNA se-
quencing. E. coli BL21(DE3) cells were transformed with the
RAP expression plasmid, and cultures grown at 37°C in 1 L of
Luria-Bertani broth with 50 g/ml carbenicillin. Once the
culture reached an OD600 of 0.6, protein expression was
induced by addition of 1 mM isopropyl--d-thiogalactoside
for 3 h at 37°C. Cells were harvested by centrifugation and
lysed in 40 ml of phosphate-buffered saline using a French
press. The soluble fraction of the cell lysate was applied to
nickel-nitrilotriacetic acid Superflow resin (Qiagen, Valencia,
CA, USA) equilibrated in 20 mM HEPES (pH 7.5) and 150
mM NaCl. The column was washed in 20 mM HEPES (pH
7.5), 1 M NaCl, and 50 mM imidazole, and further washed
with an excess amount of 20 mM HEPES (pH 7.5), 150 mM
NaCl, and 60% isopropanol to remove endotoxin (23).
Bound protein was eluted in 20 mM HEPES (pH 7.5), 150 M
NaCl, and 500 mM imidazole. RAP-containing fractions were
pooled and dialyzed against 20 mM HEPES (pH 7.5) and 150
mM NaCl. To ascertain the levels of LPS in the recombinant
RAP preparation, the Limulus amoebocyte lysate assay (Cam-
brex, East Rutherford, NJ, USA) was used, according to the
manufacturer’s instructions. The recombinant RAP used in
this study had an endotoxin level  10 pg/ml.
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Porcine articular cartilage culture
Porcine articular cartilage from the metacarpophalangeal joints
of 3- to 9-mo-old pigs was dissected into small pieces (6 mm3:
10 mg wet vol). Each piece was placed in one well of a
round-bottom 96-well plate and allowed to rest for 24 h in 200 l
of Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal bovine serum (FBS) before use. Themediumwas then
replaced, and the cartilage was rested for a further 24 h in 200
l of DMEM at 37°C (for fresh live cartilage) before the
aggrecan degradation and endocytosis assays. For freeze-thawed
cartilage experiments, cartilage pieces were frozen at80°C and
thawed in the same medium and replaced with fresh medium
before subjecting to subsequent assays.
Analysis of aggrecan degradation
Each piece of cartilage was incubated in 100l of DMEMwith or
without IL-1 (10 ng/ml) or various concentrations of MMPs
and ADAMTSs. Three pieces of cartilage were subjected to each
treatment. After incubation for various periods of time, the
conditioned media were harvested, and glycosaminoglycan
(GAG) released into the medium was measured using the
DMMB assay (5). Aggrecan fragments in the medium were
deglycosylated, as described previously (11), and analyzed by
Western blotting using an anti-ARGSV aggrecan neoepitope
antibody. Immunoreactive bands were quantified using ImageJ
(U.S. National Institutes of Health, Bethesda, MD, USA) and
results are presented as relative intensities.
Isolation of chondrocytes and cell culture
Human articular cartilage was obtained from patients after they
provided informed consent and following approval by Riverside
ethics committee. Non-OA cartilage was obtained from the knee
following amputation due to soft tissue sarcoma and osteosar-
coma with no involvement of the cartilage. Tissues were ob-
tained from 8 patients (5 male, 3 female; aged 12–55 yr, mean
age 31.6 yr). OA cartilage was obtained from patients undergo-
ing joint replacement surgery. Tissues were obtained from 7
patients (2 male, 5 female; aged 53–66 yr, mean age 61 yr).
Chondrocytes were isolated as described previously (20). Pri-
mary porcine cells and both primary and passaged human cells
were used in the experiments. For the ADAMTS-5 endocytosis
assay, cells were plated at a density of 2.5  105 cells/well
(24-well plate) in DMEM containing 10% FCS.
Analysis of ADAMTS-5 clearance
Cartilage explants or cells were incubated in 100 or 400 l of
DMEM with or without 80 M dynasore, 10 mM -CD, or 500
nM RAP. After incubation for 30 min, media were replaced
with DMEM containing 10 nM ADAMTS-5 or its domain
deletion mutants with or without 80 M dynasore or 500 nM
RAP. Four pieces of cartilage were subjected to each treat-
ment. After incubation for various periods of time, media
were collected; the protein was precipitated with TCA and
dissolved in 50 l of 1 SDS sample buffer [50 mM Tris-HCl
(pH 6.8)/5% 2-mercaptoethanol, 2% SDS and 10% glycerol].
The cartilage explants and cells were washed with DMEM and
lysed in 50 l of 2 SDS-sample buffer. All samples were
analyzed by SDS-PAGE and Western blotting using an
anti-ADAMTS-5 catalytic domain antibody. Immunoreactive
bands were quantified using ImageJ, and the amounts of
ADAMTS-5 remaining in the medium and cell lysate at each
time point were calculated as a percentage of the amount of
ADAMTS-5 at 0 h.
Immunocytochemical localization of endocytosed ADAMTS-5
Cultured cells on 4-well Lab-Tek chamber slides (Nunc,
Roskilde, Denmark) were incubated in DMEM with 10 nM
ADAMTS-5 in the absence or presence of 500 nM RAP for 1
h. Cells were washed with DMEM, fixed with 3% paraformal-
dehyde in Tris-buffered saline (TBS; 10 min, room tempera-
ture) and permeabilized with TBS containing 10 mM CaCl2
and 0.1% Triton X-100 (15 min, room temperature). To
visualize ADAMTS-5 within the cartilage, porcine articular carti-
lage explants were incubated as described above for 3 h.
Explants were washed with DMEM and fixed with 4% formalin
(24 h, room temperature). Explants were then snap-frozen and
sectioned (5-m sections) using a CM1900 cryostat (Leica
Microsystems, Wetzlar, Germany). Each sample was incubated
with anti-FLAG M2 mouse monoclonal antibody and anti-EEA1
rabbit polyclonal antibody (3 h, room temperature). Alexa Fluor
488-conjugated anti-mouse IgG and Alexa Fluor 568-conjugated
anti-rabbit IgG (Molecular Probes, Eugene, OR, USA) were used
to visualize the antigen signals (1 h, room temperature). Actin
was stained with actin stain 670 phalloidin (Cell Signaling), and
nuclei were stained with DAPI. Samples were viewed using a
Nikon Eclipse TE2000-U confocal laser scanning microscope
(Nikon, Tokyo, Japan). The data were collated using Volocity
software (Improvision, Coventry, UK).
siRNA-mediated knockdown of LRP-1 in human
articular chondrocytes
siRNA oligonucleotides for LRP-1 (On-TargetPlus SMART-
pool siRNA) and nontargeting oligonucleotide were pur-
chased from Thermo Scientific Dharmacon (Lafayette, CO,
USA). Human articular chondrocytes were plated at a density
of 1.5  106 cells/dish (6-cm dish) in DMEM containing 10%
FCS and incubated until 50% confluent. Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) was used to transfect cells
with siRNA at a final concentration of 10 nM in Opti-MEM I.
At 4 h after transfection, the Opti-MEM was removed and
replaced with DMEM containing 10% FCS.
Quantitative reverse transcriptase–PCR
RNA was extracted and prepared using the RNeasy mini kit
(Qiagen, Valencia, CA, USA) following the manufacturer’s
guidelines. cDNA was generated using a reverse-transcription
kit (Applied Biosystems, Foster City, CA, USA) and random
primers from 0.5 g of total RNA. Newly synthesized cDNA
was diluted 5-fold in DNase-free water. Four percent of this
cDNA was then used for real-time PCR assays using TaqMan
technology (Applied Biosystems). The  threshold cycle
(Ct) method of relative quantitation was used to calculate
relative mRNA levels for each transcript examined. The 60S
acidic ribosomal protein P0 (RPLP0) gene was used to
normalize the data. Predeveloped primer/probe sets for
LRP-1 and RPLP0 were purchased from Applied Biosystems.
Western blotting analysis of LRP-1 protein
Cultured cells (2105) were lysed in 50 l of 2 SDS-sample
buffer without 2-mercaptoethanol, and a portion of the lysates
was analyzed by SDS-PAGE and Western blotting using anti-
LRP-1 heavy-chain and light-chain antibodies. Immunoreactive
bands were quantified using ImageJ, and the amounts of LRP-1
heavy chain and light chain in cell lysates were calculated as a
percentage of the amount of LRP-1 or shown as relative LRP-1
expression. Cellular tubulin was used to normalize the data.
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RESULTS
Aggrecanase activity of ADAMTS-5 is greatly reduced
in live compared to dead cartilage
To investigate the ability of ADAMTS-4 and ADAMTS-5 to
cleave aggrecan in cartilage, recombinant ADAMTS-4
lacking the C-terminal Sp domain or ADAMTS-5 lacking
the C-terminal TS2 domain was added to live or freeze-
thawed porcine cartilage explants, and subsequent GAG
release was monitored. These two forms of aggrecanases
were used as they are readily available in a pure form (11,
21). Freeze-thawed cartilage was used to eliminate the
involvement of metabolically active live chondrocytes.
Freeze-thawing of cartilage-killed chondrocytes, and these
cartilages did not respond to IL-1 stimulation, while live
cartilage exhibited a 4.0-fold increase in GAG release into
the medium on IL-1 treatment (Fig. 1A). Treatment of
dead cartilage with 50 nM ADAMTS-4, 5 nM ADAMTS-5,
100 nM MMP-1, or 50 nM MMP-13 caused a 4.3-,
11.0-, 2.4-, or 2.2-fold increase in GAG release, re-
spectively. When the rate of aggrecan cleavage was
compared by measuring GAG release from dead
cartilage, ADAMTS-5 cleaved aggrecan fastest, at a
rate 19 times faster than that of ADAMTS-4 (Fig.
1B). When live cartilage was used, the amounts of
GAG released by ADAMTS-4, MMP-1, or MMP-13
were similar to those released from dead cartilage
(Fig. 1A). However, ADAMTS-5 showed much lower
levels of GAG release when added to live cartilage. A
time-course study indicated that ADAMTS-5 digested
aggrecan in dead cartilage 1.6- to 2.0-fold more
effectively than in live cartilage (Fig. 1C). Analysis of
aggrecan breakdown products with an anti-ARGSV
neoepitope antibody indicated that aggrecan was
cleaved at the Glu373-Ala374 bond, characteristic of
aggrecanase activity (Fig. 1D).
Rapid clearance of ADAMTS-5 by articular chondrocytes
To investigate the cause of reduced aggrecanase activity of
ADAMTS-5 with live cartilage, we monitored the level of
exogenously added ADAMTS-5 in the medium and in the
cartilage explants by Western blot analysis. When added to
live cartilage, ADAMTS-5 disappeared from the culture me-
diumandwas almost completely absent after 4 hwithout any
detectable fragments (Fig. 2A, B). In contrast, relatively large
amounts of ADAMTS-5 were detected in the medium of
dead cartilage even after 4h. ADAMTS-5was also detected in
extracts from dead cartilage after 2–4 h, but not in live
cartilage.We could not detect endogenousADAMTS-5, as its
level was too low to detect by thismethod.WhenADAMTS-5
was incubated with isolated chondrocytes, it was also
depleted from the medium with similar kinetics to
that seen in live cartilage, with a half-life of 80 min.
We estimated 3.5  106 ADAMTS-5 molecules were
cleared by a single chondrocyte within 1 h (Fig. 2C).
LRP-mediated endocytic clearance of ADAMTS-5
To investigate the mechanism of ADAMTS-5 disappear-
ance, we first examined the effect of proteinase inhib-
itors, but neither the broad-spectrum hydroxamate
metalloproteinase inhibitor GM6001 nor a proteinase
inhibitor cocktail (mixture of inhibitors for serine,
cysteine, and aspartic proteinases) inhibited ADAMTS-
5 disappearance. However, dynasore, an inhibitor of
dynamin, which is required for most endocytic path-
ways, including clathrin- and caveolae-mediated endo-
cytosis (24), almost completely inhibited ADAMTS-5
depletion from the medium of live cartilage (Fig. 3A).
By contrast, -CD, which inhibits caveolae-mediated
endocytosis by depleting cholesterol from the cell
membrane (25), did not inhibit it (Fig. 3A), indicating
that ADAMTS-5 disappearance is due to a clathrin-
dependent endocytic clearance. No significant cytotox-
Figure 1. Aggrecanase activity of ADAMTS-5 is greatly reduced in live compared to dead
cartilage. A) Live and freeze-thawed (dead) porcine cartilage explants were incubated
with 10 ng/ml IL-1 (IL-1), 50 nM ADAMTS-4 (TS-4), 5 nM ADAMTS-5 (TS-5), 100 nM
MMP-1, or 50 nM MMP-13 for 24 h. GAG released into the medium was measured by
DMMB assay. B) Time course of GAG released into the medium of dead cartilage
explants incubated with 20 nM ADAMTS-4 or 5 nM ADAMTS-5. C) Time course of GAG
released into the medium of live and dead cartilage explants incubated with 5 nM
ADAMTS-5. Bars and points represent means 	 sd for triplicate assays (n
3). *P  0.05;
unpaired t test. D) Western blotting analysis of the medium obtained after 24 h culture
in A for aggrecan fragments using an anti-ARGSV neoepitope antibody. L, live cartilage;
D, dead cartilage.
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icity of dynasore on chondrocytes was found by
3-(4,5-dimethylthiazole-2-yl)-2,5diphenyl tertasolium
bromide (MTT) assay (data not shown). We then
found that RAP, an antagonist of ligand binding to
LRP receptors, inhibited ADAMTS-5 uptake by live
cartilage and chondrocytes (Fig. 3B, C), suggesting
that ADAMTS-5 is endocytosed by a member of the
LRPs. The LRP-dependent internalization of
ADAMTS-5 was confirmed by immunofluorescent con-
focal microscopy. Punctate staining of ADAMTS-5 was
detected within the cells, and the staining colocalized
with EEA1, a marker for early endosomes (Fig. 3D).
The fluorescent signal of ADAMTS-5 was absent in cells
incubated without ADAMTS-5, indicating the specificity
of the staining. Consistent with the data from Western
blot analysis, the intracellular fluorescent signal for
ADAMTS-5 was abolished in the presence of RAP.
Heparin also blocked the internalization of ADAMTS-5,
suggesting that basic residues of the enzyme are in-
volved in interaction with LRP. When live cartilage was
incubated with ADAMTS-5, fluorescent ADAMTS-5 sig-
nal was observed within cells located in the superficial
zone of the cartilage, and this signal was abolished by
RAP (Fig. 3E). ADAMTS-5 was internalized even in the
presence of 50 M GM6001 (data not shown), suggest-
ing that the enzyme can penetrate into the cartilage
without matrix degradation.
siRNA-mediated knockdown of LRP-1 impairs
ADAMTS-5 endocytosis in human chondrocytes
Among themembers of the low-density lipoprotein recep-
tor family, LRP-1 is known to mediate endocytosis of a
number of proteinases and proteinase-inhibitor com-
plexes (26). Therefore, we silenced LRP-1 in normal
human chondrocytes with a gene-specific siRNA to inves-
tigate its possible involvement. As shown in Fig. 4A,
LRP-1-targeting siRNA-depleted LRP-1 mRNA levels by
93% compared to the nontargeting siRNA control. West-
ern blot analysis of the cell extracts confirmed that the
levels of the 515-kDa extracellular heavy chain and the
85-kDa light chain containing the transmembrane do-
main were reduced by 95 and 80% by targeting siRNA
compared to the nontargeting siRNA control (Fig. 4B).
Cellular uptake of ADAMTS-5 was markedly reduced in
LRP-1-depleted cells (Fig. 4C). Immunocytochemical
analysis further confirmed that ADAMTS-5 endocytosis
was impaired in the LRP-1-depleted human chondrocytes
(Fig. 4D). From these results, we conclude that LRP-1 is
the primary endocytic receptor for ADAMTS-5.
TS1 and Sp domains mediate ADAMTS-5 endocytosis
ADAMTS-5 is a multidomain metalloproteinase.
Therefore, we searched which domains are requi-
red for its endocytosis by testing a series of dom-
ain-deletion mutants (Fig. 5A). Since full-length
ADAMTS-5 (ADAMTS-5-1) is not available in a high
quantity, it was incubated with porcine chondrocytes
only for 3 h. The results showed that 75% of
ADAMTS-5-1 disappeared from the medium, and this
disappearance was inhibited by RAP (Fig. 5B). Domain-
deletion mutants were subjected to time-course studies
(Fig. 5C). Compared to deletion of the TS2 domain
alone (ADAMTS-5-2), deletion of both TS2 and Sp
domains (ADAMTS-5-3) significantly reduced the rate
of endocytosis. Further deletion of the CysR domain
resulted in only a slight further reduction. However,
the mutant without the TS1 domain (ADAMTS-5-5)
was not internalized. When the mutants were tested
for their aggrecanase activity using live and dead
cartilage explants in culture, all except ADAMTS-5-5
showed a markedly reduced GAG release with live
Figure 2. Rapid clearance of ADAMTS-5 by articular carti-
lage chondrocytes. A) Live (L) and dead (D) porcine
cartilage explants were incubated with 10 nM ADAMTS-5
(TS-5) for 0–4 h, and ADAMTS-5 in the medium and
cartilage explants was detected by Western blot analysis
using an anti-ADAMTS-5 catalytic domain antibody. B)
Densitometric analysis of immunoreactive ADAMTS-5
bands detected in the medium of A. Amount of ADAMTS-5
is expressed as a percentage of the amount of ADAMTS-5 at
0 h. C) Porcine chondrocytes were incubated as in A, and
ADAMTS-5 remaining in the medium was measured as in B.
Points represent means 	 sd for triplicate assays (n
3).
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cartilage compared to dead cartilage (Fig. 5D). From
these data, we conclude that the TS1 domain is
essential for ADAMTS-5 endocytosis but that the Sp
domain enhances the endocytic process.
Inhibition of ADAMTS-5 endocytosis by RAP
enhances aggrecan degradation in articular cartilage
We then examined the effect of RAP on normal
turnover of aggrecan in cartilage. The addition of
RAP to live porcine cartilage increased the constitu-
tive GAG release an 2-fold, whereas GAG release from
dead cartilage was not enhanced by RAP (Fig. 6A).
This effect of RAP was not altered in the presence of
polymyxin B, an inhibitor of endotoxin, indicating
that the effect was not due to endotoxin contamina-
tion in the E. coli-expressed RAP preparation. West-
ern blot analysis of the products with an anti-ARGSV
antibody indicated that RAP-enhanced aggrecan deg-
radation was due to an increase in aggrecanase
activity (Fig. 6B). These results suggest that aggreca-
nases are constitutively produced by normal carti-
Figure 3. LRP-mediated endocytic clearance of ADAMTS-5. A) Live porcine articular cartilage explants were first incubated with
80 M dynasore or 10 mM -CD for 30 min. Then, 10 nM ADAMTS-5 was added to the medium and further incubated for 0–4
h. ADAMTS-5 remaining in the medium was measured as in Fig. 2. B) Live porcine cartilage explants were incubated with 10
nM ADAMTS-5 in the presence of 500 nM RAP for 0–4 h. C) Porcine chondrocytes were incubated as in B, and ADAMTS-5
remaining in the medium was measured as in Fig. 2. Points represent means 	 sd for triplicate assays (n
3). D) Confocal
microscopy analysis of ADAMTS-5 endocytosis by porcine chondrocytes. Cells were incubated with 10 nM ADAMTS-5 (TS-5) in
the presence or absence of 500 nM RAP or 100 g/ml heparin for 1 h. Endocytosed ADAMTS-5, EEA1, cytoskeleton and nucleus
were visualized as described in Materials and Methods. E) Confocal microscopy analysis of ADAMTS-5 endocytosis by porcine
cartilage explants. Live cartilage explants were incubated with 10 nM ADAMTS-5 in a similar manner, and endocytosed
ADAMTS-5 was detected as in D. Yellow arrowheads indicate the intact surface of cartilage explants.
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lage, but their activities are down-regulated by LRP-
1-mediated endocytosis. The addition of 20 nM
recombinant ADAMTS-5-4 to dead cartilage caused
1.7-fold higher GAG release over that with live carti-
lage after 4-h incubation, and this increased to
2.9-fold after 24 h. The addition of RAP to the
ADAMTS-5-4-mediated aggrecan degradation system
significantly enhanced GAG release from live carti-
lage but had no effect on GAG release from dead
cartilage (Fig. 6C). Notably, the level of GAG re-
leased from live cartilage in the presence of RAP was
equivalent to that from dead cartilage. Western blot-
ting using an anti-ARGSV antibody confirmed that
the 3.0-fold increase in aggrecan degradation ob-
served in the presence of RAP is solely due to
increased aggrecanase activity of ADAMTS-5 in live
cartilage (Fig. 6D).
ADAMTS-5 endocytosis is impaired in OA cartilage
due to reduced protein levels of LRP-1
Because the extracellular aggrecanase activity of
ADAMTS-5 is regulated by LRP-1-mediated endocy-
tosis, we considered whether the increased degrada-
tion of aggrecan observed in OA cartilage is due to a
dysregulated endocytic pathway. Quantitative mRNA
analysis of OA and normal human cartilage showed
similar levels of LRP-1 mRNA (Fig. 7A). However,
Western blot analysis of LRP-1 protein indicated that
OA cartilage has lost most of the receptor protein
(Fig. 7B). Therefore, we considered the possibility
that ADAMTS-5 endocytosis is impaired in OA carti-
lage, making it more readily susceptible to degrada-
tion, while normal human cartilage fully retains this
Figure 4. siRNA-mediated knockdown of LRP-1 impairs ADAMTS-5 endocytosis in human chondrocytes. Human chondrocytes
transfected with nontargeting siRNA (siCtrl) or LRP-1 targeting siRNA (siLRP-1) were cultured for 2 d in DMEM containing
10% FCS. A) Results of TaqMan real-time PCR showing relative levels of mRNA for LRP-1. B) Left panels: LRP-1 heavy-chain
(515 kDa) and light-chain (85 kDa) in cell lysates were assessed by Western blot analysis using anti-LRP-1 heavy-chain and
light-chain antibodies, respectively. Right panels: densitometric analysis of immunoreactive LRP-1 bands detected in the cell
lysate. Amount of LRP-1 is expressed as a percentage of the amount of LRP-1 in untransfected cells (none). C) Cells were
incubated with 10 nM ADAMTS-5 in the presence or absence of 500 nM RAP for 0–6 h, and ADAMTS-5 remaining in the
medium was measured as in Fig. 2. Bars and points represent means 	 sd for triplicate assays (n
3). D) Confocal microscopy
analysis of ADAMTS-5 endocytosis by human chondrocytes. Cells were incubated with 10 nM ADAMTS-5 in a similar manner,
and endocytosed ADAMTS-5 was detected as in Fig. 3.
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function and efficiently removes aggrecanases from
the extracellular space, as demonstrated in Fig. 4. To
test this possibility, we examined ADAMTS-5-induced
aggrecan degradation in live and freeze-thawed
(dead) OA cartilage. We found that the addition of
ADAMTS-5 to OA cartilage resulted in a similar
release of GAG from the cartilage regardless of
whether the tissue was live or dead (Fig. 7C). Specific
aggrecanase activity detected with these cartilage
specimens and the similar susceptibility of live and
dead cartilage to degradation was confirmed using an
anti-ARGSV antibody (Fig. 7D).
DISCUSSION
LRP-1 is a multifunctional endocytic type 1 transmem-
brane receptor consisting of an extracellular 515-kDa
heavy chain and an associated 85-kDa light chain
containing the transmembrane and cytoplasmic do-
mains. It mediates internalization of 40 ligands, in-
cluding lipoproteins, ECM proteins, cell surface recep-
tors, proteinases, and proteinase-proteinase inhibitor
complexes (26). The ablation of the LRP-1 gene in
mice is embryonically lethal (27), but tissue specific
deletion of the LRP-1 gene has indicated that it plays an
Figure 5. TS1 and spacer domains mediate ADAMTS-5 endocytosis. A)
Schematic representation of ADAMTS-5 and its domain deletion mutants.
Pro, prodomain; Cat, catalytic domain; Dis, disintegrin-like domain; TS1,
thrombospondin 1 domain; Cys, cysteine-rich domain; Sp, spacer domain;
TS2, thrombospondin 2 domain. B) Porcine primary chondrocytes were
incubated with 10 nM ADAMTS-5-1 in the presence or absence of 500 nM
RAP for 3 h, and ADAMTS-5 in the medium and cell lysate was detected as
Fig. 2. C) Porcine chondrocytes were incubated with each of 10 nM
ADAMTS-5-2, ADAMTS-5-3, ADAMTS-5-4, or ADAMTS-5–5 for 0–6 h, and
each ADAMTS-5 mutant remaining in the medium was measured as in Fig.
2. D) Live and freeze-thawed (dead) porcine articular cartilage explants
were incubated with 10 ng/ml IL-1, 4 nM ADAMTS-5-1, 5 nM ADAMTS-5-2,
10 nM ADAMTS-5-3, 20 nM ADAMTS-5-4, 50 nM ADAMTS-5-5 for 24 h. GAG released into the medium was measured
by DMMB assay. Bars and points represent means 	 sd for triplicate assays (n
3). *P  0.05; unpaired t test.
Figure 6. Inhibition of ADAMTS-5 endocytosis by RAP enhances aggrecan degradation in articular cartilage. A) Time course of
GAG released into the medium of live cartilage explants incubated in the presence or absence of 500 nM RAP. B) Densitometric
analysis of immunoreactive bands of aggrecan fragments detected in the medium obtained after 48 h culture in A by Western
blotting using an anti-ARGSV neoepitope antibody. Amount of aggrecan fragment in the medium of live cartilage explants
incubated alone was taken as 1. As a control, live cartilage explants were incubated with RAP in the presence of 100 g/ml
polymyxin B (PolyB) for the indicated period of time. C) Time course of GAG released into the medium of live and
freeze-thawed (dead) cartilage explants incubated with 20 nM ADAMTS-5-4 in the presence or absence of 500 nM RAP. D)
Amount of aggrecan fragments in the medium obtained after 24 h culture in C were measured as in B. Amount of aggrecan
fragment in the medium of live cartilage explants incubated with 20 nM ADAMTS-5-4 was taken as 1. Bars and points represent
means 	 sd for triplicate assays (n
3).
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important role in protecting the vasculature, -amyloid
precursor protein trafficking, and lipid metabolism in
adipocytes and macrophage biology (see ref. 26 for
review). The work presented here demonstrates that
LRP-1 also plays a key role in regulating aggrecan
turnover in cartilage by internalizing a major aggreca-
nase, ADAMTS-5.
Many proteinases are internalized by LRP-1 after
forming a complex with specific inhibitors, as confor-
mational changes of the inhibitor on complex forma-
tion give a signal for LRP-1 recognition (see ref. 26 for
review). We considered the possibility that ADAMTS-5
might have been internalized after forming a complex
with TIMP-3, as TIMP-3 is also endocytosed by an
LRP-1-mediated pathway (ref. 20 and unpublished re-
sults). However, we concluded that TIMP-3 is not
required for ADAMTS-5 internalization from the
following observations: first, GM6001, a broad-
spectrum hydroxamate metalloproteinase inhibitor
that blocks metalloproteinase-TIMP complex forma-
tion, did not block ADAMTS-5 internalization; sec-
ond, ADAMTS-5-5, consisting of the catalytic and the
disintegrin domains, was not internalized, although it
can form a complex with TIMP-3; and third, chondro-
cytes isolated from TIMP-3-null mice internalized
ADAMTS-5 (data not shown). Thus, ADAMTS-5 and
TIMP-3 can be endocytosed independently or as a
complex. Domain deletion mutagenesis studies then
indicated that both the TS1 domain and Sp domain are
involved in effective binding of ADAMTS-5 to LRP-1,
but the TS1 domain alone is sufficient. We postulate
that basic residues in these domains are responsible for
LRP-1 binding, as ADAMTS-5 internalization is inhib-
ited by heparin. The importance of basic residues for
interaction with LRP-1 has been shown for many pro-
tein ligands (26). When full-length ADAMTS-5 is se-
creted from the cell, however, it can bind to sulfated
proteoglycans on the cell surface and in the ECM
through basic residues in its CysR and Sp domains (21).
The CysR and Sp domains are also necessary for the
expression of full aggrecanase activity of ADAMTS-5.
Therefore, the location of the enzyme and expression
of aggrecanase activity is determined by competition
between the ECM and LRP-1. However, ADAMTS-5 is
internalized by cartilage explants and isolated chondro-
cytes with similar kinetics (Fig. 2). When live cartilage
was incubated with ADAMTS-5, fluorescent ADAMTS-5
signal was observed within chondrocytes but not in the
cartilage ECM (Fig. 3E). These results suggest that
ADAMTS-5 binds loosely to the ECM and thus that the
enzyme is readily removed from the tissue by LRP-1.
When the spacer domain is removed from ADAMTS-5
(ADAMTS-5-3), its aggrecanase activity reduces only
by 25%, but the extracellular half-life increases 3-
fold. Deletion of both the CysR and Sp domains
(ADAMTS-5-4) results in the loss of most of the
aggrecanase activity (only 0.2-0.3% of the original
activity remains; ref. 21). This form can diffuse
through the interterritorial region of cartilage, as it
no longer binds to the ECM. Interestingly,
ADAMTS-5-4 retains 25% of full-length ADAMTS-5
proteolytic activity against biglycan, decorin, and
fibromodulin (21). Such processing would have po-
tential to dysregulate tissue matrix turnover and cellu-
Figure 7. ADAMTS-5 endocytosis is impaired in OA cartilage
due to reduced protein levels of LRP-1. A) Results of TaqMan
real-time PCR showing relative levels of mRNA for LRP-1 in
human OA and normal chondrocytes. B) Left panel: LRP-1
heavy chain was assessed by Western blotting using an anti-
LRP-1 heavy-chain antibody. Right panel: densitometric anal-
ysis of immunoreactive LRP-1 bands. Each value was obtained
from chondrocytes isolated from articular cartilage of patients
with OA and normal patients (n
6 each). C) Time course of
GAG released into the medium of live and freeze-thawed
(dead) cartilage explants dissected from knee joints of pa-
tients with OA (n
5) incubated with 20 nM ADAMTS-5-4. D)
Left panels: representative Western blot analysis of the media
obtained from two patients after 24 h culture in C for aggrecan
fragments using an anti-ARGSV neoepitope antibody. L, live
cartilage; D, dead cartilage. Right panel: densitometric analysis of immunoreactive bands of aggrecan fragments (n
4).
Amount of aggrecan fragment in the medium of live cartilage explants was taken as 1. Bars and points represent means 	
sd. **P  0.005; unpaired t test.
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lar environments. However, this form of the enzyme is
still removed from the tissue by LRP-1, indicating that
LRP-1 is therefore an important regulator of normal
cartilage homeostasis.
A number of ADAMTS metalloproteinases have been
reported to have an important role in development and
organ morphogenesis. For example, ADAMTS-1 is es-
sential for normal growth, structure, and function of
the kidney, adrenal gland and female reproductive
organ, myocardial trabeculation during heart devel-
opment (see ref. 10 for review), and limb joint
development (28). ADAMTS-5 plays a key role in
cardiac valve development (29), regression of the
interdigital web during mouse limb morphogenesis
along with ADAMTS-9 and ADAMTS-20 (30), control
of fibroblast-myofibroblast transition (31), and skin
excision wound healing (32). In those processes,
ADAMTSs function as versican- and aggrecan-cleaving
enzymes. Although the role of LRP-1 in post-
translational turnover of these ADAMTSs during organ
morphogenesis or wound healing is yet to be investi-
gated, our study implies that LRP-1 may regulate the
activities of other members of the ADAMTS family, if
we consider the importance of LRP-1 in development
(27). During morphogenesis and tissue remodeling,
timely ECM degradation is essential, and one possible
mechanism is endocytosis of matrix-degrading en-
zymes. The recent study of Sorvillo et al. (33) showed
that endocytosis of ultralarge von Willebrand factor-
cleaving ADAMTS-13 by dendritic cells is mediated by a
different scavenger receptor, the macrophage mannose
receptor. This process is postulated to be involved in
generation of the autoantibodies against the enzyme
seen in patients with acquired thrombotic thrombocy-
topenic purpura (33).
ADAMTS-5 has been implicated in the development
of OA, but this is controversial, because no correlation
between ADAMTS-5 mRNA levels and OA progression
have been reported (13, 17, 18). Our study has pro-
vided a new insight into this discrepancy by introducing
a role of LRP-1 in the progression of OA. In normal
healthy cartilage, the activity of ADAMTS-5 is regulated
by endocytosis, as shown by an increased aggrecan
turnover on addition of RAP. This pathway is, however,
impaired in OA cartilage. This is evident from our
observation that there were no significant differences
in the ability of exogenously added ADAMTS-5 to digest
aggrecan in live or freeze-thawed OA cartilage. A
similar impairment of LRP-1-dependent endocytosis of
MMP-13 has been reported in OA cartilage without
alteration in the mRNA levels of LRP-1 (34), but its
mechanism was not known. We have confirmed unal-
tered mRNA levels of LRP-1 in normal and OA human
cartilage and found that levels of LRP-1 protein is
substantially lower in OA cartilage. This leads to an
increase in extracellular levels of ADAMTS-5, MMP-13,
and possibly other metalloproteinase in OA cartilage.
Although the mechanism by which OA cartilage loses
LRP-1 from the cell surface has yet to be investigated,
we postulate that it is due to increased shedding of
LRP-1 from the cell surface as has been shown in
malignant cells (35, 36) and in cycling human endo-
metrium at menses (37). The shedding of LRP-1 in-
creases under inflammatory conditions, and soluble
LRP-1 is elevated in plasma of patients with rheumatoid
arthritis and systemic lupus erythematosus (38). Pro-
teinases that were reported to shed LRP-1 include
-amyloid precursor protein-cleaving enzyme (39),
MMP-14 (35), ADAM-10 (40), ADAM-12 (36, 37), and
ADAM-17 (38, 40). LRP-1 is reported to protect against
the progression of atherosclerosis in mice by suppress-
ing the expression of inflammatory mediators, such as
monocyte chemoattractant protein 1, tumor necrosis
factor , and MMP-9, while deletion of macrophage
LRP-1 increases MMP-9, which is associated with a high
frequency to plaque rupture (41). Increased shedding
of LRP-1 in chondrocytes will shift the homeostatic
balance of ECM turnover to catabolic, resulting in a
gradual loss of aggrecan and collagen fibrils. A slight
shift in enzymatic balance due to loss of LRP-1 may be
an important part of the dysregulation of aggrecanase
activity. Identification of the mechanism by which
LRP-1 is post-translationally processed will therefore
provide further insights into our understanding of the
pathogenesis of OA.
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Background: Tissue inhibitor of 
metalloproteinases-3 (TIMP-3) is endocytosed, 
but its regulatory mechanism is not well 
understood. 
Result: TIMP-3 endocytosis occurs mainly 
through low-density lipoprotein receptor-related 
protein-1 (LRP-1), but shed sLRP-1 binds 
TIMP-3. 
Conclusion: TIMP-3-sLRP-1 complexes are 
retained extracellularly with metalloproteinase 
inhibitory activity.  
Significance: LRP-1 is the master regulator of 
extracellular levels of TIMP-3.  
 
SUMMARY 
Tissue inhibitor of metalloproteinases-3 
(TIMP-3) plays a key role in regulating 
extracellular matrix turnover by inhibiting 
matrix metalloproteinases (MMPs), 
adamalysins (ADAMs) and adamalysins with 
thrombospondin motifs (ADAMTSs). We 
demonstrate that levels of this physiologically 
important inhibitor can be post-
translationally regulated by endocytosis. 
TIMP-3 was endocytosed and degraded by a 
number of cell types including chondrocytes, 
fibroblasts, and monocytes, and we found that 
the endocytic receptor low-density lipoprotein 
receptor-related protein-1 (LRP-1) plays a 
major role in TIMP-3 internalization. 
However, the cellular uptake of TIMP-3 
significantly slowed down after 10 h due to 
shedding of LRP-1 from the cell surface and 
formation of soluble LRP-1 (sLRP-1)−TIMP-
3 complexes. Addition of TIMP-3 to HTB94 
human chondrosarcoma cells increased the 
release of sLRP-1 fragments of 500, 215, 160 
and 110 kDa into the medium in a 
concentration dependent manner, and all 
these fragments were able to bind to TIMP-3. 
TIMP-3 bound to sLRP-1, which was 
resistant to endocytosis, retained its 
inhibitory activity against metalloproteinases. 
Extracellular levels of sLRP-1 can thus 
increase the half-life of TIMP-3 in the 
extracellular space, controlling the 




The tissue inhibitors of metalloproteinases 
(TIMPs) are a family of proteins that regulate 
the activity of metalloproteinases through 
formation of tight, non-covalent complexes in a 
1:1 stoichiometry (1). Among the four 
mammalian TIMPs, TIMP-3 is unique in a 
number of respects. It has a broader inhibitory 
profile than the other TIMPs, being able to 
inhibit matrix metalloproteinases (MMPs) and 
the related metalloproteinases of the ADAM (a 
disintegrin and metalloproteinase) and the 
ADAMTS (a disintegrin and metalloproteinase 
with thrombospondin motifs) families (1). 
TIMP-3 is the only member of the family that 
can bind to the extracellular matrix (ECM) (2,3), 
while the other TIMPs are readily extracted from 
the tissue. Studies using TIMP-3-null mice have 
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indicated that it is the major regulator of 
metalloproteinase activities in vivo. Ablation of 
the Timp3 gene leads to a number of defects in 
mice, including impaired lung development (4), 
dilated cardiomyopathy (5), increased apoptosis 
during mammary gland involution (6), and 
accelerated development of osteoarthritis upon 
aging (7). These are due to dysregulation of 
ECM turnover. In addition, uncontrolled activity 
of ADAMs, particularly ADAM17, resulted in 
elevated levels of TNFα and increased 
inflammation in murine models of liver 
regeneration (8), sepsis (9), and antigen-induced 
arthritis (7), and the phenotypes of the Timp3-
null mouse are reflected in a number of human 
pathologies (see ref. (1) for review). Thus, there 
is considerable interest in understanding factors 
regulating TIMP-3 levels, and it has been shown 
that transcription of TIMP-3 can be increased by 
the histone deacetylase SirT1 (10) and growth 
factors such as TGFβ (11) and oncostatin M (12) 
and reduced by promoter methylation (13). 
Translation of TIMP-3 can be reduced by miR-
21 (14), miR-221 and miR-222 (15), miR-181b 
(16) and miR-206 (17).  
We have recently shown that TIMP-3 levels 
can be post-translationally regulated by 
endocytosis and intracellular degradation and 
suggested that this is an important factor 
determining extracellular levels of TIMP-3 (18). 
In the previous studies we used endocytic 
blockers to demonstrate the cellular uptake of 
TIMP-3. For example, HTB94 chondrosarcoma 
cells transfected with an expression plasmid for 
TIMP-3 produced high levels of TIMP3 mRNA, 
but TIMP-3 protein was not detected in the 
conditioned medium. When heparin, pentosan 
polysulfate (PPS), or receptor-associated protein 
(RAP), an antagonist of ligand binding to low-
density lipoprotein (LDL) receptor and related 
receptors, was added to the cells, TIMP-3 
accumulated in the medium. These studies 
suggested that the receptor responsible for 
TIMP-3 endocytosis is a member of the LDL 
receptor-related protein (LRP) family (18). 
There are 13 members in the mammalian LDL 
receptor family that endocytose a wide variety of 
ligands and deliver them to endosomes for 
degradation (19). Among them, LDL receptor-
related protein 1 (LRP-1) endocytoses more than 
30 ligands, including proteinase-inhibitor 
complexes and ECM proteins, making it an 
important regulator of ECM composition and 
turnover (20). LRP-1 is comprised of 2 chains, a 
515 kDa α-chain that interacts with ligands via 
its 4 clusters of LDL receptor type A repeats, 
and a non-covalently associated 85 kDa β-chain 
that tethers the receptor in the membrane and 
interacts with intracellular adaptors to direct 
endocytosis via clathrin-coated pits (20). LRP-1 
can be shed from cell membranes, releasing a 
soluble form of the receptor, sLPR-1, that can 
act as a competitive inhibitor of ligand 
endocytosis (21,22).  
In this report, we used metabolically 
radiolabelled, isolated recombinant [35S]TIMP-3 
to investigate the endocytic pathways for TIMP-
3 in more detail and analyzed the distribution of 
radioactivity in different cell fractions over time. 
Using LRP-1-deficient cells and sulfated 
proteoglycan mutant cells, we examined the 
contribution of LRP-1-dependent and LRP-1-
independent pathways of TIMP-3 endocytosis. 
More importantly, our study has revealed that 
LRP-1 shed from the cell surface (sLRP-1) also 
binds to extracellular TIMP-3 and sequesters 
TIMP-3 in the medium and that TIMP-3 bound 
to sLRP-1 retained metalloproteinase inhibitory 
activity. This suggests that LRP-1 is a master 
regulator of extracellular levels of TIMP-3 and 
regulates ECM catabolism.  
 
EXPERIMENTAL PROCEDURES 
Materials — Heparin, de-N-sulfated 
heparin, chondroitin sulfate, hyaluronan and 
pronase were from Sigma-Aldrich (Dorset, UK); 
dermatan sulfate from Calbiochem (Nottingham, 
UK); PPS from Arthropharm (Sydney, 
Australia) and GM6001 from Elastin Products 
Co (Owensville, MOS, USA). Dulbecco’s 
modified Eagle’s medium (DMEM), DMEM 
without L-glutamine or phenol red, L-glutamine, 
penicillin/streptomycin, fetal calf serum (FCS), 
hygromycin B, amphotericin B and trypsin-
EDTA from PAA Laboratories (Somerset, UK); 
DMEM without L-glutamine, cysteine, 
methionine or cystine from MP Biomedicals 
(Solon, OH, USA). The catalytic domain of 
human MMP-1 (24); recombinant His-tagged 
RAP (25), ADAMTS-4 lacking the C-terminal 
spacer domain (26) and non-radiolabelled 
FLAG-tagged TIMP-3 (27) were prepared as 
previously described. 
Cell culture — HTB94 human 
chondrosarcoma and THP-1 human monocytic 
acute leukaemia cell lines were from American 
Culture Type Collection (Manassas, VA, USA). 
Human uterine cervical fibroblasts were kindly 
provided by Akira Ito (Tokyo University of 
Pharmacy and Life Sciences, Japan). CHO-K1 
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and CHO-745 (28) were generously provided by 
Jeffrey Esko (Department of Cellular and 
Molecular Medicine, University of California 
San Diego, La Jolla, USA). MEF-1 and PEA-13 
(homozygous LRP-1-deficient) (29) cells were 
generated as described previously. Syndecan-4-
deficient and wild-type MEF (30) were kindly 
provided by John R. Couchman (Department of 
Biomedical Sciences and Biotech Research and 
Innovation Centre, University of Copenhagen, 
Copenhagen, Denmark). All cells were 
maintained in DMEM with 10 % FCS, 100 U/ml 
penicillin and 100 U/ml streptomycin at 37 ºC in 
5 % CO2.  
 Porcine articular cartilage chondrocytes 
were isolated from metacarpophalangeal joints 
within 24 h of slaughter (31). Cartilage was 
incubated with 1 mg/ml Clostridium 
histolyticum collagenase (Sigma-Aldrich, 
Dorset, UK) in 10 ml DMEM with 10 % FCS 
for 4 h at 37 ºC. The digested material was 
passed through a cell strainer, washed and cells 
cultured in DMEM containing 10 % FCS, 100 
U/ml penicillin, 100 U/ml streptomycin, 2 
mg/ml amphotericin B and 10 mM HEPES at 37 
ºC in 5 % CO2. 
Expression and purification of [35S]TIMP-3 
and [35S]N-TIMP-3 — [35S]TIMP-3 and [35S]-
labelled N-terminal domain of TIMP-3 ([35S]N-
TIMP-3) were prepared by metabolic labelling. 
HEK-293/EBNA cells transfected with a 
pCEP4-based expression vector for C-terminally 
FLAG-tagged TIMP-3 (27) were grown to 
confluence in a 150 cm2 flask, washed once and 
starved for 2 h in serum-free DMEM without L-
glutamine, cysteine, methionine or cysteine. 
Cells were then grown for a further 4 days in 
serum-free DMEM without L-glutamine, 
cysteine, methionine or cysteine, supplemented 
with 30 mM sodium chlorate and 
[35S]Met/[35S]Cys (500 µCi of Redivue Pro-Mix 
L-[35S] in vitro Cell Labelling Mix (GE 
Healthcare, Buckinghamshire, UK). Conditioned 
media were collected after 4 days, centrifuged to 
remove cell debris and applied to a 2 ml anti-
FLAG M2-agarose column (Sigma-Aldrich, 
Dorset, UK). The resin was washed extensively 
and bound protein eluted with 200 µg/ml FLAG 
peptide (Sigma-Aldrich, Dorset, UK). The purity 
of recombinant [35S]TIMP-3 was confirmed by 
reducing SDS-PAGE  and autoradiography. The 
active concentration of [35S]TIMP-3 was 
determined by titration against a known 
concentration of the catalytic domain of MMP-1 
(27). 
Endocytosis of [35S]TIMP-3 — Cells were 
plated at a density of 1x106 cells/well and 
washed three times with serum-free DMEM. For 
some experiments, cells were then incubated for 
1 h at 37 ºC with GM6001 (10 µM), heparin, de-
N-sulfated heparin, PPS, chondroitin sulfate, 
dermatan sulfate, hyaluronan (all at 200 µg/ml) 
or RAP (500 nM) in DMEM with 0.1 % FCS 
before addition of [35S]TIMP-3. As a control for 
agents diluted in DMSO, the equivalent volume 
of DMSO was added to separate wells. 
[35S]TIMP-3 (1 nM) was added to cells in 2 ml 
of DMEM with 0.1% FCS. After 0-24 h 
incubation, the conditioned medium was 
removed and 5% (v/v) trichloroacetic acid 
(TCA) added (4 ºC, overnight). The TCA-
soluble fraction (2 ml) was separated from the 
TCA-insoluble fraction by centrifugation (13000 
rpm, 15 min, 4 ºC). The TCA-insoluble pellet 
was dissolved in 1 N NaOH (500 µl). The cell 
layer was washed three times with ice-cold PBS 
and solubilized in 1 N NaOH [1 ml, 1 h, room-
temperature (RT)]. Each fraction was mixed 
with 3 ml of scintillant (Goldstar Multipurpose 
Liquid Scintillation Cocktail, Meridian, Surrey, 
UK) and radioactivity counted. TCA-soluble 
radioactivity present in the [35S]TIMP-3 
preparation prior to incubation with cells (5-15% 
of total radioactivity) was subtracted from the 
amount of TCA-soluble radioactivity at each 
time point. The amount of radioactivity in the 
different fractions was calculated as a percentage 
of the total amount of [35S]TIMP-3 radioactivity 
added to the cells.  
Endocytosis of surface-bound [35S]TIMP-3 
— [35S]TIMP-3 (40 nM) in ice cold TBS was 
added to cells and incubated for 2 h at 4 ºC. To 
quantify cell surface binding of [35S]TIMP-3, 
cells were washed twice in TBS, solubilized in 1 
N NaOH (1 ml) and radioactivity quantified. In 
parallel experiments, endocytosis of cell surface-
bound [35S]TIMP-3 was quantified by washing 
cells in TBS and then incubating them for 2 h at 
37 ºC in pre-warmed DMEM with 0.1% FCS. 
After 2 h, conditioned media were harvested and 
TCA-precipitated to quantify degraded 
[35S]TIMP-3 (TCA-soluble counts in medium) 
and the amount of intact [35S]TIMP-3 released 
from the cell surface (TCA-insoluble counts in 
medium). Cell layers were treated with 0.1 % 
pronase in serum-free DMEM on ice for 10 min, 
and then centrifuged (5000 rpm, 5 min, 4 ºC) to 
allow quantification of cell surface-bound 
[35S]TIMP-3 (pronase-sensitive radioactivity) 
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and intracellular [35S]TIMP-3  (pronase-resistant 
radioactivity, solubilized in 1 ml of 1 N NaOH).  
Confocal microscopy analysis of TIMP-3 
endocytosis — HTB94, MEF-1 and PEA-13 
cells were cultured on 18 mm glass cover slips 
coated with gelatin (0.1 % w/v). Non-
radiolabelled TIMP-3 (40 nM) was added to 
cells either alone or in combination with heparin 
(200 µg/ml) or RAP (500 nM) in phenol-red free 
DMEM with 0.1% FCS (2 h, 37 ºC). Cells were 
then fixed with 3% paraformaldehyde in PBS 
(10 min, RT) and blocked with 5% (v/v) goat 
serum, 3% (w/v) bovine serum albumin in PBS 
(1 h, RT). Cells were permeabilized with PBS 
containing 0.1% (v/v) Triton X-100 (15 min, 
RT) and incubated with anti-FLAG M2 antibody 
(Sigma-Aldrich, UK, F1804, 5 µg/ml, 1 h, RT). 
Alexa Fluor 488–conjugated goat anti-mouse 
IgG (Molecular Probes, Cambridge, UK) was 
used to visualize the antigen signal (5 µg/ml, 1 h, 
RT). Actin was stained with Alexa Fluor 568-
conjugated phalloidin (Molecular Probes, 
Cambridge, UK). The signals were analyzed 
using a CCD camera-equipped microscope 
(Nikon TE-2000) with a 60× objective lens.  
siRNA targeting of syndecan-1 expression 
— HTB94 cells (1-1.5x105 cells) were 
transiently transfected with 50 nM of two 
siRNAs targeting syndecan-1 (AM12432 and 
AM142557, Ambion) or scrambled (Ambion) 
using Lipofectamine 2000 for 3 h. After 24 and 
48 h, expression of syndecan-1 was reduced by 
about 90% compared to the housekeeping gene 
GAPDH.  
Isolation of sLRP-1 from plasma — sLRP-1 
was isolated from fresh-frozen human plasma by 
a modification of previously published methods 
(32). Plasma was diluted 5-fold with 
equilibration buffer (50 mM citrate, pH 6.0, 75 
mM NaCl, 0.02 % NaN3) supplemented with 
proteinase inhibitor cocktail (P8340, Sigma-
Aldrich, Dorset, UK) and applied to a 
MacroPrep S ion exchange resin (Bio-Rad, 
Hemel Hempstead, UK) equilibrated in the same 
buffer. The resin was extensively washed in 
equilibration buffer to remove unbound material 
and bound proteins then eluted in a gradient of 
75 to 500 mM NaCl in equilibration buffer over 
10 column volumes. Eluted fractions were 
analyzed by SDS-PAGE with silver staining and 
immunoblotting for LRP-1 using the 8G1 
antibody (Abcam, Cambridge, UK).   
ELISA detection of TIMP-3 binding to 
sLRP-1 — High-binding microtitre plates 
(Corning, NY, USA) were coated with 0.4 nmol 
sLRP-1 in 50 mM citrate, pH 6.0, 75 mM NaCl 
overnight. Wells were blocked using 3 % BSA-
PBS (1 h, 37 ºC) and washed in PBS containing 
0.1 % (v/v) Tween 20 (Sigma-Aldrich, Dorset, 
UK) after this and each subsequent step. Wells 
were then incubated with recombinant TIMP-3 
in blocking solution (0.15 - 20 nM, 3 h, 37 ºC). 
Bound TIMP-3 was detected by incubation of 
wells with murine M2 anti-FLAG antibody (3 h, 
37 ºC) and then with an anti-mouse secondary 
antibody coupled to horseradish peroxidase (1 h, 
37 ºC) (DAKO, Ely, UK). Hydrolysis of 
tetramethylbenzidine substrate (KPL, 
Gaithersburg, MA, USA) was measured at 450 
nm using a BioTek EL-808 absorbance 
microplate reader (BioTek, Winooski, VT, 
USA).  
Inhibitory activity of TIMP-3 remnants — 
HTB94 cells were treated with or without TIMP-
3 (1 nM) for 0, 24 or 48 h in serum-free, phenol 
red-free DMEM. Conditioned media were 
collected and centrifuged (13000 rpm, 15 min, 4 
ºC) to remove cell debris. Recombinant 
ADAMTS-4 lacking the C-terminal spacer 
domain (1 nM) was incubated with dilutions of 
the media or with purified recombinant TIMP-3 
in assay buffer (50 mM Tris-HCl, 150 mM 
NaCl, 10 mM CaCl2, 0.05 % Brij, 0.02 % NaN3) 
for 1 h at 37 ºC. Residual activity against the 




TAMRA, custom synthesized by Bachem, 
Switzerland) was determined (0.5 µM, excitation 
wavelength 485 nm, emission wavelength 538 
nm with 495 nm cut-off) (27).  
Co-immunoprecipitation of sLRP-1 with 
TIMP-3 — HTB94 cells were incubated in 
serum-free DMEM for 24 h, the conditioned 
media collected and centrifuged (13000 rpm, 15 
min, 4 ºC) to remove cell debris. TIMP-3-FLAG 
(1 nM) was added to the conditioned medium 
(10 ml) and incubated overnight at RT with 
mixing. The solution was then applied to an anti-
FLAG M2-agarose affinity resin (1 ml) 
equilibrated in TBS and the resin extensively 
washed with 10 volumes of TBS.  Bound 
proteins were sequentially eluted with 50 mM 
Tris-HCl, pH 7.5, 10 mM CaCl2, 0.2 % NaN3 
containing 1 M NaCl (2 x 0.5 ml) and then with 
the same buffer containing 150 mM NaCl and 
200 µg/ml FLAG peptide (2 x 0.5 ml). Eluted 
samples were analysed by SDS-PAGE and 
immunoblotting using M2 anti-FLAG and 8G1 
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anti-LRP-1 antibodies. A band corresponding to 
the LRP-1 immunoreactive band was excised 
from the silver stained gel, digested with trypsin 
and analyzed by mass spectrometry. 
 
RESULTS 
TIMP-3 is endocytosed by HTB94 cells 
— Metabolically labelled [35S]TIMP-3 was 
purified and added to HTB94 cells in culture. 
The radioactivity in the TCA-insoluble fraction 
(intact [35S]TIMP-3) of the conditioned medium 
decreased over 24 h, while that in the TCA-
soluble fraction (degraded [35S]TIMP-3 
fragments) increased (Fig. 1A). Radioactivity 
was also detected in the cell and ECM layer (the 
cell-associated fraction). Treatment of the cell-
associated layer with pronase indicated that 
about half of the [35S]TIMP-3 in this fraction 
was present within cells, with the remainder was 
present on the cell surface and in the ECM. 
These results indicate that [35S]TIMP-3 bound to 
the cell surface, was endocytosed and degraded 
by the cells, and peptide fragments were released 
back into the medium. [35S]N-TIMP-3 was also 
endocytosed by HTB94 cells with 
indistinguishable kinetics, suggesting that the N-
terminal domain contains the minimal structure 
required for endocytosis.   
We previously reported that TIMP-3 
accumulated in the conditioned medium of 
HTB94 cells in the presence of RAP, an 
antagonist of ligand binding to the LRP family 
of endocytic receptors (18). In line with this 
finding, RAP (500 nM) reduced endocytosis of 
[35S]TIMP-3 by HTB94 cells, i.e., an increase in 
TCA-insoluble radioactivity and a decrease in 
TCA-soluble and cell-associated radioactivity 
(Fig. 1A). These data suggest that a member of 
the RAP-sensitive LRP family is involved in 
TIMP-3 endocytosis. Heparin (200 µg/ml) and 
PPS (200 µg/ml) similarly reduced endocytosis 
of [35S]TIMP-3 (Fig. 1A), but de-N-sulfated 
heparin, dermatan sulfate, chondroitin sulfate 
and hyaluronan (all at 200 µg/ml) had little 
effect. [35S]TIMP-3 endocytosis was unaffected 
by addition of the broad-spectrum 
metalloproteinase inhibitor GM6001, indicating 
that TIMP-3 is internalized without forming 
complexes with metalloproteinases. [35S]TIMP-3 
endocytosis and degradation was observed in a 
variety of other cell types, including porcine 
articular chondrocytes, human uterine cervical 
fibroblasts and THP-1 human monocytic 
leukemia cells. 
 Cellular uptake of exogenously added 
TIMP-3 was also investigated by confocal 
microscopy. After incubation of HTB94 cells 
with recombinant TIMP-3-FLAG for 2 h at 37 
ºC, punctate staining for TIMP-3-FLAG was 
detected inside of the cells (Fig. 1B). This 
staining was absent in cells incubated without 
TIMP-3, indicating the specificity of the 
staining. The amount of intracellular fluorescent 
signal was greatly reduced by incubation of cells 
with RAP (500 nM) and completely abolished 
by incubation with heparin (200 µg/ml). 
TIMP-3 endocytosis is reduced in LRP-
1-deficient cells — Since TIMP-3 endocytosis 
was inhibited by RAP, we postulated that a 
member of the LRP family of receptors was 
involved in TIMP-3 endocytosis. We thus 
compared [35S]TIMP-3 endocytosis by LRP-1-
deficient mouse embryonic fibroblasts (PEA-13 
cells) and wild-type cells (MEF-1). As shown in 
Fig. 2A, [35S]TIMP-3 was readily endocytosed 
by MEF-1 cells with similar kinetics to that 
observed in HTB94 cells, but [35S]TIMP-3 
endocytosis was impaired in PEA-13 cells, with 
the rate of endocytosis approximately half of 
that observed in HTB94 and MEF-1 cells (Fig. 
2B). This indicates that LRP-1 mediates a major 
pathway for TIMP-3 endocytosis, but that an 
LRP-1-independent pathway also operates in 
these cells. Similar results were obtained using 
confocal microscopy, with endocytosed TIMP-
3-FLAG visible in vesicles within MEF-1 cells, 
but lower intracellular staining observed in PEA-
13 cells (Fig. 2C).  RAP inhibited [35S]TIMP-3 
endocytosis and degradation by MEF-1 cells to 
the level observed in PEA-13 cells (Fig. 2A and 
B). In contrast, RAP had no effect on 
[35S]TIMP-3 endocytosis by PEA-13 cells. 
Based on these observation we propose that 
LRP-1 is the only member within the LRP 
family that mediates [35S]TIMP-3 endocytosis in 
these cells.  
On the other hand, heparin strongly 
inhibited [35S]TIMP-3 endocytosis by both 
MEF-1 and PEA-13 cells (Fig. 2A and B). In 
this case, only a minimal decrease in TCA-
insoluble radioactivity and little increase in 
TCA-soluble radioactivity in the medium were 
observed, and [35S]TIMP-3 was barely 
detectable in the cell-associated layer.  
We further investigated the role of LRP-
1 in [35S]TIMP-3 surface binding by adding 1 
nM [35S]TIMP-3 to cells at 4 ºC. Comparable 
binding of [35S]TIMP-3 to MEF-1 and PEA-13 
cells was observed (Fig. 2D).  Upon warming 
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the cells to 37 ºC, higher radioactivity was 
observed in MEF-1 cells, confirming their 
greater ability to endocytose [35S]TIMP-3. 
Interestingly, both MEF-1 and PEA-13 cells 
released about a third of the surface-bound 
radioactivity back into the medium, indicating 
there was a notable dissociation of [35S]TIMP-3 
from the cell surface under these experimental 
conditions. The release of TCA-soluble 
radioactivity by MEF-1 and PEA-13 cells was 
measured following cell surface binding of 
[35S]TIMP-3 and warming of the cells to 37 ºC. 
MEF-1 cells released approximately twice as 
much TCA-soluble radioactivity as PEA-13 cells 
Fig 2E), confirming the existence of LRP-1-
dependent and -independent endocytic pathways 
for TIMP-3.  
Cell surface sulfated GAGs are not 
involved in TIMP-3 endocytosis — Since highly 
sulfated polysaccharides (e.g. heparin and PPS) 
blocked TIMP-3 endocytosis (18), we postulated 
that HSPGs or CSPGs may be involved in 
TIMP-3 endocytosis. To test this possibility we 
compared [35S]TIMP-3 endocytosis by wild-type 
(CHO-K1) and mutant CHO-745 cells which 
lack HS and CS chains due to a mutation in 
xylosyltransferase (28). We observed no 
significant differences in the rate of [35S]TIMP-3 
endocytosis by CHO-K1 and CHO-745 cells 
Fig. 3A), indicating that neither HSPG nor 
CSPG are required for the internalization of 
TIMP-3. [35S]TIMP-3 endocytosis by both 
CHO-K1 and CHO-745 cells was partially 
inhibited by RAP (500 nM) (Data not shown). 
Heparin (200 µg/ml) inhibited [35S]TIMP-3 
endocytosis by CHO-745 cells (Figure 3B) 
indicating that the blocking effect of heparin is 
independent from the presence of HSPGs or 
CSPGS on the cell surface. Similarly, heparin 
blocked [35S]TIMP-3 endocytosis by CHO-K1 
cells. Interestingly, both CHO-745 and CHO-K1 
exhibited a higher amount of cell-associated 
radioactivity than HTB94 or MEF cells. 
[35S]TIMP-3 levels in this fraction were not 
affected by RAP, but were strongly inhibited by 
heparin. 
We further investigated possible 
involvement of the syndecan family in TIMP-3 
endocytosis, since some protein ligands have 
been shown to bind to the core protein of these 
proteoglycans (33). Comparable endocytosis of 
[35S]TIMP-3 was observed in syndecan-4-
deficient and wild-type MEF, and siRNA 
targeting of syndecan-1 (leading to a 90% 
reduction in expression), had no effect on 
[35S]TIMP-3 endocytosis.  
Since heparin inhibits TIMP-3 
endocytosis by cells lacking HSPG and CSPG, 
we tested whether heparin can directly interfere 
the binding of TIMP-3 to LRP-1. We isolated 
sLRP-1 from human plasma and measured 
binding of TIMP-3 and TIMP-3-heparin 
complexes to immobilized sLRP-1 by ELISA. 
TIMP-3 bound readily to LRP-1, but upon pre-
incubation with 100 µg/ml heparin, binding of 
TIMP-3 to LRP-1 was completely abolished Fig. 
3C). 
sLRP-1 inhibits TIMP-3 endocytosis — 
During the course of this study we noticed that 
for all the cell lines we tested, TIMP-3 
endocytosis was initially fast, but decreased over 
time and little endocytosis was observed after 10 
h. [35S]TIMP-3 remaining in the medium at 24 h 
([35S]TIMP-3 remnants) appeared intact by 
reducing SDS-PAGE and autoradiography, with 
no fragmentation evident. The ability of TIMP-3 
remnants to inhibit metalloproteinase activity 
was assessed by adding 1 nM TIMP-3 to HTB94 
cells for 0, 24 or 48 h, after which time TIMP-3 
remnants in the media were harvested and 
titrated against 1 nM ADAMTS-4 in vitro.  
TIMP-3 collected after 0 h incubation on HTB94 
cells completely inhibited 1 nM ADAMTS-4 
(Fig. 4A). TIMP-3 harvested after 24 and 48 h 
incubation on HTB94 cells inhibited ADAMTS-
4 activity by 60%, indicating that while the 
concentration of TIMP-3 in the medium had 
been reduced by endocytosis, the TIMP-3 
remnants remaining in the medium retained their 
full inhibitory activity against 
metalloproteinases. These data indicate that 
TIMP-3 remnants had not undergone any 
substantial structural modification or 
inactivation. 
 We therefore considered whether the 
reduced rate of [35S]TIMP-3 endocytosis was 
due to a change in the endocytic capacity of the 
cells. Although TIMP-3 has been shown to 
induce apoptosis in a variety of cell types (34), 
we found that incubation of HTB94 cells with 1 
nM [35S]TIMP-3 for 24 h had no effect on cell 
viability as measured by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. Furthermore, pre-
treatment of HTB94 cells with non-radiolabelled 
TIMP-3 for 24 h did not alter the rate of 
endocytosis of subsequently added [35S]TIMP-3. 
We then investigated the possibility that 
TIMP-3 remnants in the medium were resistant 
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to being taken up by the cells. To test this, 
[35S]TIMP-3 remnants were added to naïve cells 
that had not previously been exposed to TIMP-3. 
Remnants collected from HTB94 cells after 24 h 
of incubation were largely resistant to 
endocytosis by naïve HTB94 cells, indicating 
that the [35S]TIMP-3 remnants had become 
refractory to endocytosis (Fig. 4B). This 
phenomenon was further studied by incubating 
PEA-13 cells, which lack LRP-1, with 
[35S]TIMP-3 for 24 h, and transferring the 
conditioned medium containing [35S]TIMP-3 
remnants to naïve MEF-1 cells.  [35S]TIMP-3 
remnants from PEA-13 cells were readily 
endocytosed by naïve MEF-1 (Fig. 4C), whereas 
[35S]TIMP-3 remnants from MEF-1 cells were 
resistant to endocytosis by naïve MEF-1 cells 
(Fig. 4D). Based on these results, we postulated 
that TIMP-3 became resistant to endocytosis as a 
result of association with sLRP-1 shed from 
cells into the conditioned medium during the 
culturing period.  
sLRP-1 accumulated over time in the 
conditioned medium harvested from HTB94 
cells grown in serum-free medium in the 
absence of TIMP-3 (Fig. 4E). Binding of TIMP-
3 to sLRP-1 was investigated first by incubating 
TIMP-3-FLAG (1 nM) in vitro with the 
conditioned medium from HTB94 cells. After 
overnight incubation at ambient temperature, the 
mixture was applied to an M2 anti-FLAG resin, 
and bound proteins were eluted with FLAG 
peptide. Analysis of the eluted samples with the 
8G1 anti-LRP-1 antibody indicated that LRP-1 
was co-eluted with TIMP-3-FLAG by FLAG-
peptide (Fig. 4F). The identity of the eluted 
LRP-1 band was further confirmed by mass 
spectrometry, confirming that TIMP-3 can 
interact with sLRP-1 shed into the conditioned 
medium of cells.  
We also found that addition of TIMP-3 
to HTB94 cells increases the release of sLRP-1 
fragments of 500, 215, 160 and 110 kDa into the 
conditioned medium in a concentration-
dependent manner, suggesting that the inhibitor 
can induce shedding and fragmentation of LRP-
1 (Fig. 4G). When TIMP-3-FLAG (1 nM) was 
incubated with HTB94 cells for 24 h and 
conditioned medium was applied to an M2 anti-
FLAG resin column, bound TIMP-3-FLAG co-
eluted with the 500 kDa sLRP-1 and with LRP-1 
fragments of 215, 160 and 110 kDa (Fig. 4H). 
This indicates that these fragments generated 
upon addition of TIMP-3 to the cells are capable 
of binding to the inhibitor. 
 
DISCUSSION 
Our study has revealed a new mechanism 
for regulating levels of TIMP-3 in the 
extracellular space. We previously reported that 
levels of this physiologically and pathologically 
important inhibitor can be post-translationally 
regulated by endocytosis (18). TIMP-3 
accumulates in the medium of HTB94 
chondrosarcoma cells and porcine articular 
chondrocytes treated with receptor-associated 
protein (RAP), an antagonist of ligand binding to 
the LRP family of endocytic receptors (18). 
Using radiolabelled TIMP-3 we investigated the 
kinetics of TIMP-3 endocytosis and degradation 
by LRP-1-deficient PEA-13 mouse embryonic 
fibroblasts and their wild-type counterpart. 
TIMP-3 endocytosis was substantially reduced 
in LRP-1-deficient PEA-13 cells compared to 
wild-type cells, indicating that LRP-1 is an 
important component of the TIMP-3 endocytic 
machinery. RAP, which inhibits ligand binding 
to all LRPs, had no effect on the residual 
endocytosis of TIMP-3 by PEA-13 cells, 
indicating that LRP-1 is the only member of the 
LRP family that mediates TIMP-3 endocytosis 
in mouse embryonic fibroblasts.  
We compared the endocytosis of TIMP-3 
by several cell types, including chondrosarcoma 
cells, porcine articular chondrocytes, fibroblasts 
and monocyte-like THP-1 cells. All cell types 
showed similar kinetics for TIMP-3 endocytosis. 
The rate of TIMP-3 endocytosis was not 
constant over 24 h. After addition of [35S]TIMP-
3 to cells, endocytosis was initially rapid, but 
then slowed, so that only minimal endocytosis 
was observed after 10 h. We demonstrated that 
this reduction in endocytosis is due to interaction 
of TIMP-3 with a soluble form of LRP-1 shed 
from the cell surface into the medium. Different 
LRP-1 ‘sheddases’ have been described, 
including ADAM10, ADAM12, ADAM17, 
MT1-MMP and β-secretase (23,35-38). 
Although the specific site(s) at which these 
enzymes cleave LRP-1 have not been 
characterized, shedding is known to involve 
cleavage of the β-chain of LRP-1, releasing a 
fragment of the β-chain in complex with the 
entire ligand-binding α-chain from the cell 
membrane (39). Inflammation is a key stimulus 
for LRP-1 shedding. For example, interferon γ 
and LPS stimulate LRP-1 shedding by ADAM17 
(35). Increased levels of sLRP-1 are detectable 
in the plasma of patients with rheumatoid 
arthritis, systemic lupus erythematous (35) and 
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liver disease (32). sLRP-1 and lower molecular 
weight fragments of LRP-1 are found in brain 
and in cerebral spinal fluids, and are increased in 
older people (23). Cholesterol depletion has also 
been found to stimulate LRP-1 shedding by 
MT1-MMP and ADAM12 (36). We observed 
LRP-1 shedding in the absence of any pro-
inflammatory stimuli, and addition of IL-1 had 
no effect on the rate of TIMP-3 endocytosis by 
primary chondrocytes (S. Scilabra and H. 
Nagase, unpublished observations). Since a 
number of the proposed LRP-1 ‘sheddases’ are 
metalloproteinases, production of sLRP-1 should 
be inhibited by metalloproteinase inhibitors such 
as TIMP-3 and GM6001. However, we found 
that TIMP-3 could induce shedding of LRP-1 
and generation of LRP-1 fragments. A previous 
report showed that N-TIMP-3 inhibited MT1-
MMP- and ADAM12-mediated shedding of 
LRP-1 (36). We found that, unlike TIMP-3, N-
TIMP-3 did not induce shedding and 
fragmentation of LRP-1 (S. Scilabra and H. 
Nagase, unpublished observations), therefore we 
hypothesize that the C-terminal domain of 
TIMP-3 can play a crucial role in this process. 
GM6001 has also been shown to inhibit LRP-1 
shedding from macrophages and lung fibroblasts 
(21,35), but we found that GM6001 had no 
effect on the rate of [35S]TIMP-3 endocytosis by 
HTB94 cells. This suggests that a GM6001-
insensitive sheddase may mediate LRP-1 
shedding in HTB94 cells. The stimulus and 
sheddases responsible for LRP-1 constitutive 
shedding and TIMP-3 induced shedding in 
HTB94 cells and chondrocytes are currently 
under investigation in our laboratory. 
Shedding of LRP-1 has numerous 
consequences. Firstly, it can reduce endocytosis 
of LRP-1 ligands in a loss-of-function manner 
by reducing the number of endocytic receptors 
on the cell surface (21,36,38). Secondly, sLRP-1 
can bind to and inhibit endocytosis of its ligands, 
as we found for TIMP-3, and as has been 
reported for tPA (32). By antagonizing LRP-1-
mediate endocytosis, sLRP-1 can increase the 
half-life of TIMP-3 in the extracellular space. 
More importantly, we found that the TIMP-3-
sLRP-1 complex is still able to inhibit 
metalloproteinases. We found that the ratio 
between cell surface LRP-1 and sLRP-1 is an 
important factor that regulates the bioavailability 
of TIMP-3 in the extracellular space, and hence 
controls ECM proteolysis and proteolysis of cell 
surface molecules. 
In addition to the LRP-1-mediated pathway, 
we observed LRP-1-independent endocytosis of 
TIMP-3 in PEA-13 cells and RAP-treated 
HTB94, MEFs and CHO cells. Although this is a 
slower process compared with the LRP-1-
mediated endocytosis, it is likely to be receptor-
mediated. Members belonging to the 
macrophage mannose receptor protein family 
may be possible candidates as they have been 
shown to internalize some LRP-1 ligands and 
play a crucial role in ECM turnover. For 
instance, urokinase plasminogen activator 
receptor-associated protein/endocytic recycling 
protein Endo180 is expressed in chondrocytes 
and fibroblasts and is involved in collagen 
internalization (40,41). TIMP-1 and TIMP-2 are 
also endocytosed by LRP-1 (42,43). While 
TIMP-1 is internalized only in complex with 
MMP-9, with the binding determinants thought 
to reside on the MMP-9 (42). TIMP-2 can be 
endocytosed by LRP-1 both as a free inhibitor 
and in complex with MMP-2 or proMMP-2 (43). 
Interestingly, binding of TIMP-2 to HT1080 
cells was insensitive to RAP, suggesting that 
TIMP-2 initially binds to a cell surface receptor 
other than LRP-1 prior to endocytosis (43). 
Furthermore, endocytosis and degradation of 
TIMP-2 was only partially inhibited by RAP, 
indicating that an LRP-1-independent endocytic 
pathway also occurs (43). These studies thus 
suggest that both TIMP-2 and TIMP-3 can be 
endocytosed by LRP-1-dependent and LRP-1-
independent pathways. It would be interesting to 
determine whether TIMP-2 and TIMP-3 share 
the same the mechanism of LRP-1-independent 
endocytosis. 
Endocytosis of TIMP-3 in all tested cell 
types was almost completely inhibited by 
heparin. This suggested that an HSPG or CSPG 
might participate in TIMP-3 endocytosis, either 
as a direct endocytic receptor or as a co-receptor 
of LRP-1. HSPG have been demonstrated to 
mediate endocytosis of ligands including 
lipoproteins (44). Alternatively, HSPG might act 
as co-receptors of LRP-1-mediated endocytosis 
as proposed for thrombospondin 1 (45), tissue 
factor pathway inhibitor (46), amyloid-β (47) 
and factor VIII (48). However, we found that 
TIMP-3 endocytosis was not affected in 
xylosyltransferase-deficient CHO-745 cells, 
indicating that sulfated cell surface 
proteoglycans are not required for TIMP-3 
endocytosis. In line with this finding, TIMP-3 
endocytosis was also unimpaired in syndecan-4-
null and syndecan-1-silenced cells. We therefore 
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conclude that cell surface HSPG or CSPG do not 
mediate the LRP-1-independent pathway of 
TIMP-3 endocytosis.  
The unimpaired endocytosis of TIMP-3 in 
CHO-745 cells nullified our hypothesis that 
heparin inhibits TIMP-3 endocytosis by 
blocking interaction with a sulfated cell surface 
proteoglycan component of the endocytic 
pathway. Interestingly, heparin has been shown 
to directly inhibit interaction of other ligands, 
including factor IXa (49), apolipoprotein A-V 
(50), C4b-binding protein (51) and PAI-1 (52), 
to LRP-1. In the case of PAI-1, the heparin-
binding and LRP-1-binding regions have been 
found to overlap (53,54). Binding of proteins to 
heparin is commonly mediated by clusters of 
positively charged residues (55). Similarly, 
binding of protein ligands to LRP-1 and related 
LDL receptors is often mediated by positive 
residues, as has been demonstrated for RAP 
(56,57) and α2M (58). In the case of RAP, 
crystallography and mutagenesis studies have 
confirmed that K256 and K270 mediate binding 
to acidic pockets in the ligand binding motifs of 
the receptor (56,57). Inhibition of TIMP-3 
binding to sLRP-1 by heparin suggests that the 
heparin-binding and LRP-1-binding sites of 
TIMP-3 may also overlap. The three-
dimensional structure of full-length TIMP-3 is 
currently unavailable, but the protein is 
predicted to contain an extended patch of basic 
residues, located on the opposite face of the 
protein to the inhibitory ridge that interacts with 
metalloproteinase. This may explain why TIMP-
3-sLRP-1 complexes retain metalloproteinases 
inhibition activity. 
The phenotypes of the Timp3-/- mouse 
reveal the central role of TIMP-3 in regulating 
activity of MMPs, ADAMs and ADAMTSs. 
Our study has shown that LRP-1 plays an 
important role in controlling the extracellular 
levels of TIMP-3. It is well established that 
TIMP-3 binds to ECM (2,3), but we have shown 
here that secreted TIMP-3 can be readily 
internalized via LRP-1, and this process 
competes with TIMP-3 binding to the ECM. On 
the other hand, shed sLRP-1 sequesters TIMP-3 
from the above two reactions and increases its 
availability to extracellular MMPs, ADAMs and 
ADAMTs. It is notable that shedding of LRP-1 
is increased under inflammatory conditions. We 
therefore propose that LPR-1 is a master 
regulator of extracellular trafficking of TIMP-3 
and the ratio of cell surface LPR-1 and sLRP-1 
dictates TIMP-3 availability.  
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Figure 1: TIMP-3 is endocytosed by HTB94 chondrosarcoma cells. A, [35S]TIMP-3 (1 nM) was 
added to HTB94 chondrosarcoma cells in the absence or presence of RAP (500 nM) or heparin (200 
µg/ml), and radioactivity in different cell fractions monitored over time (n=3). TIMP-3, black 
symbols; TIMP-3 plus 500 nM RAP, open symbols; TIMP-3 plus heparin, grey symbols. B, Confocal 
microscopy analysis of TIMP-3 endocytosis by HTB94 cells. Cells were incubated for 2 h at 37 °C 
with TIMP-3-FLAG (40 nM), either alone or with heparin (200 µg/ml) or RAP (500 nM). Control 
cells were incubated without TIMP-3-FLAG. Cells were washed and permeabilized, and endocytosed 
TIMP-3-FLAG vizualised using an M2 anti-FLAG antibody and an Alexa 488-labelled secondary 
antibody (green channel). The cytoskeleton was visualized using Alexa 568-labelled phalloidin (red 
channel). Images were gathered using a 60× objective lens. Scale bar: 41 µm 
 
Figure 2: LRP-1 contributes to [35S]TIMP-3 endocytosis. A-B, [35S]TIMP-3 (1 nM) was added to 
MEF-1 (A) or PEA-13 (B) cells for 0-24 h and radioactivity in the cell-associated fraction (triangles), 
as well as in the TCA-insoluble (squares) and TCA-soluble (circles) fractions of the conditioned 
media were quantified by scintillation counting (n =3). TIMP-3, black symbols; TIMP-3 plus 500 nM 
RAP, open symbols; TIMP-3 plus 200 µg/ml heparin, grey symbols. C, Confocal microscopy analysis 
of TIMP-3 endocytosis by MEF-1 and PEA-13 cells. Cells were incubated for 2 h at 37 °C with 
TIMP-3-FLAG (40 nM), washed and permeabilized, and endocytosed TIMP-3-FLAG vizualised 
using an M2 anti-FLAG antibody and an Alexa 488-labelled secondary antibody (green channel). The 
cytoskeleton was visualized using Alexa 568-labelled phalloidin (red channel). Images were gathered 
using a 60× objective lens. Scale bar: 41 µm. D, [35S]TIMP-3 (10 nM) was added to MEF-1 (closed 
bars) or PEA-13 (open bars) cells at 4 °C for 2 h to allow surface binding.  Cells were warmed to 37 
°C for 2 h, and surface bound (pronase-sensitive), intracellular (pronase-resistant), degraded (TCA-
soluble medium) and intact-released (TCA-insoluble medium) radioactivity was quantified, (this 
result is representative of two separate experiments). E, TCA-soluble radioactivity released by MEF-1  
(solid squares) and PEA-13 (open squares) cells after surface binding of [35S]TIMP-3, (this result is 
representative of two separate experiments). 
 
Figure 3: Cell surface HSPGs and CSPGs are not required for TIMP-3 endocytosis. A-B, 
[35S]TIMP-3 (1 nM) was added to CHO-K1 (A, B, solid lines and symbols), CHO-745 (A, dashed 
lines and open symbols) or heparin treated CHO-745 (B, dashed lines and open symbols) cells for 0-
24 h and radioactivity in the cell-associated fraction (triangles), as well as in the TCA-insoluble 
(squares) and TCA-soluble (circles) fractions of the conditioned media were quantified by 
scintillation counting (n =3). C, Shed LRP purified from human plasma was coated onto microtitre 
plates and binding of TIMP-3 (0.1 – 40 nM) in the absence (◼) and presence (◻) of 100 µg/ml heparin 
was measured using an M2 anti-FLAG antibody and a horseradish peroxidase-conjugate secondary 
antibody. Control wells (○) were not coated with sLRP. 
 
Figure 4: sLRP-1 interacts with TIMP-3 and inhibits its endocytosis. A, ADAMTS-4 (1 nM) was 
incubated (1 h, 37 °C) with dilutions of recombinant TIMP-3 in TNC buffer (from 1 nM, ◻) or with 
dilutions of TIMP-3 (1 nM) incubated on HTB94 cells for 0 h (◼), 24 h (▲) or 48 h (●). As a control, 
ADAMTS-4 was incubated with conditioned medium from HTB94 cells incubated in serum-free 
medium without TIMP-3 for 24 h (○) or 48 h (△). Residual activity against FAM-AE~LQGRPISIAK-
TAMRA was determined. B, [35S]TIMP-3 (1 nM) was added to HTB94 cells for 24 h, after which 
conditioned media were harvested and transferred to naïve HTB94 cells for a further 0-24 h. 
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Radioactivity in the cell-associated fraction (▲), as well as in the TCA-insoluble (◼) and TCA-
soluble (●) fractions of the conditioned media were quantified by counting radioactivity (this result is 
representative of three separate experiments). C, [35S]TIMP-3 (1 nM) was added to PEA-13 cells for 
24 h, after which conditioned media were harvested and transferred to fresh MEF-1 cells. 
Radioactivity in the cell-associated fraction (▲), as well as in the TCA-insoluble (◼) and TCA-
soluble (●) fractions of the conditioned media were quantified by scintillation counting 
(representative of two separate experiments). D, [35S]TIMP-3 (1 nM) was added to MEF-1 cells for 24 
h, after which conditioned media were harvested and transferred to naïve MEF-1 cells. Radioactivity 
in the cell-associated fraction (▲), as well as in the TCA-insoluble (◼) and TCA-soluble (●) fractions 
of the conditioned media were quantified by scintillation counting (this result is representative of two 
separate experiments). E, Conditioned medium harvested from HTB94 cells at different times was 
analyzed by SDS-PAGE and immunoblotting using 8G1 anti-LRP-1 antibody. F, Conditioned 
medium collected from HTB94 cells was incubated with or without TIMP-3-FLAG (1 nM, overnight, 
RT) applied to an M2 anti-FLAG resin. The resin was extensively washed with TBS and then with 1 
M NaCl in TBS to remove unspecific binding. Subsequently the resin was sequentially eluted with 
200 µg/ml FLAG peptide in TBS (2 x 0.5 ml, lanes 1 and 2). Eluted samples were analyzed by SDS-
PAGE and immunoblotting using M2 anti-FLAG and 8G1 anti-LRP-1 antibodies. G, Different 
concentrations of TIMP-3 (0 to 25 nM) were incubated with HTB94 cells (24 h, 37 °C). Conditioned 
media were harvested and analyzed by SDS-PAGE and immunoblotting using 8G1 anti-LRP-1 
antibody. H, TIMP-3-FLAG was incubated with HTB94 cells (1 nM, 24 h, 37 °C). The conditioned 
medium containing TIMP-3-FLAG remnants was harvested and applied to an M2 anti-FLAG resin. 
The resin was extensively washed with TBS and then with 1 M NaCl in TBS to remove unspecific 
binding. Subsequently the resin was sequentially eluted with 200 µg/ml FLAG peptide in TBS (2 x 
0.5 ml, lanes 1 and 2). Eluted samples were analyzed by SDS-PAGE and immunoblotting using M2 
anti-FLAG and 8G1 anti-LRP-1 antibodies. 
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